0000313143-25-000012.txt : 20250206 0000313143-25-000012.hdr.sgml : 20250206 20250206062048 ACCESSION NUMBER: 0000313143-25-000012 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 80 CONFORMED PERIOD OF REPORT: 20241228 FILED AS OF DATE: 20250206 DATE AS OF CHANGE: 20250206 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HAEMONETICS CORP CENTRAL INDEX KEY: 0000313143 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 042882273 STATE OF INCORPORATION: MA FISCAL YEAR END: 0329 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-14041 FILM NUMBER: 25595329 BUSINESS ADDRESS: STREET 1: 125 SUMMER STREET CITY: BOSTON STATE: MA ZIP: 02110 BUSINESS PHONE: 7818487100 MAIL ADDRESS: STREET 1: 125 SUMMER STREET CITY: BOSTON STATE: MA ZIP: 02110 10-Q 1 hae-20241228.htm 10-Q hae-20241228
00003131433/29false2025Q334.77.34.50.525http://fasb.org/us-gaap/2024#OtherNonoperatingIncomeExpensehttp://fasb.org/us-gaap/2024#OtherNonoperatingIncomeExpensehttp://fasb.org/us-gaap/2024#OtherNonoperatingIncomeExpensexbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:pureiso4217:EURiso4217:CADxbrli:shareshae:swaputr:Ratehae:segment00003131432024-03-312024-12-2800003131432025-02-0300003131432024-09-292024-12-2800003131432023-10-012023-12-3000003131432023-04-022023-12-3000003131432024-12-2800003131432024-03-300000313143us-gaap:CommonStockMember2024-03-300000313143us-gaap:AdditionalPaidInCapitalMember2024-03-300000313143us-gaap:RetainedEarningsMember2024-03-300000313143us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-300000313143us-gaap:CommonStockMember2024-03-312024-06-290000313143us-gaap:AdditionalPaidInCapitalMember2024-03-312024-06-2900003131432024-03-312024-06-290000313143us-gaap:RetainedEarningsMember2024-03-312024-06-290000313143us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-312024-06-290000313143us-gaap:CommonStockMember2024-06-290000313143us-gaap:AdditionalPaidInCapitalMember2024-06-290000313143us-gaap:RetainedEarningsMember2024-06-290000313143us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-2900003131432024-06-290000313143us-gaap:CommonStockMember2024-06-302024-09-280000313143us-gaap:AdditionalPaidInCapitalMember2024-06-302024-09-280000313143us-gaap:RetainedEarningsMember2024-06-302024-09-2800003131432024-06-302024-09-280000313143us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-302024-09-280000313143us-gaap:CommonStockMember2024-09-280000313143us-gaap:AdditionalPaidInCapitalMember2024-09-280000313143us-gaap:RetainedEarningsMember2024-09-280000313143us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-2800003131432024-09-280000313143us-gaap:CommonStockMember2024-09-292024-12-280000313143us-gaap:AdditionalPaidInCapitalMember2024-09-292024-12-280000313143us-gaap:RetainedEarningsMember2024-09-292024-12-280000313143us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-292024-12-280000313143us-gaap:CommonStockMember2024-12-280000313143us-gaap:AdditionalPaidInCapitalMember2024-12-280000313143us-gaap:RetainedEarningsMember2024-12-280000313143us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-280000313143us-gaap:CommonStockMember2023-04-010000313143us-gaap:AdditionalPaidInCapitalMember2023-04-010000313143us-gaap:RetainedEarningsMember2023-04-010000313143us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-0100003131432023-04-010000313143us-gaap:CommonStockMember2023-04-022023-07-010000313143us-gaap:AdditionalPaidInCapitalMember2023-04-022023-07-0100003131432023-04-022023-07-010000313143us-gaap:RetainedEarningsMember2023-04-022023-07-010000313143us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-022023-07-010000313143us-gaap:CommonStockMember2023-07-010000313143us-gaap:AdditionalPaidInCapitalMember2023-07-010000313143us-gaap:RetainedEarningsMember2023-07-010000313143us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-0100003131432023-07-010000313143us-gaap:CommonStockMember2023-07-022023-09-300000313143us-gaap:AdditionalPaidInCapitalMember2023-07-022023-09-300000313143us-gaap:RetainedEarningsMember2023-07-022023-09-3000003131432023-07-022023-09-300000313143us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-022023-09-300000313143us-gaap:CommonStockMember2023-09-300000313143us-gaap:AdditionalPaidInCapitalMember2023-09-300000313143us-gaap:RetainedEarningsMember2023-09-300000313143us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-3000003131432023-09-300000313143us-gaap:CommonStockMember2023-10-012023-12-300000313143us-gaap:AdditionalPaidInCapitalMember2023-10-012023-12-300000313143us-gaap:RetainedEarningsMember2023-10-012023-12-300000313143us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-10-012023-12-300000313143us-gaap:CommonStockMember2023-12-300000313143us-gaap:AdditionalPaidInCapitalMember2023-12-300000313143us-gaap:RetainedEarningsMember2023-12-300000313143us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-3000003131432023-12-300000313143hae:AttuneMedicalMember2024-04-012024-04-010000313143hae:AttuneMedicalMember2024-04-010000313143hae:AttuneMedicalMemberus-gaap:TechnologyBasedIntangibleAssetsMember2024-04-010000313143hae:AttuneMedicalMemberus-gaap:TechnologyBasedIntangibleAssetsMember2024-04-012024-04-010000313143hae:AttuneMedicalMemberus-gaap:CustomerRelationshipsMember2024-04-010000313143hae:AttuneMedicalMemberus-gaap:CustomerRelationshipsMember2024-04-012024-04-010000313143hae:AttuneMedicalMemberus-gaap:TradeNamesMember2024-04-010000313143hae:AttuneMedicalMemberus-gaap:TradeNamesMember2024-04-012024-04-010000313143hae:AttuneMedicalMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2024-03-312024-06-290000313143hae:OpSensIncMember2023-12-122023-12-120000313143hae:OpSensIncMember2023-12-120000313143hae:OpSensIncMemberus-gaap:TechnologyBasedIntangibleAssetsMember2023-12-120000313143hae:OpSensIncMemberus-gaap:TechnologyBasedIntangibleAssetsMember2023-12-122023-12-120000313143hae:OpSensIncMemberus-gaap:CustomerRelationshipsMember2023-12-120000313143hae:OpSensIncMemberus-gaap:CustomerRelationshipsMember2023-12-122023-12-120000313143hae:OpSensIncMemberus-gaap:TradeNamesMember2023-12-120000313143hae:OpSensIncMemberus-gaap:TradeNamesMember2023-12-122023-12-120000313143hae:OpSensIncMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2023-12-122023-12-120000313143hae:WholeBloodBusinessMemberus-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberus-gaap:SubsequentEventMember2025-01-132025-01-130000313143hae:WholeBloodBusinessMemberus-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberus-gaap:SubsequentEventMember2025-01-130000313143srt:RevisionOfPriorPeriodReclassificationAdjustmentMember2024-12-280000313143srt:RevisionOfPriorPeriodReclassificationAdjustmentMember2024-03-312024-12-280000313143hae:VivasureMedicalLTDMember2024-12-280000313143srt:RevisionOfPriorPeriodReclassificationAdjustmentMemberus-gaap:InventoriesMember2024-12-280000313143srt:RevisionOfPriorPeriodReclassificationAdjustmentMemberus-gaap:PropertyPlantAndEquipmentMember2024-12-280000313143srt:RevisionOfPriorPeriodReclassificationAdjustmentMemberus-gaap:GoodwillMember2024-12-280000313143srt:RevisionOfPriorPeriodReclassificationAdjustmentMemberus-gaap:AccruedLiabilitiesMember2024-12-2800003131432024-12-292024-12-2800003131432025-12-272024-12-280000313143hae:A2020ProgramMember2024-12-280000313143hae:A2020ProgramMember2024-09-292024-12-280000313143hae:A2020ProgramMember2024-03-312024-12-280000313143hae:A2020ProgramMember2023-10-012023-12-300000313143hae:A2020ProgramMember2023-04-022023-12-300000313143hae:PortfolioRationalizationMember2024-09-292024-12-280000313143hae:PortfolioRationalizationMember2024-03-312024-12-280000313143hae:PortfolioRationalizationMember2023-04-022023-12-300000313143hae:PortfolioRationalizationMember2023-10-012023-12-300000313143hae:PortfolioRationalizationMember2024-03-300000313143hae:A2020ProgramMember2024-03-300000313143hae:PortfolioRationalizationMember2024-12-280000313143us-gaap:CostOfSalesMember2024-09-292024-12-280000313143us-gaap:CostOfSalesMember2023-10-012023-12-300000313143us-gaap:CostOfSalesMember2024-03-312024-12-280000313143us-gaap:CostOfSalesMember2023-04-022023-12-300000313143us-gaap:ResearchAndDevelopmentExpenseMember2024-09-292024-12-280000313143us-gaap:ResearchAndDevelopmentExpenseMember2023-10-012023-12-300000313143us-gaap:ResearchAndDevelopmentExpenseMember2024-03-312024-12-280000313143us-gaap:ResearchAndDevelopmentExpenseMember2023-04-022023-12-300000313143us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-09-292024-12-280000313143us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-10-012023-12-300000313143us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-03-312024-12-280000313143us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-04-022023-12-300000313143hae:PlasmaMember2024-09-292024-12-280000313143hae:PlasmaMember2023-10-012023-12-300000313143hae:PlasmaMember2024-03-312024-12-280000313143hae:PlasmaMember2023-04-022023-12-300000313143hae:BloodCenterMember2024-09-292024-12-280000313143hae:BloodCenterMember2023-10-012023-12-300000313143hae:BloodCenterMember2024-03-312024-12-280000313143hae:BloodCenterMember2023-04-022023-12-300000313143hae:HospitalMember2024-09-292024-12-280000313143hae:HospitalMember2023-10-012023-12-300000313143hae:HospitalMember2024-03-312024-12-280000313143hae:HospitalMember2023-04-022023-12-300000313143us-gaap:CorporateMember2024-09-292024-12-280000313143us-gaap:CorporateMember2023-10-012023-12-300000313143us-gaap:CorporateMember2024-03-312024-12-280000313143us-gaap:CorporateMember2023-04-022023-12-300000313143hae:StockCompensationWindfallsMember2024-09-292024-12-280000313143hae:StockCompensationWindfallsMember2023-04-022023-12-300000313143hae:A2022AcceleratedShareRepurchaseProgramMember2024-03-312024-12-280000313143hae:A2022AcceleratedShareRepurchaseProgramMember2022-08-310000313143hae:A2024AcceleratedShareRepurchaseProgramMember2024-08-280000313143hae:A2024AcceleratedShareRepurchaseProgramMember2024-08-282024-08-280000313143us-gaap:LandMember2024-12-280000313143us-gaap:LandMember2024-03-300000313143us-gaap:BuildingAndBuildingImprovementsMember2024-12-280000313143us-gaap:BuildingAndBuildingImprovementsMember2024-03-300000313143us-gaap:MachineryAndEquipmentMember2024-12-280000313143us-gaap:MachineryAndEquipmentMember2024-03-300000313143hae:OfficeEquipmentAndInformationTechnologyMember2024-12-280000313143hae:OfficeEquipmentAndInformationTechnologyMember2024-03-300000313143hae:HaemoneticsEquipmentMember2024-12-280000313143hae:HaemoneticsEquipmentMember2024-03-300000313143us-gaap:ConstructionInProgressMember2024-12-280000313143us-gaap:ConstructionInProgressMember2024-03-300000313143srt:RestatementAdjustmentMember2024-12-2800003131432024-04-252024-04-250000313143hae:PlasmaMember2024-03-300000313143hae:BloodCenterMember2024-03-300000313143hae:HospitalMember2024-03-300000313143hae:PlasmaMember2024-12-280000313143hae:BloodCenterMember2024-12-280000313143hae:HospitalMember2024-12-280000313143hae:OtherTechnologyMember2024-12-280000313143us-gaap:CustomerContractsMember2024-12-280000313143us-gaap:ComputerSoftwareIntangibleAssetMember2024-12-280000313143us-gaap:PatentsMember2024-12-280000313143us-gaap:TradeNamesMember2024-12-280000313143hae:InProcessSoftwareDevelopmentMember2024-12-280000313143hae:OtherTechnologyMember2024-03-300000313143us-gaap:CustomerContractsMember2024-03-300000313143us-gaap:ComputerSoftwareIntangibleAssetMember2024-03-300000313143us-gaap:PatentsMember2024-03-300000313143us-gaap:TradeNamesMember2024-03-300000313143us-gaap:InProcessResearchAndDevelopmentMember2024-03-300000313143hae:InProcessSoftwareDevelopmentMember2024-03-300000313143hae:AttuneMedicalMemberus-gaap:CustomerRelatedIntangibleAssetsMember2024-04-010000313143srt:MinimumMember2024-12-280000313143srt:MaximumMember2024-12-280000313143us-gaap:ConvertibleDebtMember2024-12-280000313143us-gaap:ConvertibleDebtMember2024-03-300000313143us-gaap:MediumTermNotesMember2024-12-280000313143us-gaap:MediumTermNotesMember2024-03-300000313143us-gaap:RevolvingCreditFacilityMember2024-12-280000313143us-gaap:RevolvingCreditFacilityMember2024-03-300000313143hae:BankLoansAndOtherBorrowingsMember2024-12-280000313143hae:BankLoansAndOtherBorrowingsMember2024-03-300000313143hae:ConvertibleSeniorNotesDue2026Memberus-gaap:ConvertibleDebtMember2021-03-310000313143hae:ConvertibleSeniorNotesDue2026Memberus-gaap:ConvertibleDebtMember2024-05-280000313143hae:ConvertibleSeniorNotesDue2026Memberus-gaap:ConvertibleDebtMember2024-05-282024-05-280000313143hae:ConvertibleSeniorNotesDue2026Memberus-gaap:ConvertibleDebtMember2024-12-280000313143hae:ConvertibleSeniorNotesDue2026Memberus-gaap:ConvertibleDebtMember2024-09-292024-12-280000313143hae:ConvertibleSeniorNotesDue2026Memberus-gaap:ConvertibleDebtMember2024-03-312024-12-280000313143hae:ConvertibleSeniorNotesDue2029Memberus-gaap:ConvertibleDebtMember2024-05-280000313143hae:ConvertibleSeniorNotesDue2029Memberus-gaap:ConvertibleDebtMember2024-05-282024-05-280000313143hae:ConvertibleSeniorNotesDue2029Memberus-gaap:ConvertibleDebtMemberus-gaap:DebtInstrumentRedemptionPeriodOneMember2024-05-282024-05-280000313143hae:ConvertibleSeniorNotesDue2029Memberus-gaap:ConvertibleDebtMemberus-gaap:DebtInstrumentRedemptionPeriodTwoMember2024-05-282024-05-280000313143hae:ConvertibleSeniorNotesDue2029Memberus-gaap:ConvertibleDebtMember2024-12-280000313143hae:ConvertibleSeniorNotesDue2029Memberus-gaap:ConvertibleDebtMember2024-09-292024-12-280000313143hae:ConvertibleSeniorNotesDue2029Memberus-gaap:ConvertibleDebtMember2024-03-312024-12-2800003131432024-05-2800003131432024-05-282024-05-280000313143hae:A2022RevisedCreditAgreementMemberus-gaap:MediumTermNotesMember2022-07-260000313143hae:A2022RevisedCreditAgreementMemberus-gaap:RevolvingCreditFacilityMember2022-07-260000313143hae:A2022RevisedCreditAgreementMemberus-gaap:RevolvingCreditFacilityMembersrt:MinimumMember2022-07-260000313143hae:A2022RevisedCreditAgreementMemberus-gaap:RevolvingCreditFacilityMembersrt:MaximumMember2022-07-260000313143hae:A2024RevisedCreditAgreementMemberus-gaap:MediumTermNotesMember2024-04-300000313143hae:A2024RevisedCreditAgreementMemberus-gaap:MediumTermNotesMember2024-04-302024-04-300000313143hae:A2024RevisedCreditAgreementMemberus-gaap:RevolvingCreditFacilityMember2024-04-300000313143hae:A2024RevisedCreditAgreementMemberus-gaap:MediumTermNotesMembersrt:MinimumMember2024-04-300000313143hae:A2024RevisedCreditAgreementMemberus-gaap:MediumTermNotesMembersrt:MaximumMember2024-04-300000313143hae:A2024RevisedCreditAgreementMemberus-gaap:RevolvingCreditFacilityMembersrt:MinimumMember2024-04-302024-04-300000313143hae:A2024RevisedCreditAgreementMemberus-gaap:RevolvingCreditFacilityMembersrt:MaximumMember2024-04-302024-04-3000003131432024-04-300000313143hae:RevisedCreditAgreementMemberus-gaap:UnsecuredDebtMember2024-09-292024-12-280000313143hae:RevisedCreditAgreementMemberus-gaap:UnsecuredDebtMember2024-03-312024-12-280000313143hae:A2024RevisedCreditAgreementMemberus-gaap:MediumTermNotesMember2024-12-280000313143us-gaap:LineOfCreditMember2024-12-280000313143us-gaap:ForeignExchangeContractMember2024-09-292024-12-280000313143us-gaap:ForeignExchangeContractMember2024-03-312024-12-280000313143us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-12-280000313143us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-03-300000313143us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-03-312024-12-280000313143us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2024-12-280000313143us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2024-03-300000313143us-gaap:InterestRateSwapMember2022-09-012022-09-300000313143us-gaap:InterestRateSwapMember2023-06-152023-06-150000313143us-gaap:InterestRateSwapMember2024-09-262024-09-2600003131432024-09-270000313143us-gaap:InterestRateSwapMember2024-09-270000313143us-gaap:InterestRateSwapMember2024-09-272024-09-270000313143hae:InterestRateSwap408FixedInterestRateMember2022-09-230000313143hae:InterestRateSwap408FixedInterestRateMember2024-12-280000313143hae:InterestRateSwap415FixedInterestRateMember2022-09-230000313143hae:InterestRateSwap415FixedInterestRateMember2024-12-280000313143us-gaap:InterestRateSwapMember2022-09-230000313143us-gaap:InterestRateSwapMember2024-12-280000313143us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-03-312024-12-280000313143us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2024-03-312024-12-280000313143us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-12-280000313143us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherCurrentAssetsMember2024-12-280000313143us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherCurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-300000313143us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMemberus-gaap:OtherCurrentAssetsMember2024-12-280000313143us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMemberus-gaap:OtherCurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-300000313143us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:InterestRateSwapMemberus-gaap:NondesignatedMemberus-gaap:OtherCurrentAssetsMember2024-12-280000313143us-gaap:InterestRateSwapMemberus-gaap:NondesignatedMemberus-gaap:OtherCurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-300000313143us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentAssetsMember2024-12-280000313143us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-300000313143us-gaap:FairValueMeasurementsRecurringMember2024-12-280000313143us-gaap:FairValueMeasurementsRecurringMember2024-03-300000313143us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherCurrentLiabilitiesMember2024-12-280000313143us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-300000313143us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMemberus-gaap:OtherCurrentLiabilitiesMember2024-12-280000313143us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-300000313143us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-12-280000313143us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-12-280000313143us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-280000313143us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-280000313143us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-280000313143us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-280000313143us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:InterestRateSwapMemberus-gaap:NondesignatedMemberus-gaap:OtherAssetsMember2024-12-280000313143us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:InterestRateSwapMemberus-gaap:NondesignatedMemberus-gaap:OtherAssetsMember2024-12-280000313143us-gaap:InterestRateSwapMemberus-gaap:NondesignatedMemberus-gaap:OtherAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-280000313143us-gaap:FairValueInputsLevel1Memberus-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-280000313143us-gaap:FairValueInputsLevel2Memberus-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-280000313143us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-280000313143us-gaap:FairValueInputsLevel3Memberhae:ContingentConsiderationMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-280000313143us-gaap:FairValueMeasurementsRecurringMemberhae:ContingentConsiderationMember2024-12-280000313143us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-12-280000313143us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-300000313143us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-300000313143us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-300000313143us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-300000313143us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-300000313143us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-300000313143us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-300000313143us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-300000313143us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:InterestRateSwapMemberus-gaap:NondesignatedMemberus-gaap:OtherAssetsMember2024-03-300000313143us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:InterestRateSwapMemberus-gaap:NondesignatedMemberus-gaap:OtherAssetsMember2024-03-300000313143us-gaap:InterestRateSwapMemberus-gaap:NondesignatedMemberus-gaap:OtherAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-300000313143us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMemberus-gaap:OtherCurrentLiabilitiesMember2024-03-300000313143us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-300000313143hae:RevenueBasedPaymentMemberus-gaap:FairValueInputsLevel3Memberhae:ContingentConsiderationMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-280000313143hae:RegulatoryBasedPaymentMemberus-gaap:FairValueInputsLevel3Memberhae:ContingentConsiderationMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-280000313143hae:EventBasedPaymentMemberus-gaap:FairValueInputsLevel3Memberhae:ContingentConsiderationMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-280000313143hae:AttuneMedicalMemberus-gaap:OtherCurrentLiabilitiesMember2024-12-280000313143hae:AttuneMedicalMemberus-gaap:OtherNoncurrentLiabilitiesMember2024-12-280000313143us-gaap:FairValueMeasurementsRecurringMemberhae:ContingentConsiderationMember2024-03-300000313143us-gaap:FairValueInputsLevel2Memberhae:ConvertibleSeniorNotesDue2026Member2024-12-280000313143us-gaap:FairValueInputsLevel2Memberhae:ConvertibleSeniorNotesDue2029Member2024-12-2800003131432023-04-022024-03-300000313143us-gaap:AccumulatedTranslationAdjustmentMember2024-03-300000313143us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-03-300000313143us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-03-300000313143us-gaap:AccumulatedTranslationAdjustmentMember2024-03-312024-12-280000313143us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-03-312024-12-280000313143us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-03-312024-12-280000313143us-gaap:AccumulatedTranslationAdjustmentMember2024-12-280000313143us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-12-280000313143us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-12-280000313143us-gaap:OperatingSegmentsMemberhae:PlasmaMember2024-09-292024-12-280000313143us-gaap:OperatingSegmentsMemberhae:PlasmaMember2023-10-012023-12-300000313143us-gaap:OperatingSegmentsMemberhae:PlasmaMember2024-03-312024-12-280000313143us-gaap:OperatingSegmentsMemberhae:PlasmaMember2023-04-022023-12-300000313143us-gaap:OperatingSegmentsMemberhae:BloodCenterMember2024-09-292024-12-280000313143us-gaap:OperatingSegmentsMemberhae:BloodCenterMember2023-10-012023-12-300000313143us-gaap:OperatingSegmentsMemberhae:BloodCenterMember2024-03-312024-12-280000313143us-gaap:OperatingSegmentsMemberhae:BloodCenterMember2023-04-022023-12-300000313143us-gaap:OperatingSegmentsMemberhae:HospitalMember2024-09-292024-12-280000313143us-gaap:OperatingSegmentsMemberhae:HospitalMember2023-10-012023-12-300000313143us-gaap:OperatingSegmentsMemberhae:HospitalMember2024-03-312024-12-280000313143us-gaap:OperatingSegmentsMemberhae:HospitalMember2023-04-022023-12-300000313143us-gaap:OperatingSegmentsMember2024-09-292024-12-280000313143us-gaap:OperatingSegmentsMember2023-10-012023-12-300000313143us-gaap:OperatingSegmentsMember2024-03-312024-12-280000313143us-gaap:OperatingSegmentsMember2023-04-022023-12-300000313143us-gaap:CorporateNonSegmentMember2024-09-292024-12-280000313143us-gaap:CorporateNonSegmentMember2023-10-012023-12-300000313143us-gaap:CorporateNonSegmentMember2024-03-312024-12-280000313143us-gaap:CorporateNonSegmentMember2023-04-022023-12-300000313143hae:PlasmaProductsandServicesMemberhae:PlasmaMember2024-09-292024-12-280000313143hae:PlasmaProductsandServicesMemberhae:PlasmaMember2023-10-012023-12-300000313143hae:PlasmaProductsandServicesMemberhae:PlasmaMember2024-03-312024-12-280000313143hae:PlasmaProductsandServicesMemberhae:PlasmaMember2023-04-022023-12-300000313143hae:BloodCenterProductsandServicesMemberhae:ApheresisBloodCenterMember2024-09-292024-12-280000313143hae:BloodCenterProductsandServicesMemberhae:ApheresisBloodCenterMember2023-10-012023-12-300000313143hae:BloodCenterProductsandServicesMemberhae:ApheresisBloodCenterMember2024-03-312024-12-280000313143hae:BloodCenterProductsandServicesMemberhae:ApheresisBloodCenterMember2023-04-022023-12-300000313143hae:BloodCenterProductsandServicesMemberhae:WholeBloodBloodCenterMember2024-09-292024-12-280000313143hae:BloodCenterProductsandServicesMemberhae:WholeBloodBloodCenterMember2023-10-012023-12-300000313143hae:BloodCenterProductsandServicesMemberhae:WholeBloodBloodCenterMember2024-03-312024-12-280000313143hae:BloodCenterProductsandServicesMemberhae:WholeBloodBloodCenterMember2023-04-022023-12-300000313143hae:BloodCenterProductsandServicesMemberhae:BloodCenterMember2024-09-292024-12-280000313143hae:BloodCenterProductsandServicesMemberhae:BloodCenterMember2023-10-012023-12-300000313143hae:BloodCenterProductsandServicesMemberhae:BloodCenterMember2024-03-312024-12-280000313143hae:BloodCenterProductsandServicesMemberhae:BloodCenterMember2023-04-022023-12-300000313143hae:HospitalProductsandServicesMemberhae:InterventionalTechnologiesHospitalMember2024-09-292024-12-280000313143hae:HospitalProductsandServicesMemberhae:InterventionalTechnologiesHospitalMember2023-10-012023-12-300000313143hae:HospitalProductsandServicesMemberhae:InterventionalTechnologiesHospitalMember2024-03-312024-12-280000313143hae:HospitalProductsandServicesMemberhae:InterventionalTechnologiesHospitalMember2023-04-022023-12-300000313143hae:HospitalProductsandServicesMemberhae:HemostasisManagementHospitalMember2024-09-292024-12-280000313143hae:HospitalProductsandServicesMemberhae:HemostasisManagementHospitalMember2023-10-012023-12-300000313143hae:HospitalProductsandServicesMemberhae:HemostasisManagementHospitalMember2024-03-312024-12-280000313143hae:HospitalProductsandServicesMemberhae:HemostasisManagementHospitalMember2023-04-022023-12-300000313143hae:HospitalProductsandServicesMemberhae:HospitalMember2024-09-292024-12-280000313143hae:HospitalProductsandServicesMemberhae:HospitalMember2023-10-012023-12-300000313143hae:HospitalProductsandServicesMemberhae:HospitalMember2024-03-312024-12-280000313143hae:HospitalProductsandServicesMemberhae:HospitalMember2023-04-022023-12-300000313143country:US2024-09-292024-12-280000313143country:US2023-10-012023-12-300000313143country:US2024-03-312024-12-280000313143country:US2023-04-022023-12-300000313143country:JP2024-09-292024-12-280000313143country:JP2023-10-012023-12-300000313143country:JP2024-03-312024-12-280000313143country:JP2023-04-022023-12-300000313143srt:EuropeMember2024-09-292024-12-280000313143srt:EuropeMember2023-10-012023-12-300000313143srt:EuropeMember2024-03-312024-12-280000313143srt:EuropeMember2023-04-022023-12-300000313143srt:AsiaMember2024-09-292024-12-280000313143srt:AsiaMember2023-10-012023-12-300000313143srt:AsiaMember2024-03-312024-12-280000313143srt:AsiaMember2023-04-022023-12-300000313143hae:OtherCountryorRegionMember2024-09-292024-12-280000313143hae:OtherCountryorRegionMember2023-10-012023-12-300000313143hae:OtherCountryorRegionMember2024-03-312024-12-280000313143hae:OtherCountryorRegionMember2023-04-022023-12-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
☒
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended: December 28, 2024
OR
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission File Number: 001-14041
HAEMONETICS CORPORATION
(Exact name of registrant as specified in its charter)
Massachusetts 04-2882273
(State or other jurisdiction of
incorporation or organization)		 (I.R.S. Employer
Identification No.)
125 Summer Street 
Boston,Massachusetts02110
(Address of principal executive offices)(Zip Code)
(781) 848-7100
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of Each ClassTrading SymbolName of Each Exchange on Which Registered
Common stock, $.01 par value per shareHAENew York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filerxAccelerated filer  ☐
Non-accelerated filer  ☐Smaller reporting company☐
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.) Yes ☐No x
The number of shares of $0.01 par value common stock outstanding as of February 3, 2025: 50,237,466


HAEMONETICS CORPORATION
INDEX
 PAGE
 
 
  
  
  
  
  
  
  
  
  
  
  
  
  
2

ITEM 1. FINANCIAL STATEMENTS

HAEMONETICS CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME
(Unaudited in thousands, except per share data)

 Three Months EndedNine Months Ended
December 28,
2024		December 30,
2023		December 28,
2024		December 30,
2023
Net revenues$348,542 $336,250 $1,030,225 $965,765 
Cost of goods sold154,995 158,383 474,317 450,123 
Gross profit193,547 177,867 555,908 515,642 
Operating expenses:    
Research and development15,829 13,265 46,808 38,578 
Selling, general and administrative106,459 111,713 321,653 320,518 
Amortization of acquired intangible assets12,230 6,911 36,965 21,606 
Total operating expenses134,518 131,889 405,426 380,702 
Operating income59,029 45,978 150,482 134,940 
Interest and other expense, net(9,112)(1,949)(9,148)(6,489)
Income before provision for income taxes49,917 44,029 141,334 128,451 
Provision for income taxes12,423 12,788 31,636 31,260 
Net income$37,494 $31,241 $109,698 $97,191 
Net income per share - basic$0.75 $0.62 $2.16 $1.92 
Net income per share - diluted$0.74 $0.61 $2.14 $1.89 
Weighted average shares outstanding     
Basic50,286 50,768 50,709 50,679 
Diluted50,639 51,445 51,148 51,394 
Comprehensive income$16,557 $39,564 $89,829 $103,190 

The accompanying notes are an integral part of these condensed consolidated financial statements.
3
HAEMONETICS CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited in thousands, except share data)
December 28,
2024		March 30,
2024
ASSETS  
Current assets:  
Cash and cash equivalents$320,846 $178,800 
Accounts receivable, less allowance for credit losses of $5,986 at December 28, 2024 and $5,695 at March 30, 2024
211,949 206,562 
Inventories, net359,614 317,202 
Prepaid expenses and other current assets113,459 66,339 
Total current assets1,005,868 768,903 
Property, plant and equipment, net286,107 311,362 
Intangible assets, less accumulated amortization of $311,596 at December 28, 2024 and $455,213 at March 30, 2024
465,615 406,117 
Goodwill605,266 565,082 
Deferred tax asset8,000 7,739 
Other long-term assets160,414 136,388 
Total assets$2,531,270 $2,195,591 
LIABILITIES AND STOCKHOLDERS’ EQUITY  
Current liabilities:  
Notes payable and current maturities of long-term debt$5,075 $10,229 
Accounts payable62,990 73,358 
Accrued payroll and related costs45,933 80,708 
Other current liabilities139,235 136,088 
Total current liabilities253,233 300,383 
Long-term debt1,219,762 797,564 
Deferred tax liability61,451 62,644 
Other long-term liabilities89,964 75,041 
Stockholders’ equity:  
Common stock, $0.01 par value; Authorized — 150,000,000 shares; Issued and outstanding — 50,235,051 shares at December 28, 2024 and 50,787,859 shares at March 30, 2024
502 508 
Additional paid-in capital569,629 634,627 
Retained earnings392,230 360,456 
Accumulated other comprehensive loss(55,501)(35,632)
Total stockholders’ equity906,860 959,959 
Total liabilities and stockholders’ equity$2,531,270 $2,195,591 
    
The accompanying notes are an integral part of these condensed consolidated financial statements.
4
HAEMONETICS CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(Unaudited in thousands)
 Common StockAdditional
Paid-in Capital		Retained EarningsAccumulated
Other
Comprehensive (Loss)/Income		Total
Stockholders’ Equity
 SharesPar Value
Balance, March 30, 202450,788 $508 $634,627 $360,456 $(35,632)$959,959 
Employee stock purchase plan47 — 3,441 — — 3,441 
Exercise of stock options73 1 4,703 (3,743)— 961 
Issuance of restricted stock, net of cancellations280 3 (3)— — — 
Tax withholding on employee equity awards(35)— (1,315)(8,444)— (9,759)
Purchase of capped call related to convertible notes— — (88,200)— — (88,200)
Share-based compensation expense— — 7,628 — — 7,628 
Net income— — — 38,373 — 38,373 
Other comprehensive loss— — — — (7,035)(7,035)
Balance, June 29, 202451,153 $512 $560,881 $386,642 $(42,667)$905,368 
Exercise of stock options5 — 515 (264)— 251 
Shares repurchased, including excise tax(799)(8)(23,839)(51,394)— (75,241)
Issuance of restricted stock, net of cancellations23 — — — — — 
Tax withholding on employee equity awards(1)— (39)(279)— (318)
Share-based compensation expense— — 6,857 — — 6,857 
Net income— — — 33,831 — 33,831 
Other comprehensive income— — — — 8,103 8,103 
Balance, September 28, 202450,381 $504 $544,375 $368,536 $(34,564)$878,851 
Employee stock purchase plan49 — 3,035 — — 3,035 
Exercise of stock options12 — 1,266 (761)— 505 
Shares repurchased, including excise tax(209)(2)12,761 (12,867)— (108)
Issuance of restricted stock, net of cancellations3 — — — — — 
Tax withholding on employee equity awards(1)— (22)(172)— (194)
Share-based compensation expense— — 8,214 — — 8,214 
Net income— — — 37,494 — 37,494 
Other comprehensive loss— — — — (20,937)(20,937)
Balance, December 28, 202450,235 $502 $569,629 $392,230 $(55,501)$906,860 
5
 Common StockAdditional
Paid-in Capital		Retained EarningsAccumulated
Other
Comprehensive (Loss)/Income		Total
Stockholders’ Equity
 SharesPar Value
Balance, April 1, 202350,449 $504 $594,706 $253,168 $(30,381)$817,997 
Employee stock purchase plan40 — 2,871 — — 2,871 
Exercise of stock options145 2 5,858 (5,233)— 627 
Issuance of restricted stock, net of cancellations140 2 (2)— — — 
Tax withholding on employee equity awards(68)(1)(812)(4,960)— (5,773)
Share-based compensation expense— — 6,989 — — 6,989 
Net income— — — 41,042 — 41,042 
Other comprehensive income— — — — 863 863 
Balance, July 1, 202350,706 $507 $609,610 $284,017 $(29,518)$864,616 
Exercise of stock options12 — 655 37 — 692 
Issuance of restricted stock, net of cancellations22 — — — — — 
Tax withholding on employee equity awards— — (11)(64)— (75)
Share-based compensation expense— — 6,706 — — 6,706 
Net income— — — 24,908 — 24,908 
Other comprehensive loss— — — — (3,187)(3,187)
Balance, September 30, 202350,740 $507 $616,960 $308,898 $(32,705)$893,660 
Employee stock purchase plan39 — 2,732 — — 2,732 
Exercise of stock options4 1 189 (4)— 186 
Issuance of restricted stock, net of cancellations3 — — — — — 
Tax withholding on employee equity awards(1)— (4)(36)— (40)
Share-based compensation expense— — 7,217 — — 7,217 
Net income— — — 31,241 — 31,241 
Other comprehensive income— — — — 8,323 8,323 
Balance, December 30, 202350,785 $508 $627,094 $340,099 $(24,382)$943,319 

The accompanying notes are an integral part of these condensed consolidated financial statements.

6
HAEMONETICS CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited in thousands)
 Nine Months Ended
December 28,
2024		December 30,
2023
Cash Flows from Operating Activities:  
Net income$109,698 $97,191 
Adjustments to reconcile net income to net cash provided by operating activities:  
Non-cash items:
Depreciation and amortization87,378 69,576 
Amortization of fair value inventory step-up12,319 — 
Share-based compensation expense22,699 20,912 
Impairment of intangible assets2,391 10,419 
Gain on repurchase of convertible senior notes, net(12,600)— 
Inventory reserve adjustment1,289 6,904 
Gains on sales of property, plant and equipment(14,572)(647)
Deferred tax benefit(8,593)(5,138)
Other non-cash operating activities8,114 5,748 
Change in operating assets and liabilities:
Change in accounts receivable(3,379)(27,743)
Change in inventories(65,629)(40,721)
Change in prepaid income taxes(2,638)1,730 
Change in other assets and other liabilities(34,493)(15,619)
Change in accounts payable and accrued expenses(36,816)(4,942)
Net cash provided by operating activities65,168 117,670 
Cash Flows from Investing Activities: 
Capital expenditures(23,635)(31,440)
Non-cash transfers from inventory to property, plant and equipment for Haemonetics equipment(12,649)(25,171)
Acquisition, net of cash acquired(150,906)(243,852)
Proceeds from sale of property, plant and equipment20,802 1,259 
Other investing activities(13,547)(10,129)
Net cash used in investing activities(179,935)(309,333)
Cash Flows from Financing Activities:  
Proceeds from issuance of convertible notes700,000 — 
Repurchase of convertible senior notes(185,500)— 
Purchase of capped call related to convertible notes(88,200)— 
Term loan borrowings250,000 — 
Term loan redemption(262,500)— 
Proceeds from revolving facility— 110,000 
Payments on revolving facility(50,000)— 
Repayment of term loan borrowings(3,125)(8,750)
Debt issuance costs(23,135)— 
Share repurchases(75,000)— 
Proceeds from employee stock purchase plan6,476 5,603 
Proceeds from exercise of stock options1,717 1,505 
Cash used to net share settle employee equity awards(10,243)(5,885)
Other financing activities(222)(814)
Net cash provided by financing activities260,268 101,659 
Effect of exchange rates on cash and cash equivalents(3,455)(484)
Net Change in Cash and Cash Equivalents142,046 (90,488)
Cash and Cash Equivalents at Beginning of Period178,800 284,466 
Cash and Cash Equivalents at End of Period$320,846 $193,978 
The accompanying notes are an integral part of these condensed consolidated financial statements.
7
HAEMONETICS CORPORATION AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1. BASIS OF PRESENTATION

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements of Haemonetics Corporation (“Haemonetics” or the “Company”) presented herein have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of the Company’s management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. All intercompany transactions have been eliminated. Operating results for the nine months ended December 28, 2024 are not necessarily indicative of the results that may be expected for the full fiscal year ending March 29, 2025 or any other interim period. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and footnotes included in the Annual Report on Form 10-K for the fiscal year ended March 30, 2024.

The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the financial statements to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated as required. There were no material recognized or unrecognized subsequent events as of or for the nine months ended December 28, 2024, except for those discussed in Note 3, Acquisitions, Divestitures and Strategic Investments.

2. RECENT ACCOUNTING PRONOUNCEMENTS

Standards to be Implemented

In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Codification (“ASC”) Update No. 2023-07, Segment Reporting (Topic 280). The new guidance requires public entities to provide expanded disclosures over significant segment expenses and additional disclosures related to the chief operating decision maker. ASC Update No. 2023-07 is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The new guidance is applicable to Haemonetics beginning with the fiscal 2025 Annual Report on Form 10-K. The Company is currently evaluating the impact to its interim and annual report disclosures.

In December 2023, the FASB issued ASC Update No. 2023-09, Income Taxes (Topic 740). ASC Update No. 2023-09 requires public entities to provide detailed income tax disclosures, including rate reconciliations and disaggregated income tax payment information, on an annual basis. The updated guidance is effective for fiscal years beginning after December 15, 2024 and early adoption is permitted. ASC Update No. 2023-09 is applicable to Haemonetics beginning with the fiscal 2026 Annual Report on Form 10-K and the Company is currently evaluating the impact to its annual report disclosures.

In November 2024, the FASB issued ASC Update No. 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40). ASC Update No. 2024-03 requires detailed cost and expense information disaggregated in the financial statement notes. The updated guidance is effective for fiscal years beginning after December 15, 2026 and interim reporting periods within annual reporting periods beginning after December 15, 2027, with early adoption permitted. ASC Update No. 2024-03 is applicable to Haemonetics beginning with the fiscal 2028 Annual Report on Form 10-K and the Company is currently evaluating the impact to its interim and annual report disclosures.
8
3. ACQUISITIONS, DIVESTITURES AND STRATEGIC INVESTMENTS

Acquisitions

Attune Medical

On March 5, 2024, the Company entered into a definitive agreement to acquire Advanced Cooling Therapy, Inc., d/b/a Attune Medical (“Attune Medical”), the manufacturer of the ensoETM® proactive esophageal cooling device, pursuant to which, among other things, the Company agreed to acquire all of the issued and outstanding common shares of Attune Medical. On April 1, 2024, the Company completed its acquisition of Attune Medical for total consideration of $187.7 million, which included an upfront cash payment of $162.0 million, or $150.5 million net of cash acquired, the fair value of contingent consideration of $25.3 million, and $0.4 million of working capital adjustments. The contingent consideration is based on sales growth over the next three years, which is uncapped, and the achievement of certain other milestones. The Company financed the acquisition through a combination of cash on hand and borrowings under its senior unsecured revolving credit facility.

Attune Medical's ensoETM technology is designed for use across a range of medical conditions involving patient cooling or warming, including treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery, among others. The Company’s addition of the Esophageal Protection product line through its acquisition of Attune Medical expands the Hospital business unit’s presence in electrophysiology and complements its Vascular Closure product line within Interventional Technologies, which is included in the Hospital reportable segment.

Purchase Price Allocation

The Company accounted for the acquisition as a business combination, and in accordance with FASB ASC Topic 805, Business Combinations (Topic 805), recorded the assets acquired and liabilities assumed at their fair values as of the acquisition date. The fair value of assets acquired and liabilities assumed have been recognized based on management’s estimates and assumptions using the information regarding facts and circumstances that existed at the closing date.

The purchase price of $176.2 million, net of $11.5 million of cash acquired, consists of the amounts presented below, which represent the final determination of the fair value of the identifiable assets acquired and liabilities assumed:

(In thousands) April 1, 2024
Accounts receivable$3,784 
Inventories26,300 
Prepaid expenses and other current assets906 
Property, plant and equipment200 
Intangible assets105,800 
Goodwill70,256 
Total assets acquired$207,246 
Accounts payable2,260 
Accrued payroll and related costs2,129 
Other liabilities496 
Deferred tax liability26,155 
Total liabilities assumed$31,040 
Net assets acquired$176,206 
9

The Company determined that the identifiable intangible assets were developed technology, customer contracts and related relationships and trade names. The fair values of intangible assets were based on valuation techniques with estimates and assumptions developed by the Company. Developed technology was valued using the excess earnings method. Customer contracts and related relationships were valued using the distributor method. The trademark was valued using the relief from royalty method. The cash flows used in the valuation of the intangible assets were based on estimates used to price the transaction. In developing the discount rates applied to the cash flow projections, the discount rates were benchmarked with reference to the implied rate of return from the transaction model and the weighted average cost of capital and then adjusted to reflect the relative risk of the asset.

The excess of the purchase price over the tangible assets, identifiable intangible assets and assumed liabilities was recorded as goodwill. As a result of the acquisition of Attune Medical, the Company recognized goodwill of $70.3 million based on expected synergies from integration into our Hospital business. The goodwill is not deductible for tax purposes and relates entirely to the Hospital reportable segment.

Intangible assets acquired consist of the following:
(In thousands)AmountWeighted-Average Amortization PeriodRisk-Adjusted Discount
Rates used in Purchase Price Allocation
Developed technology$96,100 10 years22.0 %
Customer contracts and related relationships7,800 10 years21.5 %
Trade names1,900 10 years21.5 %
Total$105,800 

The Company recorded a long-term net deferred tax liability of $26.2 million primarily related to fair value adjustments recorded associated with definite-lived intangible assets and inventory in which there is no tax basis, partially offset by deferred tax assets primarily related to net operating losses acquired.

Acquisition-Related Costs

The Company incurred $9.8 million of acquisition-related costs during the first quarter of fiscal 2025 in connection with the Attune Medical acquisition. These costs related to legal and other professional fees, which were recognized in selling, general and administrative on the Condensed Consolidated Statements of Income.

The Company’s condensed consolidated financial statements include the results of Attune Medical from the date the acquisition was completed. Pro forma financial information has not been presented as the acquisition is not material to the Company’s overall financial results.

OpSens Inc.

On October 10, 2023, the Company entered into an Arrangement Agreement with OpSens Inc. (“OpSens”), a medical device cardiology-focused company delivering solutions based on its proprietary optical technology, pursuant to which, among other things, the Company agreed to acquire all of the issued and outstanding common shares of OpSens. On December 12, 2023, the Company completed its acquisition of OpSens for total consideration of approximately $254.5 million, or $243.9 million, net of cash acquired. The Company financed the acquisition through a combination of cash on hand and borrowings under its senior unsecured revolving credit facility.

OpSens offers commercially and clinically validated optical technology for use primarily in interventional cardiology. OpSens’ core products include the SavvyWire®, a sensor-guided 3-in-1 guidewire for TAVR procedures, advancing the workflow of the procedure and enabling potentially shorter hospital stays for patients; and the OptoWire®, a pressure guidewire that aims to improve clinical outcomes by accurately and consistently measuring Fractional Flow Reserve (FFR) and diastolic pressure ratio (dPR) to aid clinicians in the diagnosis and treatment of patients with coronary artery disease. OpSens also manufactures a range of fiber optic sensor solutions used in medical devices and other critical industrial applications. The addition of OpSens expands the Hospital business unit portfolio in the interventional cardiology market and is included in the Hospital reportable segment.

10
Purchase Price Allocation

The Company accounted for the acquisition as a business combination, and in accordance with FASB ASC Topic 805, Business Combinations (Topic 805), recorded the assets acquired and liabilities assumed at their fair values as of the acquisition date. The fair value of assets acquired and liabilities assumed have been recognized based on management’s estimates and assumptions using the information regarding facts and circumstances that existed at the closing date.

The purchase price of $243.9 million, net of $10.6 million of cash acquired, consists of the amounts presented below, which represent the final determination of the fair value of the identifiable assets acquired and liabilities assumed:

(In thousands) December 12, 2023
Accounts receivable$5,960 
Inventories12,075 
Prepaid expenses and other current assets2,062 
Property, plant and equipment3,028 
Intangible assets172,000 
Goodwill79,400 
Other long-term assets4,705 
Total assets acquired$279,230 
Accounts payable3,251 
Accrued payroll and related costs1,723 
Other liabilities9,746 
Deferred tax liability14,805 
Other long-term liabilities5,853 
Total liabilities assumed$35,378 
Net assets acquired$243,852 

The Company determined that the identifiable intangible assets were developed technology, customer contracts and related relationships and trade names. The fair values of intangible assets were based on valuation techniques with estimates and assumptions developed by the Company. Developed technology and customer contracts and related relationships were valued using the excess earnings method. Trademarks were valued using the relief from royalty method. The cash flows used in the valuation of the intangible assets were based on estimates used to price the transaction. In developing the discount rates applied to the cash flow projections, the discount rates were benchmarked with reference to the implied rate of return from the transaction model and the weighted average cost of capital and then adjusted to reflect the relative risk of the asset.

The excess of the purchase price over the tangible assets, identifiable intangible assets and assumed liabilities was recorded as goodwill. As a result of the acquisition of OpSens, the Company recognized goodwill of $79.4 million based on expected synergies from integration into our Hospital business. The goodwill is not deductible for tax purposes and relates entirely to the Hospital reportable segment.

Intangible assets acquired consist of the following:
(In thousands)AmountWeighted-Average Amortization PeriodRisk-Adjusted Discount
Rates used in Purchase Price Allocation
Developed technology$114,900 15 years20.5 %
Customer contracts and related relationships52,300 15 years18.9 %
Trade names4,800 15 years20.5 %
Total$172,000 

The Company recorded a net long-term deferred tax liability of $14.8 million, primarily as a result of fair value adjustments recorded associated with definite-lived intangible assets and inventory in which there is no tax basis.

11
Acquisition-Related Costs

The Company incurred $6.6 million of acquisition-related costs for fiscal 2024 in connection with the OpSens acquisition. These costs related to legal and other professional fees, which were recognized in selling, general and administrative on the Condensed Consolidated Statements of Income.

The Company’s condensed consolidated financial statements include the results of OpSens from the date the acquisition was completed. Pro forma financial information has not been presented as the acquisition is not material to the Company’s overall financial results.

Divestiture of the Whole Blood Product Line

On December 3, 2024, the Company announced that it had entered into a definitive agreement to sell its Whole Blood product line and related assets within its Blood Center business unit to GVS, S.p.A (“GVS”), a manufacturer of filter solutions for applications in the healthcare and life sciences sectors. The divested assets include the Company’s complete portfolio of proprietary whole blood collection, processing and filtration solutions, along with the Company’s manufacturing facility in Covina, California where certain of these products are produced, and related equipment and assets located at the Company’s manufacturing facility in Tijuana, Mexico. On January 13, 2024, subsequent to the third quarter ended December 28, 2024, the Company completed the transaction with GVS for total cash consideration of up to $67.8 million, which includes $45.3 million upfront and up to $22.5 million in contingent consideration, based on sales growth over the next three years and the achievement of certain other milestones. As the related assets are considered held for sale as of December 28, 2024, the Company has reclassified $34.7 million of inventory, $7.3 million of property, plant and equipment, $4.5 million of goodwill and $0.5 million of accrued liabilities to Prepaid expenses and other current assets and other current liabilities in the Condensed Consolidated Balance Sheets, which were previously included in the Blood Center reportable segment.

Strategic Investments

As part of the Company’s business development activities, it holds strategic investments in certain entities. As of December 28, 2024, the Company has made total investments in Vivasure Medical LTD (“Vivasure”) of €35 million. The investments include both preferred stock and a special share that allows the Company to acquire Vivasure in accordance with an agreement between the parties. In addition, the Company made certain other strategic investments totaling $14.0 million and $7.6 million during fiscal 2025 and 2024, respectively. The Company’s strategic investments are classified as other long-term assets on the Company’s Condensed Consolidated Balance Sheets and the Company has not recorded any material adjustments to the carrying value of the Company’s strategic investments during three and nine months ended December 28, 2024 and December 30, 2023.

4. REVENUE

As of December 28, 2024, the Company had $33.3 million of transaction price allocated to remaining performance obligations related to executed contracts with an original duration of one year or more. The Company expects to recognize approximately 75% of this amount as revenue within the next twelve months and the remaining balance thereafter.

Contract Balances

The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables and contract assets, as well as customer advances, customer deposits and deferred revenue (contract liabilities) on the Condensed Consolidated Balance Sheets. The difference in timing between billing and revenue recognition primarily occurs in software licensing arrangements, resulting in contract assets and contract liabilities.

As of December 28, 2024 and March 30, 2024, the Company had contract liabilities of $35.6 million and $31.2 million, respectively. During the three and nine months ended December 28, 2024, the Company recognized $4.9 million and $26.7 million of revenue, respectively, that was included in the above March 30, 2024 contract liability balance. Contract liabilities are classified as other current liabilities on the Condensed Consolidated Balance Sheet. As of December 28, 2024 and March 30, 2024, the Company’s contract assets were immaterial.

12
5. RESTRUCTURING

On an ongoing basis, the Company reviews the global economy, the healthcare industry, and the markets in which it competes to identify opportunities for efficiencies, enhance commercial capabilities, align its resources and offer its customers better solutions. In order to realize these opportunities, the Company undertakes restructuring-type activities to transform its business.


Operational Excellence Program

In July 2019, the Board of Directors of the Company approved the Operational Excellence Program (the “2020 Program”) and delegated authority to the Company’s management to determine the detail of the initiatives that will comprise the program. During fiscal 2022, the Company revised the program to improve product and service quality, reduce cost principally in its manufacturing and supply chain operations and ensure sustainability while helping to offset impacts from a previously announced customer loss, rising inflationary pressures and effects of the COVID-19 pandemic. The Company expects to incur aggregate charges of approximately $85.0 million by the end of fiscal 2025 under the program. The majority of charges will result in cash outlays, including severance and other employee costs, and will be incurred as the specific actions required to execute these initiatives are identified and approved. During the three and nine months ended December 28, 2024, the Company incurred $1.9 million and $6.0 million, respectively, of restructuring and restructuring related costs under this program. During the three and nine months ended December 30, 2023, the Company incurred $2.6 million and $6.8 million, respectively, of restructuring and restructuring related costs under this program. Total cumulative charges under this program are $83.0 million through December 28, 2024.

Portfolio Rationalization Initiatives

In November 2023, the Company announced its plans to end of life the ClotPro analyzer system within the Hospital business unit and certain products within the Blood Center business unit, primarily in Whole Blood, including the associated manufacturing operations and closure of certain other facilities. In the three and nine months ended December 28, 2024, the Company incurred $3.1 million and $12.5 million of expenses, respectively, of restructuring and restructuring related costs in connection with these portfolio rationalization initiatives. In both the three and nine months ended December 30, 2023, the Company incurred $7.8 million of restructuring and related costs related to these portfolio rationalization initiatives.

The following table summarizes the activity for restructuring reserves related to the portfolio rationalization initiatives and the 2020 Program for the nine months ended December 28, 2024, which relates to employee severance, other employee costs, inventory reserves and lease termination fees:
(In thousands)Portfolio Rationalization2020 ProgramTotal
Balance at March 30, 2024
$11,309 $485 $11,794 
Costs incurred, net of reversals12,296 633 12,929 
Payments(10,837)(652)(11,489)
Non-cash adjustments(8,616)— (8,616)
Balance at December 28, 2024
$4,152 $466 $4,618 

The following presents the restructuring costs by line item within our accompanying unaudited Condensed Consolidated Statements of Income and Comprehensive Income:
 Three Months EndedNine Months Ended
(In thousands) December 28,
2024		December 30,
2023		December 28,
2024		December 30,
2023
Cost of goods sold$3,027 $7,065 $11,158 $7,329 
Research and development(4)343 (16)343 
Selling, general and administrative expenses492 560 1,787 371 
Total$3,515 $7,968 $12,929 $8,043 

As of December 28, 2024, the Company had a restructuring liability of $4.6 million, all of which is payable within the next twelve months.

13
In addition to the restructuring expenses included in the table above, the Company also incurred costs that do not constitute restructuring costs under ASC 420, Exit and Disposal Cost Obligations, and which the Company instead refers to as restructuring related costs. These costs consist primarily of expenditures directly related to the restructuring actions.

The tables below present restructuring and restructuring related costs by reportable segment:
Restructuring costsThree Months EndedNine Months Ended
(In thousands) December 28, 2024December 30, 2023December 28, 2024December 30, 2023
Plasma$77 $33 $284 $(164)
Blood Center685 4,546 4,241 4,546 
Hospital774 2,503 1,404 2,745 
Corporate1,979 886 7,000 916 
Total$3,515 $7,968 $12,929 $8,043 
Restructuring related costsThree Months EndedNine Months Ended
(In thousands) December 28, 2024December 30, 2023December 28, 2024December 30, 2023
Plasma$37 $72 $263 $315 
Blood Center31 93 120 166 
Hospital(68)251 40 398 
Corporate1,468 1,987 5,134 5,675 
Total$1,468 $2,403 $5,557 $6,554 
Total restructuring and restructuring related costs$4,983 $10,371 $18,486 $14,597 

6. INCOME TAXES

The Company conducts business globally and reports its results of operations in a number of foreign jurisdictions in addition to the United States. The Company’s reported tax rate differs from the statutory tax rate due to the jurisdictional mix of earnings in any given period as the foreign jurisdictions in which it operates have tax rates that differ from the U.S. statutory tax rate. The Company’s effective tax rate is adversely impacted by non-deductible expenses including executive compensation and transaction costs.

For the three and nine months ended December 28, 2024, the Company reported income tax expense of $12.4 million and $31.6 million, respectively, representing effective tax rates of 24.9% and 22.4%. The effective tax rate for the nine months ended December 28, 2024 includes $3.3 million of discrete tax benefit, primarily related to stock compensation windfalls. The discrete benefit also includes other items such as provision to return differences.

For the three and nine months ended December 30, 2023, the Company reported income tax expense of $12.8 million and $31.3 million, respectively, representing effective tax rates of 29.0% and 24.3%, respectively. The effective tax rate for the nine months ended December 30, 2023 includes $1.1 million of discrete tax benefit, of which $2.6 million relates to stock compensation windfalls, partially offset by other discrete items.

The decrease in the reported tax rate for the three months ended December 28, 2024, compared to the same period in fiscal 2024, relates primarily to the decrease in non-deductible acquisition-related expenses. The decrease in the reported tax rate for the nine months ended December 28, 2024, compared to the same period in fiscal 2024, relates primarily to increased discrete tax benefits year-over-year and decreased non-deductible acquisition-related expenses.


14
7. EARNINGS PER SHARE

The following table provides a reconciliation of the numerators and denominators of the basic and diluted earnings per share computations.
 Three Months EndedNine Months Ended
 (In thousands, except per share amounts)December 28,
2024		December 30,
2023		December 28,
2024		December 30,
2023
Basic EPS  
Net income$37,494 $31,241 $109,698 $97,191 
Weighted average shares50,286 50,768 50,709 50,679 
Basic income per share$0.75 $0.62 $2.16 $1.92 
Diluted EPS    
Net income$37,494 $31,241 $109,698 $97,191 
Basic weighted average shares50,286 50,768 50,709 50,679 
Net effect of common stock equivalents353 677 439 715 
Diluted weighted average shares50,639 51,445 51,148 51,394 
Diluted income per share$0.74 $0.61 $2.14 $1.89 

Basic earnings per share is calculated using the Company’s weighted-average outstanding common shares. Diluted earnings per share is calculated using its weighted-average outstanding common shares including the dilutive effect of stock awards as determined under the treasury stock method and the outstanding convertible senior notes as determined under the net share settlement method. From the time of the issuance of the convertible senior notes, the average market price of the Company's common shares has been less than the applicable initial conversion prices, and consequently no shares have been included in diluted earnings per share for the conversion values of both convertible senior notes. For the three and nine months ended December 28, 2024, weighted average shares outstanding, assuming dilution, excludes the impact of $0.8 million anti-dilutive shares for both periods. For the three and nine months ended December 30, 2023, weighted average shares outstanding, assuming dilution, excludes the impact of $0.6 million anti-dilutive shares for both periods.

Share Repurchase Program

In August 2022, the Company announced that its Board of Directors had approved a three-year share repurchase program authorizing the repurchase of up to $300.0 million of Haemonetics common stock, based on market conditions, through August 2025. Under the share repurchase program, the Company is authorized to repurchase, from time to time, outstanding shares of common stock in accordance with applicable laws on the open market, including under trading plans established pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and in privately negotiated transactions. The actual timing, number and value of shares repurchased will be determined by the Company at its discretion and will depend on a number of factors, including market conditions, applicable legal requirements and compliance with the terms of loan covenants. The share repurchase program may be suspended, modified or discontinued at any time, and the Company has no obligation to repurchase any amount of its common stock under the program.

In October 2024, the Company completed a $75.0 million repurchase of its common stock pursuant to an accelerated share repurchase agreement (“ASR”) entered into with Citibank N.A. (“Citibank”) in August 2024. The total number of shares repurchased under the ASR was 1.0 million at an average price per share upon final settlement of $74.36. As of December 28, 2024, the total remaining authorization for repurchases of the Company's common stock under the share repurchase program was $150.0 million.

15
8. INVENTORIES

Inventories are stated at the lower of cost or net realizable value and include the cost of material, labor and manufacturing overhead. Cost is determined with the first-in, first-out method.
(In thousands)December 28,
2024		March 30,
2024
Raw materials$101,989 $134,150 
Work-in-process32,120 15,488 
Finished goods225,505 167,564 
Total inventories$359,614 $317,202 

In the third quarter of fiscal 2025, the Company announced the divestiture of its Whole Blood product line within its Blood Center business unit and all related assets and liabilities were recognized as held for sale. The related inventory has a value of $34.7 million, which has been reclassified to Prepaid expenses and other current assets in the Condensed Consolidated Balance Sheets.


9. PROPERTY, PLANT AND EQUIPMENT

(In thousands)December 28,
2024		March 30,
2024
Land$1,999 $4,130 
Building and building improvements107,665 124,338 
Plant equipment and machinery191,063 204,622 
Office equipment and information technology129,123 129,979 
Haemonetics equipment412,561 456,414 
Construction in progress25,046 39,694 
Total867,457 959,177 
Less: accumulated depreciation(581,350)(647,815)
Property, plant and equipment, net$286,107 $311,362 

During the three and nine months ended December 28, 2024, depreciation expense was $15.2 million and $44.8 million, respectively. During the three and nine months ended December 30, 2023, depreciation expense was $14.2 million and $41.1 million, respectively.

In the third quarter of fiscal 2025, the Company announced the divestiture of its Whole Blood product line within its Blood Center business unit and all related assets and liabilities were recognized as held for sale. The related property, plant and equipment has a gross value of $39.8 million and a net carrying value of $7.3 million, which has been reclassified to Prepaid expenses and other current assets in the Condensed Consolidated Balance Sheets.

In the first quarter of fiscal 2025, the Company received $19.9 million of cash upon the sale of a manufacturing facility and related assets that previously met held for sale criteria, which resulted in a gain of $14.1 million that was recorded in selling, general and administrative expenses on the Condensed Consolidated Statements of Income.

10. LEASES

Lessor Activity
16

Assets on the Company’s balance sheet classified as Haemonetics equipment primarily consist of medical devices installed at customer sites but owned by Haemonetics. These devices are leased to customers under contractual arrangements that typically include an operating or sales-type lease as well as the purchase and consumption of a certain level of disposable products. Sales-type leases are not significant. Contract terms vary by customer and may include options to terminate the contract or options to extend the contract. Where devices are provided under operating lease arrangements, a substantial majority of the entire lease revenue is variable and subject to subsequent non-lease component (disposable products) sales. The allocation of revenue between the lease and non-lease components is based on estimated stand-alone selling prices. Operating lease revenue represents less than 3 percent of the Company’s total net sales.

11. GOODWILL AND INTANGIBLE ASSETS

The changes in the carrying amount of goodwill by operating segment for fiscal 2025 are as follows:
(In thousands)PlasmaBlood CenterHospitalTotal
Carrying amount as of March 30, 2024
$29,043 $33,484 $502,555 $565,082 
Assets held for sale— (4,475)— (4,475)
Purchase accounting adjustments— — (19,248)(19,248)
Acquisitions— — 69,542 69,542 
Currency translation— (268)(5,367)(5,635)
Carrying amount as of December 28, 2024
$29,043 $28,741 $547,482 $605,266 
The decrease in goodwill of $19.2 million for purchase accounting adjustments was primarily related to the Company obtaining additional facts and information to finalize the pre-acquisition tax returns and associated analyses for OpSens. This resulted in the Company revising its estimate of the net deferred tax liability recorded as of the acquisition date. Refer to Note 3, Acquisitions, Divestitures and Strategic Investments, for additional information regarding the acquisitions of OpSens and Attune Medical.
In the third quarter of fiscal 2025, the Company announced the divestiture of its Whole Blood product line within its Blood Center business unit and all related assets and liabilities were recognized as held for sale. The related goodwill of $4.5 million has been reclassified to Prepaid expenses and other current assets in the Condensed Consolidated Balance Sheets.

The gross carrying amount of intangible assets and the related accumulated amortization as of December 28, 2024 and March 30, 2024 is as follows:
(In thousands)Gross Carrying
Amount		Accumulated
Amortization		Net
As of December 28, 2024
  
Amortizable:
Developed technology$505,323 $146,898 $358,425 
Customer contracts and related relationships136,181 70,261 65,920 
Capitalized software85,528 74,722 10,806 
Patents and other27,504 13,579 13,925 
Trade names15,927 6,136 9,791 
Total$770,463 $311,596 $458,867 
Non-amortizable:
In-process software development$6,748 
Total$6,748 
17
(In thousands)Gross Carrying
Amount		Accumulated
Amortization		Net
As of March 30, 2024
  
Amortizable:
Developed technology$464,291 $178,413 $285,878 
Customer contracts and related relationships255,144 190,033 65,111 
Capitalized software84,837 69,491 15,346 
Patents and other24,504 11,820 12,684 
Trade names14,320 5,456 8,864 
Total$843,096 $455,213 $387,883 
Non-amortizable:
In-process research and development$13,667 
In-process software development4,567 
Total$18,234 

During fiscal 2025, the Company acquired Attune Medical and recorded $96.1 million of developed technology, $7.8 million of customer contracts and related relationships and $1.9 million of trade name intangibles based on the purchase accounting valuation. Refer to Note 3, Acquisitions, Divestitures and Strategic Investments, for additional information regarding the acquisition.

In the first quarter of fiscal 2025, the Company announced the commercialization of MVP XL and moved the related in-process research and development intangible asset to developed technologies and commenced amortization. In the second quarter of fiscal 2024, the Company recorded an intangible asset impairment charge of $10.4 million related to the intangibles acquired as part of the enicor GmbH acquisition completed in fiscal 2021 within the Hospital business unit.

In the third quarter of fiscal 2025, the Company announced the divestiture of its Whole Blood product line within its Blood Center business unit and all related assets and liabilities were recognized as held for sale. The related intangible assets are fully amortized and have a net book value of zero. The gross intangible assets value is $185.6 million.

Intangible assets include the value assigned to license rights and other developed technology, patents, customer contracts and relationships and trade names. The estimated useful lives for all of these intangible assets are approximately 5 to 15 years.

During the three and nine months ended December 28, 2024, amortization expense was $13.9 million and $42.6 million, respectively. During the three and nine months ended December 30, 2023, amortization expense was $9.3 million and $28.5 million, respectively.

Future annual amortization expense on intangible assets for the next five years is estimated to be as follows:
(In thousands)
Remainder of Fiscal 2025$12,995 
Fiscal 2026$49,879 
Fiscal 2027$47,931 
Fiscal 2028$46,160 
Fiscal 2029$44,965 

18
12. NOTES PAYABLE AND LONG-TERM DEBT

Notes payable and long-term debt consisted of the following:
(In thousands)December 28, 2024March 30, 2024
Convertible notes$982,731 $494,813 
Term loan, net of financing fees241,266 261,971 
Revolving credit facility— 50,000 
Other borrowings840 1,009 
Less: current portion(5,075)(10,229)
Long-term debt$1,219,762 $797,564 

Convertible Senior Notes

2026 Notes

In March 2021, the Company issued $500.0 million aggregate principal amount of 0% convertible senior notes due 2026 (the “2026 Notes”). The 2026 Notes are governed by the terms of the Indenture between the Company and U.S. Bank National Association, as trustee. The 2026 Notes will mature on March 1, 2026, unless earlier converted, redeemed or repurchased. In the first quarter of fiscal 2025, the Company repurchased $200.0 million of the aggregate principal amount for $185.5 million, resulting in a gain of $14.5 million related to the discount on repurchase. As the repurchase of the 2026 Notes met the criteria for extinguishment accounting, $1.9 million of unamortized debt issuance costs were allocated to the repurchase, resulting in a net gain of $12.6 million, which was recorded in Interest and other income (expense), net on the Condensed Consolidated Statements of Income.

During the third quarter of fiscal 2025, the conditions allowing holders of the 2026 Notes to convert have not been met. The 2026 Notes were therefore not convertible as of December 28, 2024 and were classified as long-term debt on the Company’s Condensed Consolidated Balance Sheets.

As of December 28, 2024, the $300.0 million principal balance was netted down by $1.9 million of remaining debt issuance costs, resulting in a net convertible note payable of $298.1 million. Interest expense related to the 2026 Notes was $0.4 million and $1.4 million for the three and nine months ended December 28, 2024, respectively, which is entirely attributable to the amortization of the debt issuance costs. The remaining debt issuance costs are amortized at an effective interest rate of 0.5%.

2029 Notes

On May 28, 2024, the Company issued $700.0 million aggregate principal amount of 2.5% convertible senior notes due 2029 (the “2029 Notes”). The 2029 Notes are governed by the terms of the Indenture between the Company and U.S. Bank National Association, as trustee. The total net proceeds from the sale of the 2029 Notes, after deducting the initial purchasers’ discounts and debt issuance costs, were $682.8 million, with a portion of funds used to repay the entirety of the balance on the revolving credit facility under the Company’s second amended and restated credit agreement, to repurchase a portion of the Company’s 2026 Notes, to complete capped call transactions in connection with the issuance of the 2029 Notes, as described further below, with the remaining proceeds available for other working capital requirements. The 2029 Notes will mature on June 1, 2029, unless earlier converted, redeemed or repurchased.

Holders may convert their notes at their option at any time prior to the close of business on the business day immediately preceding December 1, 2028 only under the following circumstances:

•During any calendar quarter (and only during such calendar quarter) beginning after September 30, 2024, if, the last reported sale price per share of the Company’s common stock exceeds 130% of the applicable conversion price on each applicable trading day for at least 20 trading days (whether or not consecutive) in the period of the 30 consecutive trading day period ending on, and including, the last trading day of the immediately preceding calendar quarter;

•During the five business day period after any five consecutive trading day period in which, for each day of that period, the trading price per $1,000 principal amount of the 2029 Notes for such trading day was less than 98% of the product of the last reported sale price of the Company’s common stock and the applicable conversion rate on such trading day;

19
•The Company issues to common stockholders any rights, options, or warrants, entitling them, for a period of not more than 60 days, to purchase shares of common stock at a price per share less than the average closing sale price of 10 consecutive trading days, or the Company’s election to make a distribution to common stockholders exceeding 10% of the previous day’s closing sale price;

•Upon the occurrence of specified corporate events, as set forth in the indenture governing the 2029 Notes; or

•Prior to the related redemption date if the Company calls the 2029 Notes for redemption.

On or after December 1, 2028, until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert all or a portion of their 2029 Notes, in multiples of $1,000 principal amount, at any time, regardless of the foregoing circumstances. The conversion rate for the 2029 Notes is 8.5385 shares of common stock per $1,000 principal amount of notes (which is equal to an initial conversion price of approximately $117.12 per share of the Company’s common stock), subject to adjustment as set forth in the Indenture. Upon conversion, the Company will pay cash up to the aggregate principal amount of the notes to be converted and pay or deliver, as the case may be, cash, common stock or a combination of cash and common stock, at the Company’s election, in respect of the remainder, if any, of the Company’s conversion obligation in excess of the aggregate principal amount of the notes being converted. If a make-whole adjustment event, as described in the Indenture, occurs and a holder elects to convert its 2029 Notes in connection with such make-whole adjustment event, such holder may be entitled to an increase in the conversion rate as described in the Indenture.

During the third quarter of fiscal 2025, the conditions allowing holders of the 2029 Notes to convert have not been met. The 2029 Notes were therefore not convertible as of December 28, 2024 and were classified as long-term debt on the Company’s consolidated balance sheets.

The 2029 Notes will be redeemable, in whole or in part, at the Company’s option at any time, and from time to time, on or after June 5, 2027 and on or before the 50th scheduled trading day immediately before the maturity date, if the last reported sale price per share of the Company’s common stock exceeds 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive), including the trading day immediately preceding the date on which the Company provides notice of redemption, during any 30 consecutive trading day period ending on, and including, the trading day immediately before the date the Company sends the related redemption notice at a redemption price equal to 100% of the principal amount of the 2029 Notes to be redeemed, plus accrued and unpaid interest to, but excluding the redemption date. Upon the occurrence of certain fundamental changes involving the Company, holders of the 2029 Notes may require the Company to repurchase for cash all or part of their 2029 Notes at a repurchase price equal to 100% of the principal amount of the 2029 Notes to be repurchased, plus
accrued and unpaid interest.

As a result of the issuance of the 2029 Notes, the Company recorded debt issuance costs of $17.2 million, which will be amortized to interest expense over the contractual term of the 2029 Notes at an effective interest rate of 3.0%.

As of December 28, 2024, the $700.0 million principal balance was netted down by $15.4 million of remaining debt issuance costs, resulting in a net convertible note payable of $684.6 million. Interest expense related to the 2029 Notes was $5.2 million and $12.1 million for the three and nine months ended December 28, 2024, respectively, which includes nominal interest expense and the amortization of the debt issuance costs.

Capped Calls

In connection with the issuance of the 2029 Notes, the Company entered into capped call transactions with certain counterparties (“Capped Calls”). The Capped Calls each have an initial strike price of approximately $117.12 per share, subject to certain adjustments, which corresponds to the initial conversion price of the 2029 Notes. The Capped Calls have initial cap prices of $180.18 per share, subject to certain adjustments. The Capped Calls are expected to partially offset the potential dilution to the Company’s common stock upon any conversion of the 2029 Notes, with such offset subject to a cap based on the cap price. The Capped Calls cover, subject to anti-dilution adjustments, approximately 5.98 million shares of the Company’s common stock. For accounting purposes, the Capped Calls are separate transactions, and not part of the 2029 Notes. As these transactions meet certain accounting criteria, the Capped Calls are recorded in stockholders’ equity and are not accounted for as derivatives. The cost of $88.2 million incurred to purchase the Capped Calls was recorded as a reduction to additional paid-in capital and will not be remeasured.




20
Credit Facilities

On July 26, 2022, the Company entered into an amended and restated credit agreement to refinance its credit facilities initially entered into in 2018 and extend their maturity date through June 2025. The amended and restated credit agreement provided for a $280.0 million senior unsecured term loan and a $420.0 million senior unsecured revolving credit facility (together, the “2022 Revised Credit Facilities”) with applicable interest rates during the period established using an annual rate equal to the Adjusted Term SOFR Rate plus an applicable rate ranging from 1.125% to 1.750% based on the Company’s consolidated net leverage ratio, as specified in the agreement.

On April 30, 2024, the Company entered into a second amended and restated credit agreement with certain lenders to refinance the 2022 Revised Credit Facilities and extend their maturity date through April 2029. The second amended and restated credit agreement provides for a $250.0 million senior unsecured term loan, the proceeds of which, along with $12.5 million of cash on hand, were used to retire the balance of the term loan under the 2022 Revised Credit Facilities, and a $750.0 million senior unsecured revolving credit facility (together, the “2024 Revised Credit Facilities”). Loans under the 2024 Revised Credit Facilities bear interest at an annual rate equal to the Adjusted Term SOFR Rate (as specified in the second amended and restated credit agreement), which is subject to a floor of 0.0%, plus an applicable rate ranging from 1.125% to 1.750% based on the Company’s consolidated net leverage ratio (as specified in the second amended and restated credit agreement) at the applicable measurement date. The revolving credit facility carries an unused fee that ranges from 0.125% to 0.250% annually based on the Company’s consolidated net leverage ratio at the applicable measurement date. The 2024 Revised Credit Facilities mature on April 30, 2029. The principal amount of the term loan under the 2024 Revised Credit Facilities amortizes quarterly through the maturity date at a rate of 2.5% for the first three years following the closing date, 5.0% for the fourth year following the closing date and 7.5% for the fifth year following the closing date, with the unpaid balance due at maturity.

Under the 2024 Revised Credit Facilities, the Company is required to maintain a consolidated leverage ratio not to exceed 4.0:1.0 or, on up to two occasions during the term of the facility, 4.5:1.0 for the four consecutive fiscal quarters ended immediately following acquisitions meeting certain criteria specified in the agreement.

The Company applied modification accounting for the credit facility refinancing, which resulted in the capitalization of an additional $5.9 million in lender fees and third-party costs. During the three and nine months ended December 28, 2024, the Company recognized $4.6 million and $16.6 million, respectively, of interest expense and amortization of debt issuance costs related to its credit facilities.

At December 28, 2024, $246.9 million was outstanding under the term loan with an effective interest rate of 6.1%, which was netted down by the $5.6 million of remaining debt discount, resulting in a net note payable of $241.3 million. The Company has scheduled principal payments of $6.3 million required during the 12 months following December 28, 2024. There were no outstanding borrowings under the revolving credit facilities at December 28, 2024. The Company also had $18.0 million of uncommitted operating lines of credit to fund its global operations under which there were no outstanding borrowings as of December 28, 2024.

The Company was in compliance with the consolidated net leverage and interest coverage ratios specified in the 2024 Revised Credit Facilities as well as all other bank covenants as of December 28, 2024.


The future aggregate amount of debt maturities are as follows:
(In thousands)
Remainder of Fiscal 2025$1,597 
Fiscal 2026$306,349 
Fiscal 2027$6,308 
Fiscal 2028$10,999 
Fiscal 2029$17,252 
Thereafter$905,210 

13. FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS

The Company manufactures, markets and sells its products globally. During the three and nine months ended December 28, 2024, 26.1% and 26.0%, respectively, of the Company’s sales were generated outside the U.S. in local currencies. The Company also incurs certain manufacturing, marketing and selling costs in international markets in local currency.

21
Accordingly, earnings and cash flows are exposed to market risk from changes in foreign currency exchange rates relative to the U.S. Dollar, the Company’s reporting currency. The Company has a program in place that is designed to mitigate the exposure to changes in foreign currency exchange rates. That program includes the use of derivative financial instruments to minimize, for a period of time, the impact on its financial results from changes in foreign exchange rates. The Company utilizes foreign currency forward contracts to hedge the anticipated cash flows from transactions denominated in foreign currencies, primarily Japanese Yen and Euro, and to a lesser extent, Swiss Franc and Mexican Peso. This does not eliminate the impact of the volatility of foreign exchange rates. However, because the Company generally enters into forward contracts one year out, rates are fixed for a one-year period, thereby facilitating financial planning and resource allocation.

Designated Foreign Currency Hedge Contracts

All of the Company’s designated foreign currency hedge contracts as of December 28, 2024 and March 30, 2024 were cash flow hedges under ASC 815, Derivatives and Hedging (“ASC 815”). The Company records the effective portion of any change in the fair value of designated foreign currency hedge contracts in other comprehensive income until the related third-party transaction occurs. Once the related third-party transaction occurs, the Company reclassifies the effective portion of any related gain or loss on the designated foreign currency hedge contracts to earnings. In the event the hedged forecasted transaction does not occur, or it becomes probable that it will not occur, the Company will reclassify the amount of any gain or loss on the related cash flow hedge to earnings at that time. The Company had designated foreign currency hedge contracts outstanding in the contract amount of $45.5 million as of December 28, 2024 and $74.0 million as of March 30, 2024. At December 28, 2024, a loss of $1.1 million, net of tax, will be reclassified to earnings within the next twelve months. Substantially all currency cash flow hedges outstanding as of December 28, 2024 mature within twelve months.

Non-Designated Foreign Currency Contracts

The Company manages its exposure to changes in foreign currency on a consolidated basis to take advantage of offsetting transactions and balances. It uses foreign currency forward contracts as a part of its strategy to manage exposure related to foreign currency denominated monetary assets and liabilities. These foreign currency forward contracts are entered into for periods consistent with currency transaction exposures, generally one month. They are not designated as cash flow or fair value hedges under ASC 815. These forward contracts are marked-to-market with changes in fair value recorded to earnings. The Company had non-designated foreign currency hedge contracts under ASC 815 outstanding in the contract amount of $82.7 million as of December 28, 2024 and $39.9 million as of March 30, 2024.

Interest Rate Swaps

Part of the Company’s interest rate risk management strategy includes the use of interest rate swaps to mitigate its exposure to changes in variable interest rates. The Company’s objective in using interest rate swaps is to add stability to interest expense and to manage and reduce the risk inherent in interest rate fluctuations.

To mitigate the interest rate risk on the Company’s senior unsecured term loan, in September 2022, the Company entered into four interest rate swaps, two of which expired in June 2023 and the remaining two were amended and extended in September 2024. The amendment and extension of the two interest rate swaps did not have a material impact on the Condensed Consolidated Financial Statements.

Loans under the 2024 Revised Credit Facilities bear interest at an annual rate equal to the 1-month USD Term SOFR, plus an applicable rate ranging from 1.125% to 1.750% based on the Company’s consolidated net leverage ratio. As a result of the amendment and extension in September 2024, the two modified interest rate swaps have an average blended fixed interest rate of 3.31% plus the applicable rate on approximately 80% of the notional value of the unsecured term loan, until their maturity in April 2029. The Company has determined both of these interest rate swaps are effective and qualify for hedge accounting treatment.

22
The Company held the following interest rate swaps as of December 28, 2024:

Hedged ItemOriginal Notional Amount
Notional Amount as of December 28, 2024
Designation DateEffective DateTermination DateFixed Interest RateEstimated Fair Value Assets (Liabilities)
(In thousands)
1-month USD Term SOFR103,600 103,600 9/27/20249/30/20244/30/20293.32%2,806 
1-month USD Term SOFR102,200 102,200 9/27/20249/30/20244/30/20293.30%3,000 
Total$205,800 $205,800 $5,806 

For the nine months ended December 28, 2024, the Company recorded a gain of $3.4 million, net of tax, in accumulated other comprehensive loss to recognize the effective portion of the fair value of the swaps that qualify as cash flow hedges.

Trade Receivables

In the ordinary course of business, the Company grants trade credit to its customers on normal credit terms. In an effort to reduce its credit risk, the Company (i) establishes credit limits for all customers, (ii) performs ongoing credit evaluations of customers’ financial condition, (iii) monitors the payment history and aging of customers’ receivables, and (iv) monitors open orders against an individual customer’s outstanding receivable balance.

The Company’s allowance for credit losses is maintained for trade accounts receivable based on the expected collectability, the historical collection experience, the length of time an account is outstanding, the financial position of the customer and information provided by credit rating services. The Company has not experienced significant customer payment defaults, or identified other significant collectability concerns.

The following is a roll forward of the allowance for credit losses:

Three Months EndedNine Months Ended
(In thousands)December 28, 2024December 30, 2023December 28, 2024December 30, 2023
Beginning balance$5,912 $5,044 $5,695 $4,932 
Credit loss123 653 339 833 
Write-offs (recoveries)(49)28 (48)(40)
Ending balance$5,986 $5,725 $5,986 $5,725 
23
Other Fair Value Measurements

Fair value is defined as the exit price that would be received from the sale of an asset or paid to transfer a liability, using assumptions that market participants would use in pricing an asset or liability. The fair value guidance establishes the following three-level hierarchy used for measuring fair value:

•Level 1 — Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.
•Level 2 — Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.
•Level 3 — Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.

The Company’s money market funds carried at fair value are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices.

Fair Value of Derivative Instruments

The following table presents the effect of the Company’s derivative instruments designated as cash flow hedges and those not designated as hedging instruments under ASC 815 in its unaudited Condensed Consolidated Statements of Income and Comprehensive Income for the nine months ended December 28, 2024:

Derivative InstrumentsAmount of Gain (Loss) Recognized
in Accumulated Other Comprehensive Loss		Amount of Gain (Loss) Reclassified
from Accumulated Other Comprehensive Loss into
Earnings		Location in
Condensed Consolidated Statements of Income and Comprehensive Income		Amount of Gain Excluded from
Effectiveness
Testing		Location in
Condensed Consolidated Statements of Income and Comprehensive Income
(In thousands)
Designated foreign currency hedge contracts, net of tax$(1,095)$(220)Net revenues, COGS and SG&A$959 Interest and other expense, net
Non-designated foreign currency hedge contracts$— $—  $2,092 Interest and other expense, net
Designated interest rate swaps, net of tax$3,353 $37 Interest and other expense, net$— 

The Company did not have fair value hedges or net investment hedges outstanding as of December 28, 2024 or March 30, 2024. As of December 28, 2024, no material deferred taxes were recognized for designated foreign currency hedges.

ASC 815 requires all derivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. The Company determines the fair value of its derivative instruments using the framework prescribed by ASC 820, Fair Value Measurements and Disclosures, by considering the estimated amount it would receive or pay to sell or transfer these instruments at the reporting date and by taking into account current interest rates, currency exchange rates, current interest rate curves, interest rate volatilities, the creditworthiness of the counterparty for assets, and its creditworthiness for liabilities. In certain instances, the Company may utilize financial models to measure fair value. Generally, the Company uses inputs that include quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; other observable inputs for the asset or liability; and inputs derived principally from, or corroborated by, observable market data by correlation or other means. As of December 28, 2024, the Company has classified its derivative assets and liabilities within Level 2 of the fair value hierarchy prescribed by ASC 815, as discussed below, because these observable inputs are available for substantially the full term of its derivative instruments.

24
The following tables present the fair value of the Company’s derivative instruments as they appear in its Condensed Consolidated Balance Sheets as of December 28, 2024 and March 30, 2024:

(In thousands)Location in Condensed Consolidated
Balance Sheets		As ofAs of
December 28, 2024March 30, 2024
Derivative Assets:   
Designated foreign currency hedge contractsOther current assets$1,186 $1,353 
Non-designated foreign currency hedge contractsOther current assets71 154 
Designated interest rate swapsOther current assets1,734 1,673 
Designated interest rate swapsOther long-term assets4,072 62 
  $7,063 $3,242 
Derivative Liabilities:   
Designated foreign currency hedge contractsOther current liabilities$1,219 $395 
Non-designated foreign currency hedge contractsOther current liabilities347 536 
  $1,566 $931 

Fair Value Measured on a Recurring Basis

Financial assets and financial liabilities measured at fair value on a recurring basis consist of the following as of December 28, 2024 and March 30, 2024.
As of December 28, 2024
(In thousands)Level 1Level 2Level 3Total
Assets   
Money market funds$170,773 $— $— $170,773 
Designated foreign currency hedge contracts— 1,186 — 1,186 
Non-designated foreign currency hedge contracts— 71 — 71 
Designated interest rate swaps— 5,806 — 5,806 
 $170,773 $7,063 $— $177,836 
Liabilities   
Designated foreign currency hedge contracts$— $1,219 $— $1,219 
Non-designated foreign currency hedge contracts— 347 — 347 
Designated interest rate swaps— — — — 
Contingent consideration— — 23,133 23,133 
 $— $1,566 $23,133 $24,699 
As of March 30, 2024
Level 1Level 2Level 3Total
Assets
Money market funds$43,073 $— $— $43,073 
Designated foreign currency hedge contracts— 1,353 — 1,353 
Non-designated foreign currency hedge contracts— 154 — 154 
Designated interest rate swaps— 1,735 — 1,735 
 $43,073 $3,242 $— $46,315 
Liabilities   
Designated foreign currency hedge contracts$— $395 $— $395 
Non-designated foreign currency hedge contracts— 536 — 536 
$— $931 $— $931 
25
Foreign currency hedge contracts - The fair value of foreign currency hedge contracts was measured using significant other observable inputs and valued by reference to over-the-counter quoted market prices for similar instruments. The Company does not believe that the fair value of these derivative instruments differs significantly from the amount that could be realized upon settlement or maturity, or that the changes in fair value will have a significant effect on its results of operations, financial condition or cash flows.

Interest rate swaps - The fair values of interest rate swaps are measured using the present value of expected future cash flows using market-based observable inputs, including credit risk and interest rate yield curves. The Company does not believe that the fair values of these derivative instruments differ significantly from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a significant effect on its results of operations, financial condition or cash flows.

Contingent consideration - The fair value of contingent consideration liabilities is based on significant unobservable inputs, including management estimates and assumptions, and is measured based on the probability-weighted present value of the payments expected to be made. Accordingly, the fair value of contingent consideration has been classified as level 3 within the fair value hierarchy.

The level 3 fair value measurements of contingent consideration liabilities include the following significant unobservable inputs:

Fair Value atValuation Unobservable
(In thousands)December 28, 2024TechniqueInputRange
Revenue-based payments$17,179 Monte Carlo Simulation ModelDiscount rate6.3%
Projected year of payments2025 - 2027
Regulatory-based payment$4,804 Monte Carlo Simulation ModelDiscount rate6.1%
Probability of payment50%
Projected year of payment2026 - 2028
Event-based payment$1,150 Monte Carlo Simulation ModelDiscount rate5.8%
Projected year of payment2028

The fair value of contingent consideration associated with the Attune Medical acquisition was $23.1 million at December 28, 2024. As of December 28, 2024, $1.7 million was included in other current liabilities and $21.4 million was included in other long-term liabilities on the Condensed Consolidated Balance Sheets.

A reconciliation of the change in the fair value of contingent consideration is included in the following table:
(In thousands)
Balance at March 30, 2024
$— 
Acquisition date fair value of contingent consideration25,000 
Purchase accounting adjustments300 
Change in fair value(2,167)
Balance at December 28, 2024
$23,133 

Other Fair Value Disclosures

The fair values of the 2026 Notes and 2029 Notes were $282.0 million and $688.9 million as of December 28, 2024, respectively, which were determined by using the market price on the last trading day of the reporting period and are considered as level 2 in the fair value hierarchy.

The senior unsecured term loan (which is carried at amortized cost), accounts receivable and accounts payable approximate fair value.

26
14. COMMITMENTS AND CONTINGENCIES

The Company is a party to various legal proceedings and claims arising out of the ordinary course of its business. The Company believes that, except for those matters described below, there are no other proceedings or claims pending against it the ultimate resolution of which could have a material adverse effect on its financial condition or results of operations. At each reporting period, management evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, Contingencies, for all matters. Legal costs are expensed as incurred.

In the fourth quarter of fiscal 2021, a putative class action complaint was filed against the Company in the Circuit Court of Cook County, Illinois by Mary Crumpton, on behalf of herself and similarly situated individuals. The Company removed the case to the United States District Court for the Northern District Illinois. See Mary Crumpton v. Haemonetics Corporation, Case No. 1:21-cv-1402. In her complaint, the plaintiff asserts that between June 2017 and August 2018 she donated plasma at a center operated by one of the Company’s customers, that the center required her to scan her fingerprint on a finger scanner that stored her fingerprint to identify her prior to plasma donation, and that the Company’s eQue donor management software sent her biometric information to a Company-owned server to be collected and stored in a manner that violated her rights under the Illinois Biometric Information Privacy Act (“BIPA”). The plaintiff seeks statutory damages, attorneys’ fees and injunctive and equitable relief. In March 2021, the Company moved to dismiss the complaint for lack of personal jurisdiction and concurrently filed a motion to dismiss for failure to state a claim and a motion to stay. In March 2022, the court denied the Company’s motion to dismiss for lack of personal jurisdiction but did not address the merits of the Company’s other positions. In March 2023, the Company filed a second motion to dismiss the complaint, which is pending before the court. During the second quarter of fiscal 2024, the Company entered into a Memorandum of Understanding providing terms that would resolve the litigation and recorded an additional loss contingency related to this matter. In the third quarter of fiscal 2024, the parties requested preliminary court approval of a final settlement agreement, which was granted in February 2024, and the Company recorded an immaterial additional loss contingency related to settlement administration, resulting in an accrual of $8.7 million within other current liabilities in its consolidated balance sheets. In March 2024, notice of the settlement was mailed to class members and the parties are now awaiting the complete administration of the settlement through the third-party administrator. In the first quarter of fiscal 2025, the Company issued payment of the $8.7 million settlement amount following the court’s final approval of the settlement agreement and dismissal of the matter with prejudice.

During the fourth quarter of fiscal 2024, a complaint was filed in the U.S. District Court for the District of Delaware by Knoninklijke Philips N.V. and IP2IPO Innovations, Ltd. (together, the “Plaintiffs”) against OpSens, OpSens Medical, Inc., a wholly-owned subsidiary of OpSens, and Haemonetics (1:24-cv-00206-CFC). The complaint alleges, inter alia, that OpSens’ interventional cardiology systems, including its OptoWire and OptoMonitor technology, infringe a single patent held by the Plaintiffs and seeks both injunctive relief and damages. The Company believes it has valid and meritorious defenses to the complaint and plans to vigorously defend against the complaint. During the first quarter of fiscal 2025, the Company recorded a loss contingency related to this matter, which did not have a material impact on its Condensed Consolidated Financial Statements.

Product Recall

In August 2023, the Company issued a voluntary recall of certain products within the Whole Blood portion of our Blood Center business unit sold to customers in the U.S. and certain foreign jurisdictions. In fiscal 2024, the Company recorded cumulative charges of $6.8 million related to inventory, returns and customer claims associated with this recall. Substantially all outstanding claims have been paid as of December 28, 2024.

27
15. ACCUMULATED OTHER COMPREHENSIVE LOSS

The components of Accumulated Other Comprehensive Loss, net of tax, are as follows:
(In thousands)Foreign CurrencyDefined Benefit PlansNet Unrealized Gain (Loss) on DerivativesTotal
Balance as of March 30, 2024$(38,274)$1,748 $894 $(35,632)
Other comprehensive income (loss) before reclassifications(1)
(21,943)— 2,257 (19,686)
Amounts reclassified from accumulated other comprehensive loss(1)
— — (183)(183)
Net current period other comprehensive income (loss)(21,943)— 2,074 (19,869)
Balance as of December 28, 2024$(60,217)$1,748 $2,968 $(55,501)
(1) Presented net of income taxes, the amounts of which are insignificant.

16. SEGMENT AND ENTERPRISE-WIDE INFORMATION

The Company determines its reportable segments by first identifying its operating segments, and then by assessing whether any components of these segments constitute a business for which discrete financial information is available and where segment management regularly reviews the operating results of that component. The Company’s reporting structure aligns with its operating structure of three global business units and the information that is regularly reviewed by the Company’s chief operating decision maker.

The Company’s reportable and operating segments are as follows:
•Plasma
•Blood Center
•Hospital

Management measures and evaluates the operating segments based on operating income. Management excludes certain corporate expenses from segment operating income. In addition, certain amounts that management considers to be non-recurring or non-operational are excluded from segment operating income because management evaluates the operating results of the segments excluding such items. Although these amounts are excluded from segment operating income, as applicable, they are included in the reconciliations that follow. Management measures and evaluates the Company’s net revenues and operating income using internally derived standard currency exchange rates that remain constant from year to year; therefore, segment information is presented on this basis.

Selected information by reportable segment is presented below:
Three Months EndedNine Months Ended
(In thousands)December 28,
2024		December 30,
2023		December 28,
2024		December 30,
2023
Net revenues(1)
Plasma$134,389 $147,560 $408,996 $429,694 
Blood Center70,730 73,528 206,373 213,167 
Hospital144,248 116,625 417,038 325,003 
Net revenues in constant currency349,367 337,713 1,032,407 967,864 
Effect of exchange rates(825)(1,463)(2,182)(2,099)
Net revenues$348,542 $336,250 $1,030,225 $965,765 
(1) Beginning in fiscal 2025, the Company integrated service revenue within its three business units. Prior periods were conformed to current presentation.
28
Three Months EndedNine Months Ended
(In thousands)December 28,
2024		December 30,
2023		December 28,
2024		December 30,
2023
Segment operating income
Plasma$70,337 $80,450 $205,902 $234,190 
Blood Center26,955 27,654 76,744 81,244 
Hospital62,114 49,355 175,710 132,132 
Segment operating income159,406 157,459 458,356 447,566 
Corporate expenses (1)
(70,273)(83,694)(214,660)(234,753)
Effect of exchange rates304 (401)267 (879)
Amortization of acquired intangible assets(12,230)(6,911)(36,965)(21,606)
Amortization of fair value inventory step-up(3,341)— (12,319)— 
Integration and transaction costs(244)(4,869)(13,449)(7,768)
Restructuring costs(3,515)(7,968)(12,929)(8,043)
Restructuring related costs(1,468)(2,403)(5,557)(6,554)
Digital transformation costs(4,620)(3,415)(15,823)(10,712)
Write downs of certain assets and PCS2 related charges(4,000)(210)(4,000)(621)
MDR and IVDR costs(1,008)(1,433)(3,125)(4,587)
Litigation-related charges18 (177)(1,057)(6,684)
Impairment of intangible assets— — (2,391)(10,419)
Gain on sale of property, plant and equipment— — 14,134 — 
Operating income$59,029 $45,978 $150,482 $134,940 
(1) Reflects shared service expenses including quality and regulatory, customer and field service, research and development, manufacturing and supply chain, as well as other corporate support functions.

Net revenues by business unit are as follows:
  Three Months EndedNine Months Ended
(In thousands)December 28,
2024		December 30,
2023		December 28,
2024		December 30,
2023
 Plasma$134,224 $147,641 $408,695 $430,056 
Apheresis55,388 52,565 158,814 156,704 
Whole Blood14,957 19,814 46,304 54,537 
 Blood Center70,345 72,379 205,118 211,241 
Interventional Technologies(1)
63,253 43,007 188,220 119,168 
Blood Management Technologies(2)
80,720 73,223 228,192 205,300 
 Hospital143,973 116,230 416,412 324,468 
Net revenues(3)
$348,542 $336,250 $1,030,225 $965,765 
(1) Interventional Technologies includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection product lines of the Hospital business unit.
(2) Blood Management Technologies includes Hemostasis Management, Cell Salvage and Transfusion Management product lines of the Hospital business unit.
(3) Beginning in fiscal 2025, the Company integrated service revenue within its three business units. Prior periods were conformed to current presentation.
29
Net revenues generated in the Company’s principle operating regions on a reported basis are as follows:
Three Months EndedNine Months Ended
(In thousands)December 28,
2024		December 30,
2023		December 28,
2024		December 30,
2023
United States$257,665 $250,804 $762,628 $724,222 
Japan16,174 14,825 46,303 41,609 
Europe44,163 37,035 133,379 115,088 
Rest of Asia25,597 30,935 71,148 80,710 
Other4,943 2,651 16,767 4,136 
Net revenues$348,542 $336,250 $1,030,225 $965,765 

30
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) should be read in conjunction with both our interim condensed consolidated financial statements and notes thereto which appear elsewhere in this Quarterly Report on Form 10-Q and our annual consolidated financial statements, notes thereto and the MD&A contained in our Annual Report on Form 10-K for the fiscal year ended March 30, 2024. The following discussion may contain forward-looking statements and should be read in conjunction with the “Cautionary Statement Regarding Forward-Looking Information” in this discussion.

Introduction

Haemonetics is a global healthcare company dedicated to providing a suite of innovative medical technology solutions that improve the quality, effectiveness and efficiency of care. We challenge ourselves to think big and make new possibilities a reality, so that our customers can make it matter for patients, every single day. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services.

We view our operations and manage our business in three principal reporting segments: Plasma, Blood Center and Hospital. For that purpose, “Plasma” includes plasma collection devices and disposables, donor management software and supporting software solutions sold to plasma customers. “Blood Center” includes blood collection and processing devices and disposables for red cells, platelets and whole blood. “Hospital” is comprised of Interventional Technologies, which includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection products, and Blood Management Technologies, which includes Hemostasis Management, Cell Salvage and Transfusion Management products.

We believe that Plasma and Hospital have growth potential, while Blood Center competes in challenging markets that require us to manage the business differently, including reducing costs, shrinking the scope of the current product line, and evaluating opportunities to exit unfavorable customer contracts.

Recent Developments

Divestiture of the Whole Blood Product Line

On December 3, 2024, we announced that we had entered into a definitive agreement to sell our Whole Blood product line and related assets within our Blood Center business unit to GVS, S.p.A (“GVS”), a manufacturer of filter solutions for applications in the healthcare and life sciences sectors. The divested assets include our complete portfolio of proprietary whole blood collection, processing and filtration solutions, along with our manufacturing facility in Covina, California where certain of these products are produced, and related equipment and assets located at our manufacturing facility in Tijuana, Mexico. On January 13, 2024, subsequent to the third quarter ended December 28, 2024, we completed the transaction with GVS for total cash consideration of up to $67.8 million, which includes $45.3 million upfront and up to $22.5 million in contingent consideration, based on sales growth over the next three years and the achievement of certain other milestones. As the related assets are considered held for sale as of December 28, 2024, we have reclassified $34.7 million of inventory, $7.3 million of property, plant and equipment, $4.5 million of goodwill and $0.5 million of accrued liabilities to Prepaid expenses and other current assets and Other current liabilities in the Condensed Consolidated Balance Sheets, which were previously included in our Blood Center reportable segment.

Accelerated Share Repurchase

In October 2024, we completed a $75.0 million repurchase of our common stock pursuant to an accelerated share repurchase agreement (“ASR”) entered into with Citibank N.A. (“Citibank”) in August 2024. The total number of shares repurchased under the ASR was 1.0 million at an average price per share upon final settlement of $74.36. As of December 28, 2024, the total remaining authorization for repurchases of our common stock under the share repurchase program was $150.0 million.


31
Issuance of Convertible Senior Notes

On May 28, 2024, we issued $700.0 million aggregate principal amount of 2.5% convertible senior notes due 2029 (the “2029 Notes”). The 2029 Notes are governed by the terms of the Indenture between the Company and U.S. Bank National Association, as trustee. The total net proceeds from the sale of the 2029 Notes, after deducting the initial purchasers’ discounts and debt issuance costs, were $682.8 million, of which $230.0 million was used to repay the entirety of the balance on the revolving credit facility under the Company’s current credit agreement, $185.5 million was used to repurchase a portion of our existing 0% convertible senior notes due 2026 and $88.2 million was used to complete capped call transactions, with the remaining proceeds available for other working capital requirements. The 2029 Notes will mature on June 1, 2029, unless earlier converted, redeemed or repurchased.

Debt Issuance and Repayment

On April 30, 2024, we entered into a second amended and restated credit agreement with certain lenders to refinance our prior credit facilities and extend their maturity date through April 2029. The second amended and restated credit agreement provides for a $250.0 million senior unsecured term loan, the proceeds of which, along with $12.5 million of cash on hand, have been used to retire the balance of the term loan under our prior credit facilities, and a $750.0 million senior unsecured revolving credit facility.

Acquisition of Attune Medical

On April 1, 2024, we completed our acquisition of Advanced Cooling Therapy, Inc., d/b/a Attune Medical (“Attune Medical”) for total consideration of $187.7 million, which included an upfront cash payment of $162.0 million, or $150.5 million net of cash acquired, the fair value of contingent consideration of $25.3 million, and $0.4 million of working capital adjustments. The contingent consideration is based on sales growth over the next three years, which is uncapped, and the achievement of certain other milestones. We financed the acquisition through a combination of cash on hand and borrowings under our senior unsecured revolving credit facility.

Attune Medical's ensoETM technology is designed for use across a range of medical conditions involving patient cooling or warming, including treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery, among others. The addition of our Esophageal Protection product line through this acquisition expands our Hospital business unit’s presence in electrophysiology and complements its Vascular Closure product line within Interventional Technologies, which is included in the Hospital reportable segment.

Financial Summary
 Three Months EndedNine Months Ended
(In thousands, except per share data)December 28,
2024		December 30,
2023		% Increase/ (Decrease)December 28,
2024		December 30,
2023		% Increase/ (Decrease)
Net revenues$348,542 $336,250 3.7 %$1,030,225 $965,765 6.7 %
Gross profit$193,547 $177,867 8.8 %$555,908 $515,642 7.8 %
% of net revenues55.5 %52.9 %54.0 %53.4 %
Operating expenses$134,518 $131,889 2.0 %$405,426 $380,702 6.5 %
Operating income$59,029 $45,978 28.4 %$150,482 $134,940 11.5 %
% of net revenues16.9 %13.7 %14.6 %14.0 %
Interest and other expense, net$(9,112)$(1,949)367.5 %$(9,148)$(6,489)41.0 %
Income before provision for income taxes$49,917 $44,029 13.4 %$141,334 $128,451 10.0 %
Provision for income taxes$12,423 $12,788 (2.9)%$31,636 $31,260 1.2 %
% of pre-tax income24.9 %29.0 %22.4 %24.3 %
Net income$37,494 $31,241 20.0 %$109,698 $97,191 12.9 %
% of net revenues10.8 %9.3 %10.6 %10.1 %
Net income per share - basic$0.75 $0.62 21.0 %$2.16 $1.92 12.5 %
Net income per share - diluted$0.74 $0.61 21.3 %$2.14 $1.89 13.2 %

32
Net revenues increased 3.7% and 6.7% during the three and nine months ended December 28, 2024, respectively, as compared with the same periods of fiscal 2024. Without the effects of foreign exchange, net revenues increased 3.6% and 6.9% during the three and nine months ended December 28, 2024, respectively, as compared with the same periods of fiscal 2024. Revenue increases in Hospital, primarily related to recent acquisitions as well as volume and price benefits, drove the overall increase, partially offset by declines in both Plasma and Blood Center during the three and nine months ended December 28, 2024.

Operating income increased 28.4% and 11.5% during the three and nine months ended December 28, 2024, respectively, as compared with the same periods of fiscal 2024. The increase during the three months ended December 28, 2024 was primarily due to operating leverage, decreased performance-based compensation, decreased portfolio rationalization costs and lower transaction and integration costs, partially offset by increased amortization of acquired intangible assets, write downs of certain assets and costs associated with the operations of recent acquisitions. The increase for the nine months ended December 28, 2024 was primarily due to operating leverage, decreased performance-based compensation and the gains realized on the sale of a manufacturing facility in the first quarter of fiscal 2025, partially offset by operating, transaction and integration costs related to recent acquisitions, increased amortization of acquired intangible assets and amortization of fair value inventory step-up.

Management’s Use of Non-GAAP Measures

Management uses non-GAAP financial measures, in addition to financial measures in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”), to monitor the financial performance of the business, make informed business decisions, establish budgets and forecast future results. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, our reported financial results prepared in accordance with U.S. GAAP. Constant currency growth, a non-GAAP financial measure, measures the change in revenue between the current and prior year periods using a constant currency conversion rate. We have provided this non-GAAP financial measure because we believe it provides meaningful information regarding our results on a consistent and comparable basis for the periods presented.


RESULTS OF OPERATIONS

Net Revenues by Geography
 Three Months Ended
(In thousands)December 28,
2024		December 30,
2023		Reported growthCurrency impact
Constant currency growth (1)
United States$257,665 $250,804 2.7 %— %2.7 %
International90,877 85,446 6.4 %0.1 %6.3 %
Net revenues$348,542 $336,250 3.7 %0.1 %3.6 %
Nine Months Ended
(In thousands)December 28,
2024		December 30,
2023		Reported growthCurrency impact
Constant currency growth (1)
United States$762,628 $724,222 5.3 %— %5.3 %
International267,597 241,543 10.8 %(1.1)%11.9 %
Net revenues$1,030,225 $965,765 6.7 %(0.2)%6.9 %
(1) Constant currency growth, a non-GAAP financial measure, measures the change in revenue between the current and prior year periods using a constant currency. See “Management’s Use of Non-GAAP Measures.”

Our principal operations are in the United States, Europe, Japan and other parts of Asia. Our products are marketed in approximately 90 countries around the world through a combination of our direct sales force and independent distributors and agents. During the three and nine months ended December 28, 2024, our revenue generated outside the U.S. was 26.1% and 26.0% of total net revenues, respectively, as compared with 25.4% and 25.0%, respectively, during the three and nine months ended December 30, 2023. International sales are generally conducted in local currencies, primarily Japanese Yen, Euro and Chinese Yuan. Our results of operations are impacted by changes in foreign exchange rates, particularly in the value of the Yen and Euro relative to the U.S. Dollar. We have placed foreign currency hedges on certain foreign currencies to mitigate our exposure to foreign currency fluctuations.

Please see the section entitled “Foreign Exchange” in this discussion for a more complete explanation of how foreign currency affects our business and our strategy for managing this exposure.
33

Net Revenues by Business Unit
 Three Months Ended
(In thousands)December 28,
2024		December 30,
2023		Reported growthCurrency impact
Constant currency growth(1)
Plasma$134,224 $147,641 (9.1)%— %(9.1)%
Apheresis55,388 52,565 5.4 %— %5.4 %
Whole Blood14,957 19,814 (24.5)%— %(24.5)%
Blood Center70,345 72,379 (2.8)%— %(2.8)%
Interventional Technologies(2)
63,253 43,007 47.1 %(0.4)%47.5 %
Blood Management Technologies(3)
80,720 73,223 10.2 %0.3 %9.9 %
Hospital143,973 116,230 23.9 %0.1 %23.8 %
Net revenues(4)
$348,542 $336,250 3.7 %0.1 %3.6 %
Nine Months Ended
(In thousands)December 28,
2024		December 30,
2023		Reported growthCurrency impact
Constant currency growth(1)
Plasma$408,695 $430,056 (5.0)%— %(5.0)%
Apheresis158,814 156,704 1.3 %(1.4)%2.7 %
Whole Blood46,304 54,537 (15.1)%(0.1)%(15.0)%
Blood Center205,118 211,241 (2.9)%(1.0)%(1.9)%
Interventional Technologies(2)
188,220 119,168 57.9 %(0.4)%58.3 %
Blood Management Technologies(3)
228,192 205,300 11.2 %— %11.2 %
Hospital416,412 324,468 28.3 %(0.2)%28.5 %
Net revenues(4)
$1,030,225 $965,765 6.7 %(0.2)%6.9 %
(1) Constant currency growth, a non-GAAP financial measure, measures the change in revenue between the current and prior year periods using a constant currency. See “Management’s Use of Non-GAAP Measures.”
(2) Interventional Technologies includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection product lines of the Hospital business unit.
(3) Blood Management Technologies includes Hemostasis Management, Cell Salvage and Transfusion Management product lines of the Hospital business unit.
(4) Beginning in fiscal 2025, the Company integrated service revenue within its three business units. Prior periods were conformed to current presentation.

Plasma

Plasma revenue decreased 9.1% and 5.0% during the three and nine months ended December 28, 2024, respectively, as compared with the same periods of fiscal 2024. Without the effects of foreign exchange, Plasma revenue decreased 9.1% and 5.0% during the three and nine months ended December 28, 2024, respectively, as compared with the same periods of fiscal 2024. The decreases during the three and nine months ended December 28, 2024 were primarily driven by lower sales volumes in North America, primarily relating to the previously announced customer transition of CSL Plasma, whose non-exclusive supply agreement with the Company is scheduled to expire in December 2025. We anticipate sales of approximately $100.0 million to CSL in fiscal 2025.


34
Blood Center

Blood Center revenue decreased 2.8% and 2.9% during the three and nine months ended December 28, 2024, respectively, as compared with the same periods of fiscal 2024. Without the effects of foreign exchange, Blood Center revenue decreased 2.8% and 1.9% during the three and nine months ended December 28, 2024, respectively, as compared with the same periods of fiscal 2024. The decreases during the three and nine months ended December 28, 2024 were primarily driven by declines in our Whole Blood business, which was divested in January 2025, subsequent to the end of the third fiscal quarter of 2025.

Hospital

Hospital revenue increased 23.9% and 28.3% during the three and nine months ended December 28, 2024, respectively, as compared with the same periods of fiscal 2024. Without the effects of foreign exchange, Hospital revenue increased 23.8% and 28.5% during the three and nine months ended December 28, 2024, respectively, as compared with the same periods of fiscal 2024. The increases during the three and nine months ended December 28, 2024 were primarily attributable to the product lines within the Interventional Technologies franchise, including benefits from the recently acquired Sensor Guided Technologies and Esophageal Protection product lines and growth in Vascular Closure, as well as contributions from the product lines within the Blood Management Technologies franchise.

Gross Profit
 Three Months EndedNine Months Ended
(In thousands)December 28,
2024		December 30,
2023		% IncreaseDecember 28,
2024		December 30,
2023		% Increase
Gross profit$193,547 $177,867 8.8 %$555,908 $515,642 7.8 %
% of net revenues55.5 %52.9 % 54.0 %53.4 % 

Gross profit increased 8.8% and 7.8% for the three and nine months ended December 28, 2024, respectively, as compared with the same periods of fiscal 2024. Without the effects of foreign exchange, gross profit increased 9.3% and 9.4% during the three and nine months ended December 28, 2024, respectively, as compared with the same periods of fiscal 2024. The increase during the three months ended December 28, 2024 was driven by increased revenues in the Hospital business, primarily volume as well as price, partially offset by the amortization of fair value inventory step-up related to the Attune Medical acquisition. The increase during the nine months ended December 28, 2024 was driven by increased revenues in the Hospital business and volume, mix and price, partially offset by amortization of fair value inventory step-up related to the Attune Medical acquisition, restructuring costs related to portfolio rationalization initiatives and foreign exchange.

Operating Expenses
 Three Months EndedNine Months Ended
(In thousands)December 28,
2024		December 30,
2023		% Increase/
(Decrease)		December 28,
2024		December 30,
2023		% Increase
Research and development$15,829 $13,265 19.3 %$46,808 $38,578 21.3 %
% of net revenues4.5 %3.9 %4.5 %4.0 %
Selling, general and administrative$106,459 $111,713 (4.7)%$321,653 $320,518 0.4 %
% of net revenues30.5 %33.2 %31.2 %33.2 %
Amortization of acquired intangible assets$12,230 $6,911 77.0 %$36,965 $21,606 71.1 %
% of net revenues3.5 %2.1 %3.6 %2.2 %
Total operating expenses$134,518 $131,889 2.0 %$405,426 $380,702 6.5 %
% of net revenues38.6 %39.2 %39.4 %39.4 %

Research and Development

Research and development expenses increased 19.3% and 21.3% during the three and nine months ended December 28, 2024, respectively, as compared with the same periods of fiscal 2024. Without the effects of foreign exchange, research and development expenses increased 19.4% and 21.4% during the three and nine months ended December 28, 2024, respectively, as compared with the same periods of fiscal 2024. The increases during the three and nine months ended December 28, 2024 were primarily due to increased headcount as a result of recent acquisitions.


35
Selling, General and Administrative

Selling, general and administrative expenses decreased 4.7% during the three months ended December 28, 2024 and increased 0.4% during the nine months ended December 28, 2024, as compared with the same periods of fiscal 2024. Without the effects of foreign exchange, selling, general, and administrative expenses decreased 5.0% during the three months ended December 28, 2024 and increased 0.4% during the nine months ended December 28, 2024, as compared with the same periods of fiscal 2024. The decrease during the three months ended December 28, 2024 was driven by decreased performance-based compensation, operating leverage and lower integration and transaction costs, partially offset by write downs of certain assets and costs associated with the operations of recent acquisitions. The increase during the nine months ended December 28, 2024 was primarily driven by digital transformation costs incurred as part of the upgrade of our enterprise resource planning system, transaction, integration and operating costs related to recent acquisitions and increased headcount, partially offset by gains realized on the sale of a manufacturing facility in the first quarter of fiscal 2025, decreases in impairment of intangible assets and decreases in litigation costs compared to the prior year period.

Amortization of Acquired Intangible Assets

We recognized amortization expense related to our acquired intangible assets of $12.2 million and $37.0 million during the three and nine months ended December 28, 2024, respectively, and $6.9 million and $21.6 million during the three and nine months ended December 30, 2023, respectively. The increases were primarily related to the amortization of the intangible assets acquired in conjunction with the recent acquisitions of OpSens and Attune Medical.

Interest and Other Expense, Net

Interest and other expense increased by $7.2 million and $2.7 million during the three and nine months ended December 28, 2024, respectively, as compared with the same periods of fiscal 2024. The increase during the three months ended December 28, 2024, as compared with the prior year period, was primarily driven by interest expense and amortization of deferred financing costs on the 2029 Notes issued in fiscal 2025 and foreign exchange. The increase during the nine months ended December 28, 2024 was primarily driven by interest expense and amortization of deferred financing costs on the 2029 Notes issued in fiscal 2025 as well as higher interest incurred on our revolving credit facilities, as compared with the same period of fiscal 2024, partially offset by the net gain on the repurchase of convertible notes during the first quarter of fiscal 2025.

Income Taxes

We conduct business globally and report our results of operations in a number of foreign jurisdictions in addition to the United States. Our reported tax rate differs from the statutory tax rate due to the jurisdictional mix of earnings in any given period as the foreign jurisdictions in which we operate have tax rates that differ from the U.S. statutory tax rate. Our effective tax rate is adversely impacted by non-deductible expenses including executive compensation and transaction costs.

For the three and nine months ended December 28, 2024, the Company reported income tax expense of $12.4 million and $31.6 million, respectively, representing effective tax rates of 24.9% and 22.4%. The effective tax rate for the nine months ended December 28, 2024 includes $3.3 million of discrete tax benefit, primarily related to stock compensation windfalls. The discrete benefit also includes other items such as provision to return differences.

For the three and nine months ended December 30, 2023, the Company reported income tax expense of $12.8 million and $31.3 million, respectively, representing effective tax rates of 29.0% and 24.3%, respectively. The effective tax rate for the nine months ended December 30, 2023 includes $1.1 million of discrete tax benefit, of which $2.6 million relates to stock compensation windfalls, partially offset by other discrete items.

The decrease in the reported tax rate for the three months ended December 28, 2024, compared to the same period in fiscal 2024, relates primarily to the decrease in non-deductible acquisition-related expenses. The decrease in the reported tax rate for the nine months ended December 28, 2024, compared to the same period in fiscal 2024, relates primarily to increased discrete tax benefits year-over-year and decreased non-deductible acquisition-related expenses.

36
Liquidity and Capital Resources

The following table contains certain key performance indicators we believe depict our liquidity and cash flow position:
(Dollars in thousands)December 28,
2024		March 30,
2024
Cash and cash equivalents$320,846 $178,800 
Working capital$752,635 $468,520 
Current ratio4.0 2.6 
Net debt position(1)
$(903,991)$(628,993)
Days sales outstanding (DSO)55 54 
Inventory turnover1.5 1.7 
(1) Net debt position is the sum of cash and cash equivalents less total debt.

Our primary sources of liquidity are cash and cash equivalents, internally generated cash flow from operations and our senior unsecured revolving credit facility. We believe these sources are sufficient to fund our cash requirements over at least the next twelve months and to meet our known long-term cash requirements, including our convertible senior notes due March 1, 2026. Our expected cash outlays relate primarily to acquisitions, investments, capital expenditures, including enhancements to our North American manufacturing facilities, share repurchases, portfolio rationalization initiatives and cash principal and interest payments under our revised credit agreements. As of December 28, 2024, we had $320.8 million in cash and cash equivalents, the majority of which is held in the U.S. or in countries from which it can be repatriated to the U.S.

In the first quarter of fiscal 2025, the Company used a portion of its proceeds from the 2029 Notes to repurchase, for $185.5 million, $200.0 million of the $500.0 million aggregate principal amount of its 0% convertible senior notes due 2026 (the “2026 Notes”), resulting in a gain of $14.5 million related to the discount on repurchase. As the repurchase of the 2026 Notes met the criteria for extinguishment accounting, $1.9 million of unamortized debt issuance costs were allocated to the repurchase, resulting in a net gain of $12.6 million. As of December 28, 2024, the $300.0 million remaining principal balance on the 2026 Notes was netted down by $1.9 million of remaining debt issuance costs, resulting in a net convertible note payable of $298.1 million. Interest expense related to the 2026 Notes was $0.4 million and $1.4 million for the three and nine months ended December 28, 2024, respectively, which is entirely attributable to the amortization of the debt issuance costs. The remaining debt issuance costs are amortized at an effective interest rate of 0.5%.

As of December 28, 2024, the $700.0 million principal balance of the 2029 Notes was netted down by $15.4 million of remaining debt issuance costs, resulting in a net convertible note payable of $684.6 million. Interest expense related to the 2029 Notes was $5.2 million and $12.1 million for the three and nine months ended December 28, 2024, respectively, which includes nominal interest expense and the amortization of the debt issuance costs.

On July 26, 2022, the Company entered into an amended and restated credit agreement to refinance its credit facilities initially entered into in 2018 and extend their maturity date through June 2025. The amended and restated credit agreement provided for a $280.0 million senior unsecured term loan and a $420.0 million senior unsecured revolving credit facility (together, the “2022 Revised Credit Facilities”) with applicable interest rates during the period established using an annual rate equal to the Adjusted Term SOFR Rate plus an applicable rate ranging from 1.125% to 1.750% based on the Company’s consolidated net leverage ratio, as specified in the agreement.

On April 30, 2024, the Company entered into a second amended and restated credit agreement with certain lenders to refinance the 2022 Revised Credit Facilities and extend their maturity date through April 2029. The second amended and restated credit agreement provides for a $250.0 million senior unsecured term loan, the proceeds of which, along with $12.5 million of cash on hand, were used to retire the balance of the term loan under the 2022 Revised Credit Facilities, and a $750.0 million senior unsecured revolving credit facility (together, the “2024 Revised Credit Facilities”). Loans under the 2024 Revised Credit Facilities bear interest at an annual rate equal to the Adjusted Term SOFR Rate (as specified in the second amended and restated credit agreement), which is subject to a floor of 0.0%, plus an applicable rate ranging from 1.125% to 1.750% based on the Company’s consolidated net leverage ratio (as specified in the second amended and restated credit agreement) at the applicable measurement date. The revolving credit facility carries an unused fee that ranges from 0.125% to 0.250% annually based on the Company’s consolidated net leverage ratio at the applicable measurement date. The 2024 Revised Credit Facilities mature on April 30, 2029. The principal amount of the term loan under the 2024 Revised Credit Facilities amortizes quarterly through the maturity date at a rate of 2.5% for the first three years following the closing date, 5.0% for the fourth year following the closing date and 7.5% for the fifth year following the closing date, with the unpaid balance due at maturity.
37
At December 28, 2024, $246.9 million was outstanding under the term loan with an effective interest rate of 6.1%. There were no outstanding borrowings under the revolving credit facilities at December 28, 2024. The Company also had $18.0 million of uncommitted operating lines of credit to fund its global operations under which there were no outstanding borrowings as of December 28, 2024.

The Company has scheduled principal payments of $1.6 million required during the remainder of fiscal 2025 related to its term loan.

During fiscal 2022, our Board of Directors approved a revised Operational Excellence Program. We estimate that we will incur aggregate charges of approximately $85.0 million by the end of fiscal 2025 under the program in connection with the Operational Excellence Program. These charges, the majority of which will result in cash outlays, including severance and other employee costs, will be incurred as the specific actions required to execute these initiatives are identified and approved and are expected to be substantially completed by the end of fiscal 2025. During the three and nine months ended December 28, 2024, the Company incurred $1.9 million and $6.0 million, respectively, of restructuring and restructuring related costs under this program.

Cash Flows
 Nine Months Ended
(In thousands)December 28,
2024		December 30,
2023
Net cash provided by (used in):  
Operating activities$65,168 $117,670 
Investing activities(179,935)(309,333)
Financing activities260,268 101,659 
Effect of exchange rate changes on cash and cash equivalents(1)
(3,455)(484)
Net change in cash and cash equivalents$142,046 $(90,488)
(1) The balance sheet is affected by spot exchange rates used to translate local currency amounts into U.S. Dollars. In accordance with U.S. GAAP, we have eliminated the effect of foreign currency throughout our cash flow statement, except for its effect on our cash and cash equivalents.

Net cash provided by operating activities decreased by $52.5 million during the nine months ended December 28, 2024, as compared with the nine months ended December 30, 2023. The decrease in cash provided by operating activities was primarily due to decreased accrued performance-based compensation, increased inventory balances and spend related to digital transformation costs incurred as part of the upgrade of our enterprise resource planning system, partially offset by collections of accounts receivable and increased net income.

Net cash used in investing activities decreased by $129.4 million during the nine months ended December 28, 2024, as compared with the nine months ended December 30, 2023. The decrease in cash used in investing activities was primarily the result of the acquisition of OpSens Inc. completed during fiscal 2024 and the proceeds from the sales of property, plant and equipment in fiscal 2025, partially offset by the acquisition of Attune Medical in fiscal 2025.

Net cash provided by financing activities increased by $158.6 million during the nine months ended December 28, 2024, as compared with the nine months ended December 30, 2023, primarily due to the issuance of the 2029 Notes, partially offset by the repurchase of a portion of the 2026 Notes, proceeds on the revolving credit facility in the previous year, capped call transactions, share repurchases, payments on the revolving credit facility in the current year and debt issuance costs.

Concentration of Credit Risk

Concentrations of credit risk with respect to trade accounts receivable are generally limited due to our large number of customers and their diversity across many geographic areas. Certain markets and industries, however, can expose us to concentrations of credit risk. For example, in the Plasma business unit, sales are concentrated with several large customers. As a result, accounts receivable extended to any one of these biopharmaceutical customers can be significant at any point in time. In addition, a portion of our trade accounts receivable outside the U.S. include sales to government-owned or supported healthcare systems in several countries, which are subject to payment delays and local economic conditions. Payment is dependent upon the financial stability and creditworthiness of those countries’ national economies.

We have not incurred significant losses on trade accounts or other receivables. We continually evaluate all receivables for potential collection risks associated with the availability of government funding and reimbursement practices. If the financial
38
condition of customers or the countries’ healthcare systems deteriorate such that their ability to make payments is uncertain, allowances may be required in future periods.

Foreign Exchange

During the three and nine months ended December 28, 2024, 26.1% and 26.0%, respectively, of our sales were generated outside the U.S., generally in foreign currencies, yet our reporting currency is the U.S. Dollar. We also incur certain manufacturing, marketing and selling costs in international markets in local currency. Our primary foreign currency exposures relate to sales denominated in Japanese Yen, Euro and Chinese Yuan. We also have foreign currency exposure related to manufacturing and other operational costs denominated in Swiss Francs, Canadian Dollars, Mexican Pesos and Malaysian Ringgit. The Yen, Euro and Yuan sales exposure is partially mitigated by costs and expenses for foreign operations and sourcing products denominated in foreign currencies.

Since our foreign currency denominated Yen, Euro and Yuan sales exceed the foreign currency denominated costs, whenever the U.S. Dollar strengthens relative to the Yen, Euro or Yuan, there is an adverse effect on our results of operations and, conversely, whenever the U.S. Dollar weakens relative to the Yen, Euro or Yuan, there is a positive effect on our results of operations. For Swiss Francs, Canadian Dollars, Mexican Pesos and Malaysian Ringgit, our primary cash flows relate to product costs or costs and expenses of local operations. Whenever the U.S. Dollar strengthens relative to these foreign currencies, there is a positive effect on our results of operations. Conversely, whenever the U.S. Dollar weakens relative to these currencies, there is an adverse effect on our results of operations.

We have a program in place that is designed to mitigate our exposure to changes in foreign currency exchange rates. That program includes the use of derivative financial instruments to minimize, for a period of time, the unforeseen impact on our financial results from changes in foreign exchange rates. We utilize forward foreign currency contracts to hedge the anticipated cash flows from transactions denominated in foreign currencies, primarily Japanese Yen and Euro, and to a lesser extent Canadian Dollar, Swiss Franc and Mexican Peso. This does not eliminate the volatility of foreign exchange rates, but because we generally enter into forward contracts one year out, rates are fixed for a one-year period, thereby facilitating financial planning and resource allocation. These contracts are designated as cash flow hedges. The final impact of currency fluctuations on the results of operations is dependent on the local currency amounts hedged and the actual local currency results.

Recent Accounting Pronouncements

Refer to Note 2, Recent Accounting Pronouncements, to the Condensed Consolidated Financial Statements for a discussion of recently issued accounting pronouncements.

Cautionary Statement Regarding Forward-Looking Information

Certain statements that we make from time to time, including statements contained in this Quarterly Report on Form 10-Q and incorporated by reference into this report, constitute “forward looking-statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements do not relate strictly to historical or current facts and reflect management’s assumptions, views, plans, objectives and projections about the future. Forward-looking statements may be identified by the use of words such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “predicts,” “foresees,” “potential” and other words of similar meaning in conjunction with, among other things: discussions of future operations; expected operating results and financial performance; the Company’s strategy for growth; product development, commercialization and anticipated performance and benefits; regulatory approvals; impacts of acquisitions or dispositions; and market position and expenditures.

Because forward-looking statements are based on current beliefs, expectations and assumptions regarding future events, they are subject to uncertainties, risks and changes that are difficult to predict and many of which are outside of the Company’s control. Investors should realize that if underlying assumptions prove inaccurate, or known or unknown risks or uncertainties materialize, the Company’s actual results and financial condition could vary materially from expectations and projections expressed or implied in its forward-looking statements. Investors are therefore cautioned not to rely on these forward-looking statements.

The following are some important factors that could cause our actual results to differ from our expectations in any forward-looking statements. For further discussion of these and other factors, see Item 1A. “Risk Factors” in our most recent Annual Report on Form 10-K (as supplemented by Part II, Item 1A. “Risks Factors” of our Quarterly Report on Form 10-Q for the first quarter ended June 29, 2024).
39

•Our ability to achieve our long-term strategic and financial-improvement goals;

•Demand for and market acceptance risks for new and existing products, including material reductions in purchasing from or loss of a significant customer;

•Our ability to develop, manufacture and market new products and technologies successfully and in a timely manner and the ability of our competitors and other third parties to develop products or technologies that render our products or technologies noncompetitive or obsolete;

•Product quality or safety concerns, leading to product recalls, withdrawals, regulatory action by the FDA (or similar non-U.S. regulatory agencies), reputational damage, declining sales or litigation;

•Security breaches of our information technology systems or our products, which could impair our ability to conduct business or compromise sensitive information of the Company or its customers, suppliers and other business partners, or of customers’ patients;

•The potential that the expected strategic benefits and opportunities from completed or planned acquisitions, including the Company’s acquisitions of OpSens Inc. and Attune Medical, divestitures or other strategic investments by the Company may not be realized or may take longer to realize than expected;

•Pricing pressures resulting from trends toward healthcare cost containment, including the continued consolidation among healthcare providers and other market participants;

•Disruptions to the continuity, availability and pricing of plastic and other raw materials, finished goods and components used in the manufacturing of our products (including those purchased from sole-source suppliers) and the related continuity of our manufacturing, sterilization, supply chain and distribution operations, including disruptions caused by natural disasters, extreme weather and other conditions caused by or related to climate change, labor strikes, terrorism acts, cyber incidents or other adverse events;

•Our ability to obtain the anticipated benefits of restructuring programs that we have or may undertake, including the Operational Excellence Program and portfolio rationalization initiatives;

•The impact of enhanced requirements to obtain regulatory approval in the U.S. and around the world and the associated timing and cost of product approval;

•Our ability to comply with established and developing U.S. and foreign legal and regulatory requirements, including the U.S. Foreign Corrupt Practices Act, European Union Medical Device Regulation and In Vitro Diagnostic Regulation and similar laws in other jurisdictions, as well as the impact of U.S. and foreign export and import restrictions and tariffs;

•The impact of changes in U.S. and international tax laws;

•Our ability to meet our debt obligations and raise additional capital when desired on terms reasonably acceptable to us;

•The potential impact of our convertible senior notes and related capped call transactions;

•Geopolitical and economic conditions in China, Taiwan, Russia, Ukraine, the Middle East and other foreign jurisdictions where we do business;

•Our ability to execute and realize anticipated benefits from our investments in emerging economies;

•The potential effect of foreign currency fluctuations and interest rate fluctuations on our net sales, expenses and resulting margins;

•Our ability to protect intellectual property and the outcome of patent litigation;

•Costs and risks associated with product liability and other litigation claims we may be subject to now or in the future;

40
•Our ability to retain and attract key personnel;

•Market conditions impacting our stock price and/or our share repurchase program, and the possibility that such share repurchase program may be delayed, suspended or discontinued;

•Our ability to achieve against our corporate responsibility initiatives and meet evolving stakeholder expectations concerning corporate responsibility matters; and

•The impact of actual or threatened public health crises.

Investors should understand that it is not possible to predict or identify all such factors and should not consider the risks described above and in Item 1A. “Risk Factors” in our Annual Report on Form 10-K (as supplemented by Part II, Item 1A. “Risk Factors” of our Quarterly Report on Form 10-Q for the first quarter ended June 29, 2024) to be a complete statement of all potential risks and uncertainties. The Company does not undertake to publicly update any forward-looking statement that may be made from time to time, whether as a result of new information or future events or developments.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Our exposures relative to market risk are due to foreign exchange risk and interest rate risk.

Foreign Exchange Risk

See the section above entitled Foreign Exchange for a discussion of how foreign currency affects our business. It is our policy to minimize, for a period of time, the unforeseen impact on our financial results of fluctuations in foreign exchange rates by using derivative financial instruments known as forward contracts to hedge anticipated cash flows from forecasted foreign currency denominated sales and costs. We do not use the financial instruments for speculative or trading activities.

We estimate the change in the fair value of all forward contracts assuming both a 10% strengthening and weakening of the U.S. Dollar relative to all other major currencies. As of December 28, 2024, in the event of a 10% strengthening of the U.S. Dollar, the change in fair value of all forward contracts would result in a $5.3 million increase in the fair value of the forward contracts, whereas a 10% weakening of the U.S. Dollar would result in a $6.5 million decrease in the fair value of the forward contracts.

Interest Rate Risk

Our exposure to changes in interest rates is associated with borrowings under our credit facilities, all of which is variable rate debt. Total outstanding debt under our senior unsecured term loan as of December 28, 2024 was $246.9 million with an effective interest rate of 6.1% based on prevailing Term SOFR rates. An increase of 100 basis points in Term SOFR rates would result in additional annual interest expense of $0.4 million. As of December 28, 2024, the notional amount on our two active interest rate swap agreements to effectively convert borrowings under our 2024 Revised Credit Facilities from a variable rate to a fixed rate were $205.8 million. These interest rate swaps are intended to mitigate the exposure to fluctuations in interest rates and qualify for hedge accounting treatment as cash flow hedges.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

We conducted an evaluation, as of December 28, 2024, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer (our principal executive officer and principal financial officer, respectively) regarding the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rule 13a-15 under the Securities Exchange Act of 1934. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of December 28, 2024.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting during the three months ended December 28, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

41
During the second quarter of fiscal 2024, we implemented the first phase of a new global enterprise resource planning (“ERP”) system, which will continue to be implemented in phases through fiscal 2026. The ERP will replace existing financial systems we have historically relied on. As each phase of the implementation occurs, we will reassess our processes and procedures, which may result in changes to our internal control over financial reporting.
42
PART II — OTHER INFORMATION

Item 1. Legal Proceedings

Information with respect to this Item may be found in Note 14, Commitments and Contingencies to the Unaudited Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q, which is incorporated herein by reference.

Item 1A. Risk Factors

Except as set forth in Part II, Item 1A. “Risk Factors” of our Quarterly Report on Form 10-Q for the first quarter ended June 29, 2024, there are no material changes from the Risk Factors previously disclosed in our Annual Report on Form 10-K for the fiscal year ended March 30, 2024.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Issuer Purchases of Equity Securities

In August 2022, the Company announced that its Board of Directors had approved a three-year share repurchase program authorizing the repurchase of up to $300.0 million of Haemonetics common stock, based on market conditions, through August 2025. Under the share repurchase program, the Company is authorized to repurchase, from time to time, outstanding shares of common stock in accordance with applicable laws on the open market, including under trading plans established pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and in privately negotiated transactions.

In October 2024, the Company completed a $75.0 million repurchase of its common stock pursuant to an ASR entered into with Citibank in August 2024. The total number of shares repurchased under the ASR was 1.0 million at an average price per share upon final settlement of $74.36. As of December 28, 2024, the total remaining authorization for repurchases of the Company's common stock under the share repurchase program was $150.0 million.

The following table provides information on the Company’s share repurchases during the third quarter of fiscal 2025:

Total Number of Shares PurchasedAverage Price Paid per ShareTotal Number of Shares Purchased as Part of Publicly Announced Program
Approximate Dollar Value of Shares that May Yet Be Purchased Under the Program
(in millions)($)(1)(2)
September 29, 2024 – October 26, 2024
———$150.0
October 27, 2024 – November 23, 2024
209,49471.60209,494150.0
November 24, 2024 – December 28, 2024
———150.0
Total
209,494209,494$150.0

Item 3. Defaults Upon Senior Securities

Not applicable.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

During the three months ended December 28, 2024, none of our directors or officers (as defined under Rule 16a-1(f) under the Securities Exchange Act of 1934) adopted or terminated trading arrangements for the sale of shares of our common stock.


43
Item 6. Exhibits
Restated Articles of Organization of the Company, reflecting Articles of Amendment dated August 23, 1993, August 21, 2006, July 26, 2018 and July 25, 2019 (filed as Exhibit 3.1 to the Company’s Form 8-K dated July 29, 2019 and incorporated herein by reference).
By-Laws of the Company, as amended through June 29, 2020 (filed as Exhibit 3.1 to the Company’s Form 8-K dated June 30, 2020 and incorporated herein by reference).
Certification pursuant to Section 302 of Sarbanes-Oxley Act of 2002, of Christopher A. Simon, President and Chief Executive Officer of the Company.
  
Certification pursuant to Section 302 of Sarbanes-Oxley of 2002, of James C. D'Arecca, Executive Vice President, Chief Financial Officer of the Company.
  
Certification Pursuant to 18 United States Code Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, of Christopher A. Simon, President and Chief Executive Officer of the Company.
  
Certification Pursuant to 18 United States Code Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, of James C. D'Arecca, Executive Vice President, Chief Financial Officer of the Company.
101*
The following materials from Haemonetics Corporation on Form 10-Q for the quarter ended December 28, 2024 formatted in inline Extensible Business Reporting Language (XBRL) includes: (i) Condensed Consolidated Statements of Income and Comprehensive Income, (ii) Condensed Consolidated Balance Sheets, (iii) Condensed Consolidated Statement of Stockholders' Equity, (iv) Condensed Consolidated Statements of Cash Flows, and (v) Notes to Condensed Consolidated Financial Statements.
104*Cover Page Interactive Data File (embedded within the Inline XBRL document and contained in Exhibit 101).
*Document filed with this report.
**Document furnished with this report.
44
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 HAEMONETICS CORPORATION 
February 6, 2025By:  /s/ Christopher A. Simon   
  Christopher A. Simon,
President and Chief Executive Officer		 
  (Principal Executive Officer)  
February 6, 2025By:  /s/ James C. D’Arecca
  James C. D’Arecca, Executive Vice President, Chief Financial Officer
(Principal Financial Officer) 


45
 EX-31.1 2 haefy25q3decex311.htm EX-31.1 Document

EXHIBIT 31.1
CERTIFICATION
I, Christopher A. Simon, certify that:
1.I have reviewed this quarterly report on Form 10-Q of Haemonetics Corporation;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

February 6, 2025
 /s/ Christopher A. Simon 
 Christopher A. Simon, President and Chief Executive Officer 
 (Principal Executive Officer) 


 EX-31.2 3 haefy25q3decex312.htm EX-31.2 Document

EXHIBIT 31.2
CERTIFICATION
I, James C. D'Arecca, certify that:
1.I have reviewed this quarterly report on Form 10-Q of Haemonetics Corporation;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

February 6, 2025
 /s/ James C. D'Arecca 
 James C. D'Arecca, Executive Vice President, Chief Financial Officer 
 (Principal Financial Officer)  


 EX-32.1 4 haefy25q3decex321.htm EX-32.1 Document

EXHIBIT 32.1

Certification Pursuant To
18 USC. Section 1350,
As Adopted Pursuant To
Section 906 of the Sarbanes/Oxley Act of 2002
In connection with the Quarterly Report of Haemonetics Corporation (the “Company”) on Form 10-Q for the period ended December 28, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Christopher A. Simon, President and Chief Executive Officer of the Company, certify, pursuant to Section 1350 of Chapter 63 of Title 18, United States Code, that this Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in this Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
February 6, 2025
 /s/ Christopher A. Simon 
 Christopher A. Simon,  
 President and Chief Executive Officer  

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Haemonetics and will be retained by Haemonetics and furnished to the Securities and Exchange Commission or its staff upon request.


 EX-32.2 5 haefy25q3decex322.htm EX-32.2 Document

EXHIBIT 32.2

Certification Pursuant To
18 USC. Section 1350,
As Adopted Pursuant To
Section 906 of the Sarbanes/Oxley Act of 2002
In connection with the Quarterly Report of Haemonetics Corporation (the “Company”) on Form 10-Q for the period ended December 28, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, James C. D'Arecca, Executive Vice President, Chief Financial Officer of the Company, certify, pursuant to Section 1350 of Chapter 63 of Title 18, United States Code, that this Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in this Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
February 6, 2025
 /s/ James C. D'Arecca 
 James C. D'Arecca,  
 Executive Vice President, Chief Financial Officer 

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Haemonetics and will be retained by Haemonetics and furnished to the Securities and Exchange Commission or its staff upon request.


 EX-101.SCH 6 hae-20241228.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - COVER PAGE link:presentationLink link:calculationLink link:definitionLink 9952151 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME link:presentationLink link:calculationLink link:definitionLink 9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 9952153 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) link:presentationLink link:calculationLink link:definitionLink 9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 9952156 - Disclosure - BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 9952157 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS link:presentationLink link:calculationLink link:definitionLink 9952158 - Disclosure - ACQUISITIONS, DIVESTITURES AND STRATEGIC INVESTMENTS link:presentationLink link:calculationLink link:definitionLink 9952159 - Disclosure - REVENUE link:presentationLink link:calculationLink link:definitionLink 9952160 - Disclosure - RESTRUCTURING link:presentationLink link:calculationLink link:definitionLink 9952161 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 9952162 - Disclosure - EARNINGS PER SHARE link:presentationLink link:calculationLink link:definitionLink 9952163 - Disclosure - INVENTORIES link:presentationLink link:calculationLink link:definitionLink 9952164 - Disclosure - PROPERTY, PLANT AND EQUIPMENT link:presentationLink link:calculationLink link:definitionLink 9952165 - Disclosure - LEASES link:presentationLink link:calculationLink link:definitionLink 9952166 - Disclosure - GOODWILL AND INTANGIBLE ASSETS link:presentationLink link:calculationLink link:definitionLink 9952167 - Disclosure - NOTES PAYABLE AND LONG-TERM DEBT link:presentationLink link:calculationLink link:definitionLink 9952168 - Disclosure - FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS link:presentationLink link:calculationLink link:definitionLink 9952169 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 9952170 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 9952171 - Disclosure - SEGMENT AND ENTERPRISE-WIDE INFORMATION link:presentationLink link:calculationLink link:definitionLink 9955511 - Disclosure - ACQUISITIONS, DIVESTITURES AND STRATEGIC INVESTMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 9955512 - Disclosure - RESTRUCTURING (Tables) link:presentationLink link:calculationLink link:definitionLink 9955513 - Disclosure - EARNINGS PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 9955514 - Disclosure - INVENTORIES (Tables) link:presentationLink link:calculationLink link:definitionLink 9955515 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 9955516 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 9955517 - Disclosure - NOTES PAYABLE AND LONG-TERM DEBT (Tables) link:presentationLink link:calculationLink link:definitionLink 9955518 - Disclosure - FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 9955519 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables) link:presentationLink link:calculationLink link:definitionLink 9955520 - Disclosure - SEGMENT AND ENTERPRISE-WIDE INFORMATION (Tables) link:presentationLink link:calculationLink link:definitionLink 9955521 - Disclosure - ACQUISITIONS, DIVESTITURES AND STRATEGIC INVESTMENTS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955522 - Disclosure - ACQUISITIONS, DIVESTITURES AND STRATEGIC INVESTMENTS - Purchase Price Allocation (Details) link:presentationLink link:calculationLink link:definitionLink 9955523 - Disclosure - ACQUISITIONS, DIVESTITURES AND STRATEGIC INVESTMENTS - Strategic Investments (Details) link:presentationLink link:calculationLink link:definitionLink 9955524 - Disclosure - REVENUE (Details) link:presentationLink link:calculationLink link:definitionLink 9955524 - Disclosure - REVENUE (Details) link:presentationLink link:calculationLink link:definitionLink 9955525 - Disclosure - RESTRUCTURING (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 9955526 - Disclosure - RESTRUCTURING (Schedule of Restructuring Reserve by Type of Cost) (Details) link:presentationLink link:calculationLink link:definitionLink 9955527 - Disclosure - RESTRUCTURING (Schedule of Restructuring and Related Costs) (Details) link:presentationLink link:calculationLink link:definitionLink 9955528 - Disclosure - INCOME TAXES (Details) link:presentationLink link:calculationLink link:definitionLink 9955529 - Disclosure - EARNINGS PER SHARE (Schedule of Earnings Per Share Reconciliation) (Details) link:presentationLink link:calculationLink link:definitionLink 9955530 - Disclosure - EARNINGS PER SHARE (Share Repurchase Program) (Details) link:presentationLink link:calculationLink link:definitionLink 9955531 - Disclosure - INVENTORIES (Schedule of Inventories) (Details) link:presentationLink link:calculationLink link:definitionLink 9955532 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Details) link:presentationLink link:calculationLink link:definitionLink 9955533 - Disclosure - LEASES (Details) link:presentationLink link:calculationLink link:definitionLink 9955534 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955535 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Schedule of Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 9955536 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9955537 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Maturity (Details) link:presentationLink link:calculationLink link:definitionLink 9955538 - Disclosure - NOTES PAYABLE AND LONG-TERM DEBT - Schedule of Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9955539 - Disclosure - NOTES PAYABLE AND LONG-TERM DEBT - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955540 - Disclosure - NOTES PAYABLE AND LONG-TERM DEBT - Schedule of Long Term Debt Maturity (Details) link:presentationLink link:calculationLink link:definitionLink 9955541 - Disclosure - FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 9955542 - Disclosure - FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Schedule of Interest Rate Swaps) (Details) link:presentationLink link:calculationLink link:definitionLink 9955543 - Disclosure - FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Allowance for Credit Losses) (Details) link:presentationLink link:calculationLink link:definitionLink 9955544 - Disclosure - FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Schedule of Effect of Derivative Instruments Designated as Cash Flow Hedges and Those Not Designated as Hedging Instruments) (Details) link:presentationLink link:calculationLink link:definitionLink 9955545 - Disclosure - FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Schedules of Derivatives) (Details) link:presentationLink link:calculationLink link:definitionLink 9955546 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink 9955547 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS (Details) link:presentationLink link:calculationLink link:definitionLink 9955548 - Disclosure - SEGMENT AND ENTERPRISE-WIDE INFORMATION (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 hae-20241228_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 hae-20241228_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 hae-20241228_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Proceeds from revolving facility Proceeds from Long-Term Lines of Credit Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Acquisitions Goodwill, Acquired During Period Statistical Measurement [Domain] Statistical Measurement [Domain] Repayment of term loan borrowings Repayments of long-term debt Repayments of Long-Term Debt Remaining authorized amount Share Repurchase Program, Remaining Authorized, Amount Cover [Abstract] Cover [Abstract] Net Change in Cash and Cash Equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Derivative, blended fixed interest rate Derivative, Blended Fixed Interest Rate Derivative, Blended Fixed Interest Rate In-process research and development In Process Research and Development [Member] Non-cash transfers from inventory to property, plant and equipment for Haemonetics equipment Transfers from Inventory to Fixed Assets Transfers from inventory to fixed assets. Inventory reserve adjustment Benefit (Provision) For Losses On Inventory Benefit (Provision) For Losses On Inventory Other current liabilities Other Liabilities, Current Trading Symbol Trading Symbol Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] All Trading Arrangements All Trading Arrangements [Member] Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Axis] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Derivative Assets Derivative Asset, Subject to Master Netting Arrangement, before Offset Non-NEOs Non-NEOs [Member] Schedule of Earnings Per Share Reconciliation Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Derivative [Line Items] Derivative [Line Items] Repurchase of convertible senior notes Decrease For Redemption Of Convertible Senior Notes Decrease For Redemption Of Convertible Senior Notes Accounts receivable, allowance Accounts Receivable, Allowance for Credit Loss, Current Purchase accounting adjustments Goodwill, Measurement Period Adjustment Disposal Group Name [Domain] Disposal Group Name [Domain] Pay vs Performance Disclosure [Line Items] Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period [Domain] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Change in accounts receivable Increase (Decrease) in Accounts Receivable Derivative [Table] Derivative [Table] Income Tax Contingency [Table] Income Tax Contingency [Table] BASIS OF PRESENTATION Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Issuance of restricted stock, net of cancellations (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Hedging Relationship [Domain] Hedging Relationship [Domain] Schedule of Fair Value of Derivative Instruments as They Appear in Consolidated Balance Sheets Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] Proceeds from exercise of stock options Proceeds from Stock Options Exercised Land Land [Member] Restructuring and Related Activities [Abstract] Restructuring and Related Activities [Abstract] Award Timing Disclosures [Line Items] Debt instrument, redemption price, percentage of previous closing price Debt Instrument, Redemption Price, Percentage of Previous Closing Price Debt Instrument, Redemption Price, Percentage of Previous Closing Price Change in other assets and other liabilities Increase (Decrease) in Other Operating Assets and Liabilities, Net Investment, Name [Domain] Investment, Name [Domain] Other Performance Measure, Amount Other Performance Measure, Amount Fiscal 2028 Finite-Lived Intangible Asset, Expected Amortization, Year Three Goodwill [Line Items] Goodwill [Line Items] LEASES Lessee, Operating Leases [Text Block] Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Contingent consideration from divestiture Business Combination, Contingent Consideration, Asset Cash Flow Hedging Cash Flow Hedging [Member] Investments, All Other Investments [Abstract] Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] United States UNITED STATES Revision of Prior Period, Reclassification, Adjustment Revision of Prior Period, Reclassification, Adjustment [Member] Net effect of common stock equivalents (in shares) Weighted Average Number of Shares Outstanding, Diluted, Adjustment Other long-term assets Other Assets, Noncurrent Entity Tax Identification Number Entity Tax Identification Number Leases [Abstract] Leases [Abstract] Gross Carrying Amount Finite-Lived Intangible Assets, Gross Schedule of Finite-Lived Intangible Assets [Table] Intangible Asset, Finite-Lived [Table] New Accounting Pronouncements and Changes in Accounting Principles [Abstract] Accounting Standards Update and Change in Accounting Principle [Abstract] Payments for legal settlements Payments for Legal Settlements Operating Segments Operating Segments [Member] Discrete tax benefit (expense) Tax Adjustments, Settlements, and Unusual Provisions Selling, general and administrative expenses Selling, General and Administrative Expenses [Member] Proceeds from issuance of convertible notes Proceeds from Convertible Debt Debt Instrument, Redemption, Period Two Debt Instrument, Redemption, Period Two [Member] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Patents and other Patents [Member] Cash Flows from Operating Activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Schedule of Accumulated Other Comprehensive Income (Loss) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Equity Components [Axis] Equity Components [Axis] Award Timing Method Award Timing Method [Text Block] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Trade names Trade names Trade Names [Member] Measurement Frequency [Axis] Measurement Frequency [Axis] Share Repurchase Program [Table] Share Repurchase Program [Table] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Insider Trading Policies and Procedures [Line Items] Revision of Prior Period, Adjustment Revision of Prior Period, Adjustment [Member] Proceeds from divestiture Proceeds from Divestiture of Businesses Proceeds, net of cash transferred Proceeds from Divestiture of Businesses, Net of Cash Divested Number of Interest Rate Swaps Remaining Number of Interest Rate Swaps Remaining Number of Interest Rate Swaps Remaining Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Adjustment to Compensation, Amount Adjustment to Compensation Amount Purchase of capped call related to convertible notes Purchase of capped call related to convertible notes Purchase Of Capped Call Related To Convertible Notes Purchase Of Capped Call Related To Convertible Notes Additional paid-in capital Additional Paid in Capital, Common Stock Compensation Amount Outstanding Recovery Compensation Amount Thereafter Long-Term Debt, Maturity, After Year Four Long-Term Debt, Maturity, After Year Four Diluted EPS Earnings Per Share, Diluted [Abstract] Disposal Group Classification [Axis] Disposal Group Classification [Axis] Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Entity Small Business Entity Small Business Company Selected Measure Amount Company Selected Measure Amount Geographical [Axis] Geographical [Axis] Schedule of Restructuring and Related Costs Restructuring and Related Costs [Table Text Block] Debt issuance costs Payments of Debt Issuance Costs Tabular List, Table Tabular List [Table Text Block] Fair Value, Inputs, Level 3 Fair Value, Inputs, Level 3 [Member] Restructuring Reserve, Accrual Adjustment Restructuring Reserve, Accrual Adjustment Shares repurchased Stock Repurchased During Period, Value Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Accounts Receivable, Allowance for Credit Loss Accounts Receivable, Allowance for Credit Loss [Table Text Block] 2024 Revised Credit Facilities 2024 Revised Credit Agreement [Member] 2024 Revised Credit Agreement Other long-term assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Employee stock purchase plan (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Anti-dilutive shares (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Gain on repurchase of convertible senior notes, net Gain (loss) on repurchase of debt instrument Gain (Loss) on Repurchase of Debt Instrument Payments Payments for Restructuring Cash and Cash Equivalents at Beginning of Period Cash and Cash Equivalents at End of Period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Current assets: Assets, Current [Abstract] Goodwill Goodwill, carrying amount, beginning balance Goodwill, carrying amount, ending balance Goodwill Consolidation Items [Axis] Consolidation Items [Axis] Beginning balance Ending balance Accounts Receivable, Allowance for Credit Loss Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Cash used to net share settle employee equity awards Payment, Tax Withholding, Share-Based Payment Arrangement Share repurchase plan, authorized amount Share Repurchase Program, Authorized, Amount INVENTORIES Inventory Disclosure [Text Block] Adjustments to additional paid in capital, convertible debt, capped call purchases Adjustments to Additional Paid in Capital, Convertible Debt, Capped Call Purchases Adjustments to Additional Paid in Capital, Convertible Debt, Capped Call Purchases Customer contracts and related relationships Customer Contracts [Member] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Product and Service [Domain] Product and Service [Domain] Employee Stock Option Share-Based Payment Arrangement, Option [Member] Goodwill [Roll Forward] Goodwill [Roll Forward] Depreciation Depreciation Estimated Fair Value Assets (Liabilities) Derivative, Fair Value, Net Other financing activities Proceeds from (Payments for) Other Financing Activities Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Security Exchange Name Security Exchange Name Award Type Award Type [Axis] Selected Information by Business Segment Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block] Currency translation Goodwill, Foreign Currency Translation Gain (Loss) Basic EPS Earnings Per Share, Basic [Abstract] Deferred debt issuance cost, writeoff Deferred Debt Issuance Cost, Writeoff Whole Blood Whole Blood, Blood Center [Member] Whole Blood, Blood Center Work-in-process Inventory, Work in Process, Net of Reserves Property, plant and equipment, net Property, plant and equipment, net Property, Plant and Equipment, Net Convertible notes Convertible Debt [Member] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Research and development Research and Development Expense Weighted-Average Amortization Period Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life Revolving credit facility Revolving Credit Facility [Member] Expiration Date Trading Arrangement Expiration Date Cash Flows from Investing Activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Contingent Consideration Contingent Consideration [Member] Contingent Consideration Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Total Shareholder Return Amount Total Shareholder Return Amount Common stock, shares issued (in shares) Common Stock, Shares, Issued Other Assets Other Assets [Member] Risk-Adjusted Discount Rates used in Purchase Price Allocation Acquired Intangible Assets, Risk-Adjusted Discount Rate Acquired Intangible Assets, Risk-Adjusted Discount Rate Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Write-offs (recoveries) Accounts Receivable, Allowance For Credit Loss, Recovery (Writeoff) Accounts Receivable, Allowance For Credit Loss, Recovery (Writeoff) Discrete Income Tax Benefit (Expense) [Axis] Discrete Income Tax Benefit (Expense) [Axis] Discrete Income Tax Benefit (Expense) Hospital Hospital Products and Services [Member] Hospital Products and Services [Member] Convertible Senior Notes Due 2029 Convertible Senior Notes Due 2029 [Member] Convertible Senior Notes Due 2029 Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Effect of exchange rates Effect of Exchange Rates on Operating Income Effect of Exchange Rates on Operating Income Less: accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Debt instrument, percent of principal amount due in year 4 Debt Instrument, Percent of Principal Amount Due In Year 4 Debt Instrument, Percent of Principal Amount Due In Year 4 Debt instrument, percent of principal amount due in year 5 Debt Instrument, Percent of Principal Amount Due In Year 5 Debt Instrument, Percent of Principal Amount Due In Year 5 Total Property, Plant and Equipment, Gross Exercise of stock options (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Amount of Gain (Loss) Recognized in Accumulated Other Comprehensive Loss Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Rest of Asia Asia [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Research and development Research and Development Expense [Member] Europe Europe [Member] Impairment of intangible assets Goodwill and Intangible Asset Impairment Common stock, shares authorized (in shares) Common Stock, Shares Authorized 2022 Accelerated Share Repurchase Program 2022 Accelerated Share Repurchase Program [Member] 2022 Accelerated Share Repurchase Program In-process software development In Process Software Development [Member] In Process Software Development [Member] Acquisition, net of cash acquired Payments to acquire businesses, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Diluted (in shares) Diluted weighted average shares (in shares) Weighted Average Number of Shares Outstanding, Diluted Designated foreign currency hedge contracts outstanding Foreign Currency Cash Flow Hedge Derivative at Fair Value, Net Expected cost Restructuring and Related Cost, Expected Cost Accrued Liabilities Accrued Liabilities [Member] Restructuring costs Restructuring Costs MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Remainder of Fiscal 2025 Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year AOCI Attributable to Parent, Net of Tax [Roll Forward] AOCI Attributable to Parent, Net of Tax [Roll Forward] Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Change in prepaid income taxes Increase (Decrease) in Prepaid Taxes Total stockholders’ equity Balance Balance Equity, Attributable to Parent Prepaid expenses and other current assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets Additional debt issuance costs capitalized Additional Debt Issuance Costs Capitalized Additional Debt Issuance Costs Capitalized Hedging Designation [Domain] Hedging Designation [Domain] Interest expense Interest Expense, Nonoperating Balance Sheet Location [Axis] Statement of Financial Position Location, Balance [Axis] Plasma Plasma [Member] Plasma [Member] Deferred tax benefit Deferred Income Tax Expense (Benefit) Capped call transaction, anti-dilution adjustment (in shares) Debt Instrument, Convertible, Capped Call Transaction, Anti-Dilution Adjustment, Shares Debt Instrument, Convertible, Capped Call Transaction, Anti-Dilution Adjustment, Shares Schedule of Goodwill Schedule of Goodwill [Table Text Block] PROPERTY, PLANT AND EQUIPMENT Property, Plant and Equipment Disclosure [Text Block] Selling, general and administrative Selling, General and Administrative Expense Fair Value, Recurring [Member] Fair Value, Recurring [Member] Income Tax Contingency [Line Items] Income Tax Contingency [Line Items] 2020 Program 2020 Program [Member] 2020 Program [Member] Accounts receivable, less allowance for credit losses of $5,986 at December 28, 2024 and $5,695 at March 30, 2024 Accounts Receivable, after Allowance for Credit Loss, Current Debt instrument, convertible, conversion price Debt Instrument, Convertible, Conversion Price Cost of goods sold Cost of Sales [Member] Impairment of intangible assets Asset Impairment Charges Debt outstanding Long-Term Debt Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Document Fiscal Period Focus Document Fiscal Period Focus Fiscal 2029 Long-Term Debt, Maturity, Year Four Legal and professional fees Business Combination, Acquisition Related Costs All Executive Categories All Executive Categories [Member] Vascular Closure, Hosptial Interventional Technologies, Hospital [Member] Interventional Technologies, Hospital Hospital Hospital [Member] Hospital [Member] Balance Sheet Location [Domain] Statement of Financial Position Location, Balance [Domain] Schedule of Restructuring Reserve by Type of Cost Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Fiscal 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Two Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] ASSETS Assets [Abstract] Other comprehensive income (loss) Net current period other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax Document Type Document Type Derivative Contract [Domain] Derivative Contract [Domain] Effective interest rate Debt Instrument, Interest Rate, Effective Percentage Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Capitalized software Computer Software, Intangible Asset [Member] Revenue-based payment Revenue-based payment [Member] Revenue-based payment Debt instrument, convertible, conversion rate Debt Instrument, Convertible, Conversion Rate Debt Instrument, Convertible, Conversion Rate Schedule of Finite-Lived Intangible Assets, Future Amortization Expense Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Non-amortizable: Indefinite-Lived Intangible Assets (Excluding Goodwill) Other borrowings Bank loans and other borrowings [Member] Bank loans and other borrowings Maximum Maximum [Member] Aggregate amortization expense Amortization of Intangible Assets Contract liabilities Contract with Customer, Liability Term loan borrowings Proceeds From Issuance Of Long-Term Debt, Excluding Line Of Credit Proceeds From Issuance Of Long-Term Debt, Excluding Line Of Credit Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Finite-lived intangible assets, net Net Finite-Lived Intangible Assets, Net Accounts payable Accounts Payable, Current Blood Center Blood Center [Member] Blood Center [Member] Write downs of certain assets and PCS2 related charges Impairment Of Assets And PCS2 Related Charges (Credits) Impairment Of Assets And PCS2 Related Charges (Credits) ACQUISITIONS, DIVESTITURES AND STRATEGIC INVESTMENTS Business Combination Disclosure [Text Block] Term loan redemption Decrease For Redemption Of Long-Term Debt Decrease For Redemption Of Long-Term Debt Current Fiscal Year End Date Current Fiscal Year End Date Convertible Senior Notes Due 2026 Convertible Senior Notes Due 2026 [Member] Convertible Senior Notes Due 2026 Statistical Measurement [Axis] Statistical Measurement [Axis] PEO Name PEO Name Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Income before provision for income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount All Award Types Award Type [Domain] Name Outstanding Recovery, Individual Name Business combination, recognized identifiable assets acquired and liabilities assumed, cash and equivalents Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Revision of Prior Period [Axis] Revision of Prior Period [Axis] Deferred tax asset Deferred Income Tax Assets, Net Non-PEO NEO Non-PEO NEO [Member] Weighted average useful life Finite-Lived Intangible Asset, Useful Life Total assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Money market funds Investments, Fair Value Disclosure Additional Paid-in Capital Additional Paid-in Capital [Member] Hedging Relationship [Axis] Hedging Relationship [Axis] MDR and IVDR costs European Medical Device Regulation Costs European Medical Device Regulation Costs Award Timing Predetermined Award Timing Predetermined [Flag] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Investment, Name [Axis] Investment, Name [Axis] Debt instrument, redemption price, percentage Debt Instrument, Redemption Price, Percentage Deferred tax liability Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Customer contracts and related relationships Customer Relationships [Member] Diluted income (loss) per share (in dollars per share) Earnings Per Share, Diluted Deferred income tax expense (benefit) Deferred Tax Assets, Derivative Instruments Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Intangible assets, amortization Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Name Measure Name Entity Interactive Data Current Entity Interactive Data Current Vivasure Medical LTD Vivasure Medical LTD [Member] Vivasure Medical LTD Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Debt instrument, redemption price, percentage of principal amount redeemed Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed Schedule of Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] RESTRUCTURING Restructuring and Related Activities Disclosure [Text Block] Share-based compensation expense Share-Based Payment Arrangement, Noncash Expense Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] Defined Benefit Plans Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Proceeds from sale of property, plant and equipment Proceeds from Sale of Property, Plant, and Equipment Inventories Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Provision for income taxes Income Tax Expense (Benefit) Stated rate (as a percent) Debt Instrument, Interest Rate, Stated Percentage Notional amount Derivative, Notional Amount Corporate Segment Reporting, Reconciling Item, Corporate Nonsegment [Member] Schedule of Investments [Line Items] Schedule of Investments [Line Items] Accounts Receivable, Allowance for Credit Loss [Roll Forward] Accounts Receivable, Allowance for Credit Loss [Roll Forward] Net revenues Revenue from Contract with Customer, Excluding Assessed Tax Schedule of Effect of Derivative Instruments Designated as Cash Flow Hedges and Those Not Designated as Hedging Instruments Derivative Instruments, Gain (Loss) [Table Text Block] Other Other Country or Region [Member] Other Country or Region [Member] Portfolio Rationalization Portfolio Rationalization [Member] Portfolio Rationalization Reported tax rate Effective Income Tax Rate Reconciliation, Percent Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Operating income Operating income Operating Income (Loss) Inventories Inventories [Member] Business Acquisition [Line Items] Business Acquisition [Line Items] Cumulative costs to date Restructuring and Related Cost, Cost Incurred to Date Number of reportable segments Number of Reportable Segments Total liabilities and stockholders’ equity Liabilities and Equity Other non-cash operating activities Other Operating Activities, Cash Flow Statement Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] All Adjustments to Compensation All Adjustments to Compensation [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Accrued payroll and related costs Employee-related Liabilities, Current Hedging Designation [Axis] Hedging Designation [Axis] Derivative Instruments, Gain (Loss) by Hedging Relationship, by Income Statement Location, by Derivative Instrument Risk [Table] Derivative Instruments, Gain (Loss) [Table] Costs incurred, net of reversals Restructuring costs Restructuring Charges Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Non-cash items: Non-Cash Items [Abstract] Non-Cash Items [Abstract] Derivative Instrument, Gain (Loss) Reclassified from AOCI into Income, Effective Portion, Statement of Income or Comprehensive Income [Extensible Enumeration] Derivative Instrument, Gain (Loss) Reclassified from AOCI into Income, Effective Portion, Statement of Income or Comprehensive Income [Extensible Enumeration] Schedule of Maturities of Long-Term Debt Schedule of Maturities of Long-Term Debt [Table Text Block] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Individual: Individual [Axis] Building and building improvements Building and Building Improvements [Member] Tax withholding on employee equity awards Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation Issuance of restricted stock, net of cancellations Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Accumulated Other Comprehensive (Loss)/Income AOCI Attributable to Parent [Member] Expected timing of satisfaction Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period Net Unrealized Gain (Loss) on Derivatives Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] Inventories, net Inventories, net Inventories, net Inventory, Net Number of interest rate swaps entered Number Of Interest Rate Swaps Entered Number Of Interest Rate Swaps Entered Product and Service [Axis] Product and Service [Axis] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Entity Address, State or Province Entity Address, State or Province Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Statement [Line Items] Statement [Line Items] Amount of Gain (Loss) Reclassified from Accumulated Other Comprehensive Loss into Earnings Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net Capped call transaction, initial cap price (in dollars per share) Debt Instrument, Convertible, Capped Call Transaction, Initial Cap Price Debt Instrument, Convertible, Capped Call Transaction, Initial Cap Price Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Operating expenses: Operating Expenses [Abstract] Net assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Property, Plant and Equipment Property, Plant and Equipment [Table Text Block] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Interest Rate Swap, 4.15% Fixed Interest Rate Interest Rate Swap, 4.15% Fixed Interest Rate [Member] Interest Rate Swap, 4.15% Fixed Interest Rate LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS Derivatives and Fair Value [Text Block] Blood Center Blood Center Products and Services [Member] Blood Center Products and Services [Member] Loss contingency, estimate of possible loss Loss Contingency, Estimate of Possible Loss Restructuring and related cost, incurred cost Restructuring and Related Cost, Incurred Cost Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block] Derivative fixed interest rate Derivative, Fixed Interest Rate Minimum Minimum [Member] Share Repurchase Program [Line Items] Share Repurchase Program [Line Items] Restatement Determination Date Restatement Determination Date Accrued payroll and related costs Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Payroll and Related Costs Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Payroll and Related Costs Adoption Date Trading Arrangement Adoption Date Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Credit loss Accounts Receivable, Credit Loss Expense (Reversal) Segments [Axis] Segments [Axis] Other long-term liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Derivative Instrument [Axis] Derivative Instrument [Axis] Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Long-term debt, gross Long-Term Debt, Gross Exercise Price Award Exercise Price EARNINGS PER SHARE Earnings Per Share [Text Block] Office equipment and information technology Office Equipment and Information Technology [Member] Office Equipment and Information Technology Arrangement Duration Trading Arrangement Duration Event-based payment Event-based payment [Member] Event-based payment Whole Blood Business Whole Blood Business [Member] Whole Blood Business Employee stock purchase plan Stock Issued During Period, Value, Employee Stock Purchase Plan Subsequent Event Subsequent Event [Member] Exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Consolidated interest coverage ratio Consolidated Interest Coverage Ratio Consolidated Interest Coverage Ratio GOODWILL AND INTANGIBLE ASSETS Goodwill and Intangible Assets Disclosure [Text Block] Stockholders’ equity: Equity, Attributable to Parent [Abstract] Gain (loss) on investments Gain (Loss) on Investments Goodwill Goodwill [Member] Investment Investments Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Segments [Domain] Segments [Domain] Restructuring Plan [Axis] Restructuring Plan [Axis] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] 2022 Revised Credit Facilities 2022 Revised Credit Agreement [Member] 2022 Revised Credit Agreement Regulatory-based payment Regulatory-based payment [Member] Regulatory-based payment Debt Instrument, Repurchase Amount Debt Instrument, Repurchase Amount Fiscal 2029 Finite-Lived Intangible Asset, Expected Amortization, Year Four All Individuals All Individuals [Member] Total consideration Business Combination, Price of Acquisition, Expected Number Of Interest Rate Swaps Terminated Number Of Interest Rate Swaps Terminated Number Of Interest Rate Swaps Terminated PEO PEO [Member] Revised Credit Agreement Revised Credit Agreement [Member] Revised Credit Agreement Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Name Trading Arrangement, Individual Name Interest and other expense, net Other Nonoperating Income (Expense) Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Intangible assets, less accumulated amortization of $311,596 at December 28, 2024 and $455,213 at March 30, 2024 Intangible Assets, Net (Excluding Goodwill) Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Disposal Group Name [Axis] Disposal Group Name [Axis] Remainder of Fiscal 2025 Long-Term Debt, Maturity, Remainder of Fiscal Year Revolving credit facility unused fee percentage Line of Credit Facility, Unused Capacity, Commitment Fee Percentage Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Assets Assets, Fair Value Disclosure [Abstract] Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Consolidated total leverage ratio Consolidated Total Leverage Ratio Consolidated Total Leverage Ratio Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Integration and transaction costs Operating Expenses, Transaction Costs Operating Expenses, Transaction Costs Local Phone Number Local Phone Number Accelerated share repurchases, settlement (payment) or receipt Accelerated Share Repurchases, Settlement (Payment) or Receipt Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Interest Rate Swap, 4.08% Fixed Interest Rate Interest Rate Swap, 4.08% Fixed Interest Rate [Member] Interest Rate Swap, 4.08% Fixed Interest Rate Maturity period for foreign currency contracts Average Remaining Maturity of Foreign Currency Derivatives Total liabilities assumed Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Total operating expenses Operating Expenses Schedule of Revenues by Business Unit and Geographic Regions Reconciliation of Revenue from Segments to Consolidated [Table Text Block] Deferred tax liability Deferred Income Tax Liabilities, Net 2024 Accelerated Share Repurchase Program 2024 Accelerated Share Repurchase Program [Member] 2024 Accelerated Share Repurchase Program Shares repurchased (in shares) Shares repurchased (in shares) Stock Repurchased During Period, Shares Change in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] PEO Total Compensation Amount PEO Total Compensation Amount Acquired intangibles Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Derivative Liabilities Derivative Liability, Subject to Master Netting Arrangement, before Offset Apheresis Apheresis, Blood Center [Member] Apheresis, Blood Center Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Income Statement Location [Axis] Statement of Income Location, Balance [Axis] Share Repurchase Program [Domain] Share Repurchase Program [Domain] Impairment of intangible assets Impairment of Intangible Assets, Finite-Lived COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Debt Instrument [Line Items] Debt Disclosure [Abstract] Common Stock Common Stock [Member] Measure: Measure [Axis] Long-Lived Asset, Held-for-Sale, Type [Axis] Long-Lived Asset, Held-for-Sale, Type [Axis] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Debt Instrument, Redemption, Period One Debt Instrument, Redemption, Period One [Member] Uncommitted Operating Lines of Credit Line of Credit [Member] Entity Emerging Growth Company Entity Emerging Growth Company Indefinite-lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets [Axis] Liabilities fair value Liabilities, Fair Value Disclosure Segment Reporting [Abstract] Segment Reporting [Abstract] Tax withholding on employee equity awards (in shares) Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Entity Central Index Key Entity Central Index Key Schedule of Inventories Schedule of Inventory, Current [Table Text Block] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Foreign Currency Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Corporate Corporate Segment [Member] ACCUMULATED OTHER COMPREHENSIVE LOSS Equity [Text Block] Change in accounts payable and accrued expenses Increase (Decrease) in Accounts Payable and Accrued Liabilities Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Equity Component [Domain] Equity Component [Domain] SEGMENT AND ENTERPRISE-WIDE INFORMATION Segment Reporting Disclosure [Text Block] Notes payable and current maturities of long-term debt Notes payable and current maturities of long-term debt Long-Term Debt, Current Maturities Japan JAPAN Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Text Block [Abstract] Amounts reclassified from Accumulated Other Comprehensive Income (Loss) Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax RECENT ACCOUNTING PRONOUNCEMENTS Accounting Standards Update and Change in Accounting Principle [Text Block] Share-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Entity Shell Company Entity Shell Company Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Loss in period Loss Contingency, Loss in Period Title Trading Arrangement, Individual Title Debt Instrument, Repurchased Face Amount Debt Instrument, Repurchased Face Amount Unsecured Debt Unsecured Debt [Member] Stock Compensation Windfalls Stock Compensation Windfalls [Member] Stock Compensation Windfalls Statement [Table] Statement [Table] Interest expense, debt Interest Expense, Debt Measurement Frequency [Domain] Measurement Frequency [Domain] Consolidation Items [Domain] Consolidation Items [Domain] City Area Code City Area Code Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Value At Acquisition Date Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Value At Acquisition Date Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Value At Acquisition Date Current liabilities: Liabilities, Current [Abstract] Share repurchase program, period in force Share Repurchase Program, Period in Force Contingent consideration Business Combination, Contingent Consideration, Liability Disposal Group Classification [Domain] Disposal Group Classification [Domain] Non-designated foreign currency hedge contracts outstanding Foreign Currency Derivative Instruments Not Designated as Hedging Instruments at Fair Value, Net Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Level 1 Fair Value, Inputs, Level 1 [Member] Stockholders' Equity Note [Abstract] Stockholders' Equity Note [Abstract] Gain on sale of property, plant and equipment Gain (Loss) on Disposition of Assets Total current assets Assets, Current Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Revision of Prior Period [Domain] Revision of Prior Period [Domain] Share repurchases Payments for Repurchase of Common Stock Fiscal 2028 Long-Term Debt, Maturity, Year Three Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Long-term debt Long-term debt Long-Term Debt, Excluding Current Maturities Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Performance obligation percent Revenue, Remaining Performance Obligation, Percentage INCOME TAXES Income Tax Disclosure [Text Block] Earnings Per Share [Abstract] Earnings Per Share [Abstract] Raw materials Inventory, Raw Materials, Net of Reserves Developed technology Other Technology [Member] Other Technology [Member] Attune Medical Attune Medical [Member] Attune Medical Retained earnings Retained Earnings (Accumulated Deficit) Gain (loss) to be reclassified within the next twelve months Cash Flow Hedge Gain (Loss) to be Reclassified within 12 Months Debt instrument, percent of principal amount due in years 1-3 Debt Instrument, Percent of Principal Amount Due In Years 1-3 Debt Instrument, Percent of Principal Amount Due In Years 1-3 Change in inventories Increase (Decrease) in Inventories Payments on revolving facility Repayments of Long-Term Lines of Credit Debt issuance costs, gross Debt Issuance Costs, Gross Schedule of Debt Schedule of Debt [Table Text Block] Other Noncurrent Liabilities Other Noncurrent Liabilities [Member] Fiscal 2027 Long-Term Debt, Maturity, Year Two Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Equity Awards Adjustments Equity Awards Adjustments [Member] Accelerated share repurchases, final price paid per share Accelerated Share Repurchases, Final Price Paid Per Share Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Underlying Securities Award Underlying Securities Amount Percentage of sales generated outside the US Percentage Of Net Sales Generated Outside Of The US Percentage Of Net Sales Generated Outside Of The US Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Adjustment Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Adjustment Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Adjustment Restructuring and Restructuring Related Costs Restructuring and Restructuring Related Costs Restructuring and Restructuring Related Costs Amendment Flag Amendment Flag Entity Registrant Name Entity Registrant Name Upfront payment Payments to Acquire Businesses, Gross Gains on sales of property, plant and equipment Sale of property Gain (Loss) on Disposition of Property Plant Equipment Accounts receivable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Gross profit Gross Profit Plant equipment and machinery Machinery and Equipment [Member] Fair Value as of Grant Date Award Grant Date Fair Value Other comprehensive income (loss) before reclassifications Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Discrete Income Tax Benefit (Expense) [Domain] Discrete Income Tax Benefit (Expense) [Domain] Discrete Income Tax Benefit (Expense) [Domain] Level 2 Fair Value, Inputs, Level 2 [Member] Debt issuance costs, net Debt Issuance Costs, Net NOTES PAYABLE AND LONG-TERM DEBT Debt Disclosure [Text Block] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Geographical [Domain] Geographical [Domain] Customer-Related Intangible Assets Customer-Related Intangible Assets [Member] Property, Plant and Equipment Property, Plant and Equipment [Member] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Face amount of debt Debt Instrument, Face Amount Developed technology Technology-Based Intangible Assets [Member] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Interest Rate Swap Interest Rate Swap [Member] Schedule of Restructuring and Related Costs [Table] Restructuring Cost [Table] Restatement Determination Date: Restatement Determination Date [Axis] Title of 12(b) Security Title of 12(b) Security Amortization of fair value inventory step-up Amortization of Fair Value Inventory Step Up Amortization of Fair Value Inventory Step Up Common stock, $0.01 par value; Authorized — 150,000,000 shares; Issued and outstanding — 50,235,051 shares at December 28, 2024 and 50,787,859 shares at March 30, 2024 Common Stock, Value, Issued Digital transformation costs Digital Transformation Costs Digital Transformation Costs Haemonetics equipment Haemonetics Equipment [Member] Haemonetics Equipment Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Schedule of Investments [Table] Schedule of Investments [Table] Other Noncurrent Assets Other Noncurrent Assets [Member] Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Assets held for sale Goodwill, Assets Held for Sale Goodwill, Assets Held for Sale Other Current Liabilities Other Current Liabilities [Member] Cash Flows from Financing Activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Amortization of acquired intangible assets Amortization of Acquired Intangible Assets Amortization of Acquired Intangible Assets Accrued liabilities Accrued Liabilities Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Basic income (loss) per share (in dollars per share) Earnings Per Share, Basic Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Schedule of Goodwill [Table] Goodwill [Table] Designated as Hedging Instrument Designated as Hedging Instrument [Member] Disposal Group, Held-for-Sale, Not Discontinued Operations Disposal Group, Held-for-Sale, Not Discontinued Operations [Member] Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Amortizable: Finite-Lived Intangible Assets, Net [Abstract] Total current liabilities Liabilities, Current Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Weighted average shares outstanding Weighted Average Number of Shares Outstanding, Diluted [Abstract] Share Repurchase Program [Axis] Share Repurchase Program [Axis] Total assets Assets Fiscal 2026 Finite-Lived Intangible Asset, Expected Amortization, Year One Cost of goods sold Cost of Goods and Services Sold Gain (loss) on extinguishment of debt, before debt issuance cost writeoff Gain (Loss) on Extinguishment of Debt, before Debt Issuance Cost Writeoff Long-Lived Assets Held-for-Sale, Name [Domain] Long-Lived Assets Held-for-Sale, Name [Domain] Capital expenditures Payments to Acquire Property, Plant, and Equipment Other long-term liabilities Other Liabilities, Noncurrent Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Termination Date Trading Arrangement Termination Date Operating lease, revenue, as a percentage of total net sales Operating Lease, Revenue, As A Percentage Of Total Net Sales Operating Lease, Revenue, As A Percentage Of Total Net Sales Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fiscal 2026 Long-Term Debt, Maturity, Year One Not Designated as Hedging Instrument Not Designated as Hedging Instrument [Member] Proceeds from employee stock purchase plan Employee Stock Ownership Plan (ESOP), Cash Contributions to ESOP Entity Address, City or Town Entity Address, City or Town Debt Instrument [Axis] Debt Instrument [Axis] Convertible notes, fair value Convertible Debt, Fair Value Disclosures Net income Net income Net income Net Income (Loss) Attributable to Parent Trading Arrangement: Trading Arrangement [Axis] Business combination, estimated working capital adjustment Business Combination, Working Capital Adjustment Business Combination, Working Capital Adjustment Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Business Acquisition [Axis] Business Acquisition [Axis] Schedule of Finite-Lived Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Contingent Consideration Fair Value, Risk-Adjusted Discount Rate Contingent Consideration Fair Value, Risk-Adjusted Discount Rate Contingent Consideration Fair Value, Risk-Adjusted Discount Rate Entity File Number Entity File Number Liabilities Liabilities, Fair Value Disclosure [Abstract] REVENUE Revenue from Contract with Customer [Text Block] Document Fiscal Year Focus Document Fiscal Year Focus Income Statement [Abstract] Income Statement [Abstract] Entity Address, Address Line One Entity Address, Address Line One Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Effect of exchange rates on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Assets fair value Assets, Fair Value Disclosure Restructuring Plan [Domain] Restructuring Plan [Domain] Name Forgone Recovery, Individual Name Document Period End Date Document Period End Date Schedule of Interest Rate Swaps Schedule of Interest Rate Derivatives [Table Text Block] Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Finished goods Inventory, Finished Goods, Net of Reserves Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Insider Trading Arrangements [Line Items] Derivative, percentage of notional value of debt Derivative, Percentage Of Notional Value Of Debt Derivative, Percentage Of Notional Value Of Debt Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Effect of exchange rates Effect of Exchange Rate on Revenues Effect of Exchange Rate on Revenues Other Current Assets Other Current Assets [Member] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Accounts payable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable Net revenues in constant currency Net Revenues, By Business Unit Before Foreign Exchange Impact Net Revenues, By Business Unit Before Foreign Exchange Impact Schedule of Business Acquisitions, by Acquisition Schedule of Business Acquisitions, by Acquisition [Table Text Block] Revenue recognized Contract with Customer, Liability, Revenue Recognized OpSens, Inc. OpSens, Inc. [Member] OpSens, Inc. Adjustment to Compensation: Adjustment to Compensation [Axis] Plasma Plasma Products and Services [Member] Plasma Products and Services [Member] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Restructuring related costs Restructuring Related Costs Restructuring Related Costs Foreign Exchange Contract Foreign Exchange Contract [Member] Document Transition Report Document Transition Report Document Quarterly Report Document Quarterly Report Other investing activities Payments to Acquire Other Investments Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Accumulated other comprehensive loss Balance as of March 30, 2024 Balance as of December 28, 2024 Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Current Reporting Status Entity Current Reporting Status Retained Earnings Retained Earnings [Member] Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Litigation-related charges Litigation Settlement, Fee Expense Hemostasis Management, Hospital Hemostasis Management, Hospital [Member] Hemostasis Management, Hospital Basic (in shares) Weighted average shares (in shares) Weighted Average Number of Shares Outstanding, Basic Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Property, plant and equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Executive Category: Executive Category [Axis] Term loan, net of financing fees Medium-Term Note [Member] Payment to acquire investment Payments to Acquire Investments Name Awards Close in Time to MNPI Disclosures, Individual Name Other liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other Construction in progress Construction in Progress [Member] Capped call transaction, initial strike price (in dollars per share) Debt Instrument, Convertible, Capped Call Transaction, Initial Strike Price Debt Instrument, Convertible, Capped Call Transaction, Initial Strike Price Entity Filer Category Entity Filer Category Amount of Gain Excluded from Effectiveness Testing Gain (Loss) from Components Excluded from Assessment of Fair Value Hedge Effectiveness, Net Restructuring liability Balance at March 30, 2024 Balance at December 28, 2024 Restructuring Reserve Balance (in shares) Balance (in shares) Shares, Issued Performance obligation amount Revenue, Remaining Performance Obligation, Amount Statement of Income Location, Balance [Domain] Statement of Income Location, Balance [Domain] Interest rate floor Debt Instrument, Interest Rate, Floor Debt Instrument, Interest Rate, Floor Company Selected Measure Name Company Selected Measure Name EX-101.PRE 10 hae-20241228_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 12 R1.htm IDEA: XBRL DOCUMENT v3.25.0.1
COVER PAGE - shares
 9 Months Ended
Dec. 28, 2024
Feb. 03, 2025
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Dec. 28, 2024  
Document Transition Report false  
Entity File Number 001-14041  
Entity Registrant Name HAEMONETICS CORPORATION  
Entity Central Index Key 0000313143  
Current Fiscal Year End Date --03-29  
Document Fiscal Year Focus 2025  
Document Fiscal Period Focus Q3  
Amendment Flag false  
Entity Incorporation, State or Country Code MA  
Entity Tax Identification Number 04-2882273  
Entity Address, Address Line One 125 Summer Street  
Entity Address, City or Town Boston,  
Entity Address, State or Province MA  
Entity Address, Postal Zip Code 02110  
City Area Code 781  
Local Phone Number 848-7100  
Title of 12(b) Security Common stock, $.01 par value per share  
Trading Symbol HAE  
Security Exchange Name NYSE  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   50,237,466
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.25.0.1
CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Dec. 28, 2024
Dec. 30, 2023
Dec. 28, 2024
Dec. 30, 2023
Income Statement [Abstract]        
Net revenues $ 348,542 $ 336,250 $ 1,030,225 $ 965,765
Cost of goods sold 154,995 158,383 474,317 450,123
Gross profit 193,547 177,867 555,908 515,642
Operating expenses:        
Research and development 15,829 13,265 46,808 38,578
Selling, general and administrative 106,459 111,713 321,653 320,518
Amortization of acquired intangible assets 12,230 6,911 36,965 21,606
Total operating expenses 134,518 131,889 405,426 380,702
Operating income 59,029 45,978 150,482 134,940
Interest and other expense, net (9,112) (1,949) (9,148) (6,489)
Income before provision for income taxes 49,917 44,029 141,334 128,451
Provision for income taxes 12,423 12,788 31,636 31,260
Net income $ 37,494 $ 31,241 $ 109,698 $ 97,191
Basic income (loss) per share (in dollars per share) $ 0.75 $ 0.62 $ 2.16 $ 1.92
Diluted income (loss) per share (in dollars per share) $ 0.74 $ 0.61 $ 2.14 $ 1.89
Weighted average shares outstanding        
Basic (in shares) 50,286 50,768 50,709 50,679
Diluted (in shares) 50,639 51,445 51,148 51,394
Comprehensive income $ 16,557 $ 39,564 $ 89,829 $ 103,190
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.25.0.1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 28, 2024
Mar. 30, 2024
Current assets:    
Cash and cash equivalents $ 320,846 $ 178,800
Accounts receivable, less allowance for credit losses of $5,986 at December 28, 2024 and $5,695 at March 30, 2024 211,949 206,562
Inventories, net 359,614 317,202
Prepaid expenses and other current assets 113,459 66,339
Total current assets 1,005,868 768,903
Property, plant and equipment, net 286,107 311,362
Intangible assets, less accumulated amortization of $311,596 at December 28, 2024 and $455,213 at March 30, 2024 465,615 406,117
Goodwill 605,266 565,082
Deferred tax asset 8,000 7,739
Other long-term assets 160,414 136,388
Total assets 2,531,270 2,195,591
Current liabilities:    
Notes payable and current maturities of long-term debt 5,075 10,229
Accounts payable 62,990 73,358
Accrued payroll and related costs 45,933 80,708
Other current liabilities 139,235 136,088
Total current liabilities 253,233 300,383
Long-term debt 1,219,762 797,564
Deferred tax liability 61,451 62,644
Other long-term liabilities 89,964 75,041
Stockholders’ equity:    
Common stock, $0.01 par value; Authorized — 150,000,000 shares; Issued and outstanding — 50,235,051 shares at December 28, 2024 and 50,787,859 shares at March 30, 2024 502 508
Additional paid-in capital 569,629 634,627
Retained earnings 392,230 360,456
Accumulated other comprehensive loss (55,501) (35,632)
Total stockholders’ equity 906,860 959,959
Total liabilities and stockholders’ equity $ 2,531,270 $ 2,195,591
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.25.0.1
CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) - USD ($)
$ in Thousands
Dec. 28, 2024
Mar. 30, 2024
Statement of Financial Position [Abstract]    
Accounts receivable, allowance $ 5,986 $ 5,695
Intangible assets, amortization $ 311,596 $ 455,213
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, shares authorized (in shares) 150,000,000 150,000,000
Common stock, shares issued (in shares) 50,235,051 50,787,859
Common stock, shares outstanding (in shares) 50,235,051 50,787,859
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.25.0.1
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Retained Earnings
Accumulated Other Comprehensive (Loss)/Income
Balance (in shares) at Apr. 01, 2023   50,449,000      
Balance at Apr. 01, 2023 $ 817,997 $ 504 $ 594,706 $ 253,168 $ (30,381)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Employee stock purchase plan (in shares)   40,000      
Employee stock purchase plan 2,871   2,871    
Exercise of stock options (in shares)   145,000      
Exercise of stock options 627 $ 2 5,858 (5,233)  
Issuance of restricted stock, net of cancellations (in shares)   140,000      
Issuance of restricted stock, net of cancellations 0 $ 2 (2)    
Tax withholding on employee equity awards (in shares)   (68,000)      
Tax withholding on employee equity awards (5,773) $ (1) (812) (4,960)  
Share-based compensation expense 6,989   6,989    
Net income 41,042     41,042  
Other comprehensive income (loss) 863       863
Balance (in shares) at Jul. 01, 2023   50,706,000      
Balance at Jul. 01, 2023 864,616 $ 507 609,610 284,017 (29,518)
Balance (in shares) at Apr. 01, 2023   50,449,000      
Balance at Apr. 01, 2023 817,997 $ 504 594,706 253,168 (30,381)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net income 97,191        
Balance (in shares) at Dec. 30, 2023   50,785,000      
Balance at Dec. 30, 2023 943,319 $ 508 627,094 340,099 (24,382)
Balance (in shares) at Jul. 01, 2023   50,706,000      
Balance at Jul. 01, 2023 864,616 $ 507 609,610 284,017 (29,518)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Exercise of stock options (in shares)   12,000      
Exercise of stock options 692 $ 0 655 37  
Issuance of restricted stock, net of cancellations (in shares)   22,000      
Issuance of restricted stock, net of cancellations 0        
Tax withholding on employee equity awards (in shares)   0      
Tax withholding on employee equity awards (75) $ 0 (11) (64)  
Share-based compensation expense 6,706   6,706    
Net income 24,908     24,908  
Other comprehensive income (loss) (3,187)       (3,187)
Balance (in shares) at Sep. 30, 2023   50,740,000      
Balance at Sep. 30, 2023 893,660 $ 507 616,960 308,898 (32,705)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Employee stock purchase plan (in shares)   39,000      
Employee stock purchase plan 2,732   2,732    
Exercise of stock options (in shares)   4,000      
Exercise of stock options 186 $ 1 189 (4)  
Issuance of restricted stock, net of cancellations (in shares)   3,000      
Issuance of restricted stock, net of cancellations 0 $ 0 0    
Tax withholding on employee equity awards (in shares)   (1,000)      
Tax withholding on employee equity awards (40)   (4) (36)  
Share-based compensation expense 7,217   7,217    
Net income 31,241        
Other comprehensive income (loss) 8,323       8,323
Balance (in shares) at Dec. 30, 2023   50,785,000      
Balance at Dec. 30, 2023 943,319 $ 508 627,094 340,099 (24,382)
Balance (in shares) at Mar. 30, 2024   50,788,000      
Balance at Mar. 30, 2024 959,959 $ 508 634,627 360,456 (35,632)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Employee stock purchase plan (in shares)   47,000      
Employee stock purchase plan 3,441   3,441    
Exercise of stock options (in shares)   73,000      
Exercise of stock options 961 $ 1 4,703 (3,743)  
Issuance of restricted stock, net of cancellations (in shares)   280,000      
Issuance of restricted stock, net of cancellations 0 $ 3 (3)    
Tax withholding on employee equity awards (in shares)   (35,000)      
Tax withholding on employee equity awards (9,759) $ 0 (1,315) (8,444)  
Adjustments to additional paid in capital, convertible debt, capped call purchases 88,200   88,200    
Share-based compensation expense 7,628   7,628    
Net income 38,373     38,373  
Other comprehensive income (loss) (7,035)       (7,035)
Balance (in shares) at Jun. 29, 2024   51,153,000      
Balance at Jun. 29, 2024 905,368 $ 512 560,881 386,642 (42,667)
Balance (in shares) at Mar. 30, 2024   50,788,000      
Balance at Mar. 30, 2024 959,959 $ 508 634,627 360,456 (35,632)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net income 109,698        
Other comprehensive income (loss) (19,869)        
Balance (in shares) at Dec. 28, 2024   50,235,000      
Balance at Dec. 28, 2024 906,860 $ 502 569,629 392,230 (55,501)
Balance (in shares) at Jun. 29, 2024   51,153,000      
Balance at Jun. 29, 2024 905,368 $ 512 560,881 386,642 (42,667)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Exercise of stock options (in shares)   5,000      
Exercise of stock options $ 251 $ 0 515 (264)  
Shares repurchased (in shares) (799,000)        
Shares repurchased $ (75,241) $ (8) (23,839) (51,394)  
Issuance of restricted stock, net of cancellations (in shares)   23,000      
Issuance of restricted stock, net of cancellations 0        
Tax withholding on employee equity awards (in shares)   (1,000)      
Tax withholding on employee equity awards (318) $ 0 (39) (279)  
Share-based compensation expense 6,857   6,857    
Net income 33,831     33,831  
Other comprehensive income (loss) 8,103       8,103
Balance (in shares) at Sep. 28, 2024   50,381,000      
Balance at Sep. 28, 2024 878,851 $ 504 544,375 368,536 (34,564)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Employee stock purchase plan (in shares)   49,000      
Employee stock purchase plan 3,035   3,035    
Exercise of stock options (in shares)   12,000      
Exercise of stock options $ 505 $ 0 1,266 (761)  
Shares repurchased (in shares) (209,000)        
Shares repurchased $ (108) $ (2) 12,761 (12,867)  
Issuance of restricted stock, net of cancellations (in shares)   3,000      
Issuance of restricted stock, net of cancellations 0        
Tax withholding on employee equity awards (in shares)   (1,000)      
Tax withholding on employee equity awards (194) $ 0 (22) (172)  
Share-based compensation expense 8,214   8,214    
Net income 37,494     37,494  
Other comprehensive income (loss) (20,937)       (20,937)
Balance (in shares) at Dec. 28, 2024   50,235,000      
Balance at Dec. 28, 2024 $ 906,860 $ 502 $ 569,629 $ 392,230 $ (55,501)
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.25.0.1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 9 Months Ended
Dec. 28, 2024
Dec. 30, 2023
Cash Flows from Operating Activities:    
Net income $ 109,698 $ 97,191
Non-cash items:    
Depreciation and amortization 87,378 69,576
Amortization of fair value inventory step-up 12,319 0
Share-based compensation expense 22,699 20,912
Impairment of intangible assets 2,391 10,419
Gain on repurchase of convertible senior notes, net (12,600) 0
Inventory reserve adjustment 1,289 6,904
Gains on sales of property, plant and equipment (14,572) (647)
Deferred tax benefit (8,593) (5,138)
Other non-cash operating activities 8,114 5,748
Change in operating assets and liabilities:    
Change in accounts receivable (3,379) (27,743)
Change in inventories (65,629) (40,721)
Change in prepaid income taxes (2,638) 1,730
Change in other assets and other liabilities (34,493) (15,619)
Change in accounts payable and accrued expenses (36,816) (4,942)
Net cash provided by operating activities 65,168 117,670
Cash Flows from Investing Activities:    
Capital expenditures (23,635) (31,440)
Non-cash transfers from inventory to property, plant and equipment for Haemonetics equipment (12,649) (25,171)
Acquisition, net of cash acquired (150,906) (243,852)
Proceeds from sale of property, plant and equipment 20,802 1,259
Other investing activities (13,547) (10,129)
Net cash used in investing activities (179,935) (309,333)
Cash Flows from Financing Activities:    
Proceeds from issuance of convertible notes 700,000 0
Repurchase of convertible senior notes (185,500) 0
Purchase of capped call related to convertible notes (88,200) 0
Term loan borrowings 250,000 0
Term loan redemption (262,500) 0
Proceeds from revolving facility 0 110,000
Payments on revolving facility 50,000 0
Repayment of term loan borrowings (3,125) (8,750)
Debt issuance costs (23,135) 0
Share repurchases (75,000) 0
Proceeds from employee stock purchase plan 6,476 5,603
Proceeds from exercise of stock options 1,717 1,505
Cash used to net share settle employee equity awards (10,243) (5,885)
Other financing activities (222) (814)
Net cash provided by financing activities 260,268 101,659
Effect of exchange rates on cash and cash equivalents (3,455) (484)
Net Change in Cash and Cash Equivalents 142,046 (90,488)
Cash and Cash Equivalents at Beginning of Period 178,800 284,466
Cash and Cash Equivalents at End of Period $ 320,846 $ 193,978
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.25.0.1
BASIS OF PRESENTATION
 9 Months Ended
Dec. 28, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
BASIS OF PRESENTATION
1. BASIS OF PRESENTATION

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements of Haemonetics Corporation (“Haemonetics” or the “Company”) presented herein have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of the Company’s management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. All intercompany transactions have been eliminated. Operating results for the nine months ended December 28, 2024 are not necessarily indicative of the results that may be expected for the full fiscal year ending March 29, 2025 or any other interim period. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and footnotes included in the Annual Report on Form 10-K for the fiscal year ended March 30, 2024.

The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the financial statements to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated as required. There were no material recognized or unrecognized subsequent events as of or for the nine months ended December 28, 2024, except for those discussed in Note 3, Acquisitions, Divestitures and Strategic Investments.
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.25.0.1
RECENT ACCOUNTING PRONOUNCEMENTS
 9 Months Ended
Dec. 28, 2024
Accounting Standards Update and Change in Accounting Principle [Abstract]  
RECENT ACCOUNTING PRONOUNCEMENTS
2. RECENT ACCOUNTING PRONOUNCEMENTS

Standards to be Implemented

In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Codification (“ASC”) Update No. 2023-07, Segment Reporting (Topic 280). The new guidance requires public entities to provide expanded disclosures over significant segment expenses and additional disclosures related to the chief operating decision maker. ASC Update No. 2023-07 is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The new guidance is applicable to Haemonetics beginning with the fiscal 2025 Annual Report on Form 10-K. The Company is currently evaluating the impact to its interim and annual report disclosures.

In December 2023, the FASB issued ASC Update No. 2023-09, Income Taxes (Topic 740). ASC Update No. 2023-09 requires public entities to provide detailed income tax disclosures, including rate reconciliations and disaggregated income tax payment information, on an annual basis. The updated guidance is effective for fiscal years beginning after December 15, 2024 and early adoption is permitted. ASC Update No. 2023-09 is applicable to Haemonetics beginning with the fiscal 2026 Annual Report on Form 10-K and the Company is currently evaluating the impact to its annual report disclosures.

In November 2024, the FASB issued ASC Update No. 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40). ASC Update No. 2024-03 requires detailed cost and expense information disaggregated in the financial statement notes. The updated guidance is effective for fiscal years beginning after December 15, 2026 and interim reporting periods within annual reporting periods beginning after December 15, 2027, with early adoption permitted. ASC Update No. 2024-03 is applicable to Haemonetics beginning with the fiscal 2028 Annual Report on Form 10-K and the Company is currently evaluating the impact to its interim and annual report disclosures.
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.25.0.1
ACQUISITIONS, DIVESTITURES AND STRATEGIC INVESTMENTS
 9 Months Ended
Dec. 28, 2024
Investments, All Other Investments [Abstract]  
ACQUISITIONS, DIVESTITURES AND STRATEGIC INVESTMENTS
3. ACQUISITIONS, DIVESTITURES AND STRATEGIC INVESTMENTS

Acquisitions

Attune Medical

On March 5, 2024, the Company entered into a definitive agreement to acquire Advanced Cooling Therapy, Inc., d/b/a Attune Medical (“Attune Medical”), the manufacturer of the ensoETM® proactive esophageal cooling device, pursuant to which, among other things, the Company agreed to acquire all of the issued and outstanding common shares of Attune Medical. On April 1, 2024, the Company completed its acquisition of Attune Medical for total consideration of $187.7 million, which included an upfront cash payment of $162.0 million, or $150.5 million net of cash acquired, the fair value of contingent consideration of $25.3 million, and $0.4 million of working capital adjustments. The contingent consideration is based on sales growth over the next three years, which is uncapped, and the achievement of certain other milestones. The Company financed the acquisition through a combination of cash on hand and borrowings under its senior unsecured revolving credit facility.

Attune Medical's ensoETM technology is designed for use across a range of medical conditions involving patient cooling or warming, including treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery, among others. The Company’s addition of the Esophageal Protection product line through its acquisition of Attune Medical expands the Hospital business unit’s presence in electrophysiology and complements its Vascular Closure product line within Interventional Technologies, which is included in the Hospital reportable segment.

Purchase Price Allocation

The Company accounted for the acquisition as a business combination, and in accordance with FASB ASC Topic 805, Business Combinations (Topic 805), recorded the assets acquired and liabilities assumed at their fair values as of the acquisition date. The fair value of assets acquired and liabilities assumed have been recognized based on management’s estimates and assumptions using the information regarding facts and circumstances that existed at the closing date.

The purchase price of $176.2 million, net of $11.5 million of cash acquired, consists of the amounts presented below, which represent the final determination of the fair value of the identifiable assets acquired and liabilities assumed:

(In thousands) April 1, 2024
Accounts receivable$3,784 
Inventories26,300 
Prepaid expenses and other current assets906 
Property, plant and equipment200 
Intangible assets105,800 
Goodwill70,256 
Total assets acquired$207,246 
Accounts payable2,260 
Accrued payroll and related costs2,129 
Other liabilities496 
Deferred tax liability26,155 
Total liabilities assumed$31,040 
Net assets acquired$176,206 
The Company determined that the identifiable intangible assets were developed technology, customer contracts and related relationships and trade names. The fair values of intangible assets were based on valuation techniques with estimates and assumptions developed by the Company. Developed technology was valued using the excess earnings method. Customer contracts and related relationships were valued using the distributor method. The trademark was valued using the relief from royalty method. The cash flows used in the valuation of the intangible assets were based on estimates used to price the transaction. In developing the discount rates applied to the cash flow projections, the discount rates were benchmarked with reference to the implied rate of return from the transaction model and the weighted average cost of capital and then adjusted to reflect the relative risk of the asset.

The excess of the purchase price over the tangible assets, identifiable intangible assets and assumed liabilities was recorded as goodwill. As a result of the acquisition of Attune Medical, the Company recognized goodwill of $70.3 million based on expected synergies from integration into our Hospital business. The goodwill is not deductible for tax purposes and relates entirely to the Hospital reportable segment.

Intangible assets acquired consist of the following:
(In thousands)AmountWeighted-Average Amortization PeriodRisk-Adjusted Discount
Rates used in Purchase Price Allocation
Developed technology$96,100 10 years22.0 %
Customer contracts and related relationships7,800 10 years21.5 %
Trade names1,900 10 years21.5 %
Total$105,800 

The Company recorded a long-term net deferred tax liability of $26.2 million primarily related to fair value adjustments recorded associated with definite-lived intangible assets and inventory in which there is no tax basis, partially offset by deferred tax assets primarily related to net operating losses acquired.

Acquisition-Related Costs

The Company incurred $9.8 million of acquisition-related costs during the first quarter of fiscal 2025 in connection with the Attune Medical acquisition. These costs related to legal and other professional fees, which were recognized in selling, general and administrative on the Condensed Consolidated Statements of Income.

The Company’s condensed consolidated financial statements include the results of Attune Medical from the date the acquisition was completed. Pro forma financial information has not been presented as the acquisition is not material to the Company’s overall financial results.

OpSens Inc.

On October 10, 2023, the Company entered into an Arrangement Agreement with OpSens Inc. (“OpSens”), a medical device cardiology-focused company delivering solutions based on its proprietary optical technology, pursuant to which, among other things, the Company agreed to acquire all of the issued and outstanding common shares of OpSens. On December 12, 2023, the Company completed its acquisition of OpSens for total consideration of approximately $254.5 million, or $243.9 million, net of cash acquired. The Company financed the acquisition through a combination of cash on hand and borrowings under its senior unsecured revolving credit facility.

OpSens offers commercially and clinically validated optical technology for use primarily in interventional cardiology. OpSens’ core products include the SavvyWire®, a sensor-guided 3-in-1 guidewire for TAVR procedures, advancing the workflow of the procedure and enabling potentially shorter hospital stays for patients; and the OptoWire®, a pressure guidewire that aims to improve clinical outcomes by accurately and consistently measuring Fractional Flow Reserve (FFR) and diastolic pressure ratio (dPR) to aid clinicians in the diagnosis and treatment of patients with coronary artery disease. OpSens also manufactures a range of fiber optic sensor solutions used in medical devices and other critical industrial applications. The addition of OpSens expands the Hospital business unit portfolio in the interventional cardiology market and is included in the Hospital reportable segment.
Purchase Price Allocation

The Company accounted for the acquisition as a business combination, and in accordance with FASB ASC Topic 805, Business Combinations (Topic 805), recorded the assets acquired and liabilities assumed at their fair values as of the acquisition date. The fair value of assets acquired and liabilities assumed have been recognized based on management’s estimates and assumptions using the information regarding facts and circumstances that existed at the closing date.

The purchase price of $243.9 million, net of $10.6 million of cash acquired, consists of the amounts presented below, which represent the final determination of the fair value of the identifiable assets acquired and liabilities assumed:

(In thousands) December 12, 2023
Accounts receivable$5,960 
Inventories12,075 
Prepaid expenses and other current assets2,062 
Property, plant and equipment3,028 
Intangible assets172,000 
Goodwill79,400 
Other long-term assets4,705 
Total assets acquired$279,230 
Accounts payable3,251 
Accrued payroll and related costs1,723 
Other liabilities9,746 
Deferred tax liability14,805 
Other long-term liabilities5,853 
Total liabilities assumed$35,378 
Net assets acquired$243,852 

The Company determined that the identifiable intangible assets were developed technology, customer contracts and related relationships and trade names. The fair values of intangible assets were based on valuation techniques with estimates and assumptions developed by the Company. Developed technology and customer contracts and related relationships were valued using the excess earnings method. Trademarks were valued using the relief from royalty method. The cash flows used in the valuation of the intangible assets were based on estimates used to price the transaction. In developing the discount rates applied to the cash flow projections, the discount rates were benchmarked with reference to the implied rate of return from the transaction model and the weighted average cost of capital and then adjusted to reflect the relative risk of the asset.

The excess of the purchase price over the tangible assets, identifiable intangible assets and assumed liabilities was recorded as goodwill. As a result of the acquisition of OpSens, the Company recognized goodwill of $79.4 million based on expected synergies from integration into our Hospital business. The goodwill is not deductible for tax purposes and relates entirely to the Hospital reportable segment.

Intangible assets acquired consist of the following:
(In thousands)AmountWeighted-Average Amortization PeriodRisk-Adjusted Discount
Rates used in Purchase Price Allocation
Developed technology$114,900 15 years20.5 %
Customer contracts and related relationships52,300 15 years18.9 %
Trade names4,800 15 years20.5 %
Total$172,000 

The Company recorded a net long-term deferred tax liability of $14.8 million, primarily as a result of fair value adjustments recorded associated with definite-lived intangible assets and inventory in which there is no tax basis.
Acquisition-Related Costs

The Company incurred $6.6 million of acquisition-related costs for fiscal 2024 in connection with the OpSens acquisition. These costs related to legal and other professional fees, which were recognized in selling, general and administrative on the Condensed Consolidated Statements of Income.

The Company’s condensed consolidated financial statements include the results of OpSens from the date the acquisition was completed. Pro forma financial information has not been presented as the acquisition is not material to the Company’s overall financial results.

Divestiture of the Whole Blood Product Line

On December 3, 2024, the Company announced that it had entered into a definitive agreement to sell its Whole Blood product line and related assets within its Blood Center business unit to GVS, S.p.A (“GVS”), a manufacturer of filter solutions for applications in the healthcare and life sciences sectors. The divested assets include the Company’s complete portfolio of proprietary whole blood collection, processing and filtration solutions, along with the Company’s manufacturing facility in Covina, California where certain of these products are produced, and related equipment and assets located at the Company’s manufacturing facility in Tijuana, Mexico. On January 13, 2024, subsequent to the third quarter ended December 28, 2024, the Company completed the transaction with GVS for total cash consideration of up to $67.8 million, which includes $45.3 million upfront and up to $22.5 million in contingent consideration, based on sales growth over the next three years and the achievement of certain other milestones. As the related assets are considered held for sale as of December 28, 2024, the Company has reclassified $34.7 million of inventory, $7.3 million of property, plant and equipment, $4.5 million of goodwill and $0.5 million of accrued liabilities to Prepaid expenses and other current assets and other current liabilities in the Condensed Consolidated Balance Sheets, which were previously included in the Blood Center reportable segment.

Strategic Investments

As part of the Company’s business development activities, it holds strategic investments in certain entities. As of December 28, 2024, the Company has made total investments in Vivasure Medical LTD (“Vivasure”) of €35 million. The investments include both preferred stock and a special share that allows the Company to acquire Vivasure in accordance with an agreement between the parties. In addition, the Company made certain other strategic investments totaling $14.0 million and $7.6 million during fiscal 2025 and 2024, respectively. The Company’s strategic investments are classified as other long-term assets on the Company’s Condensed Consolidated Balance Sheets and the Company has not recorded any material adjustments to the carrying value of the Company’s strategic investments during three and nine months ended December 28, 2024 and December 30, 2023.
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.25.0.1
REVENUE
 9 Months Ended
Dec. 28, 2024
Revenue from Contract with Customer [Abstract]  
REVENUE
4. REVENUE

As of December 28, 2024, the Company had $33.3 million of transaction price allocated to remaining performance obligations related to executed contracts with an original duration of one year or more. The Company expects to recognize approximately 75% of this amount as revenue within the next twelve months and the remaining balance thereafter.

Contract Balances

The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables and contract assets, as well as customer advances, customer deposits and deferred revenue (contract liabilities) on the Condensed Consolidated Balance Sheets. The difference in timing between billing and revenue recognition primarily occurs in software licensing arrangements, resulting in contract assets and contract liabilities.

As of December 28, 2024 and March 30, 2024, the Company had contract liabilities of $35.6 million and $31.2 million, respectively. During the three and nine months ended December 28, 2024, the Company recognized $4.9 million and $26.7 million of revenue, respectively, that was included in the above March 30, 2024 contract liability balance. Contract liabilities are classified as other current liabilities on the Condensed Consolidated Balance Sheet. As of December 28, 2024 and March 30, 2024, the Company’s contract assets were immaterial.
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.25.0.1
RESTRUCTURING
 9 Months Ended
Dec. 28, 2024
Restructuring and Related Activities [Abstract]  
RESTRUCTURING
5. RESTRUCTURING

On an ongoing basis, the Company reviews the global economy, the healthcare industry, and the markets in which it competes to identify opportunities for efficiencies, enhance commercial capabilities, align its resources and offer its customers better solutions. In order to realize these opportunities, the Company undertakes restructuring-type activities to transform its business.


Operational Excellence Program

In July 2019, the Board of Directors of the Company approved the Operational Excellence Program (the “2020 Program”) and delegated authority to the Company’s management to determine the detail of the initiatives that will comprise the program. During fiscal 2022, the Company revised the program to improve product and service quality, reduce cost principally in its manufacturing and supply chain operations and ensure sustainability while helping to offset impacts from a previously announced customer loss, rising inflationary pressures and effects of the COVID-19 pandemic. The Company expects to incur aggregate charges of approximately $85.0 million by the end of fiscal 2025 under the program. The majority of charges will result in cash outlays, including severance and other employee costs, and will be incurred as the specific actions required to execute these initiatives are identified and approved. During the three and nine months ended December 28, 2024, the Company incurred $1.9 million and $6.0 million, respectively, of restructuring and restructuring related costs under this program. During the three and nine months ended December 30, 2023, the Company incurred $2.6 million and $6.8 million, respectively, of restructuring and restructuring related costs under this program. Total cumulative charges under this program are $83.0 million through December 28, 2024.

Portfolio Rationalization Initiatives

In November 2023, the Company announced its plans to end of life the ClotPro analyzer system within the Hospital business unit and certain products within the Blood Center business unit, primarily in Whole Blood, including the associated manufacturing operations and closure of certain other facilities. In the three and nine months ended December 28, 2024, the Company incurred $3.1 million and $12.5 million of expenses, respectively, of restructuring and restructuring related costs in connection with these portfolio rationalization initiatives. In both the three and nine months ended December 30, 2023, the Company incurred $7.8 million of restructuring and related costs related to these portfolio rationalization initiatives.

The following table summarizes the activity for restructuring reserves related to the portfolio rationalization initiatives and the 2020 Program for the nine months ended December 28, 2024, which relates to employee severance, other employee costs, inventory reserves and lease termination fees:
(In thousands)Portfolio Rationalization2020 ProgramTotal
Balance at March 30, 2024
$11,309 $485 $11,794 
Costs incurred, net of reversals12,296 633 12,929 
Payments(10,837)(652)(11,489)
Non-cash adjustments(8,616)— (8,616)
Balance at December 28, 2024
$4,152 $466 $4,618 

The following presents the restructuring costs by line item within our accompanying unaudited Condensed Consolidated Statements of Income and Comprehensive Income:
 Three Months EndedNine Months Ended
(In thousands) December 28,
2024		December 30,
2023		December 28,
2024		December 30,
2023
Cost of goods sold$3,027 $7,065 $11,158 $7,329 
Research and development(4)343 (16)343 
Selling, general and administrative expenses492 560 1,787 371 
Total$3,515 $7,968 $12,929 $8,043 

As of December 28, 2024, the Company had a restructuring liability of $4.6 million, all of which is payable within the next twelve months.
In addition to the restructuring expenses included in the table above, the Company also incurred costs that do not constitute restructuring costs under ASC 420, Exit and Disposal Cost Obligations, and which the Company instead refers to as restructuring related costs. These costs consist primarily of expenditures directly related to the restructuring actions.

The tables below present restructuring and restructuring related costs by reportable segment:
Restructuring costsThree Months EndedNine Months Ended
(In thousands) December 28, 2024December 30, 2023December 28, 2024December 30, 2023
Plasma$77 $33 $284 $(164)
Blood Center685 4,546 4,241 4,546 
Hospital774 2,503 1,404 2,745 
Corporate1,979 886 7,000 916 
Total$3,515 $7,968 $12,929 $8,043 
Restructuring related costsThree Months EndedNine Months Ended
(In thousands) December 28, 2024December 30, 2023December 28, 2024December 30, 2023
Plasma$37 $72 $263 $315 
Blood Center31 93 120 166 
Hospital(68)251 40 398 
Corporate1,468 1,987 5,134 5,675 
Total$1,468 $2,403 $5,557 $6,554 
Total restructuring and restructuring related costs$4,983 $10,371 $18,486 $14,597 
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.25.0.1
INCOME TAXES
 9 Months Ended
Dec. 28, 2024
Income Tax Disclosure [Abstract]  
INCOME TAXES
6. INCOME TAXES

The Company conducts business globally and reports its results of operations in a number of foreign jurisdictions in addition to the United States. The Company’s reported tax rate differs from the statutory tax rate due to the jurisdictional mix of earnings in any given period as the foreign jurisdictions in which it operates have tax rates that differ from the U.S. statutory tax rate. The Company’s effective tax rate is adversely impacted by non-deductible expenses including executive compensation and transaction costs.

For the three and nine months ended December 28, 2024, the Company reported income tax expense of $12.4 million and $31.6 million, respectively, representing effective tax rates of 24.9% and 22.4%. The effective tax rate for the nine months ended December 28, 2024 includes $3.3 million of discrete tax benefit, primarily related to stock compensation windfalls. The discrete benefit also includes other items such as provision to return differences.

For the three and nine months ended December 30, 2023, the Company reported income tax expense of $12.8 million and $31.3 million, respectively, representing effective tax rates of 29.0% and 24.3%, respectively. The effective tax rate for the nine months ended December 30, 2023 includes $1.1 million of discrete tax benefit, of which $2.6 million relates to stock compensation windfalls, partially offset by other discrete items.

The decrease in the reported tax rate for the three months ended December 28, 2024, compared to the same period in fiscal 2024, relates primarily to the decrease in non-deductible acquisition-related expenses. The decrease in the reported tax rate for the nine months ended December 28, 2024, compared to the same period in fiscal 2024, relates primarily to increased discrete tax benefits year-over-year and decreased non-deductible acquisition-related expenses.
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.25.0.1
EARNINGS PER SHARE
 9 Months Ended
Dec. 28, 2024
Earnings Per Share [Abstract]  
EARNINGS PER SHARE
7. EARNINGS PER SHARE

The following table provides a reconciliation of the numerators and denominators of the basic and diluted earnings per share computations.
 Three Months EndedNine Months Ended
 (In thousands, except per share amounts)December 28,
2024		December 30,
2023		December 28,
2024		December 30,
2023
Basic EPS  
Net income$37,494 $31,241 $109,698 $97,191 
Weighted average shares50,286 50,768 50,709 50,679 
Basic income per share$0.75 $0.62 $2.16 $1.92 
Diluted EPS    
Net income$37,494 $31,241 $109,698 $97,191 
Basic weighted average shares50,286 50,768 50,709 50,679 
Net effect of common stock equivalents353 677 439 715 
Diluted weighted average shares50,639 51,445 51,148 51,394 
Diluted income per share$0.74 $0.61 $2.14 $1.89 

Basic earnings per share is calculated using the Company’s weighted-average outstanding common shares. Diluted earnings per share is calculated using its weighted-average outstanding common shares including the dilutive effect of stock awards as determined under the treasury stock method and the outstanding convertible senior notes as determined under the net share settlement method. From the time of the issuance of the convertible senior notes, the average market price of the Company's common shares has been less than the applicable initial conversion prices, and consequently no shares have been included in diluted earnings per share for the conversion values of both convertible senior notes. For the three and nine months ended December 28, 2024, weighted average shares outstanding, assuming dilution, excludes the impact of $0.8 million anti-dilutive shares for both periods. For the three and nine months ended December 30, 2023, weighted average shares outstanding, assuming dilution, excludes the impact of $0.6 million anti-dilutive shares for both periods.

Share Repurchase Program

In August 2022, the Company announced that its Board of Directors had approved a three-year share repurchase program authorizing the repurchase of up to $300.0 million of Haemonetics common stock, based on market conditions, through August 2025. Under the share repurchase program, the Company is authorized to repurchase, from time to time, outstanding shares of common stock in accordance with applicable laws on the open market, including under trading plans established pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and in privately negotiated transactions. The actual timing, number and value of shares repurchased will be determined by the Company at its discretion and will depend on a number of factors, including market conditions, applicable legal requirements and compliance with the terms of loan covenants. The share repurchase program may be suspended, modified or discontinued at any time, and the Company has no obligation to repurchase any amount of its common stock under the program.

In October 2024, the Company completed a $75.0 million repurchase of its common stock pursuant to an accelerated share repurchase agreement (“ASR”) entered into with Citibank N.A. (“Citibank”) in August 2024. The total number of shares repurchased under the ASR was 1.0 million at an average price per share upon final settlement of $74.36. As of December 28, 2024, the total remaining authorization for repurchases of the Company's common stock under the share repurchase program was $150.0 million.
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.25.0.1
INVENTORIES
 9 Months Ended
Dec. 28, 2024
Inventory Disclosure [Abstract]  
INVENTORIES
8. INVENTORIES

Inventories are stated at the lower of cost or net realizable value and include the cost of material, labor and manufacturing overhead. Cost is determined with the first-in, first-out method.
(In thousands)December 28,
2024		March 30,
2024
Raw materials$101,989 $134,150 
Work-in-process32,120 15,488 
Finished goods225,505 167,564 
Total inventories$359,614 $317,202 

In the third quarter of fiscal 2025, the Company announced the divestiture of its Whole Blood product line within its Blood Center business unit and all related assets and liabilities were recognized as held for sale. The related inventory has a value of $34.7 million, which has been reclassified to Prepaid expenses and other current assets in the Condensed Consolidated Balance Sheets.
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.25.0.1
PROPERTY, PLANT AND EQUIPMENT
 9 Months Ended
Dec. 28, 2024
Property, Plant and Equipment [Abstract]  
PROPERTY, PLANT AND EQUIPMENT
9. PROPERTY, PLANT AND EQUIPMENT

(In thousands)December 28,
2024		March 30,
2024
Land$1,999 $4,130 
Building and building improvements107,665 124,338 
Plant equipment and machinery191,063 204,622 
Office equipment and information technology129,123 129,979 
Haemonetics equipment412,561 456,414 
Construction in progress25,046 39,694 
Total867,457 959,177 
Less: accumulated depreciation(581,350)(647,815)
Property, plant and equipment, net$286,107 $311,362 

During the three and nine months ended December 28, 2024, depreciation expense was $15.2 million and $44.8 million, respectively. During the three and nine months ended December 30, 2023, depreciation expense was $14.2 million and $41.1 million, respectively.

In the third quarter of fiscal 2025, the Company announced the divestiture of its Whole Blood product line within its Blood Center business unit and all related assets and liabilities were recognized as held for sale. The related property, plant and equipment has a gross value of $39.8 million and a net carrying value of $7.3 million, which has been reclassified to Prepaid expenses and other current assets in the Condensed Consolidated Balance Sheets.

In the first quarter of fiscal 2025, the Company received $19.9 million of cash upon the sale of a manufacturing facility and related assets that previously met held for sale criteria, which resulted in a gain of $14.1 million that was recorded in selling, general and administrative expenses on the Condensed Consolidated Statements of Income.
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.25.0.1
LEASES
 9 Months Ended
Dec. 28, 2024
Leases [Abstract]  
LEASES
10. LEASES

Lessor Activity
Assets on the Company’s balance sheet classified as Haemonetics equipment primarily consist of medical devices installed at customer sites but owned by Haemonetics. These devices are leased to customers under contractual arrangements that typically include an operating or sales-type lease as well as the purchase and consumption of a certain level of disposable products. Sales-type leases are not significant. Contract terms vary by customer and may include options to terminate the contract or options to extend the contract. Where devices are provided under operating lease arrangements, a substantial majority of the entire lease revenue is variable and subject to subsequent non-lease component (disposable products) sales. The allocation of revenue between the lease and non-lease components is based on estimated stand-alone selling prices. Operating lease revenue represents less than 3 percent of the Company’s total net sales.
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.25.0.1
GOODWILL AND INTANGIBLE ASSETS
 9 Months Ended
Dec. 28, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
GOODWILL AND INTANGIBLE ASSETS
11. GOODWILL AND INTANGIBLE ASSETS

The changes in the carrying amount of goodwill by operating segment for fiscal 2025 are as follows:
(In thousands)PlasmaBlood CenterHospitalTotal
Carrying amount as of March 30, 2024
$29,043 $33,484 $502,555 $565,082 
Assets held for sale— (4,475)— (4,475)
Purchase accounting adjustments— — (19,248)(19,248)
Acquisitions— — 69,542 69,542 
Currency translation— (268)(5,367)(5,635)
Carrying amount as of December 28, 2024
$29,043 $28,741 $547,482 $605,266 
The decrease in goodwill of $19.2 million for purchase accounting adjustments was primarily related to the Company obtaining additional facts and information to finalize the pre-acquisition tax returns and associated analyses for OpSens. This resulted in the Company revising its estimate of the net deferred tax liability recorded as of the acquisition date. Refer to Note 3, Acquisitions, Divestitures and Strategic Investments, for additional information regarding the acquisitions of OpSens and Attune Medical.
In the third quarter of fiscal 2025, the Company announced the divestiture of its Whole Blood product line within its Blood Center business unit and all related assets and liabilities were recognized as held for sale. The related goodwill of $4.5 million has been reclassified to Prepaid expenses and other current assets in the Condensed Consolidated Balance Sheets.

The gross carrying amount of intangible assets and the related accumulated amortization as of December 28, 2024 and March 30, 2024 is as follows:
(In thousands)Gross Carrying
Amount		Accumulated
Amortization		Net
As of December 28, 2024
  
Amortizable:
Developed technology$505,323 $146,898 $358,425 
Customer contracts and related relationships136,181 70,261 65,920 
Capitalized software85,528 74,722 10,806 
Patents and other27,504 13,579 13,925 
Trade names15,927 6,136 9,791 
Total$770,463 $311,596 $458,867 
Non-amortizable:
In-process software development$6,748 
Total$6,748 
(In thousands)Gross Carrying
Amount		Accumulated
Amortization		Net
As of March 30, 2024
  
Amortizable:
Developed technology$464,291 $178,413 $285,878 
Customer contracts and related relationships255,144 190,033 65,111 
Capitalized software84,837 69,491 15,346 
Patents and other24,504 11,820 12,684 
Trade names14,320 5,456 8,864 
Total$843,096 $455,213 $387,883 
Non-amortizable:
In-process research and development$13,667 
In-process software development4,567 
Total$18,234 

During fiscal 2025, the Company acquired Attune Medical and recorded $96.1 million of developed technology, $7.8 million of customer contracts and related relationships and $1.9 million of trade name intangibles based on the purchase accounting valuation. Refer to Note 3, Acquisitions, Divestitures and Strategic Investments, for additional information regarding the acquisition.

In the first quarter of fiscal 2025, the Company announced the commercialization of MVP XL and moved the related in-process research and development intangible asset to developed technologies and commenced amortization. In the second quarter of fiscal 2024, the Company recorded an intangible asset impairment charge of $10.4 million related to the intangibles acquired as part of the enicor GmbH acquisition completed in fiscal 2021 within the Hospital business unit.

In the third quarter of fiscal 2025, the Company announced the divestiture of its Whole Blood product line within its Blood Center business unit and all related assets and liabilities were recognized as held for sale. The related intangible assets are fully amortized and have a net book value of zero. The gross intangible assets value is $185.6 million.

Intangible assets include the value assigned to license rights and other developed technology, patents, customer contracts and relationships and trade names. The estimated useful lives for all of these intangible assets are approximately 5 to 15 years.

During the three and nine months ended December 28, 2024, amortization expense was $13.9 million and $42.6 million, respectively. During the three and nine months ended December 30, 2023, amortization expense was $9.3 million and $28.5 million, respectively.

Future annual amortization expense on intangible assets for the next five years is estimated to be as follows:
(In thousands)
Remainder of Fiscal 2025$12,995 
Fiscal 2026$49,879 
Fiscal 2027$47,931 
Fiscal 2028$46,160 
Fiscal 2029$44,965 
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.25.0.1
NOTES PAYABLE AND LONG-TERM DEBT
 9 Months Ended
Dec. 28, 2024
Debt Disclosure [Abstract]  
NOTES PAYABLE AND LONG-TERM DEBT
12. NOTES PAYABLE AND LONG-TERM DEBT

Notes payable and long-term debt consisted of the following:
(In thousands)December 28, 2024March 30, 2024
Convertible notes$982,731 $494,813 
Term loan, net of financing fees241,266 261,971 
Revolving credit facility— 50,000 
Other borrowings840 1,009 
Less: current portion(5,075)(10,229)
Long-term debt$1,219,762 $797,564 

Convertible Senior Notes

2026 Notes

In March 2021, the Company issued $500.0 million aggregate principal amount of 0% convertible senior notes due 2026 (the “2026 Notes”). The 2026 Notes are governed by the terms of the Indenture between the Company and U.S. Bank National Association, as trustee. The 2026 Notes will mature on March 1, 2026, unless earlier converted, redeemed or repurchased. In the first quarter of fiscal 2025, the Company repurchased $200.0 million of the aggregate principal amount for $185.5 million, resulting in a gain of $14.5 million related to the discount on repurchase. As the repurchase of the 2026 Notes met the criteria for extinguishment accounting, $1.9 million of unamortized debt issuance costs were allocated to the repurchase, resulting in a net gain of $12.6 million, which was recorded in Interest and other income (expense), net on the Condensed Consolidated Statements of Income.

During the third quarter of fiscal 2025, the conditions allowing holders of the 2026 Notes to convert have not been met. The 2026 Notes were therefore not convertible as of December 28, 2024 and were classified as long-term debt on the Company’s Condensed Consolidated Balance Sheets.

As of December 28, 2024, the $300.0 million principal balance was netted down by $1.9 million of remaining debt issuance costs, resulting in a net convertible note payable of $298.1 million. Interest expense related to the 2026 Notes was $0.4 million and $1.4 million for the three and nine months ended December 28, 2024, respectively, which is entirely attributable to the amortization of the debt issuance costs. The remaining debt issuance costs are amortized at an effective interest rate of 0.5%.

2029 Notes

On May 28, 2024, the Company issued $700.0 million aggregate principal amount of 2.5% convertible senior notes due 2029 (the “2029 Notes”). The 2029 Notes are governed by the terms of the Indenture between the Company and U.S. Bank National Association, as trustee. The total net proceeds from the sale of the 2029 Notes, after deducting the initial purchasers’ discounts and debt issuance costs, were $682.8 million, with a portion of funds used to repay the entirety of the balance on the revolving credit facility under the Company’s second amended and restated credit agreement, to repurchase a portion of the Company’s 2026 Notes, to complete capped call transactions in connection with the issuance of the 2029 Notes, as described further below, with the remaining proceeds available for other working capital requirements. The 2029 Notes will mature on June 1, 2029, unless earlier converted, redeemed or repurchased.

Holders may convert their notes at their option at any time prior to the close of business on the business day immediately preceding December 1, 2028 only under the following circumstances:

•During any calendar quarter (and only during such calendar quarter) beginning after September 30, 2024, if, the last reported sale price per share of the Company’s common stock exceeds 130% of the applicable conversion price on each applicable trading day for at least 20 trading days (whether or not consecutive) in the period of the 30 consecutive trading day period ending on, and including, the last trading day of the immediately preceding calendar quarter;

•During the five business day period after any five consecutive trading day period in which, for each day of that period, the trading price per $1,000 principal amount of the 2029 Notes for such trading day was less than 98% of the product of the last reported sale price of the Company’s common stock and the applicable conversion rate on such trading day;
•The Company issues to common stockholders any rights, options, or warrants, entitling them, for a period of not more than 60 days, to purchase shares of common stock at a price per share less than the average closing sale price of 10 consecutive trading days, or the Company’s election to make a distribution to common stockholders exceeding 10% of the previous day’s closing sale price;

•Upon the occurrence of specified corporate events, as set forth in the indenture governing the 2029 Notes; or

•Prior to the related redemption date if the Company calls the 2029 Notes for redemption.

On or after December 1, 2028, until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert all or a portion of their 2029 Notes, in multiples of $1,000 principal amount, at any time, regardless of the foregoing circumstances. The conversion rate for the 2029 Notes is 8.5385 shares of common stock per $1,000 principal amount of notes (which is equal to an initial conversion price of approximately $117.12 per share of the Company’s common stock), subject to adjustment as set forth in the Indenture. Upon conversion, the Company will pay cash up to the aggregate principal amount of the notes to be converted and pay or deliver, as the case may be, cash, common stock or a combination of cash and common stock, at the Company’s election, in respect of the remainder, if any, of the Company’s conversion obligation in excess of the aggregate principal amount of the notes being converted. If a make-whole adjustment event, as described in the Indenture, occurs and a holder elects to convert its 2029 Notes in connection with such make-whole adjustment event, such holder may be entitled to an increase in the conversion rate as described in the Indenture.

During the third quarter of fiscal 2025, the conditions allowing holders of the 2029 Notes to convert have not been met. The 2029 Notes were therefore not convertible as of December 28, 2024 and were classified as long-term debt on the Company’s consolidated balance sheets.

The 2029 Notes will be redeemable, in whole or in part, at the Company’s option at any time, and from time to time, on or after June 5, 2027 and on or before the 50th scheduled trading day immediately before the maturity date, if the last reported sale price per share of the Company’s common stock exceeds 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive), including the trading day immediately preceding the date on which the Company provides notice of redemption, during any 30 consecutive trading day period ending on, and including, the trading day immediately before the date the Company sends the related redemption notice at a redemption price equal to 100% of the principal amount of the 2029 Notes to be redeemed, plus accrued and unpaid interest to, but excluding the redemption date. Upon the occurrence of certain fundamental changes involving the Company, holders of the 2029 Notes may require the Company to repurchase for cash all or part of their 2029 Notes at a repurchase price equal to 100% of the principal amount of the 2029 Notes to be repurchased, plus
accrued and unpaid interest.

As a result of the issuance of the 2029 Notes, the Company recorded debt issuance costs of $17.2 million, which will be amortized to interest expense over the contractual term of the 2029 Notes at an effective interest rate of 3.0%.

As of December 28, 2024, the $700.0 million principal balance was netted down by $15.4 million of remaining debt issuance costs, resulting in a net convertible note payable of $684.6 million. Interest expense related to the 2029 Notes was $5.2 million and $12.1 million for the three and nine months ended December 28, 2024, respectively, which includes nominal interest expense and the amortization of the debt issuance costs.

Capped Calls

In connection with the issuance of the 2029 Notes, the Company entered into capped call transactions with certain counterparties (“Capped Calls”). The Capped Calls each have an initial strike price of approximately $117.12 per share, subject to certain adjustments, which corresponds to the initial conversion price of the 2029 Notes. The Capped Calls have initial cap prices of $180.18 per share, subject to certain adjustments. The Capped Calls are expected to partially offset the potential dilution to the Company’s common stock upon any conversion of the 2029 Notes, with such offset subject to a cap based on the cap price. The Capped Calls cover, subject to anti-dilution adjustments, approximately 5.98 million shares of the Company’s common stock. For accounting purposes, the Capped Calls are separate transactions, and not part of the 2029 Notes. As these transactions meet certain accounting criteria, the Capped Calls are recorded in stockholders’ equity and are not accounted for as derivatives. The cost of $88.2 million incurred to purchase the Capped Calls was recorded as a reduction to additional paid-in capital and will not be remeasured.
Credit Facilities

On July 26, 2022, the Company entered into an amended and restated credit agreement to refinance its credit facilities initially entered into in 2018 and extend their maturity date through June 2025. The amended and restated credit agreement provided for a $280.0 million senior unsecured term loan and a $420.0 million senior unsecured revolving credit facility (together, the “2022 Revised Credit Facilities”) with applicable interest rates during the period established using an annual rate equal to the Adjusted Term SOFR Rate plus an applicable rate ranging from 1.125% to 1.750% based on the Company’s consolidated net leverage ratio, as specified in the agreement.

On April 30, 2024, the Company entered into a second amended and restated credit agreement with certain lenders to refinance the 2022 Revised Credit Facilities and extend their maturity date through April 2029. The second amended and restated credit agreement provides for a $250.0 million senior unsecured term loan, the proceeds of which, along with $12.5 million of cash on hand, were used to retire the balance of the term loan under the 2022 Revised Credit Facilities, and a $750.0 million senior unsecured revolving credit facility (together, the “2024 Revised Credit Facilities”). Loans under the 2024 Revised Credit Facilities bear interest at an annual rate equal to the Adjusted Term SOFR Rate (as specified in the second amended and restated credit agreement), which is subject to a floor of 0.0%, plus an applicable rate ranging from 1.125% to 1.750% based on the Company’s consolidated net leverage ratio (as specified in the second amended and restated credit agreement) at the applicable measurement date. The revolving credit facility carries an unused fee that ranges from 0.125% to 0.250% annually based on the Company’s consolidated net leverage ratio at the applicable measurement date. The 2024 Revised Credit Facilities mature on April 30, 2029. The principal amount of the term loan under the 2024 Revised Credit Facilities amortizes quarterly through the maturity date at a rate of 2.5% for the first three years following the closing date, 5.0% for the fourth year following the closing date and 7.5% for the fifth year following the closing date, with the unpaid balance due at maturity.

Under the 2024 Revised Credit Facilities, the Company is required to maintain a consolidated leverage ratio not to exceed 4.0:1.0 or, on up to two occasions during the term of the facility, 4.5:1.0 for the four consecutive fiscal quarters ended immediately following acquisitions meeting certain criteria specified in the agreement.

The Company applied modification accounting for the credit facility refinancing, which resulted in the capitalization of an additional $5.9 million in lender fees and third-party costs. During the three and nine months ended December 28, 2024, the Company recognized $4.6 million and $16.6 million, respectively, of interest expense and amortization of debt issuance costs related to its credit facilities.

At December 28, 2024, $246.9 million was outstanding under the term loan with an effective interest rate of 6.1%, which was netted down by the $5.6 million of remaining debt discount, resulting in a net note payable of $241.3 million. The Company has scheduled principal payments of $6.3 million required during the 12 months following December 28, 2024. There were no outstanding borrowings under the revolving credit facilities at December 28, 2024. The Company also had $18.0 million of uncommitted operating lines of credit to fund its global operations under which there were no outstanding borrowings as of December 28, 2024.

The Company was in compliance with the consolidated net leverage and interest coverage ratios specified in the 2024 Revised Credit Facilities as well as all other bank covenants as of December 28, 2024.


The future aggregate amount of debt maturities are as follows:
(In thousands)
Remainder of Fiscal 2025$1,597 
Fiscal 2026$306,349 
Fiscal 2027$6,308 
Fiscal 2028$10,999 
Fiscal 2029$17,252 
Thereafter$905,210 
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.25.0.1
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS
 9 Months Ended
Dec. 28, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS
13. FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS

The Company manufactures, markets and sells its products globally. During the three and nine months ended December 28, 2024, 26.1% and 26.0%, respectively, of the Company’s sales were generated outside the U.S. in local currencies. The Company also incurs certain manufacturing, marketing and selling costs in international markets in local currency.
Accordingly, earnings and cash flows are exposed to market risk from changes in foreign currency exchange rates relative to the U.S. Dollar, the Company’s reporting currency. The Company has a program in place that is designed to mitigate the exposure to changes in foreign currency exchange rates. That program includes the use of derivative financial instruments to minimize, for a period of time, the impact on its financial results from changes in foreign exchange rates. The Company utilizes foreign currency forward contracts to hedge the anticipated cash flows from transactions denominated in foreign currencies, primarily Japanese Yen and Euro, and to a lesser extent, Swiss Franc and Mexican Peso. This does not eliminate the impact of the volatility of foreign exchange rates. However, because the Company generally enters into forward contracts one year out, rates are fixed for a one-year period, thereby facilitating financial planning and resource allocation.

Designated Foreign Currency Hedge Contracts

All of the Company’s designated foreign currency hedge contracts as of December 28, 2024 and March 30, 2024 were cash flow hedges under ASC 815, Derivatives and Hedging (“ASC 815”). The Company records the effective portion of any change in the fair value of designated foreign currency hedge contracts in other comprehensive income until the related third-party transaction occurs. Once the related third-party transaction occurs, the Company reclassifies the effective portion of any related gain or loss on the designated foreign currency hedge contracts to earnings. In the event the hedged forecasted transaction does not occur, or it becomes probable that it will not occur, the Company will reclassify the amount of any gain or loss on the related cash flow hedge to earnings at that time. The Company had designated foreign currency hedge contracts outstanding in the contract amount of $45.5 million as of December 28, 2024 and $74.0 million as of March 30, 2024. At December 28, 2024, a loss of $1.1 million, net of tax, will be reclassified to earnings within the next twelve months. Substantially all currency cash flow hedges outstanding as of December 28, 2024 mature within twelve months.

Non-Designated Foreign Currency Contracts

The Company manages its exposure to changes in foreign currency on a consolidated basis to take advantage of offsetting transactions and balances. It uses foreign currency forward contracts as a part of its strategy to manage exposure related to foreign currency denominated monetary assets and liabilities. These foreign currency forward contracts are entered into for periods consistent with currency transaction exposures, generally one month. They are not designated as cash flow or fair value hedges under ASC 815. These forward contracts are marked-to-market with changes in fair value recorded to earnings. The Company had non-designated foreign currency hedge contracts under ASC 815 outstanding in the contract amount of $82.7 million as of December 28, 2024 and $39.9 million as of March 30, 2024.

Interest Rate Swaps

Part of the Company’s interest rate risk management strategy includes the use of interest rate swaps to mitigate its exposure to changes in variable interest rates. The Company’s objective in using interest rate swaps is to add stability to interest expense and to manage and reduce the risk inherent in interest rate fluctuations.

To mitigate the interest rate risk on the Company’s senior unsecured term loan, in September 2022, the Company entered into four interest rate swaps, two of which expired in June 2023 and the remaining two were amended and extended in September 2024. The amendment and extension of the two interest rate swaps did not have a material impact on the Condensed Consolidated Financial Statements.

Loans under the 2024 Revised Credit Facilities bear interest at an annual rate equal to the 1-month USD Term SOFR, plus an applicable rate ranging from 1.125% to 1.750% based on the Company’s consolidated net leverage ratio. As a result of the amendment and extension in September 2024, the two modified interest rate swaps have an average blended fixed interest rate of 3.31% plus the applicable rate on approximately 80% of the notional value of the unsecured term loan, until their maturity in April 2029. The Company has determined both of these interest rate swaps are effective and qualify for hedge accounting treatment.
The Company held the following interest rate swaps as of December 28, 2024:

Hedged ItemOriginal Notional Amount
Notional Amount as of December 28, 2024
Designation DateEffective DateTermination DateFixed Interest RateEstimated Fair Value Assets (Liabilities)
(In thousands)
1-month USD Term SOFR103,600 103,600 9/27/20249/30/20244/30/20293.32%2,806 
1-month USD Term SOFR102,200 102,200 9/27/20249/30/20244/30/20293.30%3,000 
Total$205,800 $205,800 $5,806 

For the nine months ended December 28, 2024, the Company recorded a gain of $3.4 million, net of tax, in accumulated other comprehensive loss to recognize the effective portion of the fair value of the swaps that qualify as cash flow hedges.

Trade Receivables

In the ordinary course of business, the Company grants trade credit to its customers on normal credit terms. In an effort to reduce its credit risk, the Company (i) establishes credit limits for all customers, (ii) performs ongoing credit evaluations of customers’ financial condition, (iii) monitors the payment history and aging of customers’ receivables, and (iv) monitors open orders against an individual customer’s outstanding receivable balance.

The Company’s allowance for credit losses is maintained for trade accounts receivable based on the expected collectability, the historical collection experience, the length of time an account is outstanding, the financial position of the customer and information provided by credit rating services. The Company has not experienced significant customer payment defaults, or identified other significant collectability concerns.

The following is a roll forward of the allowance for credit losses:

Three Months EndedNine Months Ended
(In thousands)December 28, 2024December 30, 2023December 28, 2024December 30, 2023
Beginning balance$5,912 $5,044 $5,695 $4,932 
Credit loss123 653 339 833 
Write-offs (recoveries)(49)28 (48)(40)
Ending balance$5,986 $5,725 $5,986 $5,725 
Other Fair Value Measurements

Fair value is defined as the exit price that would be received from the sale of an asset or paid to transfer a liability, using assumptions that market participants would use in pricing an asset or liability. The fair value guidance establishes the following three-level hierarchy used for measuring fair value:

•Level 1 — Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.
•Level 2 — Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.
•Level 3 — Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.

The Company’s money market funds carried at fair value are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices.

Fair Value of Derivative Instruments

The following table presents the effect of the Company’s derivative instruments designated as cash flow hedges and those not designated as hedging instruments under ASC 815 in its unaudited Condensed Consolidated Statements of Income and Comprehensive Income for the nine months ended December 28, 2024:

Derivative InstrumentsAmount of Gain (Loss) Recognized
in Accumulated Other Comprehensive Loss		Amount of Gain (Loss) Reclassified
from Accumulated Other Comprehensive Loss into
Earnings		Location in
Condensed Consolidated Statements of Income and Comprehensive Income		Amount of Gain Excluded from
Effectiveness
Testing		Location in
Condensed Consolidated Statements of Income and Comprehensive Income
(In thousands)
Designated foreign currency hedge contracts, net of tax$(1,095)$(220)Net revenues, COGS and SG&A$959 Interest and other expense, net
Non-designated foreign currency hedge contracts$— $—  $2,092 Interest and other expense, net
Designated interest rate swaps, net of tax$3,353 $37 Interest and other expense, net$— 

The Company did not have fair value hedges or net investment hedges outstanding as of December 28, 2024 or March 30, 2024. As of December 28, 2024, no material deferred taxes were recognized for designated foreign currency hedges.

ASC 815 requires all derivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. The Company determines the fair value of its derivative instruments using the framework prescribed by ASC 820, Fair Value Measurements and Disclosures, by considering the estimated amount it would receive or pay to sell or transfer these instruments at the reporting date and by taking into account current interest rates, currency exchange rates, current interest rate curves, interest rate volatilities, the creditworthiness of the counterparty for assets, and its creditworthiness for liabilities. In certain instances, the Company may utilize financial models to measure fair value. Generally, the Company uses inputs that include quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; other observable inputs for the asset or liability; and inputs derived principally from, or corroborated by, observable market data by correlation or other means. As of December 28, 2024, the Company has classified its derivative assets and liabilities within Level 2 of the fair value hierarchy prescribed by ASC 815, as discussed below, because these observable inputs are available for substantially the full term of its derivative instruments.
The following tables present the fair value of the Company’s derivative instruments as they appear in its Condensed Consolidated Balance Sheets as of December 28, 2024 and March 30, 2024:

(In thousands)Location in Condensed Consolidated
Balance Sheets		As ofAs of
December 28, 2024March 30, 2024
Derivative Assets:   
Designated foreign currency hedge contractsOther current assets$1,186 $1,353 
Non-designated foreign currency hedge contractsOther current assets71 154 
Designated interest rate swapsOther current assets1,734 1,673 
Designated interest rate swapsOther long-term assets4,072 62 
  $7,063 $3,242 
Derivative Liabilities:   
Designated foreign currency hedge contractsOther current liabilities$1,219 $395 
Non-designated foreign currency hedge contractsOther current liabilities347 536 
  $1,566 $931 

Fair Value Measured on a Recurring Basis

Financial assets and financial liabilities measured at fair value on a recurring basis consist of the following as of December 28, 2024 and March 30, 2024.
As of December 28, 2024
(In thousands)Level 1Level 2Level 3Total
Assets   
Money market funds$170,773 $— $— $170,773 
Designated foreign currency hedge contracts— 1,186 — 1,186 
Non-designated foreign currency hedge contracts— 71 — 71 
Designated interest rate swaps— 5,806 — 5,806 
 $170,773 $7,063 $— $177,836 
Liabilities   
Designated foreign currency hedge contracts$— $1,219 $— $1,219 
Non-designated foreign currency hedge contracts— 347 — 347 
Designated interest rate swaps— — — — 
Contingent consideration— — 23,133 23,133 
 $— $1,566 $23,133 $24,699 
As of March 30, 2024
Level 1Level 2Level 3Total
Assets
Money market funds$43,073 $— $— $43,073 
Designated foreign currency hedge contracts— 1,353 — 1,353 
Non-designated foreign currency hedge contracts— 154 — 154 
Designated interest rate swaps— 1,735 — 1,735 
 $43,073 $3,242 $— $46,315 
Liabilities   
Designated foreign currency hedge contracts$— $395 $— $395 
Non-designated foreign currency hedge contracts— 536 — 536 
$— $931 $— $931 
Foreign currency hedge contracts - The fair value of foreign currency hedge contracts was measured using significant other observable inputs and valued by reference to over-the-counter quoted market prices for similar instruments. The Company does not believe that the fair value of these derivative instruments differs significantly from the amount that could be realized upon settlement or maturity, or that the changes in fair value will have a significant effect on its results of operations, financial condition or cash flows.

Interest rate swaps - The fair values of interest rate swaps are measured using the present value of expected future cash flows using market-based observable inputs, including credit risk and interest rate yield curves. The Company does not believe that the fair values of these derivative instruments differ significantly from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a significant effect on its results of operations, financial condition or cash flows.

Contingent consideration - The fair value of contingent consideration liabilities is based on significant unobservable inputs, including management estimates and assumptions, and is measured based on the probability-weighted present value of the payments expected to be made. Accordingly, the fair value of contingent consideration has been classified as level 3 within the fair value hierarchy.

The level 3 fair value measurements of contingent consideration liabilities include the following significant unobservable inputs:

Fair Value atValuation Unobservable
(In thousands)December 28, 2024TechniqueInputRange
Revenue-based payments$17,179 Monte Carlo Simulation ModelDiscount rate6.3%
Projected year of payments2025 - 2027
Regulatory-based payment$4,804 Monte Carlo Simulation ModelDiscount rate6.1%
Probability of payment50%
Projected year of payment2026 - 2028
Event-based payment$1,150 Monte Carlo Simulation ModelDiscount rate5.8%
Projected year of payment2028

The fair value of contingent consideration associated with the Attune Medical acquisition was $23.1 million at December 28, 2024. As of December 28, 2024, $1.7 million was included in other current liabilities and $21.4 million was included in other long-term liabilities on the Condensed Consolidated Balance Sheets.

A reconciliation of the change in the fair value of contingent consideration is included in the following table:
(In thousands)
Balance at March 30, 2024
$— 
Acquisition date fair value of contingent consideration25,000 
Purchase accounting adjustments300 
Change in fair value(2,167)
Balance at December 28, 2024
$23,133 

Other Fair Value Disclosures

The fair values of the 2026 Notes and 2029 Notes were $282.0 million and $688.9 million as of December 28, 2024, respectively, which were determined by using the market price on the last trading day of the reporting period and are considered as level 2 in the fair value hierarchy.
The senior unsecured term loan (which is carried at amortized cost), accounts receivable and accounts payable approximate fair value.
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.25.0.1
COMMITMENTS AND CONTINGENCIES
 9 Months Ended
Dec. 28, 2024
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES
14. COMMITMENTS AND CONTINGENCIES

The Company is a party to various legal proceedings and claims arising out of the ordinary course of its business. The Company believes that, except for those matters described below, there are no other proceedings or claims pending against it the ultimate resolution of which could have a material adverse effect on its financial condition or results of operations. At each reporting period, management evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, Contingencies, for all matters. Legal costs are expensed as incurred.

In the fourth quarter of fiscal 2021, a putative class action complaint was filed against the Company in the Circuit Court of Cook County, Illinois by Mary Crumpton, on behalf of herself and similarly situated individuals. The Company removed the case to the United States District Court for the Northern District Illinois. See Mary Crumpton v. Haemonetics Corporation, Case No. 1:21-cv-1402. In her complaint, the plaintiff asserts that between June 2017 and August 2018 she donated plasma at a center operated by one of the Company’s customers, that the center required her to scan her fingerprint on a finger scanner that stored her fingerprint to identify her prior to plasma donation, and that the Company’s eQue donor management software sent her biometric information to a Company-owned server to be collected and stored in a manner that violated her rights under the Illinois Biometric Information Privacy Act (“BIPA”). The plaintiff seeks statutory damages, attorneys’ fees and injunctive and equitable relief. In March 2021, the Company moved to dismiss the complaint for lack of personal jurisdiction and concurrently filed a motion to dismiss for failure to state a claim and a motion to stay. In March 2022, the court denied the Company’s motion to dismiss for lack of personal jurisdiction but did not address the merits of the Company’s other positions. In March 2023, the Company filed a second motion to dismiss the complaint, which is pending before the court. During the second quarter of fiscal 2024, the Company entered into a Memorandum of Understanding providing terms that would resolve the litigation and recorded an additional loss contingency related to this matter. In the third quarter of fiscal 2024, the parties requested preliminary court approval of a final settlement agreement, which was granted in February 2024, and the Company recorded an immaterial additional loss contingency related to settlement administration, resulting in an accrual of $8.7 million within other current liabilities in its consolidated balance sheets. In March 2024, notice of the settlement was mailed to class members and the parties are now awaiting the complete administration of the settlement through the third-party administrator. In the first quarter of fiscal 2025, the Company issued payment of the $8.7 million settlement amount following the court’s final approval of the settlement agreement and dismissal of the matter with prejudice.

During the fourth quarter of fiscal 2024, a complaint was filed in the U.S. District Court for the District of Delaware by Knoninklijke Philips N.V. and IP2IPO Innovations, Ltd. (together, the “Plaintiffs”) against OpSens, OpSens Medical, Inc., a wholly-owned subsidiary of OpSens, and Haemonetics (1:24-cv-00206-CFC). The complaint alleges, inter alia, that OpSens’ interventional cardiology systems, including its OptoWire and OptoMonitor technology, infringe a single patent held by the Plaintiffs and seeks both injunctive relief and damages. The Company believes it has valid and meritorious defenses to the complaint and plans to vigorously defend against the complaint. During the first quarter of fiscal 2025, the Company recorded a loss contingency related to this matter, which did not have a material impact on its Condensed Consolidated Financial Statements.

Product Recall

In August 2023, the Company issued a voluntary recall of certain products within the Whole Blood portion of our Blood Center business unit sold to customers in the U.S. and certain foreign jurisdictions. In fiscal 2024, the Company recorded cumulative charges of $6.8 million related to inventory, returns and customer claims associated with this recall. Substantially all outstanding claims have been paid as of December 28, 2024.
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.25.0.1
ACCUMULATED OTHER COMPREHENSIVE LOSS
 9 Months Ended
Dec. 28, 2024
Stockholders' Equity Note [Abstract]  
ACCUMULATED OTHER COMPREHENSIVE LOSS
15. ACCUMULATED OTHER COMPREHENSIVE LOSS

The components of Accumulated Other Comprehensive Loss, net of tax, are as follows:
(In thousands)Foreign CurrencyDefined Benefit PlansNet Unrealized Gain (Loss) on DerivativesTotal
Balance as of March 30, 2024$(38,274)$1,748 $894 $(35,632)
Other comprehensive income (loss) before reclassifications(1)
(21,943)— 2,257 (19,686)
Amounts reclassified from accumulated other comprehensive loss(1)
— — (183)(183)
Net current period other comprehensive income (loss)(21,943)— 2,074 (19,869)
Balance as of December 28, 2024$(60,217)$1,748 $2,968 $(55,501)
(1) Presented net of income taxes, the amounts of which are insignificant.
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.25.0.1
SEGMENT AND ENTERPRISE-WIDE INFORMATION
 9 Months Ended
Dec. 28, 2024
Segment Reporting [Abstract]  
SEGMENT AND ENTERPRISE-WIDE INFORMATION
16. SEGMENT AND ENTERPRISE-WIDE INFORMATION

The Company determines its reportable segments by first identifying its operating segments, and then by assessing whether any components of these segments constitute a business for which discrete financial information is available and where segment management regularly reviews the operating results of that component. The Company’s reporting structure aligns with its operating structure of three global business units and the information that is regularly reviewed by the Company’s chief operating decision maker.

The Company’s reportable and operating segments are as follows:
•Plasma
•Blood Center
•Hospital

Management measures and evaluates the operating segments based on operating income. Management excludes certain corporate expenses from segment operating income. In addition, certain amounts that management considers to be non-recurring or non-operational are excluded from segment operating income because management evaluates the operating results of the segments excluding such items. Although these amounts are excluded from segment operating income, as applicable, they are included in the reconciliations that follow. Management measures and evaluates the Company’s net revenues and operating income using internally derived standard currency exchange rates that remain constant from year to year; therefore, segment information is presented on this basis.

Selected information by reportable segment is presented below:
Three Months EndedNine Months Ended
(In thousands)December 28,
2024		December 30,
2023		December 28,
2024		December 30,
2023
Net revenues(1)
Plasma$134,389 $147,560 $408,996 $429,694 
Blood Center70,730 73,528 206,373 213,167 
Hospital144,248 116,625 417,038 325,003 
Net revenues in constant currency349,367 337,713 1,032,407 967,864 
Effect of exchange rates(825)(1,463)(2,182)(2,099)
Net revenues$348,542 $336,250 $1,030,225 $965,765 
(1) Beginning in fiscal 2025, the Company integrated service revenue within its three business units. Prior periods were conformed to current presentation.
Three Months EndedNine Months Ended
(In thousands)December 28,
2024		December 30,
2023		December 28,
2024		December 30,
2023
Segment operating income
Plasma$70,337 $80,450 $205,902 $234,190 
Blood Center26,955 27,654 76,744 81,244 
Hospital62,114 49,355 175,710 132,132 
Segment operating income159,406 157,459 458,356 447,566 
Corporate expenses (1)
(70,273)(83,694)(214,660)(234,753)
Effect of exchange rates304 (401)267 (879)
Amortization of acquired intangible assets(12,230)(6,911)(36,965)(21,606)
Amortization of fair value inventory step-up(3,341)— (12,319)— 
Integration and transaction costs(244)(4,869)(13,449)(7,768)
Restructuring costs(3,515)(7,968)(12,929)(8,043)
Restructuring related costs(1,468)(2,403)(5,557)(6,554)
Digital transformation costs(4,620)(3,415)(15,823)(10,712)
Write downs of certain assets and PCS2 related charges(4,000)(210)(4,000)(621)
MDR and IVDR costs(1,008)(1,433)(3,125)(4,587)
Litigation-related charges18 (177)(1,057)(6,684)
Impairment of intangible assets— — (2,391)(10,419)
Gain on sale of property, plant and equipment— — 14,134 — 
Operating income$59,029 $45,978 $150,482 $134,940 
(1) Reflects shared service expenses including quality and regulatory, customer and field service, research and development, manufacturing and supply chain, as well as other corporate support functions.

Net revenues by business unit are as follows:
  Three Months EndedNine Months Ended
(In thousands)December 28,
2024		December 30,
2023		December 28,
2024		December 30,
2023
 Plasma$134,224 $147,641 $408,695 $430,056 
Apheresis55,388 52,565 158,814 156,704 
Whole Blood14,957 19,814 46,304 54,537 
 Blood Center70,345 72,379 205,118 211,241 
Interventional Technologies(1)
63,253 43,007 188,220 119,168 
Blood Management Technologies(2)
80,720 73,223 228,192 205,300 
 Hospital143,973 116,230 416,412 324,468 
Net revenues(3)
$348,542 $336,250 $1,030,225 $965,765 
(1) Interventional Technologies includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection product lines of the Hospital business unit.
(2) Blood Management Technologies includes Hemostasis Management, Cell Salvage and Transfusion Management product lines of the Hospital business unit.
(3) Beginning in fiscal 2025, the Company integrated service revenue within its three business units. Prior periods were conformed to current presentation.
Net revenues generated in the Company’s principle operating regions on a reported basis are as follows:
Three Months EndedNine Months Ended
(In thousands)December 28,
2024		December 30,
2023		December 28,
2024		December 30,
2023
United States$257,665 $250,804 $762,628 $724,222 
Japan16,174 14,825 46,303 41,609 
Europe44,163 37,035 133,379 115,088 
Rest of Asia25,597 30,935 71,148 80,710 
Other4,943 2,651 16,767 4,136 
Net revenues$348,542 $336,250 $1,030,225 $965,765 
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.25.0.1
Pay vs Performance Disclosure - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Dec. 28, 2024
Sep. 28, 2024
Jun. 29, 2024
Dec. 30, 2023
Sep. 30, 2023
Jul. 01, 2023
Dec. 28, 2024
Dec. 30, 2023
Pay vs Performance Disclosure                
Net income $ 37,494 $ 33,831 $ 38,373 $ 31,241 $ 24,908 $ 41,042 $ 109,698 $ 97,191
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.25.0.1
Insider Trading Arrangements
 3 Months Ended
Dec. 28, 2024
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.25.0.1
ACQUISITIONS, DIVESTITURES AND STRATEGIC INVESTMENTS (Tables)
 9 Months Ended
Dec. 28, 2024
Investments, All Other Investments [Abstract]  
Schedule of Business Acquisitions, by Acquisition
The purchase price of $176.2 million, net of $11.5 million of cash acquired, consists of the amounts presented below, which represent the final determination of the fair value of the identifiable assets acquired and liabilities assumed:

(In thousands) April 1, 2024
Accounts receivable$3,784 
Inventories26,300 
Prepaid expenses and other current assets906 
Property, plant and equipment200 
Intangible assets105,800 
Goodwill70,256 
Total assets acquired$207,246 
Accounts payable2,260 
Accrued payroll and related costs2,129 
Other liabilities496 
Deferred tax liability26,155 
Total liabilities assumed$31,040 
Net assets acquired$176,206 
The purchase price of $243.9 million, net of $10.6 million of cash acquired, consists of the amounts presented below, which represent the final determination of the fair value of the identifiable assets acquired and liabilities assumed:

(In thousands) December 12, 2023
Accounts receivable$5,960 
Inventories12,075 
Prepaid expenses and other current assets2,062 
Property, plant and equipment3,028 
Intangible assets172,000 
Goodwill79,400 
Other long-term assets4,705 
Total assets acquired$279,230 
Accounts payable3,251 
Accrued payroll and related costs1,723 
Other liabilities9,746 
Deferred tax liability14,805 
Other long-term liabilities5,853 
Total liabilities assumed$35,378 
Net assets acquired$243,852 
Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination
Intangible assets acquired consist of the following:
(In thousands)AmountWeighted-Average Amortization PeriodRisk-Adjusted Discount
Rates used in Purchase Price Allocation
Developed technology$96,100 10 years22.0 %
Customer contracts and related relationships7,800 10 years21.5 %
Trade names1,900 10 years21.5 %
Total$105,800 
Intangible assets acquired consist of the following:
(In thousands)AmountWeighted-Average Amortization PeriodRisk-Adjusted Discount
Rates used in Purchase Price Allocation
Developed technology$114,900 15 years20.5 %
Customer contracts and related relationships52,300 15 years18.9 %
Trade names4,800 15 years20.5 %
Total$172,000 
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.25.0.1
RESTRUCTURING (Tables)
 9 Months Ended
Dec. 28, 2024
Restructuring and Related Activities [Abstract]  
Schedule of Restructuring Reserve by Type of Cost
The following table summarizes the activity for restructuring reserves related to the portfolio rationalization initiatives and the 2020 Program for the nine months ended December 28, 2024, which relates to employee severance, other employee costs, inventory reserves and lease termination fees:
(In thousands)Portfolio Rationalization2020 ProgramTotal
Balance at March 30, 2024
$11,309 $485 $11,794 
Costs incurred, net of reversals12,296 633 12,929 
Payments(10,837)(652)(11,489)
Non-cash adjustments(8,616)— (8,616)
Balance at December 28, 2024
$4,152 $466 $4,618 
Schedule of Restructuring and Related Costs
The following presents the restructuring costs by line item within our accompanying unaudited Condensed Consolidated Statements of Income and Comprehensive Income:
 Three Months EndedNine Months Ended
(In thousands) December 28,
2024		December 30,
2023		December 28,
2024		December 30,
2023
Cost of goods sold$3,027 $7,065 $11,158 $7,329 
Research and development(4)343 (16)343 
Selling, general and administrative expenses492 560 1,787 371 
Total$3,515 $7,968 $12,929 $8,043 
The tables below present restructuring and restructuring related costs by reportable segment:
Restructuring costsThree Months EndedNine Months Ended
(In thousands) December 28, 2024December 30, 2023December 28, 2024December 30, 2023
Plasma$77 $33 $284 $(164)
Blood Center685 4,546 4,241 4,546 
Hospital774 2,503 1,404 2,745 
Corporate1,979 886 7,000 916 
Total$3,515 $7,968 $12,929 $8,043 
Restructuring related costsThree Months EndedNine Months Ended
(In thousands) December 28, 2024December 30, 2023December 28, 2024December 30, 2023
Plasma$37 $72 $263 $315 
Blood Center31 93 120 166 
Hospital(68)251 40 398 
Corporate1,468 1,987 5,134 5,675 
Total$1,468 $2,403 $5,557 $6,554 
Total restructuring and restructuring related costs$4,983 $10,371 $18,486 $14,597 
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.25.0.1
EARNINGS PER SHARE (Tables)
 9 Months Ended
Dec. 28, 2024
Earnings Per Share [Abstract]  
Schedule of Earnings Per Share Reconciliation
The following table provides a reconciliation of the numerators and denominators of the basic and diluted earnings per share computations.
 Three Months EndedNine Months Ended
 (In thousands, except per share amounts)December 28,
2024		December 30,
2023		December 28,
2024		December 30,
2023
Basic EPS  
Net income$37,494 $31,241 $109,698 $97,191 
Weighted average shares50,286 50,768 50,709 50,679 
Basic income per share$0.75 $0.62 $2.16 $1.92 
Diluted EPS    
Net income$37,494 $31,241 $109,698 $97,191 
Basic weighted average shares50,286 50,768 50,709 50,679 
Net effect of common stock equivalents353 677 439 715 
Diluted weighted average shares50,639 51,445 51,148 51,394 
Diluted income per share$0.74 $0.61 $2.14 $1.89 
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.25.0.1
INVENTORIES (Tables)
 9 Months Ended
Dec. 28, 2024
Inventory Disclosure [Abstract]  
Schedule of Inventories
Inventories are stated at the lower of cost or net realizable value and include the cost of material, labor and manufacturing overhead. Cost is determined with the first-in, first-out method.
(In thousands)December 28,
2024		March 30,
2024
Raw materials$101,989 $134,150 
Work-in-process32,120 15,488 
Finished goods225,505 167,564 
Total inventories$359,614 $317,202 

In the third quarter of fiscal 2025, the Company announced the divestiture of its Whole Blood product line within its Blood Center business unit and all related assets and liabilities were recognized as held for sale. The related inventory has a value of $34.7 million, which has been reclassified to Prepaid expenses and other current assets in the Condensed Consolidated Balance Sheets.
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.25.0.1
PROPERTY, PLANT AND EQUIPMENT (Tables)
 9 Months Ended
Dec. 28, 2024
Property, Plant and Equipment [Abstract]  
Property, Plant and Equipment
(In thousands)December 28,
2024		March 30,
2024
Land$1,999 $4,130 
Building and building improvements107,665 124,338 
Plant equipment and machinery191,063 204,622 
Office equipment and information technology129,123 129,979 
Haemonetics equipment412,561 456,414 
Construction in progress25,046 39,694 
Total867,457 959,177 
Less: accumulated depreciation(581,350)(647,815)
Property, plant and equipment, net$286,107 $311,362 
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.25.0.1
GOODWILL AND INTANGIBLE ASSETS (Tables)
 9 Months Ended
Dec. 28, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Goodwill
The changes in the carrying amount of goodwill by operating segment for fiscal 2025 are as follows:
(In thousands)PlasmaBlood CenterHospitalTotal
Carrying amount as of March 30, 2024
$29,043 $33,484 $502,555 $565,082 
Assets held for sale— (4,475)— (4,475)
Purchase accounting adjustments— — (19,248)(19,248)
Acquisitions— — 69,542 69,542 
Currency translation— (268)(5,367)(5,635)
Carrying amount as of December 28, 2024
$29,043 $28,741 $547,482 $605,266 
Schedule of Finite-Lived Intangible Assets
The gross carrying amount of intangible assets and the related accumulated amortization as of December 28, 2024 and March 30, 2024 is as follows:
(In thousands)Gross Carrying
Amount		Accumulated
Amortization		Net
As of December 28, 2024
  
Amortizable:
Developed technology$505,323 $146,898 $358,425 
Customer contracts and related relationships136,181 70,261 65,920 
Capitalized software85,528 74,722 10,806 
Patents and other27,504 13,579 13,925 
Trade names15,927 6,136 9,791 
Total$770,463 $311,596 $458,867 
Non-amortizable:
In-process software development$6,748 
Total$6,748 
(In thousands)Gross Carrying
Amount		Accumulated
Amortization		Net
As of March 30, 2024
  
Amortizable:
Developed technology$464,291 $178,413 $285,878 
Customer contracts and related relationships255,144 190,033 65,111 
Capitalized software84,837 69,491 15,346 
Patents and other24,504 11,820 12,684 
Trade names14,320 5,456 8,864 
Total$843,096 $455,213 $387,883 
Non-amortizable:
In-process research and development$13,667 
In-process software development4,567 
Total$18,234 
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense
Future annual amortization expense on intangible assets for the next five years is estimated to be as follows:
(In thousands)
Remainder of Fiscal 2025$12,995 
Fiscal 2026$49,879 
Fiscal 2027$47,931 
Fiscal 2028$46,160 
Fiscal 2029$44,965 
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.25.0.1
NOTES PAYABLE AND LONG-TERM DEBT (Tables)
 9 Months Ended
Dec. 28, 2024
Debt Disclosure [Abstract]  
Schedule of Debt
Notes payable and long-term debt consisted of the following:
(In thousands)December 28, 2024March 30, 2024
Convertible notes$982,731 $494,813 
Term loan, net of financing fees241,266 261,971 
Revolving credit facility— 50,000 
Other borrowings840 1,009 
Less: current portion(5,075)(10,229)
Long-term debt$1,219,762 $797,564 
Schedule of Maturities of Long-Term Debt
The future aggregate amount of debt maturities are as follows:
(In thousands)
Remainder of Fiscal 2025$1,597 
Fiscal 2026$306,349 
Fiscal 2027$6,308 
Fiscal 2028$10,999 
Fiscal 2029$17,252 
Thereafter$905,210 
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.25.0.1
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Tables)
 9 Months Ended
Dec. 28, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Interest Rate Swaps
The Company held the following interest rate swaps as of December 28, 2024:

Hedged ItemOriginal Notional Amount
Notional Amount as of December 28, 2024
Designation DateEffective DateTermination DateFixed Interest RateEstimated Fair Value Assets (Liabilities)
(In thousands)
1-month USD Term SOFR103,600 103,600 9/27/20249/30/20244/30/20293.32%2,806 
1-month USD Term SOFR102,200 102,200 9/27/20249/30/20244/30/20293.30%3,000 
Total$205,800 $205,800 $5,806 
Accounts Receivable, Allowance for Credit Loss
The following is a roll forward of the allowance for credit losses:

Three Months EndedNine Months Ended
(In thousands)December 28, 2024December 30, 2023December 28, 2024December 30, 2023
Beginning balance$5,912 $5,044 $5,695 $4,932 
Credit loss123 653 339 833 
Write-offs (recoveries)(49)28 (48)(40)
Ending balance$5,986 $5,725 $5,986 $5,725 
Schedule of Effect of Derivative Instruments Designated as Cash Flow Hedges and Those Not Designated as Hedging Instruments
The following table presents the effect of the Company’s derivative instruments designated as cash flow hedges and those not designated as hedging instruments under ASC 815 in its unaudited Condensed Consolidated Statements of Income and Comprehensive Income for the nine months ended December 28, 2024:

Derivative InstrumentsAmount of Gain (Loss) Recognized
in Accumulated Other Comprehensive Loss		Amount of Gain (Loss) Reclassified
from Accumulated Other Comprehensive Loss into
Earnings		Location in
Condensed Consolidated Statements of Income and Comprehensive Income		Amount of Gain Excluded from
Effectiveness
Testing		Location in
Condensed Consolidated Statements of Income and Comprehensive Income
(In thousands)
Designated foreign currency hedge contracts, net of tax$(1,095)$(220)Net revenues, COGS and SG&A$959 Interest and other expense, net
Non-designated foreign currency hedge contracts$— $—  $2,092 Interest and other expense, net
Designated interest rate swaps, net of tax$3,353 $37 Interest and other expense, net$— 
Schedule of Fair Value of Derivative Instruments as They Appear in Consolidated Balance Sheets
The following tables present the fair value of the Company’s derivative instruments as they appear in its Condensed Consolidated Balance Sheets as of December 28, 2024 and March 30, 2024:

(In thousands)Location in Condensed Consolidated
Balance Sheets		As ofAs of
December 28, 2024March 30, 2024
Derivative Assets:   
Designated foreign currency hedge contractsOther current assets$1,186 $1,353 
Non-designated foreign currency hedge contractsOther current assets71 154 
Designated interest rate swapsOther current assets1,734 1,673 
Designated interest rate swapsOther long-term assets4,072 62 
  $7,063 $3,242 
Derivative Liabilities:   
Designated foreign currency hedge contractsOther current liabilities$1,219 $395 
Non-designated foreign currency hedge contractsOther current liabilities347 536 
  $1,566 $931 
Schedule of Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis
Financial assets and financial liabilities measured at fair value on a recurring basis consist of the following as of December 28, 2024 and March 30, 2024.
As of December 28, 2024
(In thousands)Level 1Level 2Level 3Total
Assets   
Money market funds$170,773 $— $— $170,773 
Designated foreign currency hedge contracts— 1,186 — 1,186 
Non-designated foreign currency hedge contracts— 71 — 71 
Designated interest rate swaps— 5,806 — 5,806 
 $170,773 $7,063 $— $177,836 
Liabilities   
Designated foreign currency hedge contracts$— $1,219 $— $1,219 
Non-designated foreign currency hedge contracts— 347 — 347 
Designated interest rate swaps— — — — 
Contingent consideration— — 23,133 23,133 
 $— $1,566 $23,133 $24,699 
As of March 30, 2024
Level 1Level 2Level 3Total
Assets
Money market funds$43,073 $— $— $43,073 
Designated foreign currency hedge contracts— 1,353 — 1,353 
Non-designated foreign currency hedge contracts— 154 — 154 
Designated interest rate swaps— 1,735 — 1,735 
 $43,073 $3,242 $— $46,315 
Liabilities   
Designated foreign currency hedge contracts$— $395 $— $395 
Non-designated foreign currency hedge contracts— 536 — 536 
$— $931 $— $931 
The level 3 fair value measurements of contingent consideration liabilities include the following significant unobservable inputs:

Fair Value atValuation Unobservable
(In thousands)December 28, 2024TechniqueInputRange
Revenue-based payments$17,179 Monte Carlo Simulation ModelDiscount rate6.3%
Projected year of payments2025 - 2027
Regulatory-based payment$4,804 Monte Carlo Simulation ModelDiscount rate6.1%
Probability of payment50%
Projected year of payment2026 - 2028
Event-based payment$1,150 Monte Carlo Simulation ModelDiscount rate5.8%
Projected year of payment2028
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
A reconciliation of the change in the fair value of contingent consideration is included in the following table:
(In thousands)
Balance at March 30, 2024
$— 
Acquisition date fair value of contingent consideration25,000 
Purchase accounting adjustments300 
Change in fair value(2,167)
Balance at December 28, 2024
$23,133 
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.25.0.1
ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)
 9 Months Ended
Dec. 28, 2024
Stockholders' Equity Note [Abstract]  
Schedule of Accumulated Other Comprehensive Income (Loss)
The components of Accumulated Other Comprehensive Loss, net of tax, are as follows:
(In thousands)Foreign CurrencyDefined Benefit PlansNet Unrealized Gain (Loss) on DerivativesTotal
Balance as of March 30, 2024$(38,274)$1,748 $894 $(35,632)
Other comprehensive income (loss) before reclassifications(1)
(21,943)— 2,257 (19,686)
Amounts reclassified from accumulated other comprehensive loss(1)
— — (183)(183)
Net current period other comprehensive income (loss)(21,943)— 2,074 (19,869)
Balance as of December 28, 2024$(60,217)$1,748 $2,968 $(55,501)
(1) Presented net of income taxes, the amounts of which are insignificant.
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.25.0.1
SEGMENT AND ENTERPRISE-WIDE INFORMATION (Tables)
 9 Months Ended
Dec. 28, 2024
Segment Reporting [Abstract]  
Selected Information by Business Segment
Selected information by reportable segment is presented below:
Three Months EndedNine Months Ended
(In thousands)December 28,
2024		December 30,
2023		December 28,
2024		December 30,
2023
Net revenues(1)
Plasma$134,389 $147,560 $408,996 $429,694 
Blood Center70,730 73,528 206,373 213,167 
Hospital144,248 116,625 417,038 325,003 
Net revenues in constant currency349,367 337,713 1,032,407 967,864 
Effect of exchange rates(825)(1,463)(2,182)(2,099)
Net revenues$348,542 $336,250 $1,030,225 $965,765 
(1) Beginning in fiscal 2025, the Company integrated service revenue within its three business units. Prior periods were conformed to current presentation.
Three Months EndedNine Months Ended
(In thousands)December 28,
2024		December 30,
2023		December 28,
2024		December 30,
2023
Segment operating income
Plasma$70,337 $80,450 $205,902 $234,190 
Blood Center26,955 27,654 76,744 81,244 
Hospital62,114 49,355 175,710 132,132 
Segment operating income159,406 157,459 458,356 447,566 
Corporate expenses (1)
(70,273)(83,694)(214,660)(234,753)
Effect of exchange rates304 (401)267 (879)
Amortization of acquired intangible assets(12,230)(6,911)(36,965)(21,606)
Amortization of fair value inventory step-up(3,341)— (12,319)— 
Integration and transaction costs(244)(4,869)(13,449)(7,768)
Restructuring costs(3,515)(7,968)(12,929)(8,043)
Restructuring related costs(1,468)(2,403)(5,557)(6,554)
Digital transformation costs(4,620)(3,415)(15,823)(10,712)
Write downs of certain assets and PCS2 related charges(4,000)(210)(4,000)(621)
MDR and IVDR costs(1,008)(1,433)(3,125)(4,587)
Litigation-related charges18 (177)(1,057)(6,684)
Impairment of intangible assets— — (2,391)(10,419)
Gain on sale of property, plant and equipment— — 14,134 — 
Operating income$59,029 $45,978 $150,482 $134,940 
(1) Reflects shared service expenses including quality and regulatory, customer and field service, research and development, manufacturing and supply chain, as well as other corporate support functions.
Schedule of Revenues by Business Unit and Geographic Regions
Net revenues by business unit are as follows:
  Three Months EndedNine Months Ended
(In thousands)December 28,
2024		December 30,
2023		December 28,
2024		December 30,
2023
 Plasma$134,224 $147,641 $408,695 $430,056 
Apheresis55,388 52,565 158,814 156,704 
Whole Blood14,957 19,814 46,304 54,537 
 Blood Center70,345 72,379 205,118 211,241 
Interventional Technologies(1)
63,253 43,007 188,220 119,168 
Blood Management Technologies(2)
80,720 73,223 228,192 205,300 
 Hospital143,973 116,230 416,412 324,468 
Net revenues(3)
$348,542 $336,250 $1,030,225 $965,765 
(1) Interventional Technologies includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection product lines of the Hospital business unit.
(2) Blood Management Technologies includes Hemostasis Management, Cell Salvage and Transfusion Management product lines of the Hospital business unit.
(3) Beginning in fiscal 2025, the Company integrated service revenue within its three business units. Prior periods were conformed to current presentation.
Net revenues generated in the Company’s principle operating regions on a reported basis are as follows:
Three Months EndedNine Months Ended
(In thousands)December 28,
2024		December 30,
2023		December 28,
2024		December 30,
2023
United States$257,665 $250,804 $762,628 $724,222 
Japan16,174 14,825 46,303 41,609 
Europe44,163 37,035 133,379 115,088 
Rest of Asia25,597 30,935 71,148 80,710 
Other4,943 2,651 16,767 4,136 
Net revenues$348,542 $336,250 $1,030,225 $965,765 
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.25.0.1
ACQUISITIONS, DIVESTITURES AND STRATEGIC INVESTMENTS - Narrative (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Jan. 13, 2025
Apr. 01, 2024
Dec. 12, 2023
Jun. 29, 2024
Dec. 28, 2024
Dec. 30, 2023
Mar. 30, 2024
Business Acquisition [Line Items]              
Payments to acquire businesses, net of cash acquired         $ 150,906 $ 243,852  
Inventories, net         (359,614)   $ (317,202)
Property, plant and equipment, net         (286,107)   (311,362)
Assets held for sale         (4,475)    
Prepaid expenses and other current assets         113,459   66,339
Other current liabilities         139,235   $ 136,088
Revision of Prior Period, Reclassification, Adjustment              
Business Acquisition [Line Items]              
Inventories, net         34,700    
Property, plant and equipment, net         7,300    
Assets held for sale         4,500    
Accrued liabilities         500    
Revision of Prior Period, Reclassification, Adjustment | Inventories              
Business Acquisition [Line Items]              
Prepaid expenses and other current assets         34,700    
Revision of Prior Period, Reclassification, Adjustment | Property, Plant and Equipment              
Business Acquisition [Line Items]              
Prepaid expenses and other current assets         7,300    
Revision of Prior Period, Reclassification, Adjustment | Goodwill              
Business Acquisition [Line Items]              
Prepaid expenses and other current assets         4,500    
Revision of Prior Period, Reclassification, Adjustment | Accrued Liabilities              
Business Acquisition [Line Items]              
Other current liabilities         $ 500    
Disposal Group, Held-for-Sale, Not Discontinued Operations | Whole Blood Business | Subsequent Event              
Business Acquisition [Line Items]              
Proceeds, net of cash transferred $ 67,800            
Proceeds from divestiture 45,300            
Contingent consideration from divestiture $ 22,500            
Attune Medical              
Business Acquisition [Line Items]              
Total consideration   $ 187,700          
Upfront payment   162,000          
Payments to acquire businesses, net of cash acquired   150,500          
Contingent consideration   25,300          
Business combination, estimated working capital adjustment   400          
Business combination, recognized identifiable assets acquired and liabilities assumed, cash and equivalents   $ 11,500          
Attune Medical | Selling, general and administrative expenses              
Business Acquisition [Line Items]              
Legal and professional fees       $ 9,800      
OpSens, Inc.              
Business Acquisition [Line Items]              
Upfront payment     $ 254,500        
Payments to acquire businesses, net of cash acquired     243,900        
Business combination, recognized identifiable assets acquired and liabilities assumed, cash and equivalents     10,600        
OpSens, Inc. | Selling, general and administrative expenses              
Business Acquisition [Line Items]              
Legal and professional fees     $ 6,600        
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.25.0.1
ACQUISITIONS, DIVESTITURES AND STRATEGIC INVESTMENTS - Purchase Price Allocation (Details) - USD ($)
$ in Thousands
Apr. 01, 2024
Dec. 12, 2023
Dec. 28, 2024
Mar. 30, 2024
Business Acquisition [Line Items]        
Goodwill     $ 605,266 $ 565,082
Attune Medical        
Business Acquisition [Line Items]        
Accounts receivable $ 3,784      
Inventories 26,300      
Prepaid expenses and other current assets 906      
Property, plant and equipment 200      
Intangible assets 105,800      
Goodwill 70,256      
Total assets acquired 207,246      
Accounts payable 2,260      
Accrued payroll and related costs 2,129      
Other liabilities 496      
Deferred tax liability 26,155      
Total liabilities assumed 31,040      
Net assets acquired 176,206      
Business combination, recognized identifiable assets acquired and liabilities assumed, cash and equivalents 11,500      
Attune Medical | Developed technology        
Business Acquisition [Line Items]        
Acquired intangibles $ 96,100      
Weighted-Average Amortization Period 10 years      
Risk-Adjusted Discount Rates used in Purchase Price Allocation 22.00%      
Attune Medical | Customer contracts and related relationships        
Business Acquisition [Line Items]        
Acquired intangibles $ 7,800      
Weighted-Average Amortization Period 10 years      
Risk-Adjusted Discount Rates used in Purchase Price Allocation 21.50%      
Attune Medical | Trade names        
Business Acquisition [Line Items]        
Acquired intangibles $ 1,900      
Weighted-Average Amortization Period 10 years      
Risk-Adjusted Discount Rates used in Purchase Price Allocation 21.50%      
OpSens, Inc.        
Business Acquisition [Line Items]        
Accounts receivable   $ 5,960    
Inventories   12,075    
Prepaid expenses and other current assets   2,062    
Property, plant and equipment   3,028    
Intangible assets   172,000    
Goodwill   79,400    
Other long-term assets   4,705    
Total assets acquired   279,230    
Accounts payable   3,251    
Accrued payroll and related costs   1,723    
Other liabilities   9,746    
Deferred tax liability   14,805    
Other long-term liabilities   5,853    
Total liabilities assumed   35,378    
Net assets acquired   243,852    
Business combination, recognized identifiable assets acquired and liabilities assumed, cash and equivalents   10,600    
OpSens, Inc. | Developed technology        
Business Acquisition [Line Items]        
Acquired intangibles   $ 114,900    
Weighted-Average Amortization Period   15 years    
Risk-Adjusted Discount Rates used in Purchase Price Allocation   20.50%    
OpSens, Inc. | Customer contracts and related relationships        
Business Acquisition [Line Items]        
Acquired intangibles   $ 52,300    
Weighted-Average Amortization Period   15 years    
Risk-Adjusted Discount Rates used in Purchase Price Allocation   18.90%    
OpSens, Inc. | Trade names        
Business Acquisition [Line Items]        
Acquired intangibles   $ 4,800    
Weighted-Average Amortization Period   15 years    
Risk-Adjusted Discount Rates used in Purchase Price Allocation   20.50%    
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.25.0.1
ACQUISITIONS, DIVESTITURES AND STRATEGIC INVESTMENTS - Strategic Investments (Details)
$ in Thousands, € in Millions
 3 Months Ended 9 Months Ended
Dec. 28, 2024
USD ($)
Dec. 30, 2023
USD ($)
Dec. 28, 2024
USD ($)
Dec. 30, 2023
USD ($)
Dec. 28, 2024
EUR (€)
Schedule of Investments [Line Items]          
Payment to acquire investment     $ 14,000 $ 7,600  
Gain (loss) on investments $ 0 $ 0 $ 0 $ 0  
Vivasure Medical LTD          
Schedule of Investments [Line Items]          
Investment | €         € 35.0
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.25.0.1
REVENUE (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Dec. 28, 2024
Dec. 28, 2024
Mar. 30, 2024
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]      
Performance obligation amount $ 33.3 $ 33.3  
Contract liabilities 35.6 35.6 $ 31.2
Revenue recognized $ 4.9 $ 26.7  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-12-29      
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]      
Performance obligation percent 75.00% 75.00%  
Expected timing of satisfaction 12 months 12 months  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-12-27      
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]      
Performance obligation percent 25.00% 25.00%  
Expected timing of satisfaction  
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.25.0.1
RESTRUCTURING (Narrative) (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Dec. 28, 2024
Dec. 30, 2023
Dec. 28, 2024
Dec. 30, 2023
Mar. 30, 2024
Restructuring Cost and Reserve [Line Items]          
Restructuring and Restructuring Related Costs $ 4,983 $ 10,371 $ 18,486 $ 14,597  
Restructuring liability 4,618   4,618   $ 11,794
2020 Program          
Restructuring Cost and Reserve [Line Items]          
Expected cost 85,000   85,000    
Restructuring and related cost, incurred cost 1,900   6,000    
Restructuring and Restructuring Related Costs   2,600   6,800  
Cumulative costs to date 83,000   83,000    
Restructuring liability 466   466   485
Portfolio Rationalization          
Restructuring Cost and Reserve [Line Items]          
Restructuring and Restructuring Related Costs 3,100 $ 7,800 12,500 $ 7,800  
Restructuring liability $ 4,152   $ 4,152   $ 11,309
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.25.0.1
RESTRUCTURING (Schedule of Restructuring Reserve by Type of Cost) (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Dec. 28, 2024
Dec. 30, 2023
Dec. 28, 2024
Dec. 30, 2023
Restructuring Reserve [Roll Forward]        
Balance at March 30, 2024     $ 11,794  
Costs incurred, net of reversals $ 3,515 $ 7,968 12,929 $ 8,043
Payments     (11,489)  
Restructuring Reserve, Accrual Adjustment     8,616  
Balance at December 28, 2024 4,618   4,618  
Portfolio Rationalization        
Restructuring Reserve [Roll Forward]        
Balance at March 30, 2024     11,309  
Costs incurred, net of reversals     12,296  
Payments     (10,837)  
Restructuring Reserve, Accrual Adjustment     8,616  
Balance at December 28, 2024 4,152   4,152  
2020 Program        
Restructuring Reserve [Roll Forward]        
Balance at March 30, 2024     485  
Costs incurred, net of reversals     633  
Payments     (652)  
Restructuring Reserve, Accrual Adjustment     0  
Balance at December 28, 2024 $ 466   $ 466  
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.25.0.1
RESTRUCTURING (Schedule of Restructuring and Related Costs) (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Dec. 28, 2024
Dec. 30, 2023
Dec. 28, 2024
Dec. 30, 2023
Restructuring Cost and Reserve [Line Items]        
Restructuring costs $ 3,515 $ 7,968 $ 12,929 $ 8,043
Restructuring related costs 1,468 2,403 5,557 6,554
Restructuring and Restructuring Related Costs 4,983 10,371 18,486 14,597
Plasma        
Restructuring Cost and Reserve [Line Items]        
Restructuring costs 77 33 284 (164)
Restructuring related costs 37 72 263 315
Blood Center        
Restructuring Cost and Reserve [Line Items]        
Restructuring costs 685 4,546 4,241 4,546
Restructuring related costs 31 93 120 166
Hospital        
Restructuring Cost and Reserve [Line Items]        
Restructuring costs 774 2,503 1,404 2,745
Restructuring related costs (68) 251 40 398
Corporate        
Restructuring Cost and Reserve [Line Items]        
Restructuring costs 1,979 886 7,000 916
Restructuring related costs 1,468 1,987 5,134 5,675
Cost of goods sold        
Restructuring Cost and Reserve [Line Items]        
Restructuring costs 3,027 7,065 11,158 7,329
Research and development        
Restructuring Cost and Reserve [Line Items]        
Restructuring costs (4) 343 (16) 343
Selling, general and administrative expenses        
Restructuring Cost and Reserve [Line Items]        
Restructuring costs $ 492 $ 560 $ 1,787 $ 371
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.25.0.1
INCOME TAXES (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Dec. 28, 2024
Dec. 30, 2023
Dec. 28, 2024
Dec. 30, 2023
Income Tax Contingency [Line Items]        
Provision for income taxes $ 12,423 $ 12,788 $ 31,636 $ 31,260
Reported tax rate 24.90% 29.00% 22.40% 24.30%
Discrete tax benefit (expense)       $ (1,100)
Stock Compensation Windfalls        
Income Tax Contingency [Line Items]        
Discrete tax benefit (expense) $ (3,300)     $ (2,600)
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.25.0.1
EARNINGS PER SHARE (Schedule of Earnings Per Share Reconciliation) (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 9 Months Ended
Dec. 28, 2024
Sep. 28, 2024
Jun. 29, 2024
Dec. 30, 2023
Sep. 30, 2023
Jul. 01, 2023
Dec. 28, 2024
Dec. 30, 2023
Basic EPS                
Net income $ 37,494 $ 33,831 $ 38,373 $ 31,241 $ 24,908 $ 41,042 $ 109,698 $ 97,191
Weighted average shares (in shares) 50,286,000     50,768,000     50,709,000 50,679,000
Basic income (loss) per share (in dollars per share) $ 0.75     $ 0.62     $ 2.16 $ 1.92
Diluted EPS                
Net income $ 37,494 $ 33,831 $ 38,373 $ 31,241 $ 24,908 $ 41,042 $ 109,698 $ 97,191
Net effect of common stock equivalents (in shares) 353,000     677,000     439,000 715,000
Diluted weighted average shares (in shares) 50,639,000     51,445,000     51,148,000 51,394,000
Diluted income (loss) per share (in dollars per share) $ 0.74     $ 0.61     $ 2.14 $ 1.89
Anti-dilutive shares (in shares) 800,000     600,000     800,000 600,000
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.25.0.1
EARNINGS PER SHARE (Share Repurchase Program) (Details)
shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Aug. 28, 2024
USD ($)
$ / shares
shares
Dec. 28, 2024
USD ($)
shares
Sep. 28, 2024
shares
Dec. 28, 2024
USD ($)
Aug. 31, 2022
USD ($)
Share Repurchase Program [Line Items]          
Shares repurchased (in shares) | shares   209 799    
Remaining authorized amount   $ 150,000   $ 150,000  
2022 Accelerated Share Repurchase Program          
Share Repurchase Program [Line Items]          
Share repurchase program, period in force       3 years  
Share repurchase plan, authorized amount         $ 300,000
2024 Accelerated Share Repurchase Program          
Share Repurchase Program [Line Items]          
Accelerated share repurchases, settlement (payment) or receipt $ 75,000        
Shares repurchased (in shares) | shares 1,000        
Accelerated share repurchases, final price paid per share | $ / shares $ 74.36        
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.25.0.1
INVENTORIES (Schedule of Inventories) (Details) - USD ($)
$ in Thousands
Dec. 28, 2024
Mar. 30, 2024
Inventory Disclosure [Abstract]    
Raw materials $ 101,989 $ 134,150
Work-in-process 32,120 15,488
Finished goods 225,505 167,564
Inventories, net $ 359,614 $ 317,202
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.25.0.1
PROPERTY, PLANT AND EQUIPMENT (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Apr. 25, 2024
Dec. 28, 2024
Dec. 30, 2023
Dec. 28, 2024
Dec. 30, 2023
Mar. 30, 2024
Property, Plant and Equipment [Line Items]            
Total   $ 867,457   $ 867,457   $ 959,177
Less: accumulated depreciation   (581,350)   (581,350)   (647,815)
Property, plant and equipment, net   286,107   286,107   311,362
Depreciation   15,200 $ 14,200 44,800 $ 41,100  
Proceeds from sale of property, plant and equipment $ 19,900     20,802 1,259  
Sale of property $ 14,100     14,572 $ 647  
Revision of Prior Period, Adjustment            
Property, Plant and Equipment [Line Items]            
Total   39,800   39,800    
Land            
Property, Plant and Equipment [Line Items]            
Total   1,999   1,999   4,130
Building and building improvements            
Property, Plant and Equipment [Line Items]            
Total   107,665   107,665   124,338
Plant equipment and machinery            
Property, Plant and Equipment [Line Items]            
Total   191,063   191,063   204,622
Office equipment and information technology            
Property, Plant and Equipment [Line Items]            
Total   129,123   129,123   129,979
Haemonetics equipment            
Property, Plant and Equipment [Line Items]            
Total   412,561   412,561   456,414
Construction in progress            
Property, Plant and Equipment [Line Items]            
Total   $ 25,046   $ 25,046   $ 39,694
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.25.0.1
LEASES (Details)
 9 Months Ended
Dec. 28, 2024
Leases [Abstract]  
Operating lease, revenue, as a percentage of total net sales 3.00%
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.25.0.1
GOODWILL AND INTANGIBLE ASSETS - Narrative (Details) - USD ($)
 3 Months Ended 9 Months Ended
Dec. 28, 2024
Dec. 30, 2023
Sep. 30, 2023
Dec. 28, 2024
Dec. 30, 2023
Apr. 01, 2024
Mar. 30, 2024
Finite-Lived Intangible Assets [Line Items]              
Assets held for sale       $ (4,475,000)      
Impairment of intangible assets     $ 10,400,000        
Finite-lived intangible assets, net $ 458,867,000     458,867,000     $ 387,883,000
Gross Carrying Amount 770,463,000     770,463,000     843,096,000
Aggregate amortization expense 13,900,000 $ 9,300,000   42,600,000 $ 28,500,000    
Revision of Prior Period, Reclassification, Adjustment              
Finite-Lived Intangible Assets [Line Items]              
Assets held for sale       4,500,000      
Blood Center              
Finite-Lived Intangible Assets [Line Items]              
Assets held for sale       (4,475,000)      
Finite-lived intangible assets, net 0     0      
Gross Carrying Amount 185,600,000     185,600,000      
Developed technology | Attune Medical              
Finite-Lived Intangible Assets [Line Items]              
Acquired intangibles           $ 96,100,000  
Customer-Related Intangible Assets | Attune Medical              
Finite-Lived Intangible Assets [Line Items]              
Acquired intangibles           7,800,000  
Trade names              
Finite-Lived Intangible Assets [Line Items]              
Finite-lived intangible assets, net 9,791,000     9,791,000     8,864,000
Gross Carrying Amount $ 15,927,000     $ 15,927,000     $ 14,320,000
Trade names | Attune Medical              
Finite-Lived Intangible Assets [Line Items]              
Acquired intangibles           $ 1,900,000  
Minimum              
Finite-Lived Intangible Assets [Line Items]              
Weighted average useful life 5 years     5 years      
Maximum              
Finite-Lived Intangible Assets [Line Items]              
Weighted average useful life 15 years     15 years      
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.25.0.1
GOODWILL AND INTANGIBLE ASSETS - Schedule of Goodwill (Details)
$ in Thousands
 9 Months Ended
Dec. 28, 2024
USD ($)
Goodwill [Roll Forward]  
Goodwill, carrying amount, beginning balance $ 565,082
Assets held for sale (4,475)
Purchase accounting adjustments (19,248)
Acquisitions 69,542
Currency translation (5,635)
Goodwill, carrying amount, ending balance 605,266
Plasma  
Goodwill [Roll Forward]  
Goodwill, carrying amount, beginning balance 29,043
Assets held for sale 0
Purchase accounting adjustments 0
Acquisitions 0
Currency translation 0
Goodwill, carrying amount, ending balance 29,043
Blood Center  
Goodwill [Roll Forward]  
Goodwill, carrying amount, beginning balance 33,484
Assets held for sale (4,475)
Purchase accounting adjustments 0
Acquisitions 0
Currency translation (268)
Goodwill, carrying amount, ending balance 28,741
Hospital  
Goodwill [Roll Forward]  
Goodwill, carrying amount, beginning balance 502,555
Assets held for sale 0
Purchase accounting adjustments (19,248)
Acquisitions 69,542
Currency translation (5,367)
Goodwill, carrying amount, ending balance $ 547,482
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.25.0.1
GOODWILL AND INTANGIBLE ASSETS - Intangible Assets (Details) - USD ($)
Dec. 28, 2024
Mar. 30, 2024
Amortizable:    
Gross Carrying Amount $ 770,463,000 $ 843,096,000
Accumulated Amortization 311,596,000 455,213,000
Net 458,867,000 387,883,000
Non-amortizable: 6,748,000 18,234,000
Blood Center    
Amortizable:    
Gross Carrying Amount 185,600,000  
Net 0  
In-process software development    
Amortizable:    
Non-amortizable: 6,748,000 4,567,000
In-process research and development    
Amortizable:    
Non-amortizable:   13,667,000
Developed technology    
Amortizable:    
Gross Carrying Amount 505,323,000 464,291,000
Accumulated Amortization 146,898,000 178,413,000
Net 358,425,000 285,878,000
Customer contracts and related relationships    
Amortizable:    
Gross Carrying Amount 136,181,000 255,144,000
Accumulated Amortization 70,261,000 190,033,000
Net 65,920,000 65,111,000
Capitalized software    
Amortizable:    
Gross Carrying Amount 85,528,000 84,837,000
Accumulated Amortization 74,722,000 69,491,000
Net 10,806,000 15,346,000
Patents and other    
Amortizable:    
Gross Carrying Amount 27,504,000 24,504,000
Accumulated Amortization 13,579,000 11,820,000
Net 13,925,000 12,684,000
Trade names    
Amortizable:    
Gross Carrying Amount 15,927,000 14,320,000
Accumulated Amortization 6,136,000 5,456,000
Net $ 9,791,000 $ 8,864,000
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.25.0.1
GOODWILL AND INTANGIBLE ASSETS - Maturity (Details)
$ in Thousands
Dec. 28, 2024
USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]  
Remainder of Fiscal 2025 $ 12,995
Fiscal 2026 49,879
Fiscal 2027 47,931
Fiscal 2028 46,160
Fiscal 2029 $ 44,965
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.25.0.1
NOTES PAYABLE AND LONG-TERM DEBT - Schedule of Debt (Details) - USD ($)
$ in Thousands
Dec. 28, 2024
Mar. 30, 2024
Debt Instrument [Line Items]    
Notes payable and current maturities of long-term debt $ (5,075) $ (10,229)
Long-term debt 1,219,762 797,564
Convertible notes    
Debt Instrument [Line Items]    
Debt outstanding 982,731 494,813
Term loan, net of financing fees    
Debt Instrument [Line Items]    
Debt outstanding 241,266 261,971
Revolving credit facility    
Debt Instrument [Line Items]    
Debt outstanding 0 50,000
Other borrowings    
Debt Instrument [Line Items]    
Debt outstanding $ 840 $ 1,009
XML 64 R53.htm IDEA: XBRL DOCUMENT v3.25.0.1
NOTES PAYABLE AND LONG-TERM DEBT - Narrative (Details) - USD ($)
$ / shares in Units, shares in Thousands
 3 Months Ended 9 Months Ended
May 28, 2024
Apr. 30, 2024
Dec. 28, 2024
Dec. 28, 2024
Dec. 30, 2023
Mar. 30, 2024
Jul. 26, 2022
Mar. 31, 2021
Debt Instrument [Line Items]                
Gain (loss) on repurchase of debt instrument       $ 12,600,000 $ 0      
Proceeds from issuance of convertible notes       700,000,000 0      
Capped call transaction, initial strike price (in dollars per share) $ 117.12              
Capped call transaction, initial cap price (in dollars per share) $ 180.18              
Capped call transaction, anti-dilution adjustment (in shares) 5,980              
Purchase of capped call related to convertible notes $ 88,200,000     88,200,000 0      
Repayments of long-term debt       3,125,000 $ 8,750,000      
Debt instrument, percent of principal amount due in years 1-3   2.50%            
Debt instrument, percent of principal amount due in year 4   5.00%            
Debt instrument, percent of principal amount due in year 5   7.50%            
Consolidated total leverage ratio   4.0            
Consolidated interest coverage ratio   4.5            
Fiscal 2026     $ 306,349,000 306,349,000        
Convertible notes                
Debt Instrument [Line Items]                
Debt outstanding     982,731,000 982,731,000   $ 494,813,000    
Term loan, net of financing fees                
Debt Instrument [Line Items]                
Long-term debt, gross     246,900,000 246,900,000        
Debt outstanding     $ 241,266,000 $ 241,266,000   261,971,000    
Effective interest rate     6.10% 6.10%        
Revolving credit facility                
Debt Instrument [Line Items]                
Debt outstanding     $ 0 $ 0   $ 50,000,000    
Uncommitted Operating Lines of Credit                
Debt Instrument [Line Items]                
Debt outstanding     0 0        
Maximum borrowing capacity     18,000,000.0 18,000,000.0        
Convertible Senior Notes Due 2026 | Convertible notes                
Debt Instrument [Line Items]                
Face amount of debt               $ 500,000,000
Stated rate (as a percent)               0.00%
Debt Instrument, Repurchased Face Amount 200,000,000              
Debt Instrument, Repurchase Amount 185,500,000              
Gain (loss) on extinguishment of debt, before debt issuance cost writeoff 14,500,000              
Deferred debt issuance cost, writeoff 1,900,000              
Gain (loss) on repurchase of debt instrument (12,600,000)              
Long-term debt, gross     300,000,000 300,000,000        
Debt issuance costs, net     1,900,000 1,900,000        
Debt outstanding     298,100,000 298,100,000        
Interest expense, debt     $ 400,000 $ 1,400,000        
Effective interest rate     0.50% 0.50%        
Convertible Senior Notes Due 2029 | Convertible notes                
Debt Instrument [Line Items]                
Face amount of debt $ 700,000,000              
Stated rate (as a percent) 2.50%              
Debt issuance costs, net     $ 15,400,000 $ 15,400,000        
Debt outstanding     684,600,000 684,600,000        
Interest expense, debt     5,200,000 12,100,000        
Effective interest rate 3.00%              
Proceeds from issuance of convertible notes $ 682,800,000              
Debt instrument, redemption price, percentage 130.00%              
Debt instrument, redemption price, percentage of principal amount redeemed 98.00%              
Debt instrument, redemption price, percentage of previous closing price 10.00%              
Debt instrument, convertible, conversion rate 8.5385              
Debt instrument, convertible, conversion price $ 117.12              
Debt issuance costs, gross $ 17,200,000              
Convertible Senior Notes Due 2029 | Convertible notes | Debt Instrument, Redemption, Period One                
Debt Instrument [Line Items]                
Debt instrument, redemption price, percentage 130.00%              
Convertible Senior Notes Due 2029 | Convertible notes | Debt Instrument, Redemption, Period Two                
Debt Instrument [Line Items]                
Debt instrument, redemption price, percentage 100.00%              
2022 Revised Credit Facilities | Term loan, net of financing fees                
Debt Instrument [Line Items]                
Face amount of debt             $ 280,000,000  
2022 Revised Credit Facilities | Revolving credit facility                
Debt Instrument [Line Items]                
Maximum borrowing capacity             $ 420,000,000  
2022 Revised Credit Facilities | Revolving credit facility | Minimum                
Debt Instrument [Line Items]                
Stated rate (as a percent)             1.125%  
2022 Revised Credit Facilities | Revolving credit facility | Maximum                
Debt Instrument [Line Items]                
Stated rate (as a percent)             1.75%  
2024 Revised Credit Facilities | Term loan, net of financing fees                
Debt Instrument [Line Items]                
Face amount of debt   $ 250,000,000            
Debt issuance costs, net     5,600,000 5,600,000        
Repayments of long-term debt   $ 12,500,000            
Fiscal 2026     6,300,000 6,300,000        
2024 Revised Credit Facilities | Term loan, net of financing fees | Minimum                
Debt Instrument [Line Items]                
Stated rate (as a percent)   1.125%            
Interest rate floor   0.00%            
2024 Revised Credit Facilities | Term loan, net of financing fees | Maximum                
Debt Instrument [Line Items]                
Stated rate (as a percent)   1.75%            
2024 Revised Credit Facilities | Revolving credit facility                
Debt Instrument [Line Items]                
Maximum borrowing capacity   $ 750,000,000            
Additional debt issuance costs capitalized   $ 5,900,000            
2024 Revised Credit Facilities | Revolving credit facility | Minimum                
Debt Instrument [Line Items]                
Revolving credit facility unused fee percentage   0.125%            
2024 Revised Credit Facilities | Revolving credit facility | Maximum                
Debt Instrument [Line Items]                
Revolving credit facility unused fee percentage   0.25%            
Revised Credit Agreement | Unsecured Debt                
Debt Instrument [Line Items]                
Interest expense     $ 4,600,000 $ 16,600,000        
XML 65 R54.htm IDEA: XBRL DOCUMENT v3.25.0.1
NOTES PAYABLE AND LONG-TERM DEBT - Schedule of Long Term Debt Maturity (Details)
$ in Thousands
Dec. 28, 2024
USD ($)
Debt Disclosure [Abstract]  
Remainder of Fiscal 2025 $ 1,597
Fiscal 2026 306,349
Fiscal 2027 6,308
Fiscal 2028 10,999
Fiscal 2029 17,252
Thereafter $ 905,210
XML 66 R55.htm IDEA: XBRL DOCUMENT v3.25.0.1
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Narrative) (Details)
 1 Months Ended 3 Months Ended 9 Months Ended
Sep. 27, 2024
swap
Sep. 26, 2024
swap
Jun. 15, 2023
swap
Sep. 30, 2022
swap
Dec. 28, 2024
USD ($)
Dec. 28, 2024
USD ($)
Apr. 01, 2024
USD ($)
Mar. 30, 2024
USD ($)
Sep. 23, 2022
USD ($)
Derivative [Line Items]                  
Number of Interest Rate Swaps Remaining | swap 2                
Level 2 | Convertible Senior Notes Due 2026                  
Derivative [Line Items]                  
Convertible notes, fair value         $ 282,000,000 $ 282,000,000      
Level 2 | Convertible Senior Notes Due 2029                  
Derivative [Line Items]                  
Convertible notes, fair value         688,900,000 688,900,000      
Term loan, net of financing fees                  
Derivative [Line Items]                  
Debt outstanding         $ 241,266,000 $ 241,266,000   $ 261,971,000  
Foreign Exchange Contract                  
Derivative [Line Items]                  
Percentage of sales generated outside the US         26.10% 26.00%      
Maturity period for foreign currency contracts           1 year      
Interest Rate Swap                  
Derivative [Line Items]                  
Number of interest rate swaps entered | swap       4          
Derivative, percentage of notional value of debt 80.00%                
Derivative, blended fixed interest rate 3.31%                
Notional amount         $ 205,800,000 $ 205,800,000     $ 205,800,000
Number Of Interest Rate Swaps Terminated | swap   2 2            
Designated as Hedging Instrument | Foreign Exchange Contract                  
Derivative [Line Items]                  
Deferred income tax expense (benefit)         0 0      
Designated as Hedging Instrument | Foreign Exchange Contract                  
Derivative [Line Items]                  
Designated foreign currency hedge contracts outstanding         45,500,000 45,500,000   74,000,000.0  
Designated as Hedging Instrument | Cash Flow Hedging                  
Derivative [Line Items]                  
Gain (loss) to be reclassified within the next twelve months           1,100,000      
Not Designated as Hedging Instrument | Foreign Exchange Contract                  
Derivative [Line Items]                  
Non-designated foreign currency hedge contracts outstanding         82,700,000 82,700,000   $ 39,900,000  
Attune Medical                  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                  
Contingent consideration             $ 25,300,000    
Attune Medical | Other Current Liabilities                  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                  
Contingent consideration         1,700,000 1,700,000      
Attune Medical | Other Noncurrent Liabilities                  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                  
Contingent consideration         $ 21,400,000 $ 21,400,000      
XML 67 R56.htm IDEA: XBRL DOCUMENT v3.25.0.1
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Schedule of Interest Rate Swaps) (Details) - USD ($)
$ in Thousands
Dec. 28, 2024
Mar. 30, 2024
Sep. 23, 2022
Fair Value, Recurring [Member]      
Derivative [Line Items]      
Derivative Assets $ 7,063 $ 3,242  
Derivative Liabilities 1,566 931  
Interest Rate Swap      
Derivative [Line Items]      
Notional amount 205,800   $ 205,800
Estimated Fair Value Assets (Liabilities) 5,806    
Interest Rate Swap | Fair Value, Recurring [Member] | Designated as Hedging Instrument      
Derivative [Line Items]      
Derivative Liabilities 0    
Interest Rate Swap | Level 2 | Fair Value, Recurring [Member] | Designated as Hedging Instrument      
Derivative [Line Items]      
Derivative Liabilities 0    
Interest Rate Swap | Other Current Assets | Fair Value, Recurring [Member] | Not Designated as Hedging Instrument      
Derivative [Line Items]      
Derivative Assets   1,673  
Interest Rate Swap | Other Current Assets | Level 2 | Fair Value, Recurring [Member] | Not Designated as Hedging Instrument      
Derivative [Line Items]      
Derivative Assets 1,734    
Interest Rate Swap | Other Noncurrent Assets | Fair Value, Recurring [Member] | Designated as Hedging Instrument      
Derivative [Line Items]      
Derivative Liabilities   62  
Interest Rate Swap | Other Noncurrent Assets | Level 2 | Fair Value, Recurring [Member] | Designated as Hedging Instrument      
Derivative [Line Items]      
Derivative Liabilities 4,072    
Interest Rate Swap, 4.08% Fixed Interest Rate      
Derivative [Line Items]      
Notional amount $ 103,600   103,600
Derivative fixed interest rate 3.32%    
Estimated Fair Value Assets (Liabilities) $ 2,806    
Interest Rate Swap, 4.15% Fixed Interest Rate      
Derivative [Line Items]      
Notional amount $ 102,200   $ 102,200
Derivative fixed interest rate 3.30%    
Estimated Fair Value Assets (Liabilities) $ 3,000    
Foreign Exchange Contract | Fair Value, Recurring [Member] | Designated as Hedging Instrument      
Derivative [Line Items]      
Derivative Assets 1,186 1,353  
Derivative Liabilities 1,219 395  
Foreign Exchange Contract | Fair Value, Recurring [Member] | Not Designated as Hedging Instrument      
Derivative [Line Items]      
Derivative Assets 71 154  
Derivative Liabilities 347 536  
Foreign Exchange Contract | Level 2 | Fair Value, Recurring [Member] | Designated as Hedging Instrument      
Derivative [Line Items]      
Derivative Assets   1,353  
Derivative Liabilities   395  
Foreign Exchange Contract | Level 2 | Fair Value, Recurring [Member] | Not Designated as Hedging Instrument      
Derivative [Line Items]      
Derivative Assets   154  
Foreign Exchange Contract | Other Current Assets | Fair Value, Recurring [Member] | Designated as Hedging Instrument      
Derivative [Line Items]      
Derivative Assets   1,353  
Foreign Exchange Contract | Other Current Assets | Fair Value, Recurring [Member] | Not Designated as Hedging Instrument      
Derivative [Line Items]      
Derivative Assets   $ 154  
Foreign Exchange Contract | Other Current Assets | Level 2 | Fair Value, Recurring [Member] | Designated as Hedging Instrument      
Derivative [Line Items]      
Derivative Assets 1,186    
Foreign Exchange Contract | Other Current Assets | Level 2 | Fair Value, Recurring [Member] | Not Designated as Hedging Instrument      
Derivative [Line Items]      
Derivative Assets $ 71    
XML 68 R57.htm IDEA: XBRL DOCUMENT v3.25.0.1
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Allowance for Credit Losses) (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Dec. 28, 2024
Dec. 30, 2023
Dec. 28, 2024
Dec. 30, 2023
Accounts Receivable, Allowance for Credit Loss [Roll Forward]        
Beginning balance $ 5,912 $ 5,044 $ 5,695 $ 4,932
Credit loss 123 653 339 833
Write-offs (recoveries) (49) 28 (48) (40)
Ending balance $ 5,986 $ 5,725 $ 5,986 $ 5,725
XML 69 R58.htm IDEA: XBRL DOCUMENT v3.25.0.1
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Schedule of Effect of Derivative Instruments Designated as Cash Flow Hedges and Those Not Designated as Hedging Instruments) (Details)
$ in Thousands
 9 Months Ended
Dec. 28, 2024
USD ($)
Derivative Instruments, Gain (Loss) [Line Items]  
Derivative Instrument, Gain (Loss) Reclassified from AOCI into Income, Effective Portion, Statement of Income or Comprehensive Income [Extensible Enumeration] Interest and other expense, net
Designated as Hedging Instrument | Cash Flow Hedging  
Derivative Instruments, Gain (Loss) [Line Items]  
Amount of Gain (Loss) Recognized in Accumulated Other Comprehensive Loss $ (1,095)
Amount of Gain (Loss) Reclassified from Accumulated Other Comprehensive Loss into Earnings (220)
Amount of Gain Excluded from Effectiveness Testing 959
Designated as Hedging Instrument | Interest Rate Swap  
Derivative Instruments, Gain (Loss) [Line Items]  
Amount of Gain (Loss) Recognized in Accumulated Other Comprehensive Loss 3,353
Amount of Gain (Loss) Reclassified from Accumulated Other Comprehensive Loss into Earnings 37
Amount of Gain Excluded from Effectiveness Testing 0
Not Designated as Hedging Instrument | Foreign Exchange Contract  
Derivative Instruments, Gain (Loss) [Line Items]  
Amount of Gain (Loss) Recognized in Accumulated Other Comprehensive Loss 0
Amount of Gain (Loss) Reclassified from Accumulated Other Comprehensive Loss into Earnings 0
Amount of Gain Excluded from Effectiveness Testing $ 2,092
XML 70 R59.htm IDEA: XBRL DOCUMENT v3.25.0.1
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Schedules of Derivatives) (Details) - USD ($)
$ in Thousands
 9 Months Ended
Dec. 28, 2024
Mar. 30, 2024
Liabilities    
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Value At Acquisition Date $ 25,000  
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Adjustment 300  
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings (2,167)  
Fair Value, Recurring [Member]    
Assets    
Money market funds 170,773 $ 43,073
Derivative Assets 7,063 3,242
Assets fair value 177,836 46,315
Liabilities    
Derivative Liabilities 1,566 931
Liabilities fair value 24,699 931
Fair Value, Recurring [Member] | Level 1    
Assets    
Money market funds 170,773 43,073
Assets fair value 170,773 43,073
Liabilities    
Liabilities fair value 0 0
Fair Value, Recurring [Member] | Level 2    
Assets    
Money market funds 0 0
Assets fair value 7,063 3,242
Liabilities    
Liabilities fair value 1,566 931
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3    
Liabilities    
Liabilities fair value 23,133 0
Fair Value, Recurring [Member] | Foreign Exchange Contract | Designated as Hedging Instrument    
Assets    
Derivative Assets 1,186 1,353
Liabilities    
Derivative Liabilities 1,219 395
Fair Value, Recurring [Member] | Foreign Exchange Contract | Designated as Hedging Instrument | Level 1    
Assets    
Derivative Assets 0 0
Liabilities    
Derivative Liabilities 0 0
Fair Value, Recurring [Member] | Foreign Exchange Contract | Designated as Hedging Instrument | Level 2    
Assets    
Derivative Assets   1,353
Liabilities    
Derivative Liabilities   395
Fair Value, Recurring [Member] | Foreign Exchange Contract | Not Designated as Hedging Instrument    
Assets    
Derivative Assets 71 154
Liabilities    
Derivative Liabilities 347 536
Fair Value, Recurring [Member] | Foreign Exchange Contract | Not Designated as Hedging Instrument | Level 1    
Assets    
Derivative Assets 0 0
Liabilities    
Derivative Liabilities 0 0
Fair Value, Recurring [Member] | Foreign Exchange Contract | Not Designated as Hedging Instrument | Level 2    
Assets    
Derivative Assets   154
Fair Value, Recurring [Member] | Foreign Exchange Contract | Other Current Assets | Designated as Hedging Instrument    
Assets    
Derivative Assets   1,353
Fair Value, Recurring [Member] | Foreign Exchange Contract | Other Current Assets | Designated as Hedging Instrument | Level 2    
Assets    
Derivative Assets 1,186  
Fair Value, Recurring [Member] | Foreign Exchange Contract | Other Current Assets | Not Designated as Hedging Instrument    
Assets    
Derivative Assets   154
Fair Value, Recurring [Member] | Foreign Exchange Contract | Other Current Assets | Not Designated as Hedging Instrument | Level 2    
Assets    
Derivative Assets 71  
Fair Value, Recurring [Member] | Foreign Exchange Contract | Other Current Liabilities | Designated as Hedging Instrument    
Liabilities    
Derivative Liabilities   395
Fair Value, Recurring [Member] | Foreign Exchange Contract | Other Current Liabilities | Designated as Hedging Instrument | Level 2    
Liabilities    
Derivative Liabilities 1,219  
Fair Value, Recurring [Member] | Foreign Exchange Contract | Other Current Liabilities | Not Designated as Hedging Instrument    
Liabilities    
Derivative Liabilities   536
Fair Value, Recurring [Member] | Foreign Exchange Contract | Other Current Liabilities | Not Designated as Hedging Instrument | Level 2    
Liabilities    
Derivative Liabilities 347 536
Fair Value, Recurring [Member] | Interest Rate Swap | Designated as Hedging Instrument    
Liabilities    
Derivative Liabilities 0  
Fair Value, Recurring [Member] | Interest Rate Swap | Designated as Hedging Instrument | Level 1    
Liabilities    
Derivative Liabilities 0  
Fair Value, Recurring [Member] | Interest Rate Swap | Designated as Hedging Instrument | Level 2    
Liabilities    
Derivative Liabilities 0  
Fair Value, Recurring [Member] | Interest Rate Swap | Other Current Assets | Not Designated as Hedging Instrument    
Assets    
Derivative Assets   1,673
Fair Value, Recurring [Member] | Interest Rate Swap | Other Current Assets | Not Designated as Hedging Instrument | Level 2    
Assets    
Derivative Assets 1,734  
Fair Value, Recurring [Member] | Interest Rate Swap | Other Assets | Not Designated as Hedging Instrument    
Assets    
Derivative Assets 5,806 1,735
Fair Value, Recurring [Member] | Interest Rate Swap | Other Assets | Not Designated as Hedging Instrument | Level 1    
Assets    
Derivative Assets 0 0
Fair Value, Recurring [Member] | Interest Rate Swap | Other Assets | Not Designated as Hedging Instrument | Level 2    
Assets    
Derivative Assets 5,806 1,735
Fair Value, Recurring [Member] | Contingent Consideration    
Liabilities    
Liabilities fair value 23,133 $ 0
Fair Value, Recurring [Member] | Contingent Consideration | Fair Value, Inputs, Level 3    
Liabilities    
Liabilities fair value 23,133  
Fair Value, Recurring [Member] | Contingent Consideration | Fair Value, Inputs, Level 3 | Revenue-based payment    
Liabilities    
Liabilities fair value $ 17,179  
Contingent Consideration Fair Value, Risk-Adjusted Discount Rate 6.30%  
Fair Value, Recurring [Member] | Contingent Consideration | Fair Value, Inputs, Level 3 | Regulatory-based payment    
Liabilities    
Liabilities fair value $ 4,804  
Contingent Consideration Fair Value, Risk-Adjusted Discount Rate 6.10%  
Fair Value, Recurring [Member] | Contingent Consideration | Fair Value, Inputs, Level 3 | Event-based payment    
Liabilities    
Liabilities fair value $ 1,150  
Contingent Consideration Fair Value, Risk-Adjusted Discount Rate 5.80%  
XML 71 R60.htm IDEA: XBRL DOCUMENT v3.25.0.1
COMMITMENTS AND CONTINGENCIES (Details) - USD ($)
$ in Thousands
 9 Months Ended 12 Months Ended
Dec. 28, 2024
Mar. 30, 2024
Commitments and Contingencies Disclosure [Abstract]    
Loss contingency, estimate of possible loss   $ 8,700
Payments for legal settlements $ 8,700  
Loss in period   $ 6,800
XML 72 R61.htm IDEA: XBRL DOCUMENT v3.25.0.1
ACCUMULATED OTHER COMPREHENSIVE LOSS (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Dec. 28, 2024
Sep. 28, 2024
Jun. 29, 2024
Dec. 30, 2023
Sep. 30, 2023
Jul. 01, 2023
Dec. 28, 2024
AOCI Attributable to Parent, Net of Tax [Roll Forward]              
Balance as of March 30, 2024     $ (35,632)       $ (35,632)
Other comprehensive income (loss) before reclassifications             (19,686)
Amounts reclassified from Accumulated Other Comprehensive Income (Loss)             (183)
Net current period other comprehensive income (loss) $ (20,937) $ 8,103 (7,035) $ 8,323 $ (3,187) $ 863 (19,869)
Balance as of December 28, 2024 (55,501)           (55,501)
Foreign Currency              
AOCI Attributable to Parent, Net of Tax [Roll Forward]              
Balance as of March 30, 2024     (38,274)       (38,274)
Other comprehensive income (loss) before reclassifications             (21,943)
Amounts reclassified from Accumulated Other Comprehensive Income (Loss)             0
Net current period other comprehensive income (loss)             (21,943)
Balance as of December 28, 2024 (60,217)           (60,217)
Defined Benefit Plans              
AOCI Attributable to Parent, Net of Tax [Roll Forward]              
Balance as of March 30, 2024     1,748       1,748
Other comprehensive income (loss) before reclassifications             0
Amounts reclassified from Accumulated Other Comprehensive Income (Loss)             0
Net current period other comprehensive income (loss)             0
Balance as of December 28, 2024 1,748           1,748
Net Unrealized Gain (Loss) on Derivatives              
AOCI Attributable to Parent, Net of Tax [Roll Forward]              
Balance as of March 30, 2024     $ 894       894
Other comprehensive income (loss) before reclassifications             2,257
Amounts reclassified from Accumulated Other Comprehensive Income (Loss)             (183)
Net current period other comprehensive income (loss)             2,074
Balance as of December 28, 2024 $ 2,968           $ 2,968
XML 73 R62.htm IDEA: XBRL DOCUMENT v3.25.0.1
SEGMENT AND ENTERPRISE-WIDE INFORMATION (Details)
$ in Thousands
 3 Months Ended 9 Months Ended
Dec. 28, 2024
USD ($)
Dec. 30, 2023
USD ($)
Dec. 28, 2024
USD ($)
segment
Dec. 30, 2023
USD ($)
Segment Reporting Information [Line Items]        
Number of reportable segments | segment     3  
Net revenues in constant currency $ 349,367 $ 337,713 $ 1,032,407 $ 967,864
Effect of exchange rates (825) (1,463) (2,182) (2,099)
Net revenues 348,542 336,250 1,030,225 965,765
Operating income 59,029 45,978 150,482 134,940
Effect of exchange rates 304 (401) 267 (879)
Amortization of acquired intangible assets 12,230 6,911 36,965 21,606
Amortization of fair value inventory step-up 3,341 0 12,319 0
Integration and transaction costs (244) (4,869) (13,449) (7,768)
Restructuring costs (3,515) (7,968) 12,929 8,043
Restructuring related costs 1,468 2,403 5,557 6,554
Digital transformation costs 4,620 3,415 15,823 10,712
Write downs of certain assets and PCS2 related charges (4,000) (210) 4,000 (621)
MDR and IVDR costs (1,008) (1,433) (3,125) (4,587)
Litigation-related charges 18 (177) (1,057) (6,684)
Impairment of intangible assets 0 0 (2,391) (10,419)
Gain on sale of property, plant and equipment 0 0 14,134 0
United States        
Segment Reporting Information [Line Items]        
Net revenues 257,665 250,804 762,628 724,222
Japan        
Segment Reporting Information [Line Items]        
Net revenues 16,174 14,825 46,303 41,609
Europe        
Segment Reporting Information [Line Items]        
Net revenues 44,163 37,035 133,379 115,088
Rest of Asia        
Segment Reporting Information [Line Items]        
Net revenues 25,597 30,935 71,148 80,710
Other        
Segment Reporting Information [Line Items]        
Net revenues 4,943 2,651 16,767 4,136
Plasma        
Segment Reporting Information [Line Items]        
Net revenues in constant currency 134,389 147,560 408,996 429,694
Restructuring related costs 37 72 263 315
Plasma | Plasma        
Segment Reporting Information [Line Items]        
Net revenues 134,224 147,641 408,695 430,056
Blood Center        
Segment Reporting Information [Line Items]        
Net revenues in constant currency 70,730 73,528 206,373 213,167
Restructuring related costs 31 93 120 166
Blood Center | Blood Center        
Segment Reporting Information [Line Items]        
Net revenues 70,345 72,379 205,118 211,241
Apheresis | Blood Center        
Segment Reporting Information [Line Items]        
Net revenues 55,388 52,565 158,814 156,704
Whole Blood | Blood Center        
Segment Reporting Information [Line Items]        
Net revenues 14,957 19,814 46,304 54,537
Hospital        
Segment Reporting Information [Line Items]        
Net revenues in constant currency 144,248 116,625 417,038 325,003
Restructuring related costs (68) 251 40 398
Hospital | Hospital        
Segment Reporting Information [Line Items]        
Net revenues 143,973 116,230 416,412 324,468
Vascular Closure, Hosptial | Hospital        
Segment Reporting Information [Line Items]        
Net revenues 63,253 43,007 188,220 119,168
Hemostasis Management, Hospital | Hospital        
Segment Reporting Information [Line Items]        
Net revenues 80,720 73,223 228,192 205,300
Operating Segments        
Segment Reporting Information [Line Items]        
Operating income 159,406 157,459 458,356 447,566
Operating Segments | Plasma        
Segment Reporting Information [Line Items]        
Operating income 70,337 80,450 205,902 234,190
Operating Segments | Blood Center        
Segment Reporting Information [Line Items]        
Operating income 26,955 27,654 76,744 81,244
Operating Segments | Hospital        
Segment Reporting Information [Line Items]        
Operating income 62,114 49,355 175,710 132,132
Corporate        
Segment Reporting Information [Line Items]        
Operating income $ 70,273 $ 83,694 $ 214,660 $ 234,753
EXCEL 74 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 76 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 78 FilingSummary.xml IDEA: XBRL DOCUMENT 3.25.0.1 html 373 330 1 false 99 0 false 9 false false R1.htm 0000001 - Document - COVER PAGE Sheet http://www.haemonetics.com/role/COVERPAGE COVER PAGE Cover 1 false false R2.htm 9952151 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME Sheet http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME Statements 2 false false R3.htm 9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS CONDENSED CONSOLIDATED BALANCE SHEETS Statements 3 false false R4.htm 9952153 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) Sheet http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParentheticals CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) Statements 4 false false R5.htm 9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Sheet http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statements 5 false false R6.htm 9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 9952156 - Disclosure - BASIS OF PRESENTATION Sheet http://www.haemonetics.com/role/BASISOFPRESENTATION BASIS OF PRESENTATION Notes 7 false false R8.htm 9952157 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS Sheet http://www.haemonetics.com/role/RECENTACCOUNTINGPRONOUNCEMENTS RECENT ACCOUNTING PRONOUNCEMENTS Notes 8 false false R9.htm 9952158 - Disclosure - ACQUISITIONS, DIVESTITURES AND STRATEGIC INVESTMENTS Sheet http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTS ACQUISITIONS, DIVESTITURES AND STRATEGIC INVESTMENTS Notes 9 false false R10.htm 9952159 - Disclosure - REVENUE Sheet http://www.haemonetics.com/role/REVENUE REVENUE Notes 10 false false R11.htm 9952160 - Disclosure - RESTRUCTURING Sheet http://www.haemonetics.com/role/RESTRUCTURING RESTRUCTURING Notes 11 false false R12.htm 9952161 - Disclosure - INCOME TAXES Sheet http://www.haemonetics.com/role/INCOMETAXES INCOME TAXES Notes 12 false false R13.htm 9952162 - Disclosure - EARNINGS PER SHARE Sheet http://www.haemonetics.com/role/EARNINGSPERSHARE EARNINGS PER SHARE Notes 13 false false R14.htm 9952163 - Disclosure - INVENTORIES Sheet http://www.haemonetics.com/role/INVENTORIES INVENTORIES Notes 14 false false R15.htm 9952164 - Disclosure - PROPERTY, PLANT AND EQUIPMENT Sheet http://www.haemonetics.com/role/PROPERTYPLANTANDEQUIPMENT PROPERTY, PLANT AND EQUIPMENT Notes 15 false false R16.htm 9952165 - Disclosure - LEASES Sheet http://www.haemonetics.com/role/LEASES LEASES Notes 16 false false R17.htm 9952166 - Disclosure - GOODWILL AND INTANGIBLE ASSETS Sheet http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETS GOODWILL AND INTANGIBLE ASSETS Notes 17 false false R18.htm 9952167 - Disclosure - NOTES??PAYABLE AND LONG-TERM DEBT Notes http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBT NOTES??PAYABLE AND LONG-TERM DEBT Notes 18 false false R19.htm 9952168 - Disclosure - FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS Sheet http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTS FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS Notes 19 false false R20.htm 9952169 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.haemonetics.com/role/COMMITMENTSANDCONTINGENCIES COMMITMENTS AND CONTINGENCIES Notes 20 false false R21.htm 9952170 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS Sheet http://www.haemonetics.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS ACCUMULATED OTHER COMPREHENSIVE LOSS Notes 21 false false R22.htm 9952171 - Disclosure - SEGMENT AND ENTERPRISE-WIDE INFORMATION Sheet http://www.haemonetics.com/role/SEGMENTANDENTERPRISEWIDEINFORMATION SEGMENT AND ENTERPRISE-WIDE INFORMATION Notes 22 false false R23.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 23 false false R24.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 24 false false R25.htm 9955511 - Disclosure - ACQUISITIONS, DIVESTITURES AND STRATEGIC INVESTMENTS (Tables) Sheet http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSTables ACQUISITIONS, DIVESTITURES AND STRATEGIC INVESTMENTS (Tables) Tables http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTS 25 false false R26.htm 9955512 - Disclosure - RESTRUCTURING (Tables) Sheet http://www.haemonetics.com/role/RESTRUCTURINGTables RESTRUCTURING (Tables) Tables http://www.haemonetics.com/role/RESTRUCTURING 26 false false R27.htm 9955513 - Disclosure - EARNINGS PER SHARE (Tables) Sheet http://www.haemonetics.com/role/EARNINGSPERSHARETables EARNINGS PER SHARE (Tables) Tables http://www.haemonetics.com/role/EARNINGSPERSHARE 27 false false R28.htm 9955514 - Disclosure - INVENTORIES (Tables) Sheet http://www.haemonetics.com/role/INVENTORIESTables INVENTORIES (Tables) Tables http://www.haemonetics.com/role/INVENTORIES 28 false false R29.htm 9955515 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables) Sheet http://www.haemonetics.com/role/PROPERTYPLANTANDEQUIPMENTTables PROPERTY, PLANT AND EQUIPMENT (Tables) Tables http://www.haemonetics.com/role/PROPERTYPLANTANDEQUIPMENT 29 false false R30.htm 9955516 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables) Sheet http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSTables GOODWILL AND INTANGIBLE ASSETS (Tables) Tables http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETS 30 false false R31.htm 9955517 - Disclosure - NOTES??PAYABLE AND LONG-TERM DEBT (Tables) Notes http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTTables NOTES??PAYABLE AND LONG-TERM DEBT (Tables) Tables http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBT 31 false false R32.htm 9955518 - Disclosure - FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Tables) Sheet http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSTables FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Tables) Tables http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTS 32 false false R33.htm 9955519 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables) Sheet http://www.haemonetics.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSTables ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables) Tables http://www.haemonetics.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS 33 false false R34.htm 9955520 - Disclosure - SEGMENT AND ENTERPRISE-WIDE INFORMATION (Tables) Sheet http://www.haemonetics.com/role/SEGMENTANDENTERPRISEWIDEINFORMATIONTables SEGMENT AND ENTERPRISE-WIDE INFORMATION (Tables) Tables http://www.haemonetics.com/role/SEGMENTANDENTERPRISEWIDEINFORMATION 34 false false R35.htm 9955521 - Disclosure - ACQUISITIONS, DIVESTITURES AND STRATEGIC INVESTMENTS - Narrative (Details) Sheet http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSNarrativeDetails ACQUISITIONS, DIVESTITURES AND STRATEGIC INVESTMENTS - Narrative (Details) Details http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSTables 35 false false R36.htm 9955522 - Disclosure - ACQUISITIONS, DIVESTITURES AND STRATEGIC INVESTMENTS - Purchase Price Allocation (Details) Sheet http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSPurchasePriceAllocationDetails ACQUISITIONS, DIVESTITURES AND STRATEGIC INVESTMENTS - Purchase Price Allocation (Details) Details 36 false false R37.htm 9955523 - Disclosure - ACQUISITIONS, DIVESTITURES AND STRATEGIC INVESTMENTS - Strategic Investments (Details) Sheet http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSStrategicInvestmentsDetails ACQUISITIONS, DIVESTITURES AND STRATEGIC INVESTMENTS - Strategic Investments (Details) Details 37 false false R38.htm 9955524 - Disclosure - REVENUE (Details) Sheet http://www.haemonetics.com/role/REVENUEDetails REVENUE (Details) Details http://www.haemonetics.com/role/REVENUE 38 false false R39.htm 9955525 - Disclosure - RESTRUCTURING (Narrative) (Details) Sheet http://www.haemonetics.com/role/RESTRUCTURINGNarrativeDetails RESTRUCTURING (Narrative) (Details) Details http://www.haemonetics.com/role/RESTRUCTURINGTables 39 false false R40.htm 9955526 - Disclosure - RESTRUCTURING (Schedule of Restructuring Reserve by Type of Cost) (Details) Sheet http://www.haemonetics.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails RESTRUCTURING (Schedule of Restructuring Reserve by Type of Cost) (Details) Details http://www.haemonetics.com/role/RESTRUCTURINGTables 40 false false R41.htm 9955527 - Disclosure - RESTRUCTURING (Schedule of Restructuring and Related Costs) (Details) Sheet http://www.haemonetics.com/role/RESTRUCTURINGScheduleofRestructuringandRelatedCostsDetails RESTRUCTURING (Schedule of Restructuring and Related Costs) (Details) Details http://www.haemonetics.com/role/RESTRUCTURINGTables 41 false false R42.htm 9955528 - Disclosure - INCOME TAXES (Details) Sheet http://www.haemonetics.com/role/INCOMETAXESDetails INCOME TAXES (Details) Details http://www.haemonetics.com/role/INCOMETAXES 42 false false R43.htm 9955529 - Disclosure - EARNINGS PER SHARE (Schedule of Earnings Per Share Reconciliation) (Details) Sheet http://www.haemonetics.com/role/EARNINGSPERSHAREScheduleofEarningsPerShareReconciliationDetails EARNINGS PER SHARE (Schedule of Earnings Per Share Reconciliation) (Details) Details http://www.haemonetics.com/role/EARNINGSPERSHARETables 43 false false R44.htm 9955530 - Disclosure - EARNINGS PER SHARE (Share Repurchase Program) (Details) Sheet http://www.haemonetics.com/role/EARNINGSPERSHAREShareRepurchaseProgramDetails EARNINGS PER SHARE (Share Repurchase Program) (Details) Details http://www.haemonetics.com/role/EARNINGSPERSHARETables 44 false false R45.htm 9955531 - Disclosure - INVENTORIES (Schedule of Inventories) (Details) Sheet http://www.haemonetics.com/role/INVENTORIESScheduleofInventoriesDetails INVENTORIES (Schedule of Inventories) (Details) Details http://www.haemonetics.com/role/INVENTORIESTables 45 false false R46.htm 9955532 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Details) Sheet http://www.haemonetics.com/role/PROPERTYPLANTANDEQUIPMENTDetails PROPERTY, PLANT AND EQUIPMENT (Details) Details http://www.haemonetics.com/role/PROPERTYPLANTANDEQUIPMENTTables 46 false false R47.htm 9955533 - Disclosure - LEASES (Details) Sheet http://www.haemonetics.com/role/LEASESDetails LEASES (Details) Details http://www.haemonetics.com/role/LEASES 47 false false R48.htm 9955534 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Narrative (Details) Sheet http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails GOODWILL AND INTANGIBLE ASSETS - Narrative (Details) Details 48 false false R49.htm 9955535 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Schedule of Goodwill (Details) Sheet http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofGoodwillDetails GOODWILL AND INTANGIBLE ASSETS - Schedule of Goodwill (Details) Details 49 false false R50.htm 9955536 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Intangible Assets (Details) Sheet http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails GOODWILL AND INTANGIBLE ASSETS - Intangible Assets (Details) Details 50 false false R51.htm 9955537 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Maturity (Details) Sheet http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSMaturityDetails GOODWILL AND INTANGIBLE ASSETS - Maturity (Details) Details 51 false false R52.htm 9955538 - Disclosure - NOTES??PAYABLE AND LONG-TERM DEBT - Schedule of Debt (Details) Notes http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTScheduleofDebtDetails NOTES??PAYABLE AND LONG-TERM DEBT - Schedule of Debt (Details) Details 52 false false R53.htm 9955539 - Disclosure - NOTES??PAYABLE AND LONG-TERM DEBT - Narrative (Details) Notes http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTNarrativeDetails NOTES??PAYABLE AND LONG-TERM DEBT - Narrative (Details) Details 53 false false R54.htm 9955540 - Disclosure - NOTES??PAYABLE AND LONG-TERM DEBT - Schedule of Long Term Debt Maturity (Details) Notes http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTScheduleofLongTermDebtMaturityDetails NOTES??PAYABLE AND LONG-TERM DEBT - Schedule of Long Term Debt Maturity (Details) Details 54 false false R55.htm 9955541 - Disclosure - FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Narrative) (Details) Sheet http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Narrative) (Details) Details http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSTables 55 false false R56.htm 9955542 - Disclosure - FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Schedule of Interest Rate Swaps) (Details) Sheet http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofInterestRateSwapsDetails FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Schedule of Interest Rate Swaps) (Details) Details http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSTables 56 false false R57.htm 9955543 - Disclosure - FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Allowance for Credit Losses) (Details) Sheet http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSAllowanceforCreditLossesDetails FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Allowance for Credit Losses) (Details) Details http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSTables 57 false false R58.htm 9955544 - Disclosure - FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Schedule of Effect of Derivative Instruments Designated as Cash Flow Hedges and Those Not Designated as Hedging Instruments) (Details) Sheet http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofEffectofDerivativeInstrumentsDesignatedasCashFlowHedgesandThoseNotDesignatedasHedgingInstrumentsDetails FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Schedule of Effect of Derivative Instruments Designated as Cash Flow Hedges and Those Not Designated as Hedging Instruments) (Details) Details http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSTables 58 false false R59.htm 9955545 - Disclosure - FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Schedules of Derivatives) (Details) Sheet http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSSchedulesofDerivativesDetails FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Schedules of Derivatives) (Details) Details http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSTables 59 false false R60.htm 9955546 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) Sheet http://www.haemonetics.com/role/COMMITMENTSANDCONTINGENCIESDetails COMMITMENTS AND CONTINGENCIES (Details) Details http://www.haemonetics.com/role/COMMITMENTSANDCONTINGENCIES 60 false false R61.htm 9955547 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS (Details) Sheet http://www.haemonetics.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSDetails ACCUMULATED OTHER COMPREHENSIVE LOSS (Details) Details http://www.haemonetics.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSTables 61 false false R62.htm 9955548 - Disclosure - SEGMENT AND ENTERPRISE-WIDE INFORMATION (Details) Sheet http://www.haemonetics.com/role/SEGMENTANDENTERPRISEWIDEINFORMATIONDetails SEGMENT AND ENTERPRISE-WIDE INFORMATION (Details) Details http://www.haemonetics.com/role/SEGMENTANDENTERPRISEWIDEINFORMATIONTables 62 false false All Reports Book All Reports hae-20241228.htm hae-20241228.xsd hae-20241228_cal.xml hae-20241228_def.xml hae-20241228_lab.xml hae-20241228_pre.xml http://fasb.org/srt/2024 http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 81 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "hae-20241228.htm": { "nsprefix": "hae", "nsuri": "http://www.haemonetics.com/20241228", "dts": { "inline": { "local": [ "hae-20241228.htm" ] }, "schema": { "local": [ "hae-20241228.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "calculationLink": { "local": [ "hae-20241228_cal.xml" ] }, "definitionLink": { "local": [ "hae-20241228_def.xml" ] }, "labelLink": { "local": [ "hae-20241228_lab.xml" ] }, "presentationLink": { "local": [ "hae-20241228_pre.xml" ] } }, "keyStandard": 284, "keyCustom": 46, "axisStandard": 29, "axisCustom": 1, "memberStandard": 61, "memberCustom": 36, "hidden": { "total": 14, "http://fasb.org/us-gaap/2024": 9, "http://xbrl.sec.gov/dei/2024": 5 }, "contextCount": 373, "entityCount": 1, "segmentCount": 99, "elementCount": 668, "unitCount": 9, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 1036, "http://xbrl.sec.gov/dei/2024": 29, "http://xbrl.sec.gov/ecd/2024": 4, "http://fasb.org/srt/2024": 1 }, "report": { "R1": { "role": "http://www.haemonetics.com/role/COVERPAGE", "longName": "0000001 - Document - COVER PAGE", "shortName": "COVER PAGE", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME", "longName": "9952151 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "unique": true } }, "R3": { "role": "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "longName": "9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParentheticals", "longName": "9952153 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "longName": "9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-40", "name": "us-gaap:SharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-45", "name": "us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "unique": true } }, "R6": { "role": "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "longName": "9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DepreciationAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "unique": true } }, "R7": { "role": "http://www.haemonetics.com/role/BASISOFPRESENTATION", "longName": "9952156 - Disclosure - BASIS OF PRESENTATION", "shortName": "BASIS OF PRESENTATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.haemonetics.com/role/RECENTACCOUNTINGPRONOUNCEMENTS", "longName": "9952157 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS", "shortName": "RECENT ACCOUNTING PRONOUNCEMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTS", "longName": "9952158 - Disclosure - ACQUISITIONS, DIVESTITURES AND STRATEGIC INVESTMENTS", "shortName": "ACQUISITIONS, DIVESTITURES AND STRATEGIC INVESTMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.haemonetics.com/role/REVENUE", "longName": "9952159 - Disclosure - REVENUE", "shortName": "REVENUE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.haemonetics.com/role/RESTRUCTURING", "longName": "9952160 - Disclosure - RESTRUCTURING", "shortName": "RESTRUCTURING", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.haemonetics.com/role/INCOMETAXES", "longName": "9952161 - Disclosure - INCOME TAXES", "shortName": "INCOME TAXES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.haemonetics.com/role/EARNINGSPERSHARE", "longName": "9952162 - Disclosure - EARNINGS PER SHARE", "shortName": "EARNINGS PER SHARE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.haemonetics.com/role/INVENTORIES", "longName": "9952163 - Disclosure - INVENTORIES", "shortName": "INVENTORIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.haemonetics.com/role/PROPERTYPLANTANDEQUIPMENT", "longName": "9952164 - Disclosure - PROPERTY, PLANT AND EQUIPMENT", "shortName": "PROPERTY, PLANT AND EQUIPMENT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.haemonetics.com/role/LEASES", "longName": "9952165 - Disclosure - LEASES", "shortName": "LEASES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETS", "longName": "9952166 - Disclosure - GOODWILL AND INTANGIBLE ASSETS", "shortName": "GOODWILL AND INTANGIBLE ASSETS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBT", "longName": "9952167 - Disclosure - NOTES\u00a0PAYABLE AND LONG-TERM DEBT", "shortName": "NOTES\u00a0PAYABLE AND LONG-TERM DEBT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTS", "longName": "9952168 - Disclosure - FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS", "shortName": "FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativesAndFairValueTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativesAndFairValueTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.haemonetics.com/role/COMMITMENTSANDCONTINGENCIES", "longName": "9952169 - Disclosure - COMMITMENTS AND CONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.haemonetics.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS", "longName": "9952170 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS", "shortName": "ACCUMULATED OTHER COMPREHENSIVE LOSS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.haemonetics.com/role/SEGMENTANDENTERPRISEWIDEINFORMATION", "longName": "9952171 - Disclosure - SEGMENT AND ENTERPRISE-WIDE INFORMATION", "shortName": "SEGMENT AND ENTERPRISE-WIDE INFORMATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true } }, "R23": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true }, "uniqueAnchor": null }, "R24": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-3", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSTables", "longName": "9955511 - Disclosure - ACQUISITIONS, DIVESTITURES AND STRATEGIC INVESTMENTS (Tables)", "shortName": "ACQUISITIONS, DIVESTITURES AND STRATEGIC INVESTMENTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.haemonetics.com/role/RESTRUCTURINGTables", "longName": "9955512 - Disclosure - RESTRUCTURING (Tables)", "shortName": "RESTRUCTURING (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.haemonetics.com/role/EARNINGSPERSHARETables", "longName": "9955513 - Disclosure - EARNINGS PER SHARE (Tables)", "shortName": "EARNINGS PER SHARE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.haemonetics.com/role/INVENTORIESTables", "longName": "9955514 - Disclosure - INVENTORIES (Tables)", "shortName": "INVENTORIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.haemonetics.com/role/PROPERTYPLANTANDEQUIPMENTTables", "longName": "9955515 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables)", "shortName": "PROPERTY, PLANT AND EQUIPMENT (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSTables", "longName": "9955516 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables)", "shortName": "GOODWILL AND INTANGIBLE ASSETS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTTables", "longName": "9955517 - Disclosure - NOTES\u00a0PAYABLE AND LONG-TERM DEBT (Tables)", "shortName": "NOTES\u00a0PAYABLE AND LONG-TERM DEBT (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSTables", "longName": "9955518 - Disclosure - FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Tables)", "shortName": "FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInterestRateDerivativesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInterestRateDerivativesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.haemonetics.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSTables", "longName": "9955519 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)", "shortName": "ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.haemonetics.com/role/SEGMENTANDENTERPRISEWIDEINFORMATIONTables", "longName": "9955520 - Disclosure - SEGMENT AND ENTERPRISE-WIDE INFORMATION (Tables)", "shortName": "SEGMENT AND ENTERPRISE-WIDE INFORMATION (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSNarrativeDetails", "longName": "9955521 - Disclosure - ACQUISITIONS, DIVESTITURES AND STRATEGIC INVESTMENTS - Narrative (Details)", "shortName": "ACQUISITIONS, DIVESTITURES AND STRATEGIC INVESTMENTS - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-94", "name": "us-gaap:InventoryNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "unique": true } }, "R36": { "role": "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSPurchasePriceAllocationDetails", "longName": "9955522 - Disclosure - ACQUISITIONS, DIVESTITURES AND STRATEGIC INVESTMENTS - Purchase Price Allocation (Details)", "shortName": "ACQUISITIONS, DIVESTITURES AND STRATEGIC INVESTMENTS - Purchase Price Allocation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-75", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "unique": true } }, "R37": { "role": "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSStrategicInvestmentsDetails", "longName": "9955523 - Disclosure - ACQUISITIONS, DIVESTITURES AND STRATEGIC INVESTMENTS - Strategic Investments (Details)", "shortName": "ACQUISITIONS, DIVESTITURES AND STRATEGIC INVESTMENTS - Strategic Investments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PaymentsToAcquireInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PaymentsToAcquireInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.haemonetics.com/role/REVENUEDetails", "longName": "9955524 - Disclosure - REVENUE (Details)", "shortName": "REVENUE (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:RevenueRemainingPerformanceObligation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:ContractWithCustomerLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "unique": true } }, "R39": { "role": "http://www.haemonetics.com/role/RESTRUCTURINGNarrativeDetails", "longName": "9955525 - Disclosure - RESTRUCTURING (Narrative) (Details)", "shortName": "RESTRUCTURING (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-3", "name": "hae:RestructuringandRestructuringRelatedCosts", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-104", "name": "us-gaap:RestructuringAndRelatedCostIncurredCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "unique": true } }, "R40": { "role": "http://www.haemonetics.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails", "longName": "9955526 - Disclosure - RESTRUCTURING (Schedule of Restructuring Reserve by Type of Cost) (Details)", "shortName": "RESTRUCTURING (Schedule of Restructuring Reserve by Type of Cost) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:RestructuringReserve", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PaymentsForRestructuring", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "unique": true } }, "R41": { "role": "http://www.haemonetics.com/role/RESTRUCTURINGScheduleofRestructuringandRelatedCostsDetails", "longName": "9955527 - Disclosure - RESTRUCTURING (Schedule of Restructuring and Related Costs) (Details)", "shortName": "RESTRUCTURING (Schedule of Restructuring and Related Costs) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:RestructuringCharges", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-127", "name": "us-gaap:RestructuringCharges", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "unique": true } }, "R42": { "role": "http://www.haemonetics.com/role/INCOMETAXESDetails", "longName": "9955528 - Disclosure - INCOME TAXES (Details)", "shortName": "INCOME TAXES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "unique": true } }, "R43": { "role": "http://www.haemonetics.com/role/EARNINGSPERSHAREScheduleofEarningsPerShareReconciliationDetails", "longName": "9955529 - Disclosure - EARNINGS PER SHARE (Schedule of Earnings Per Share Reconciliation) (Details)", "shortName": "EARNINGS PER SHARE (Schedule of Earnings Per Share Reconciliation) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "unique": true } }, "R44": { "role": "http://www.haemonetics.com/role/EARNINGSPERSHAREShareRepurchaseProgramDetails", "longName": "9955530 - Disclosure - EARNINGS PER SHARE (Share Repurchase Program) (Details)", "shortName": "EARNINGS PER SHARE (Share Repurchase Program) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:StockRepurchasedDuringPeriodShares", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-145", "name": "us-gaap:StockRepurchaseProgramPeriodInForce1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "unique": true } }, "R45": { "role": "http://www.haemonetics.com/role/INVENTORIESScheduleofInventoriesDetails", "longName": "9955531 - Disclosure - INVENTORIES (Schedule of Inventories) (Details)", "shortName": "INVENTORIES (Schedule of Inventories) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.haemonetics.com/role/PROPERTYPLANTANDEQUIPMENTDetails", "longName": "9955532 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Details)", "shortName": "PROPERTY, PLANT AND EQUIPMENT (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "unique": true } }, "R47": { "role": "http://www.haemonetics.com/role/LEASESDetails", "longName": "9955533 - Disclosure - LEASES (Details)", "shortName": "LEASES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-1", "name": "hae:OperatingLeaseRevenueAsAPercentageOfTotalNetSales", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "hae:OperatingLeaseRevenueAsAPercentageOfTotalNetSales", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails", "longName": "9955534 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Narrative (Details)", "shortName": "GOODWILL AND INTANGIBLE ASSETS - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-1", "name": "hae:GoodwillAssetsHeldForSale", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-58", "name": "us-gaap:GoodwillAndIntangibleAssetImpairment", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "unique": true } }, "R49": { "role": "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofGoodwillDetails", "longName": "9955535 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Schedule of Goodwill (Details)", "shortName": "GOODWILL AND INTANGIBLE ASSETS - Schedule of Goodwill (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillPurchaseAccountingAdjustments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "unique": true } }, "R50": { "role": "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails", "longName": "9955536 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Intangible Assets (Details)", "shortName": "GOODWILL AND INTANGIBLE ASSETS - Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "unique": true } }, "R51": { "role": "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSMaturityDetails", "longName": "9955537 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Maturity (Details)", "shortName": "GOODWILL AND INTANGIBLE ASSETS - Maturity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTScheduleofDebtDetails", "longName": "9955538 - Disclosure - NOTES\u00a0PAYABLE AND LONG-TERM DEBT - Schedule of Debt (Details)", "shortName": "NOTES\u00a0PAYABLE AND LONG-TERM DEBT - Schedule of Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:LongTermDebtCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-191", "name": "us-gaap:LongTermDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "unique": true } }, "R53": { "role": "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTNarrativeDetails", "longName": "9955539 - Disclosure - NOTES\u00a0PAYABLE AND LONG-TERM DEBT - Narrative (Details)", "shortName": "NOTES\u00a0PAYABLE AND LONG-TERM DEBT - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GainLossOnRepurchaseOfDebtInstrument", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-206", "name": "hae:DebtInstrumentConvertibleCappedCallTransactionInitialStrikePrice", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "unique": true } }, "R54": { "role": "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTScheduleofLongTermDebtMaturityDetails", "longName": "9955540 - Disclosure - NOTES\u00a0PAYABLE AND LONG-TERM DEBT - Schedule of Long Term Debt Maturity (Details)", "shortName": "NOTES\u00a0PAYABLE AND LONG-TERM DEBT - Schedule of Long Term Debt Maturity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "longName": "9955541 - Disclosure - FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Narrative) (Details)", "shortName": "FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-234", "name": "hae:NumberOfInterestRateSwapsRemaining", "unitRef": "swap", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-234", "name": "hae:NumberOfInterestRateSwapsRemaining", "unitRef": "swap", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofInterestRateSwapsDetails", "longName": "9955542 - Disclosure - FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Schedule of Interest Rate Swaps) (Details)", "shortName": "FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Schedule of Interest Rate Swaps) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-254", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-242", "name": "us-gaap:DerivativeFairValueOfDerivativeNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInterestRateDerivativesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "unique": true } }, "R57": { "role": "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSAllowanceforCreditLossesDetails", "longName": "9955543 - Disclosure - FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Allowance for Credit Losses) (Details)", "shortName": "FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Allowance for Credit Losses) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-31", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-31", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofEffectofDerivativeInstrumentsDesignatedasCashFlowHedgesandThoseNotDesignatedasHedgingInstrumentsDetails", "longName": "9955544 - Disclosure - FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Schedule of Effect of Derivative Instruments Designated as Cash Flow Hedges and Those Not Designated as Hedging Instruments) (Details)", "shortName": "FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Schedule of Effect of Derivative Instruments Designated as Cash Flow Hedges and Those Not Designated as Hedging Instruments) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-228", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-228", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSSchedulesofDerivativesDetails", "longName": "9955545 - Disclosure - FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Schedules of Derivatives) (Details)", "shortName": "FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Schedules of Derivatives) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-1", "name": "hae:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityValueAtAcquisitionDate", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "hae:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityValueAtAcquisitionDate", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.haemonetics.com/role/COMMITMENTSANDCONTINGENCIESDetails", "longName": "9955546 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)", "shortName": "COMMITMENTS AND CONTINGENCIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:LossContingencyEstimateOfPossibleLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:LossContingencyEstimateOfPossibleLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.haemonetics.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSDetails", "longName": "9955547 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS (Details)", "shortName": "ACCUMULATED OTHER COMPREHENSIVE LOSS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "unique": true } }, "R62": { "role": "http://www.haemonetics.com/role/SEGMENTANDENTERPRISEWIDEINFORMATIONDetails", "longName": "9955548 - Disclosure - SEGMENT AND ENTERPRISE-WIDE INFORMATION (Details)", "shortName": "SEGMENT AND ENTERPRISE-WIDE INFORMATION (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hae-20241228.htm", "first": true, "unique": true } } }, "tag": { "hae_A2020ProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "A2020ProgramMember", "presentation": [ "http://www.haemonetics.com/role/RESTRUCTURINGNarrativeDetails", "http://www.haemonetics.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2020 Program", "label": "2020 Program [Member]", "documentation": "2020 Program [Member]" } } }, "auth_ref": [] }, "hae_A2022AcceleratedShareRepurchaseProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "A2022AcceleratedShareRepurchaseProgramMember", "presentation": [ "http://www.haemonetics.com/role/EARNINGSPERSHAREShareRepurchaseProgramDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2022 Accelerated Share Repurchase Program", "label": "2022 Accelerated Share Repurchase Program [Member]", "documentation": "2022 Accelerated Share Repurchase Program" } } }, "auth_ref": [] }, "hae_A2022RevisedCreditAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "A2022RevisedCreditAgreementMember", "presentation": [ "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2022 Revised Credit Facilities", "label": "2022 Revised Credit Agreement [Member]", "documentation": "2022 Revised Credit Agreement" } } }, "auth_ref": [] }, "hae_A2024AcceleratedShareRepurchaseProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "A2024AcceleratedShareRepurchaseProgramMember", "presentation": [ "http://www.haemonetics.com/role/EARNINGSPERSHAREShareRepurchaseProgramDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024 Accelerated Share Repurchase Program", "label": "2024 Accelerated Share Repurchase Program [Member]", "documentation": "2024 Accelerated Share Repurchase Program" } } }, "auth_ref": [] }, "hae_A2024RevisedCreditAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "A2024RevisedCreditAgreementMember", "presentation": [ "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024 Revised Credit Facilities", "label": "2024 Revised Credit Agreement [Member]", "documentation": "2024 Revised Credit Agreement" } } }, "auth_ref": [] }, "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AOCIAttributableToParentNetOfTaxRollForward", "presentation": [ "http://www.haemonetics.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AcceleratedShareRepurchasesFinalPricePaidPerShare", "presentation": [ "http://www.haemonetics.com/role/EARNINGSPERSHAREShareRepurchaseProgramDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accelerated share repurchases, final price paid per share", "label": "Accelerated Share Repurchases, Final Price Paid Per Share", "documentation": "Final price paid per share for the purchase of the targeted number of shares, determined by an average market price over a fixed period of time." } } }, "auth_ref": [ "r139" ] }, "us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AcceleratedShareRepurchasesSettlementPaymentOrReceipt", "crdr": "debit", "presentation": [ "http://www.haemonetics.com/role/EARNINGSPERSHAREShareRepurchaseProgramDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accelerated share repurchases, settlement (payment) or receipt", "label": "Accelerated Share Repurchases, Settlement (Payment) or Receipt", "documentation": "Amount of cash receipt from (payment to) bank; or stock received from (issuance to) bank in the settlement of the accelerated share repurchase agreement." } } }, "auth_ref": [ "r139" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r82", "r905" ] }, "hae_AccountsReceivableAllowanceForCreditLossRecoveryWriteoff": { "xbrltype": "monetaryItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "AccountsReceivableAllowanceForCreditLossRecoveryWriteoff", "crdr": "credit", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSAllowanceforCreditLossesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Write-offs (recoveries)", "label": "Accounts Receivable, Allowance For Credit Loss, Recovery (Writeoff)", "documentation": "Accounts Receivable, Allowance For Credit Loss, Recovery (Writeoff)" } } }, "auth_ref": [] }, "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable, Allowance for Credit Loss", "label": "Accounts Receivable, Allowance for Credit Loss [Table Text Block]", "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable." } } }, "auth_ref": [ "r1072" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, less allowance for credit losses of $5,986 at December\u00a028, 2024 and $5,695 at March\u00a030, 2024", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r1070" ] }, "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrentAndNoncurrent", "crdr": "credit", "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accrued liabilities", "label": "Accrued Liabilities", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities." } } }, "auth_ref": [ "r154" ] }, "us-gaap_AccruedLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesMember", "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued Liabilities", "label": "Accrued Liabilities [Member]", "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered." } } }, "auth_ref": [ "r85" ] }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "presentation": [ "http://www.haemonetics.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plans", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent." } } }, "auth_ref": [ "r4", "r5", "r15", "r28", "r103", "r1045", "r1046", "r1047" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "presentation": [ "http://www.haemonetics.com/role/PROPERTYPLANTANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r44", "r224", "r662" ] }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "presentation": [ "http://www.haemonetics.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net Unrealized Gain (Loss) on Derivatives", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent." } } }, "auth_ref": [ "r238", "r245", "r246", "r545", "r865", "r1045" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": [ "http://www.haemonetics.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r244", "r245", "r584", "r586", "r587", "r588", "r589", "r590" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.haemonetics.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSDetails", "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive loss", "periodStartLabel": "Balance as of March 30, 2024", "periodEndLabel": "Balance as of December 28, 2024", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r27", "r28", "r104", "r231", "r659", "r698", "r702" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "presentation": [ "http://www.haemonetics.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r244", "r245", "r584", "r586", "r587", "r588", "r589", "r590" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive (Loss)/Income", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r2", "r15", "r28", "r555", "r558", "r602", "r693", "r694", "r1045", "r1046", "r1047", "r1056", "r1057", "r1058", "r1059" ] }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedTranslationAdjustmentMember", "presentation": [ "http://www.haemonetics.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent." } } }, "auth_ref": [ "r3", "r15", "r28", "r101", "r102", "r245", "r246", "r586", "r587", "r588", "r589", "r590", "r1045" ] }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Amortization Period", "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life", "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r364", "r854" ] }, "hae_AcquiredIntangibleAssetsRiskAdjustedDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "AcquiredIntangibleAssetsRiskAdjustedDiscountRate", "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-Adjusted Discount Rates used in Purchase Price Allocation", "label": "Acquired Intangible Assets, Risk-Adjusted Discount Rate", "documentation": "Acquired Intangible Assets, Risk-Adjusted Discount Rate" } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r972" ] }, "hae_AdditionalDebtIssuanceCostsCapitalized": { "xbrltype": "monetaryItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "AdditionalDebtIssuanceCostsCapitalized", "crdr": "debit", "presentation": [ "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional debt issuance costs capitalized", "label": "Additional Debt Issuance Costs Capitalized", "documentation": "Additional Debt Issuance Costs Capitalized" } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital, Common Stock", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r92" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r711", "r1056", "r1057", "r1058", "r1059", "r1125", "r1191" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r985" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r985" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r985" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r985" ] }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "debit", "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Tax withholding on employee equity awards", "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation", "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [] }, "hae_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtCappedCallPurchases": { "xbrltype": "monetaryItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "AdjustmentsToAdditionalPaidInCapitalConvertibleDebtCappedCallPurchases", "crdr": "debit", "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to additional paid in capital, convertible debt, capped call purchases", "label": "Adjustments to Additional Paid in Capital, Convertible Debt, Capped Call Purchases", "documentation": "Adjustments to Additional Paid in Capital, Convertible Debt, Capped Call Purchases" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation expense", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r52", "r53", "r483" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table", "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]" } } }, "auth_ref": [ "r1018" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r944", "r954", "r964", "r996" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r947", "r957", "r967", "r999" ] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Pension Adjustments Service Cost", "label": "Aggregate Pension Adjustments Service Cost [Member]" } } }, "auth_ref": [ "r1019" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r985" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r992" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r948", "r958", "r968", "r992", "r1000", "r1004", "r1012" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r1010" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivable", "crdr": "credit", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSAllowanceforCreditLossesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Accounts Receivable, Allowance for Credit Loss", "documentation": "Amount of allowance for credit loss on accounts receivable." } } }, "auth_ref": [ "r232", "r331", "r342", "r343", "r345", "r1157" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParentheticals" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, allowance", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": [ "r232", "r331", "r342" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivableRollforward", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSAllowanceforCreditLossesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]", "label": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://www.haemonetics.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "hae_AmortizationOfAcquiredIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "AmortizationOfAcquiredIntangibleAssets", "crdr": "debit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME", "http://www.haemonetics.com/role/SEGMENTANDENTERPRISEWIDEINFORMATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of acquired intangible assets", "label": "Amortization of Acquired Intangible Assets", "documentation": "Amortization of Acquired Intangible Assets" } } }, "auth_ref": [] }, "hae_AmortizationOfFairValueInventoryStepUp": { "xbrltype": "monetaryItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "AmortizationOfFairValueInventoryStepUp", "crdr": "debit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.haemonetics.com/role/SEGMENTANDENTERPRISEWIDEINFORMATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of fair value inventory step-up", "label": "Amortization of Fair Value Inventory Step Up", "documentation": "Amortization of Fair Value Inventory Step Up" } } }, "auth_ref": [] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": [ "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Aggregate amortization expense", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r10", "r361", "r368", "r879" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.haemonetics.com/role/EARNINGSPERSHAREScheduleofEarningsPerShareReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Anti-dilutive shares (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r289" ] }, "hae_ApheresisBloodCenterMember": { "xbrltype": "domainItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "ApheresisBloodCenterMember", "presentation": [ "http://www.haemonetics.com/role/SEGMENTANDENTERPRISEWIDEINFORMATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Apheresis", "label": "Apheresis, Blood Center [Member]", "documentation": "Apheresis, Blood Center" } } }, "auth_ref": [] }, "srt_AsiaMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "AsiaMember", "presentation": [ "http://www.haemonetics.com/role/SEGMENTANDENTERPRISEWIDEINFORMATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rest of Asia", "label": "Asia [Member]", "documentation": "Continent of Asia." } } }, "auth_ref": [ "r1037", "r1038", "r1039", "r1040", "r1193", "r1194", "r1195", "r1196" ] }, "us-gaap_AssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetImpairmentCharges", "crdr": "debit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment of intangible assets", "label": "Asset Impairment Charges", "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill." } } }, "auth_ref": [ "r10", "r42" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r152", "r163", "r228", "r256", "r293", "r299", "r317", "r321", "r335", "r405", "r406", "r408", "r409", "r410", "r411", "r412", "r414", "r415", "r543", "r546", "r582", "r656", "r737", "r872", "r873", "r905", "r935", "r1109", "r1110", "r1147" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r220", "r234", "r256", "r335", "r405", "r406", "r408", "r409", "r410", "r411", "r412", "r414", "r415", "r543", "r546", "r582", "r905", "r1109", "r1110", "r1147" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "verboseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSSchedulesofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets fair value", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r569", "r570", "r897" ] }, "us-gaap_AssetsFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosureAbstract", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSSchedulesofDerivativesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Assets", "label": "Assets, Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "hae_AttuneMedicalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "AttuneMedicalMember", "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSNarrativeDetails", "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSPurchasePriceAllocationDetails", "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Attune Medical", "label": "Attune Medical [Member]", "documentation": "Attune Medical" } } }, "auth_ref": [] }, "us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AverageRemainingMaturityOfForeignCurrencyDerivatives1", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maturity period for foreign currency contracts", "label": "Average Remaining Maturity of Foreign Currency Derivatives", "documentation": "Average period remaining before foreign currency exchange rate derivatives mature or expire, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r1007" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r1008" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r1003" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r1003" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r1003" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r1003" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r1003" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r1003" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r1006" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r1005" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r1004" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r1004" ] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationAxis", "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSNarrativeDetails", "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofInterestRateSwapsDetails", "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSSchedulesofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Axis]", "label": "Statement of Financial Position Location, Balance [Axis]", "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": [ "r382", "r1159", "r1160" ] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationDomain", "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSNarrativeDetails", "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofInterestRateSwapsDetails", "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSSchedulesofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Domain]", "label": "Statement of Financial Position Location, Balance [Domain]", "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": [ "r69", "r72", "r382", "r1159", "r1160" ] }, "hae_BankLoansAndOtherBorrowingsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "BankLoansAndOtherBorrowingsMember", "presentation": [ "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other borrowings", "label": "Bank loans and other borrowings [Member]", "documentation": "Bank loans and other borrowings" } } }, "auth_ref": [] }, "hae_BenefitProvisionForLossesOnInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "BenefitProvisionForLossesOnInventory", "crdr": "credit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Inventory reserve adjustment", "label": "Benefit (Provision) For Losses On Inventory", "documentation": "Benefit (Provision) For Losses On Inventory" } } }, "auth_ref": [] }, "hae_BloodCenterMember": { "xbrltype": "domainItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "BloodCenterMember", "presentation": [ "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails", "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails", "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofGoodwillDetails", "http://www.haemonetics.com/role/RESTRUCTURINGScheduleofRestructuringandRelatedCostsDetails", "http://www.haemonetics.com/role/SEGMENTANDENTERPRISEWIDEINFORMATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Blood Center", "label": "Blood Center [Member]", "documentation": "Blood Center [Member]" } } }, "auth_ref": [] }, "hae_BloodCenterProductsandServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "BloodCenterProductsandServicesMember", "presentation": [ "http://www.haemonetics.com/role/SEGMENTANDENTERPRISEWIDEINFORMATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Blood Center", "label": "Blood Center Products and Services [Member]", "documentation": "Blood Center Products and Services [Member]" } } }, "auth_ref": [] }, "us-gaap_BuildingAndBuildingImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BuildingAndBuildingImprovementsMember", "presentation": [ "http://www.haemonetics.com/role/PROPERTYPLANTANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Building and building improvements", "label": "Building and Building Improvements [Member]", "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSNarrativeDetails", "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSPurchasePriceAllocationDetails", "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Acquiree [Domain]", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r362", "r363", "r364", "r365", "r366", "r537", "r892", "r893" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSNarrativeDetails", "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSPurchasePriceAllocationDetails", "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Axis]", "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r56", "r57", "r362", "r363", "r364", "r365", "r366", "r537", "r892", "r893" ] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionLineItems", "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSNarrativeDetails", "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Line Items]", "label": "Business Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r537" ] }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationAcquisitionRelatedCosts", "crdr": "debit", "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal and professional fees", "label": "Business Combination, Acquisition Related Costs", "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities." } } }, "auth_ref": [ "r55" ] }, "us-gaap_BusinessCombinationContingentConsiderationAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationAsset", "crdr": "debit", "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration from divestiture", "label": "Business Combination, Contingent Consideration, Asset", "documentation": "Amount of asset recognized arising from contingent consideration in a business combination." } } }, "auth_ref": [ "r63", "r142", "r540" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationLiability", "crdr": "credit", "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSNarrativeDetails", "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration", "label": "Business Combination, Contingent Consideration, Liability", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination." } } }, "auth_ref": [ "r62", "r142", "r540", "r571", "r572", "r573" ] }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationDisclosureTextBlock", "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTS" ], "lang": { "en-us": { "role": { "terseLabel": "ACQUISITIONS, DIVESTITURES AND STRATEGIC INVESTMENTS", "label": "Business Combination Disclosure [Text Block]", "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)." } } }, "auth_ref": [ "r140", "r538" ] }, "us-gaap_BusinessCombinationPriceOfAcquisitionExpected": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationPriceOfAcquisitionExpected", "crdr": "credit", "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total consideration", "label": "Business Combination, Price of Acquisition, Expected", "documentation": "Purchase price of expected business acquisition prior to consideration being transferred. Excludes asset acquisition." } } }, "auth_ref": [ "r1026" ] }, "hae_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedPayrollAndRelatedCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedPayrollAndRelatedCosts", "crdr": "credit", "calculation": { "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued payroll and related costs", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Payroll and Related Costs", "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Payroll and Related Costs" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "crdr": "debit", "calculation": { "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSPurchasePriceAllocationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets acquired", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets", "documentation": "Amount of assets acquired at the acquisition date." } } }, "auth_ref": [ "r59" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "crdr": "debit", "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSNarrativeDetails", "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business combination, recognized identifiable assets acquired and liabilities assumed, cash and equivalents", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r59" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets", "crdr": "debit", "calculation": { "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": [ "r59" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "crdr": "debit", "calculation": { "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables", "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": [ "r59" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable", "crdr": "credit", "calculation": { "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable", "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date." } } }, "auth_ref": [ "r59" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther", "crdr": "credit", "calculation": { "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other", "documentation": "Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date." } } }, "auth_ref": [ "r59" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "crdr": "credit", "calculation": { "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax liability", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date." } } }, "auth_ref": [ "r59" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "calculation": { "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date." } } }, "auth_ref": [ "r59" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "crdr": "debit", "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSPurchasePriceAllocationDetails", "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquired intangibles", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date." } } }, "auth_ref": [ "r58", "r59" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "crdr": "debit", "calculation": { "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory", "documentation": "The amount of inventory recognized as of the acquisition date." } } }, "auth_ref": [ "r58", "r59" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "crdr": "credit", "calculation": { "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSPurchasePriceAllocationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities assumed", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities", "documentation": "Amount of liabilities assumed at the acquisition date." } } }, "auth_ref": [ "r59" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "crdr": "debit", "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net assets acquired", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed." } } }, "auth_ref": [ "r58", "r59" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther", "crdr": "credit", "calculation": { "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other", "documentation": "Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date." } } }, "auth_ref": [ "r59" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets", "crdr": "debit", "calculation": { "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets", "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": [ "r59" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date." } } }, "auth_ref": [ "r58", "r59" ] }, "hae_BusinessCombinationWorkingCapitalAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "BusinessCombinationWorkingCapitalAdjustment", "crdr": "credit", "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business combination, estimated working capital adjustment", "label": "Business Combination, Working Capital Adjustment", "documentation": "Business Combination, Working Capital Adjustment" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r34", "r222", "r859" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and Cash Equivalents at Beginning of Period", "periodEndLabel": "Cash and Cash Equivalents at End of Period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r34", "r121", "r253" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net Change in Cash and Cash Equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1", "r121" ] }, "us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths", "crdr": "credit", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain (loss) to be reclassified within the next twelve months", "label": "Cash Flow Hedge Gain (Loss) to be Reclassified within 12 Months", "documentation": "The estimated net amount of existing gains or losses on cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months." } } }, "auth_ref": [ "r79" ] }, "us-gaap_CashFlowHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowHedgingMember", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofEffectofDerivativeInstrumentsDesignatedasCashFlowHedgesandThoseNotDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Flow Hedging", "label": "Cash Flow Hedging [Member]", "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk." } } }, "auth_ref": [ "r67" ] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r983" ] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year", "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]" } } }, "auth_ref": [ "r980" ] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested", "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]" } } }, "auth_ref": [ "r978" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://www.haemonetics.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r984" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r984" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.haemonetics.com/role/COMMITMENTSANDCONTINGENCIES" ], "lang": { "en-us": { "role": { "terseLabel": "COMMITMENTS AND CONTINGENCIES", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r131", "r395", "r396", "r842", "r1099", "r1105" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r923", "r924", "r925", "r927", "r928", "r929", "r932", "r1056", "r1057", "r1059", "r1125", "r1190", "r1191" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParentheticals" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r91" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParentheticals" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r91", "r725" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParentheticals" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r91" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParentheticals" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares outstanding (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r16", "r91", "r725", "r743", "r1191", "r1192" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, $0.01 par value; Authorized \u2014 150,000,000 shares; Issued and outstanding \u2014 50,235,051 shares at December\u00a028, 2024 and 50,787,859 shares at March\u00a030, 2024", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r91", "r658", "r905" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r989" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r988" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r990" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r987" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Comprehensive income", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r29", "r241", "r243", "r248", "r650", "r667", "r668" ] }, "us-gaap_ComputerSoftwareIntangibleAssetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComputerSoftwareIntangibleAssetMember", "presentation": [ "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capitalized software", "label": "Computer Software, Intangible Asset [Member]", "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks." } } }, "auth_ref": [ "r854", "r858", "r1086", "r1087", "r1088", "r1089", "r1091", "r1093", "r1096", "r1097" ] }, "hae_ConsolidatedInterestCoverageRatio": { "xbrltype": "pureItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "ConsolidatedInterestCoverageRatio", "presentation": [ "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidated interest coverage ratio", "label": "Consolidated Interest Coverage Ratio", "documentation": "Consolidated Interest Coverage Ratio" } } }, "auth_ref": [] }, "hae_ConsolidatedTotalLeverageRatio": { "xbrltype": "pureItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "ConsolidatedTotalLeverageRatio", "presentation": [ "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidated total leverage ratio", "label": "Consolidated Total Leverage Ratio", "documentation": "Consolidated Total Leverage Ratio" } } }, "auth_ref": [] }, "srt_ConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsAxis", "presentation": [ "http://www.haemonetics.com/role/SEGMENTANDENTERPRISEWIDEINFORMATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Axis]", "label": "Consolidation Items [Axis]", "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments." } } }, "auth_ref": [ "r161", "r174", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r258", "r293", "r301", "r315", "r316", "r317", "r318", "r319", "r321", "r322", "r323", "r405", "r406", "r407", "r408", "r410", "r411", "r412", "r413", "r414", "r872", "r873", "r1041", "r1042", "r1109", "r1110" ] }, "srt_ConsolidationItemsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsDomain", "presentation": [ "http://www.haemonetics.com/role/SEGMENTANDENTERPRISEWIDEINFORMATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Domain]", "label": "Consolidation Items [Domain]", "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments." } } }, "auth_ref": [ "r161", "r174", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r258", "r293", "r301", "r315", "r316", "r317", "r318", "r319", "r321", "r322", "r323", "r405", "r406", "r407", "r408", "r410", "r411", "r412", "r413", "r414", "r872", "r873", "r1041", "r1042", "r1109", "r1110" ] }, "us-gaap_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConstructionInProgressMember", "presentation": [ "http://www.haemonetics.com/role/PROPERTYPLANTANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Construction in progress", "label": "Construction in Progress [Member]", "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [] }, "us-gaap_ContingentConsiderationByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContingentConsiderationByTypeAxis", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSSchedulesofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent Consideration by Type [Axis]", "label": "Contingent Consideration by Type [Axis]", "documentation": "Information by type of contingent consideration." } } }, "auth_ref": [] }, "hae_ContingentConsiderationFairValueRiskAdjustedDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "ContingentConsiderationFairValueRiskAdjustedDiscountRate", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSSchedulesofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent Consideration Fair Value, Risk-Adjusted Discount Rate", "label": "Contingent Consideration Fair Value, Risk-Adjusted Discount Rate", "documentation": "Contingent Consideration Fair Value, Risk-Adjusted Discount Rate" } } }, "auth_ref": [] }, "hae_ContingentConsiderationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "ContingentConsiderationMember", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSSchedulesofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent Consideration", "label": "Contingent Consideration [Member]", "documentation": "Contingent Consideration" } } }, "auth_ref": [] }, "us-gaap_ContingentConsiderationTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContingentConsiderationTypeDomain", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSSchedulesofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent Consideration Type [Domain]", "label": "Contingent Consideration Type [Domain]", "documentation": "Description of contingent payment arrangement." } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": [ "http://www.haemonetics.com/role/REVENUEDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract liabilities", "label": "Contract with Customer, Liability", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r460", "r461", "r472" ] }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": [ "http://www.haemonetics.com/role/REVENUEDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue recognized", "label": "Contract with Customer, Liability, Revenue Recognized", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": [ "r473" ] }, "us-gaap_ConvertibleDebtFairValueDisclosures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleDebtFairValueDisclosures", "crdr": "credit", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible notes, fair value", "label": "Convertible Debt, Fair Value Disclosures", "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock." } } }, "auth_ref": [ "r1127", "r1128", "r1129", "r1130", "r1137" ] }, "us-gaap_ConvertibleDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleDebtMember", "presentation": [ "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTNarrativeDetails", "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible notes", "label": "Convertible Debt [Member]", "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock." } } }, "auth_ref": [ "r133", "r417", "r418", "r428", "r429", "r430", "r434", "r435", "r436", "r437", "r438", "r881", "r882", "r883", "r884", "r885" ] }, "hae_ConvertibleSeniorNotesDue2026Member": { "xbrltype": "domainItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "ConvertibleSeniorNotesDue2026Member", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible Senior Notes Due 2026", "label": "Convertible Senior Notes Due 2026 [Member]", "documentation": "Convertible Senior Notes Due 2026" } } }, "auth_ref": [] }, "hae_ConvertibleSeniorNotesDue2029Member": { "xbrltype": "domainItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "ConvertibleSeniorNotesDue2029Member", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible Senior Notes Due 2029", "label": "Convertible Senior Notes Due 2029 [Member]", "documentation": "Convertible Senior Notes Due 2029" } } }, "auth_ref": [] }, "us-gaap_CorporateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateMember", "presentation": [ "http://www.haemonetics.com/role/RESTRUCTURINGScheduleofRestructuringandRelatedCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate", "label": "Corporate Segment [Member]", "documentation": "Component of an entity that usually provides financial, operational and administrative support and is considered an operating segment. Excludes intersegment elimination and reconciling items." } } }, "auth_ref": [ "r1062" ] }, "us-gaap_CorporateNonSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateNonSegmentMember", "presentation": [ "http://www.haemonetics.com/role/SEGMENTANDENTERPRISEWIDEINFORMATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate", "label": "Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]", "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment." } } }, "auth_ref": [ "r20", "r316", "r317", "r318", "r319", "r322", "r1065" ] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of goods sold", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r107", "r108", "r612" ] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfSalesMember", "presentation": [ "http://www.haemonetics.com/role/RESTRUCTURINGScheduleofRestructuringandRelatedCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of goods sold", "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.haemonetics.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerContractsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerContractsMember", "presentation": [ "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer contracts and related relationships", "label": "Customer Contracts [Member]", "documentation": "Entity's established relationships with its customers through contracts." } } }, "auth_ref": [ "r61", "r1086", "r1087", "r1088", "r1089", "r1091", "r1093", "r1096", "r1097" ] }, "us-gaap_CustomerRelatedIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerRelatedIntangibleAssetsMember", "presentation": [ "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer-Related Intangible Assets", "label": "Customer-Related Intangible Assets [Member]", "documentation": "Customer-related asset, including, but not limited to, customer lists, and noncontractual customer relationships." } } }, "auth_ref": [ "r23", "r1086", "r1087", "r1088", "r1089", "r1091", "r1093", "r1096", "r1097" ] }, "us-gaap_CustomerRelationshipsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerRelationshipsMember", "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer contracts and related relationships", "label": "Customer Relationships [Member]", "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships." } } }, "auth_ref": [ "r61", "r1086", "r1087", "r1088", "r1089", "r1091", "r1093", "r1096", "r1097" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBT" ], "lang": { "en-us": { "role": { "terseLabel": "NOTES\u00a0PAYABLE AND LONG-TERM DEBT", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r132", "r254", "r377", "r378", "r379", "r380", "r381", "r403", "r404", "r416", "r422", "r423", "r424", "r425", "r426", "r427", "r432", "r439", "r440", "r442", "r592" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r25", "r84", "r85", "r153", "r155", "r258", "r417", "r418", "r419", "r420", "r421", "r423", "r428", "r429", "r430", "r431", "r433", "r434", "r435", "r436", "r437", "r438", "r881", "r882", "r883", "r884", "r885", "r904", "r1052", "r1100", "r1101", "r1102", "r1145", "r1146" ] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "presentation": [ "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt, gross", "label": "Long-Term Debt, Gross", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r25", "r155", "r443" ] }, "hae_DebtInstrumentConvertibleCappedCallTransactionAntiDilutionAdjustmentShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "DebtInstrumentConvertibleCappedCallTransactionAntiDilutionAdjustmentShares", "presentation": [ "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capped call transaction, anti-dilution adjustment (in shares)", "label": "Debt Instrument, Convertible, Capped Call Transaction, Anti-Dilution Adjustment, Shares", "documentation": "Debt Instrument, Convertible, Capped Call Transaction, Anti-Dilution Adjustment, Shares" } } }, "auth_ref": [] }, "hae_DebtInstrumentConvertibleCappedCallTransactionInitialCapPrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "DebtInstrumentConvertibleCappedCallTransactionInitialCapPrice", "presentation": [ "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capped call transaction, initial cap price (in dollars per share)", "label": "Debt Instrument, Convertible, Capped Call Transaction, Initial Cap Price", "documentation": "Debt Instrument, Convertible, Capped Call Transaction, Initial Cap Price" } } }, "auth_ref": [] }, "hae_DebtInstrumentConvertibleCappedCallTransactionInitialStrikePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "DebtInstrumentConvertibleCappedCallTransactionInitialStrikePrice", "presentation": [ "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capped call transaction, initial strike price (in dollars per share)", "label": "Debt Instrument, Convertible, Capped Call Transaction, Initial Strike Price", "documentation": "Debt Instrument, Convertible, Capped Call Transaction, Initial Strike Price" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentConvertibleConversionPrice1", "presentation": [ "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, convertible, conversion price", "label": "Debt Instrument, Convertible, Conversion Price", "documentation": "The price per share of the conversion feature embedded in the debt instrument." } } }, "auth_ref": [ "r134", "r419" ] }, "hae_DebtInstrumentConvertibleConversionRate": { "xbrltype": "pureItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "DebtInstrumentConvertibleConversionRate", "presentation": [ "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, convertible, conversion rate", "label": "Debt Instrument, Convertible, Conversion Rate", "documentation": "Debt Instrument, Convertible, Conversion Rate" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Face amount of debt", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r417", "r592", "r593", "r882", "r883", "r904" ] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": [ "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective interest rate", "label": "Debt Instrument, Interest Rate, Effective Percentage", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": [ "r87", "r445", "r592", "r593", "r904" ] }, "hae_DebtInstrumentInterestRateFloor": { "xbrltype": "percentItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "DebtInstrumentInterestRateFloor", "presentation": [ "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate floor", "label": "Debt Instrument, Interest Rate, Floor", "documentation": "Debt Instrument, Interest Rate, Floor" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stated rate (as a percent)", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r87", "r418" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTNarrativeDetails", "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r258", "r417", "r418", "r419", "r420", "r421", "r423", "r428", "r429", "r430", "r431", "r433", "r434", "r435", "r436", "r437", "r438", "r441", "r881", "r882", "r883", "r884", "r885", "r904", "r1052", "r1145", "r1146" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r25", "r258", "r417", "r418", "r419", "r420", "r421", "r423", "r428", "r429", "r430", "r431", "r433", "r434", "r435", "r436", "r437", "r438", "r881", "r882", "r883", "r884", "r885", "r904", "r1052", "r1100", "r1101", "r1102", "r1145", "r1146" ] }, "hae_DebtInstrumentPercentOfPrincipalAmountDueInYear4": { "xbrltype": "percentItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "DebtInstrumentPercentOfPrincipalAmountDueInYear4", "presentation": [ "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, percent of principal amount due in year 4", "label": "Debt Instrument, Percent of Principal Amount Due In Year 4", "documentation": "Debt Instrument, Percent of Principal Amount Due In Year 4" } } }, "auth_ref": [] }, "hae_DebtInstrumentPercentOfPrincipalAmountDueInYear5": { "xbrltype": "percentItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "DebtInstrumentPercentOfPrincipalAmountDueInYear5", "presentation": [ "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, percent of principal amount due in year 5", "label": "Debt Instrument, Percent of Principal Amount Due In Year 5", "documentation": "Debt Instrument, Percent of Principal Amount Due In Year 5" } } }, "auth_ref": [] }, "hae_DebtInstrumentPercentOfPrincipalAmountDueInYears13": { "xbrltype": "percentItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "DebtInstrumentPercentOfPrincipalAmountDueInYears13", "presentation": [ "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, percent of principal amount due in years 1-3", "label": "Debt Instrument, Percent of Principal Amount Due In Years 1-3", "documentation": "Debt Instrument, Percent of Principal Amount Due In Years 1-3" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentRedemptionPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRedemptionPeriodAxis", "presentation": [ "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Redemption, Period [Axis]", "label": "Debt Instrument, Redemption, Period [Axis]", "documentation": "Information by period of debt redemption feature under terms of debt agreement." } } }, "auth_ref": [ "r159" ] }, "us-gaap_DebtInstrumentRedemptionPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRedemptionPeriodDomain", "presentation": [ "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Redemption, Period [Domain]", "label": "Debt Instrument, Redemption, Period [Domain]", "documentation": "Period as defined under terms of the debt agreement for debt redemption features." } } }, "auth_ref": [ "r159" ] }, "us-gaap_DebtInstrumentRedemptionPeriodOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRedemptionPeriodOneMember", "presentation": [ "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Redemption, Period One", "label": "Debt Instrument, Redemption, Period One [Member]", "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement." } } }, "auth_ref": [ "r159" ] }, "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRedemptionPeriodTwoMember", "presentation": [ "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Redemption, Period Two", "label": "Debt Instrument, Redemption, Period Two [Member]", "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement." } } }, "auth_ref": [ "r159" ] }, "us-gaap_DebtInstrumentRedemptionPricePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRedemptionPricePercentage", "presentation": [ "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, redemption price, percentage", "label": "Debt Instrument, Redemption Price, Percentage", "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer." } } }, "auth_ref": [ "r159" ] }, "hae_DebtInstrumentRedemptionPricePercentageOfPreviousClosingPrice": { "xbrltype": "percentItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "DebtInstrumentRedemptionPricePercentageOfPreviousClosingPrice", "presentation": [ "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, redemption price, percentage of previous closing price", "label": "Debt Instrument, Redemption Price, Percentage of Previous Closing Price", "documentation": "Debt Instrument, Redemption Price, Percentage of Previous Closing Price" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed", "presentation": [ "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, redemption price, percentage of principal amount redeemed", "label": "Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed", "documentation": "Percentage of principal amount of debt redeemed." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentRepurchaseAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRepurchaseAmount", "crdr": "debit", "presentation": [ "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Repurchase Amount", "label": "Debt Instrument, Repurchase Amount", "documentation": "Fair value amount of debt instrument that was repurchased." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentRepurchasedFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRepurchasedFaceAmount", "crdr": "debit", "presentation": [ "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Repurchased Face Amount", "label": "Debt Instrument, Repurchased Face Amount", "documentation": "Face (par) amount of the original debt instrument that was repurchased." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": [ "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTNarrativeDetails", "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": [ "r25", "r50", "r51", "r80", "r136", "r137", "r258", "r417", "r418", "r419", "r420", "r421", "r423", "r428", "r429", "r430", "r431", "r433", "r434", "r435", "r436", "r437", "r438", "r441", "r881", "r882", "r883", "r884", "r885", "r904", "r1052", "r1145", "r1146" ] }, "hae_DecreaseForRedemptionOfConvertibleSeniorNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "DecreaseForRedemptionOfConvertibleSeniorNotes", "crdr": "credit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repurchase of convertible senior notes", "label": "Decrease For Redemption Of Convertible Senior Notes", "documentation": "Decrease For Redemption Of Convertible Senior Notes" } } }, "auth_ref": [] }, "hae_DecreaseForRedemptionOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "DecreaseForRedemptionOfLongTermDebt", "crdr": "credit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Term loan redemption", "label": "Decrease For Redemption Of Long-Term Debt", "documentation": "Decrease For Redemption Of Long-Term Debt" } } }, "auth_ref": [] }, "us-gaap_DeferredFinanceCostsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFinanceCostsGross", "crdr": "debit", "presentation": [ "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt issuance costs, gross", "label": "Debt Issuance Costs, Gross", "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r1145", "r1146" ] }, "us-gaap_DeferredFinanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFinanceCostsNet", "crdr": "debit", "presentation": [ "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt issuance costs, net", "label": "Debt Issuance Costs, Net", "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r1112", "r1144", "r1145", "r1146" ] }, "us-gaap_DeferredIncomeTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxAssetsNet", "crdr": "debit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax asset", "label": "Deferred Income Tax Assets, Net", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting." } } }, "auth_ref": [ "r513", "r514" ] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax benefit", "label": "Deferred Income Tax Expense (Benefit)", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r10", "r170", "r1054" ] }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxLiabilitiesNet", "crdr": "credit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax liability", "label": "Deferred Income Tax Liabilities, Net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting." } } }, "auth_ref": [ "r513", "r514", "r657" ] }, "us-gaap_DeferredTaxAssetsDerivativeInstruments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsDerivativeInstruments", "crdr": "debit", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Deferred income tax expense (benefit)", "label": "Deferred Tax Assets, Derivative Instruments", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from derivative instruments." } } }, "auth_ref": [ "r1117" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "presentation": [ "http://www.haemonetics.com/role/PROPERTYPLANTANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r10", "r43" ] }, "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationAndAmortization", "crdr": "debit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization, Nonproduction", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": [ "r10", "r43" ] }, "hae_DerivativeBlendedFixedInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "DerivativeBlendedFixedInterestRate", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative, blended fixed interest rate", "label": "Derivative, Blended Fixed Interest Rate", "documentation": "Derivative, Blended Fixed Interest Rate" } } }, "auth_ref": [] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeContractTypeDomain", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofEffectofDerivativeInstrumentsDesignatedasCashFlowHedgesandThoseNotDesignatedasHedgingInstrumentsDetails", "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofInterestRateSwapsDetails", "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSSchedulesofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Contract [Domain]", "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r716", "r718", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r738", "r739", "r740", "r741", "r751", "r752", "r753", "r754", "r757", "r758", "r759", "r760", "r816", "r817", "r818", "r819", "r923", "r925", "r1131", "r1132", "r1133", "r1134", "r1135", "r1136", "r1138", "r1139" ] }, "us-gaap_DerivativeFairValueOfDerivativeAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeFairValueOfDerivativeAsset", "crdr": "debit", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofInterestRateSwapsDetails", "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSSchedulesofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Assets", "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset", "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement." } } }, "auth_ref": [ "r22", "r100", "r145", "r147", "r235", "r864" ] }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeFairValueOfDerivativeLiability", "crdr": "credit", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofInterestRateSwapsDetails", "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSSchedulesofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Liabilities", "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset", "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement." } } }, "auth_ref": [ "r22", "r100", "r145", "r147", "r235", "r864" ] }, "us-gaap_DerivativeFairValueOfDerivativeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeFairValueOfDerivativeNet", "crdr": "debit", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofInterestRateSwapsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated Fair Value Assets (Liabilities)", "label": "Derivative, Fair Value, Net", "documentation": "Fair value of the assets less the liabilities of a derivative or group of derivatives." } } }, "auth_ref": [ "r581" ] }, "us-gaap_DerivativeFixedInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeFixedInterestRate", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofInterestRateSwapsDetails", "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSSchedulesofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative fixed interest rate", "label": "Derivative, Fixed Interest Rate", "documentation": "Fixed interest rate related to the interest rate derivative." } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofEffectofDerivativeInstrumentsDesignatedasCashFlowHedgesandThoseNotDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instrument, Gain (Loss) Reclassified from AOCI into Income, Effective Portion, Statement of Income or Comprehensive Income [Extensible Enumeration]", "label": "Derivative Instrument, Gain (Loss) Reclassified from AOCI into Income, Effective Portion, Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement of income or comprehensive income that includes gain (loss) from effective portion of derivative instrument reclassified from accumulated other comprehensive income (AOCI) into income." } } }, "auth_ref": [ "r551" ] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentRiskAxis", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofEffectofDerivativeInstrumentsDesignatedasCashFlowHedgesandThoseNotDesignatedasHedgingInstrumentsDetails", "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofInterestRateSwapsDetails", "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSSchedulesofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instrument [Axis]", "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r70", "r73", "r74", "r148", "r716", "r718", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r738", "r739", "r740", "r741", "r751", "r752", "r753", "r754", "r757", "r758", "r759", "r760", "r816", "r817", "r818", "r819", "r864", "r923", "r925", "r1131", "r1132", "r1133", "r1134", "r1135", "r1136", "r1138", "r1139" ] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofEffectofDerivativeInstrumentsDesignatedasCashFlowHedgesandThoseNotDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship [Axis]", "label": "Hedging Relationship [Axis]", "documentation": "Information by type of hedging relationship." } } }, "auth_ref": [ "r17", "r70", "r73" ] }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofEffectofDerivativeInstrumentsDesignatedasCashFlowHedgesandThoseNotDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments, Gain (Loss) by Hedging Relationship, by Income Statement Location, by Derivative Instrument Risk [Table]", "label": "Derivative Instruments, Gain (Loss) [Table]", "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments." } } }, "auth_ref": [ "r17", "r70", "r73", "r74", "r77", "r78", "r552" ] }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsGainLossLineItems", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofEffectofDerivativeInstrumentsDesignatedasCashFlowHedgesandThoseNotDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r552" ] }, "us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet", "crdr": "credit", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofEffectofDerivativeInstrumentsDesignatedasCashFlowHedgesandThoseNotDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amount of Gain (Loss) Reclassified from Accumulated Other Comprehensive Loss into Earnings", "label": "Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net", "documentation": "The effective portion of net gain (loss) reclassified from accumulated other comprehensive income into income on derivative instruments designated and qualifying as hedging instruments." } } }, "auth_ref": [ "r21", "r149" ] }, "us-gaap_DerivativeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLineItems", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofInterestRateSwapsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Line Items]", "label": "Derivative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r561" ] }, "us-gaap_DerivativeNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeNotionalAmount", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofInterestRateSwapsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Notional amount", "label": "Derivative, Notional Amount", "documentation": "Nominal or face amount used to calculate payment on derivative." } } }, "auth_ref": [ "r1123", "r1124" ] }, "hae_DerivativePercentageOfNotionalValueOfDebt": { "xbrltype": "percentItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "DerivativePercentageOfNotionalValueOfDebt", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative, percentage of notional value of debt", "label": "Derivative, Percentage Of Notional Value Of Debt", "documentation": "Derivative, Percentage Of Notional Value Of Debt" } } }, "auth_ref": [] }, "us-gaap_DerivativeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeTable", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofInterestRateSwapsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Table]", "label": "Derivative [Table]", "documentation": "Disclosure of information about derivative instrument or group of derivative instruments, including, but not limited to, type of derivative instrument, risk being hedged, notional amount, hedge designation, related hedged item, inception date, and maturity date." } } }, "auth_ref": [ "r17", "r64", "r65", "r66", "r68", "r71", "r73", "r75", "r76", "r78", "r561" ] }, "us-gaap_DerivativesAndFairValueTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativesAndFairValueTextBlock", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTS" ], "lang": { "en-us": { "role": { "terseLabel": "FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS", "label": "Derivatives and Fair Value [Text Block]", "documentation": "The entire disclosure for derivatives and fair value of assets and liabilities." } } }, "auth_ref": [ "r144", "r151" ] }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DesignatedAsHedgingInstrumentMember", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofEffectofDerivativeInstrumentsDesignatedasCashFlowHedgesandThoseNotDesignatedasHedgingInstrumentsDetails", "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofInterestRateSwapsDetails", "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSSchedulesofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Designated as Hedging Instrument", "label": "Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": [ "r17" ] }, "hae_DigitalTransformationCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "DigitalTransformationCosts", "crdr": "debit", "presentation": [ "http://www.haemonetics.com/role/SEGMENTANDENTERPRISEWIDEINFORMATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Digital transformation costs", "label": "Digital Transformation Costs", "documentation": "Digital Transformation Costs" } } }, "auth_ref": [] }, "hae_DiscreteIncomeTaxBenefitExpenseAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "DiscreteIncomeTaxBenefitExpenseAxis", "presentation": [ "http://www.haemonetics.com/role/INCOMETAXESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discrete Income Tax Benefit (Expense) [Axis]", "label": "Discrete Income Tax Benefit (Expense) [Axis]", "documentation": "Discrete Income Tax Benefit (Expense)" } } }, "auth_ref": [] }, "hae_DiscreteIncomeTaxBenefitExpenseDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "DiscreteIncomeTaxBenefitExpenseDomain", "presentation": [ "http://www.haemonetics.com/role/INCOMETAXESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discrete Income Tax Benefit (Expense) [Domain]", "label": "Discrete Income Tax Benefit (Expense) [Domain]", "documentation": "Discrete Income Tax Benefit (Expense) [Domain]" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupClassificationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupClassificationAxis", "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Classification [Axis]", "label": "Disposal Group Classification [Axis]", "documentation": "Information by disposal group classification." } } }, "auth_ref": [ "r218" ] }, "us-gaap_DisposalGroupClassificationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupClassificationDomain", "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Classification [Domain]", "label": "Disposal Group Classification [Domain]", "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupHeldforsaleNotDiscontinuedOperationsMember", "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group, Held-for-Sale, Not Discontinued Operations", "label": "Disposal Group, Held-for-Sale, Not Discontinued Operations [Member]", "documentation": "Disposal group that is classified as held-for-sale. Excludes disposals classified as discontinued operations." } } }, "auth_ref": [ "r6", "r19", "r218" ] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Name [Domain]", "label": "Disposal Group Name [Domain]", "documentation": "Name of disposal group." } } }, "auth_ref": [ "r892", "r893" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.haemonetics.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.haemonetics.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.haemonetics.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.haemonetics.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r939" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://www.haemonetics.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r971" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.haemonetics.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year", "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]" } } }, "auth_ref": [ "r982" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share [Abstract]", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME", "http://www.haemonetics.com/role/EARNINGSPERSHAREScheduleofEarningsPerShareReconciliationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Basic income (loss) per share (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r249", "r268", "r269", "r271", "r272", "r273", "r275", "r282", "r284", "r286", "r287", "r288", "r292", "r535", "r542", "r566", "r567", "r651", "r669", "r866" ] }, "us-gaap_EarningsPerShareBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasicAbstract", "presentation": [ "http://www.haemonetics.com/role/EARNINGSPERSHAREScheduleofEarningsPerShareReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basic EPS", "label": "Earnings Per Share, Basic [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME", "http://www.haemonetics.com/role/EARNINGSPERSHAREScheduleofEarningsPerShareReconciliationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Diluted income (loss) per share (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r249", "r268", "r269", "r271", "r272", "r273", "r275", "r284", "r286", "r287", "r288", "r292", "r535", "r542", "r566", "r567", "r651", "r669", "r866" ] }, "us-gaap_EarningsPerShareDilutedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDilutedAbstract", "presentation": [ "http://www.haemonetics.com/role/EARNINGSPERSHAREScheduleofEarningsPerShareReconciliationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Diluted EPS", "label": "Earnings Per Share, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.haemonetics.com/role/EARNINGSPERSHARE" ], "lang": { "en-us": { "role": { "terseLabel": "EARNINGS PER SHARE", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r281", "r289", "r290", "r291" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of exchange rates on cash and cash equivalents", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r583" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": [ "http://www.haemonetics.com/role/INCOMETAXESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reported tax rate", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r516", "r895" ] }, "hae_EffectofExchangeRateonRevenues": { "xbrltype": "monetaryItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "EffectofExchangeRateonRevenues", "crdr": "credit", "presentation": [ "http://www.haemonetics.com/role/SEGMENTANDENTERPRISEWIDEINFORMATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of exchange rates", "label": "Effect of Exchange Rate on Revenues", "documentation": "Effect of Exchange Rate on Revenues" } } }, "auth_ref": [] }, "hae_EffectofExchangeRatesonOperatingIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "EffectofExchangeRatesonOperatingIncome", "crdr": "credit", "presentation": [ "http://www.haemonetics.com/role/SEGMENTANDENTERPRISEWIDEINFORMATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of exchange rates", "label": "Effect of Exchange Rates on Operating Income", "documentation": "Effect of Exchange Rates on Operating Income" } } }, "auth_ref": [] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued payroll and related costs", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r85" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Stock Option", "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOwnershipPlanESOPCashContributionsToESOP": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOwnershipPlanESOPCashContributionsToESOP", "crdr": "debit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from employee stock purchase plan", "label": "Employee Stock Ownership Plan (ESOP), Cash Contributions to ESOP", "documentation": "This item represents the amount of cash contributions during the period made by the entity to the Employee Stock Ownership Plan (ESOP)." } } }, "auth_ref": [ "r54" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.haemonetics.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.haemonetics.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.haemonetics.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.haemonetics.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.haemonetics.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r937" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.haemonetics.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.haemonetics.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.haemonetics.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r937" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://www.haemonetics.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://www.haemonetics.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r937" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.haemonetics.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.haemonetics.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r1021" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://www.haemonetics.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r937" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://www.haemonetics.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r937" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://www.haemonetics.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r937" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.haemonetics.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r937" ] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Footnote", "label": "Equity Awards Adjustments, Footnote [Text Block]" } } }, "auth_ref": [ "r976" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table", "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]" } } }, "auth_ref": [ "r1017" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments", "label": "Equity Awards Adjustments [Member]" } } }, "auth_ref": [ "r1017" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table", "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]" } } }, "auth_ref": [ "r1017" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [ "http://www.haemonetics.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSDetails", "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r16", "r213", "r244", "r245", "r246", "r259", "r260", "r261", "r265", "r273", "r276", "r278", "r294", "r336", "r341", "r374", "r459", "r522", "r523", "r530", "r531", "r532", "r536", "r541", "r542", "r554", "r555", "r556", "r557", "r558", "r560", "r565", "r584", "r586", "r587", "r588", "r589", "r590", "r595", "r598", "r602", "r666", "r693", "r694", "r695", "r711", "r763" ] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "EquityMethodInvesteeNameDomain", "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSStrategicInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Domain]", "label": "Investment, Name [Domain]", "documentation": "Name of investment including named security. Excludes entity that is consolidated." } } }, "auth_ref": [ "r332", "r333", "r334", "r529", "r1023", "r1024", "r1025", "r1119", "r1120", "r1121", "r1122" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r986" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r944", "r954", "r964", "r996" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r941", "r951", "r961", "r993" ] }, "srt_EuropeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "EuropeMember", "presentation": [ "http://www.haemonetics.com/role/SEGMENTANDENTERPRISEWIDEINFORMATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Europe", "label": "Europe [Member]", "documentation": "Continent of Europe." } } }, "auth_ref": [ "r1037", "r1038", "r1039", "r1040", "r1193", "r1194", "r1195", "r1196" ] }, "hae_EuropeanMedicalDeviceRegulationCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "EuropeanMedicalDeviceRegulationCosts", "crdr": "debit", "presentation": [ "http://www.haemonetics.com/role/SEGMENTANDENTERPRISEWIDEINFORMATIONDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "MDR and IVDR costs", "label": "European Medical Device Regulation Costs", "documentation": "European Medical Device Regulation Costs" } } }, "auth_ref": [] }, "hae_EventBasedPaymentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "EventBasedPaymentMember", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSSchedulesofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Event-based payment", "label": "Event-based payment [Member]", "documentation": "Event-based payment" } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r992" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSSchedulesofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r569", "r570", "r578", "r897" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSSchedulesofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r569", "r570", "r578", "r897" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofInterestRateSwapsDetails", "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSSchedulesofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r430", "r476", "r477", "r478", "r479", "r480", "r481", "r568", "r570", "r571", "r572", "r573", "r577", "r578", "r580", "r606", "r607", "r608", "r882", "r883", "r889", "r890", "r891", "r897", "r900" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofInterestRateSwapsDetails", "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSSchedulesofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Axis]", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r569", "r570", "r571", "r573", "r897", "r1129", "r1140" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSSchedulesofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 1", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r430", "r476", "r481", "r570", "r578", "r606", "r889", "r890", "r891", "r897" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofInterestRateSwapsDetails", "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSSchedulesofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r430", "r476", "r481", "r570", "r571", "r578", "r607", "r882", "r883", "r889", "r890", "r891", "r897" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSSchedulesofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Inputs, Level 3", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r430", "r476", "r477", "r478", "r479", "r480", "r481", "r570", "r571", "r572", "r573", "r578", "r608", "r882", "r883", "r889", "r890", "r891", "r897", "r900" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability." } } }, "auth_ref": [ "r574", "r576", "r579" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofInterestRateSwapsDetails", "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSSchedulesofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Domain]", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [ "r569", "r570", "r571", "r573", "r897", "r1129", "r1140" ] }, "hae_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustment", "crdr": "credit", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSSchedulesofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Adjustment", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Adjustment", "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Adjustment" } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "crdr": "credit", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSSchedulesofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)." } } }, "auth_ref": [ "r575", "r579" ] }, "hae_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityValueAtAcquisitionDate": { "xbrltype": "monetaryItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityValueAtAcquisitionDate", "crdr": "debit", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSSchedulesofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Value At Acquisition Date", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Value At Acquisition Date", "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Value At Acquisition Date" } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofInterestRateSwapsDetails", "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSSchedulesofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r430", "r476", "r477", "r478", "r479", "r480", "r481", "r568", "r570", "r571", "r572", "r573", "r577", "r578", "r580", "r606", "r607", "r608", "r882", "r883", "r889", "r890", "r891", "r897", "r900" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofInterestRateSwapsDetails", "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSSchedulesofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring [Member]", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r897", "r1126", "r1127", "r1128", "r1129", "r1130", "r1140" ] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": [ "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average useful life", "label": "Finite-Lived Intangible Asset, Useful Life", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": { "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParentheticals", "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets, amortization", "verboseLabel": "Accumulated Amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r226", "r347", "r367", "r879" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "presentation": [ "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fiscal 2026", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r369", "r854", "r879" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "crdr": "debit", "presentation": [ "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remainder of Fiscal 2025", "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year." } } }, "auth_ref": [ "r1197" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "presentation": [ "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fiscal 2029", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r369", "r854", "r879" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "presentation": [ "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fiscal 2028", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r369", "r854", "r879" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "presentation": [ "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fiscal 2027", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r369", "r854", "r879" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSPurchasePriceAllocationDetails", "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails", "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r360", "r362", "r363", "r364", "r366", "r367", "r371", "r372", "r613", "r617", "r854" ] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "calculation": { "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails", "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Carrying Amount", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r347", "r367", "r617", "r879" ] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails", "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets [Line Items]", "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r360", "r367", "r371", "r372", "r373", "r613", "r854", "r879" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSPurchasePriceAllocationDetails", "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails", "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r360", "r362", "r363", "r364", "r366", "r367", "r371", "r372", "r854" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails", "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-lived intangible assets, net", "totalLabel": "Net", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r613", "r1093" ] }, "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNetAbstract", "presentation": [ "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortizable:", "label": "Finite-Lived Intangible Assets, Net [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ForeignCurrencyCashFlowHedgeDerivativeAtFairValueNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyCashFlowHedgeDerivativeAtFairValueNet", "crdr": "debit", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Designated foreign currency hedge contracts outstanding", "label": "Foreign Currency Cash Flow Hedge Derivative at Fair Value, Net", "documentation": "Fair value as of the balance sheet date of all foreign currency derivatives designated as cash flow hedging instruments." } } }, "auth_ref": [ "r145", "r146", "r148" ] }, "us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAtFairValueNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAtFairValueNet", "crdr": "debit", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-designated foreign currency hedge contracts outstanding", "label": "Foreign Currency Derivative Instruments Not Designated as Hedging Instruments at Fair Value, Net", "documentation": "Fair value as of the balance sheet date of all foreign currency derivatives not designated as hedging instruments." } } }, "auth_ref": [ "r11" ] }, "us-gaap_ForeignExchangeContractMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignExchangeContractMember", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofEffectofDerivativeInstrumentsDesignatedasCashFlowHedgesandThoseNotDesignatedasHedgingInstrumentsDetails", "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofInterestRateSwapsDetails", "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSSchedulesofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Exchange Contract", "label": "Foreign Exchange Contract [Member]", "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates." } } }, "auth_ref": [ "r864", "r889", "r896", "r897" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r948", "r958", "r968", "r1000" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r948", "r958", "r968", "r1000" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r948", "r958", "r968", "r1000" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r948", "r958", "r968", "r1000" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r948", "r958", "r968", "r1000" ] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year", "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]" } } }, "auth_ref": [ "r981" ] }, "us-gaap_GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet", "crdr": "credit", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofEffectofDerivativeInstrumentsDesignatedasCashFlowHedgesandThoseNotDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amount of Gain Excluded from Effectiveness Testing", "label": "Gain (Loss) from Components Excluded from Assessment of Fair Value Hedge Effectiveness, Net", "documentation": "Net gain (loss) relating to components of the gain (loss) on the fair value hedging instrument excluded from the assessment of fair value hedge effectiveness. Recognized in earnings." } } }, "auth_ref": [ "r150", "r550" ] }, "us-gaap_GainLossOnDispositionOfAssets1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnDispositionOfAssets1", "crdr": "credit", "presentation": [ "http://www.haemonetics.com/role/SEGMENTANDENTERPRISEWIDEINFORMATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain on sale of property, plant and equipment", "label": "Gain (Loss) on Disposition of Assets", "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee." } } }, "auth_ref": [ "r1051" ] }, "us-gaap_GainLossOnInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnInvestments", "crdr": "credit", "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSStrategicInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain (loss) on investments", "label": "Gain (Loss) on Investments", "documentation": "Amount of realized and unrealized gain (loss) on investment." } } }, "auth_ref": [ "r112", "r114", "r1022" ] }, "us-gaap_GainLossOnRepurchaseOfDebtInstrument": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnRepurchaseOfDebtInstrument", "crdr": "credit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gain on repurchase of convertible senior notes, net", "terseLabel": "Gain (loss) on repurchase of debt instrument", "label": "Gain (Loss) on Repurchase of Debt Instrument", "documentation": "Amount of gain (loss) from the difference between the repurchase price of a debt instrument initially issued by the entity and the net carrying amount of the debt at the time of its repurchase." } } }, "auth_ref": [] }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnSaleOfPropertyPlantEquipment", "crdr": "credit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 12.0 } }, "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.haemonetics.com/role/PROPERTYPLANTANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gains on sales of property, plant and equipment", "terseLabel": "Sale of property", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property." } } }, "auth_ref": [ "r10" ] }, "us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost", "crdr": "credit", "presentation": [ "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain (loss) on extinguishment of debt, before debt issuance cost writeoff", "label": "Gain (Loss) on Extinguishment of Debt, before Debt Issuance Cost Writeoff", "documentation": "Reflects the difference between the fair value of payments made to legally extinguish a debt and its carrying value at that time. This item excludes the write-off of amounts previously capitalized as debt issuance costs." } } }, "auth_ref": [ "r48", "r49" ] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 }, "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSPurchasePriceAllocationDetails", "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "periodStartLabel": "Goodwill, carrying amount, beginning balance", "periodEndLabel": "Goodwill, carrying amount, ending balance", "label": "Goodwill", "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r225", "r348", "r648", "r873", "r878", "r898", "r905", "r1075", "r1082" ] }, "us-gaap_GoodwillAcquiredDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAcquiredDuringPeriod", "crdr": "debit", "presentation": [ "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisitions", "label": "Goodwill, Acquired During Period", "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination." } } }, "auth_ref": [ "r351", "r878" ] }, "us-gaap_GoodwillAndIntangibleAssetImpairment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetImpairment", "crdr": "debit", "presentation": [ "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment of intangible assets", "label": "Goodwill and Intangible Asset Impairment", "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill." } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]", "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": [ "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETS" ], "lang": { "en-us": { "role": { "terseLabel": "GOODWILL AND INTANGIBLE ASSETS", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for goodwill and intangible assets." } } }, "auth_ref": [ "r1073", "r1085" ] }, "hae_GoodwillAssetsHeldForSale": { "xbrltype": "monetaryItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "GoodwillAssetsHeldForSale", "crdr": "debit", "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSNarrativeDetails", "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails", "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofGoodwillDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Assets held for sale", "label": "Goodwill, Assets Held for Sale", "documentation": "Goodwill, Assets Held for Sale" } } }, "auth_ref": [] }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": [ "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Currency translation", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) asset representing future economic benefit from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r355" ] }, "us-gaap_GoodwillLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillLineItems", "presentation": [ "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Line Items]", "label": "Goodwill [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r878" ] }, "us-gaap_GoodwillMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillMember", "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Goodwill [Member]", "documentation": "Asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [] }, "us-gaap_GoodwillPurchaseAccountingAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillPurchaseAccountingAdjustments", "crdr": "debit", "presentation": [ "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase accounting adjustments", "label": "Goodwill, Measurement Period Adjustment", "documentation": "Amount of increase (decrease) from measurement period adjustment of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r0", "r1081" ] }, "us-gaap_GoodwillRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillRollForward", "presentation": [ "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Roll Forward]", "label": "Goodwill [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "totalLabel": "Gross profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r105", "r109", "r162", "r256", "r335", "r405", "r406", "r408", "r409", "r410", "r411", "r412", "r414", "r415", "r582", "r867", "r872", "r1061", "r1064", "r1066", "r1067", "r1068", "r1109" ] }, "hae_HaemoneticsEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "HaemoneticsEquipmentMember", "presentation": [ "http://www.haemonetics.com/role/PROPERTYPLANTANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Haemonetics equipment", "label": "Haemonetics Equipment [Member]", "documentation": "Haemonetics Equipment" } } }, "auth_ref": [] }, "us-gaap_HedgingDesignationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingDesignationAxis", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofEffectofDerivativeInstrumentsDesignatedasCashFlowHedgesandThoseNotDesignatedasHedgingInstrumentsDetails", "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofInterestRateSwapsDetails", "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSSchedulesofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Axis]", "label": "Hedging Designation [Axis]", "documentation": "Information by designation of purpose of derivative instrument." } } }, "auth_ref": [ "r17", "r552" ] }, "us-gaap_HedgingDesignationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingDesignationDomain", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofEffectofDerivativeInstrumentsDesignatedasCashFlowHedgesandThoseNotDesignatedasHedgingInstrumentsDetails", "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofInterestRateSwapsDetails", "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSSchedulesofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Domain]", "label": "Hedging Designation [Domain]", "documentation": "Designation of purpose of derivative instrument." } } }, "auth_ref": [ "r17" ] }, "us-gaap_HedgingRelationshipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingRelationshipDomain", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofEffectofDerivativeInstrumentsDesignatedasCashFlowHedgesandThoseNotDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship [Domain]", "label": "Hedging Relationship [Domain]", "documentation": "Nature or intent of a hedge." } } }, "auth_ref": [ "r17" ] }, "hae_HemostasisManagementHospitalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "HemostasisManagementHospitalMember", "presentation": [ "http://www.haemonetics.com/role/SEGMENTANDENTERPRISEWIDEINFORMATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hemostasis Management, Hospital", "label": "Hemostasis Management, Hospital [Member]", "documentation": "Hemostasis Management, Hospital" } } }, "auth_ref": [] }, "hae_HospitalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "HospitalMember", "presentation": [ "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofGoodwillDetails", "http://www.haemonetics.com/role/RESTRUCTURINGScheduleofRestructuringandRelatedCostsDetails", "http://www.haemonetics.com/role/SEGMENTANDENTERPRISEWIDEINFORMATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hospital", "label": "Hospital [Member]", "documentation": "Hospital [Member]" } } }, "auth_ref": [] }, "hae_HospitalProductsandServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "HospitalProductsandServicesMember", "presentation": [ "http://www.haemonetics.com/role/SEGMENTANDENTERPRISEWIDEINFORMATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hospital", "label": "Hospital Products and Services [Member]", "documentation": "Hospital Products and Services [Member]" } } }, "auth_ref": [] }, "hae_ImpairmentOfAssetsAndPCS2RelatedChargesCredits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "ImpairmentOfAssetsAndPCS2RelatedChargesCredits", "crdr": "debit", "presentation": [ "http://www.haemonetics.com/role/SEGMENTANDENTERPRISEWIDEINFORMATIONDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Write downs of certain assets and PCS2 related charges", "label": "Impairment Of Assets And PCS2 Related Charges (Credits)", "documentation": "Impairment Of Assets And PCS2 Related Charges (Credits)" } } }, "auth_ref": [] }, "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOfIntangibleAssetsFinitelived", "crdr": "debit", "presentation": [ "http://www.haemonetics.com/role/SEGMENTANDENTERPRISEWIDEINFORMATIONDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Impairment of intangible assets", "label": "Impairment of Intangible Assets, Finite-Lived", "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value." } } }, "auth_ref": [ "r361", "r1051", "r1098" ] }, "us-gaap_InProcessResearchAndDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InProcessResearchAndDevelopmentMember", "presentation": [ "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "In-process research and development", "label": "In Process Research and Development [Member]", "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process." } } }, "auth_ref": [ "r1086", "r1087", "r1088", "r1089", "r1090", "r1091", "r1093", "r1095", "r1096", "r1097" ] }, "hae_InProcessSoftwareDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "InProcessSoftwareDevelopmentMember", "presentation": [ "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "In-process software development", "label": "In Process Software Development [Member]", "documentation": "In Process Software Development [Member]" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "totalLabel": "Income before provision for income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r106", "r157", "r162", "r652", "r664", "r867", "r872", "r1061", "r1064", "r1066", "r1067", "r1068" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Name [Axis]", "label": "Disposal Group Name [Axis]", "documentation": "Information by name of disposal group." } } }, "auth_ref": [ "r892", "r893" ] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSNarrativeDetails", "http://www.haemonetics.com/role/RESTRUCTURINGScheduleofRestructuringandRelatedCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r375", "r382", "r387", "r575", "r576", "r579", "r690", "r692", "r748", "r854", "r899", "r1161" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSNarrativeDetails", "http://www.haemonetics.com/role/RESTRUCTURINGScheduleofRestructuringandRelatedCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statement of Income Location, Balance [Domain]", "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r382", "r387", "r575", "r576", "r579", "r690", "r692", "r748", "r854", "r899", "r1161" ] }, "us-gaap_IncomeTaxContingencyLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxContingencyLineItems", "presentation": [ "http://www.haemonetics.com/role/INCOMETAXESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Contingency [Line Items]", "label": "Income Tax Contingency [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxContingencyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxContingencyTable", "presentation": [ "http://www.haemonetics.com/role/INCOMETAXESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Contingency [Table]", "label": "Income Tax Contingency [Table]", "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months." } } }, "auth_ref": [ "r1116" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.haemonetics.com/role/INCOMETAXES" ], "lang": { "en-us": { "role": { "terseLabel": "INCOME TAXES", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": [ "r257", "r512", "r516", "r517", "r518", "r519", "r520", "r521", "r524", "r526", "r527", "r528", "r710", "r895" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME", "http://www.haemonetics.com/role/INCOMETAXESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Provision for income taxes", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r164", "r171", "r277", "r278", "r293", "r307", "r321", "r515", "r516", "r525", "r670", "r895" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Change in accounts payable and accrued expenses", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": [ "r9" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Change in accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r9" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Change in inventories", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r9" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Change in operating assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "crdr": "credit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 14.0 } }, "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Change in other assets and other liabilities", "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net", "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other." } } }, "auth_ref": [ "r9" ] }, "us-gaap_IncreaseDecreaseInPrepaidTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidTaxes", "crdr": "credit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Change in prepaid income taxes", "label": "Increase (Decrease) in Prepaid Taxes", "documentation": "Amount of increase (decrease) of consideration paid in advance for income and other taxes that provide economic benefits in future periods." } } }, "auth_ref": [ "r9" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets [Axis]", "label": "Indefinite-Lived Intangible Assets [Axis]", "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r360", "r365", "r370", "r879" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "crdr": "debit", "presentation": [ "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-amortizable:", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r347", "r370", "r879" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company." } } }, "auth_ref": [ "r360", "r365", "r370", "r879" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r948", "r958", "r968", "r992", "r1000", "r1004", "r1012" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r1010" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r940", "r1016" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r940", "r1016" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r940", "r1016" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets, less accumulated amortization of $311,596 at December\u00a028, 2024 and $455,213 at March\u00a030, 2024", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r360", "r1093", "r1095" ] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseDebt", "crdr": "debit", "presentation": [ "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense, debt", "label": "Interest Expense, Debt", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": [ "r113", "r436", "r446", "r884", "r885" ] }, "us-gaap_InterestExpenseNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseNonoperating", "crdr": "debit", "presentation": [ "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense", "label": "Interest Expense, Nonoperating", "documentation": "Amount of interest expense classified as nonoperating." } } }, "auth_ref": [ "r303", "r1048" ] }, "hae_InterestRateSwap408FixedInterestRateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "InterestRateSwap408FixedInterestRateMember", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofInterestRateSwapsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swap, 4.08% Fixed Interest Rate", "label": "Interest Rate Swap, 4.08% Fixed Interest Rate [Member]", "documentation": "Interest Rate Swap, 4.08% Fixed Interest Rate" } } }, "auth_ref": [] }, "hae_InterestRateSwap415FixedInterestRateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "InterestRateSwap415FixedInterestRateMember", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofInterestRateSwapsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swap, 4.15% Fixed Interest Rate", "label": "Interest Rate Swap, 4.15% Fixed Interest Rate [Member]", "documentation": "Interest Rate Swap, 4.15% Fixed Interest Rate" } } }, "auth_ref": [] }, "us-gaap_InterestRateSwapMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestRateSwapMember", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofEffectofDerivativeInstrumentsDesignatedasCashFlowHedgesandThoseNotDesignatedasHedgingInstrumentsDetails", "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofInterestRateSwapsDetails", "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSSchedulesofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swap", "label": "Interest Rate Swap [Member]", "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period." } } }, "auth_ref": [ "r855", "r930", "r931" ] }, "hae_InterventionalTechnologiesHospitalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "InterventionalTechnologiesHospitalMember", "presentation": [ "http://www.haemonetics.com/role/SEGMENTANDENTERPRISEWIDEINFORMATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vascular Closure, Hosptial", "label": "Interventional Technologies, Hospital [Member]", "documentation": "Interventional Technologies, Hospital" } } }, "auth_ref": [] }, "us-gaap_InventoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoriesMember", "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Inventories [Member]", "documentation": "Tangible personal property held for sale in the ordinary course of business, or in process of, or to be consumed in, production for sale." } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Inventory Disclosure [Abstract]", "label": "Inventory Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureTextBlock", "presentation": [ "http://www.haemonetics.com/role/INVENTORIES" ], "lang": { "en-us": { "role": { "terseLabel": "INVENTORIES", "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": [ "r346" ] }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "calculation": { "http://www.haemonetics.com/role/INVENTORIESScheduleofInventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.haemonetics.com/role/INVENTORIESScheduleofInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finished goods", "label": "Inventory, Finished Goods, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, "auth_ref": [ "r125", "r861" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 }, "http://www.haemonetics.com/role/INVENTORIESScheduleofInventoriesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSNarrativeDetails", "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.haemonetics.com/role/INVENTORIESScheduleofInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories, net", "negatedTerseLabel": "Inventories, net", "totalLabel": "Inventories, net", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r233", "r860", "r905" ] }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryRawMaterialsNetOfReserves", "crdr": "debit", "calculation": { "http://www.haemonetics.com/role/INVENTORIESScheduleofInventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.haemonetics.com/role/INVENTORIESScheduleofInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Raw materials", "label": "Inventory, Raw Materials, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process." } } }, "auth_ref": [ "r125", "r863" ] }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWorkInProcessNetOfReserves", "crdr": "debit", "calculation": { "http://www.haemonetics.com/role/INVENTORIESScheduleofInventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.haemonetics.com/role/INVENTORIESScheduleofInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Work-in-process", "label": "Inventory, Work in Process, Net of Reserves", "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing." } } }, "auth_ref": [ "r125", "r862" ] }, "us-gaap_Investments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Investments", "crdr": "debit", "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSStrategicInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment", "label": "Investments", "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments." } } }, "auth_ref": [ "r654", "r655", "r920", "r922" ] }, "us-gaap_InvestmentsAllOtherInvestmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsAllOtherInvestmentsAbstract", "lang": { "en-us": { "role": { "label": "Investments, All Other Investments [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InvestmentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSSchedulesofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Money market funds", "label": "Investments, Fair Value Disclosure", "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method." } } }, "auth_ref": [ "r1126", "r1127", "r1137" ] }, "country_JP": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "JP", "presentation": [ "http://www.haemonetics.com/role/SEGMENTANDENTERPRISEWIDEINFORMATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Japan", "label": "JAPAN" } } }, "auth_ref": [] }, "us-gaap_LandMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LandMember", "presentation": [ "http://www.haemonetics.com/role/PROPERTYPLANTANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Land", "label": "Land [Member]", "documentation": "Part of earth's surface not covered by water." } } }, "auth_ref": [ "r1115" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Leases [Abstract]", "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.haemonetics.com/role/LEASES" ], "lang": { "en-us": { "role": { "terseLabel": "LEASES", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r597" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders\u2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r96", "r156", "r661", "r905", "r1053", "r1071", "r1141" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r86", "r221", "r256", "r335", "r405", "r406", "r408", "r409", "r410", "r411", "r412", "r414", "r415", "r544", "r546", "r547", "r582", "r905", "r1109", "r1147", "r1148" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesFairValueDisclosure", "crdr": "credit", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSSchedulesofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities fair value", "label": "Liabilities, Fair Value Disclosure", "documentation": "Fair value of financial and nonfinancial obligations." } } }, "auth_ref": [ "r570", "r1126" ] }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesFairValueDisclosureAbstract", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSSchedulesofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities", "label": "Liabilities, Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum borrowing capacity", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r83", "r88" ] }, "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "presentation": [ "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolving credit facility unused fee percentage", "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage", "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditMember", "presentation": [ "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Uncommitted Operating Lines of Credit", "label": "Line of Credit [Member]", "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars." } } }, "auth_ref": [] }, "us-gaap_LitigationSettlementExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LitigationSettlementExpense", "crdr": "debit", "presentation": [ "http://www.haemonetics.com/role/SEGMENTANDENTERPRISEWIDEINFORMATIONDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Litigation-related charges", "label": "Litigation Settlement, Fee Expense", "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees." } } }, "auth_ref": [ "r1036" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://www.haemonetics.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongLivedAssetsHeldForSaleByAssetTypeAxis", "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Asset, Held-for-Sale, Type [Axis]", "label": "Long-Lived Asset, Held-for-Sale, Type [Axis]", "documentation": "Information by long-lived asset held for sale." } } }, "auth_ref": [ "r14" ] }, "us-gaap_LongLivedAssetsHeldForSaleNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongLivedAssetsHeldForSaleNameDomain", "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Assets Held-for-Sale, Name [Domain]", "label": "Long-Lived Assets Held-for-Sale, Name [Domain]", "documentation": "A name of the assets to be disposed." } } }, "auth_ref": [ "r14" ] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTScheduleofDebtDetails": { "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTNarrativeDetails", "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt outstanding", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r25", "r155", "r429", "r444", "r882", "r883", "r904", "r1156" ] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtCurrent", "crdr": "credit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 }, "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTScheduleofDebtDetails": { "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Notes payable and current maturities of long-term debt", "negatedTerseLabel": "Notes payable and current maturities of long-term debt", "label": "Long-Term Debt, Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": [ "r229" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "presentation": [ "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTNarrativeDetails", "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTScheduleofLongTermDebtMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fiscal 2026", "label": "Long-Term Debt, Maturity, Year One", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r13", "r258", "r434" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "crdr": "credit", "presentation": [ "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTScheduleofLongTermDebtMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fiscal 2029", "label": "Long-Term Debt, Maturity, Year Four", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r13", "r258", "r434" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "presentation": [ "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTScheduleofLongTermDebtMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fiscal 2028", "label": "Long-Term Debt, Maturity, Year Three", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r13", "r258", "r434" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "presentation": [ "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTScheduleofLongTermDebtMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fiscal 2027", "label": "Long-Term Debt, Maturity, Year Two", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r13", "r258", "r434" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "crdr": "credit", "presentation": [ "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTScheduleofLongTermDebtMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remainder of Fiscal 2025", "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year." } } }, "auth_ref": [ "r1055" ] }, "hae_LongTermDebtMaturityAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "LongTermDebtMaturityAfterYearFour", "crdr": "credit", "presentation": [ "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTScheduleofLongTermDebtMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Long-Term Debt, Maturity, After Year Four", "documentation": "Long-Term Debt, Maturity, After Year Four" } } }, "auth_ref": [] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 }, "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTScheduleofDebtDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt", "totalLabel": "Long-term debt", "label": "Long-Term Debt, Excluding Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r230" ] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTNarrativeDetails", "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r25", "r1100", "r1101", "r1102" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTNarrativeDetails", "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r25", "r47", "r1100", "r1101", "r1102" ] }, "us-gaap_LossContingencyEstimateOfPossibleLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyEstimateOfPossibleLoss", "crdr": "debit", "presentation": [ "http://www.haemonetics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss contingency, estimate of possible loss", "label": "Loss Contingency, Estimate of Possible Loss", "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date." } } }, "auth_ref": [ "r397", "r398", "r401", "r402", "r510", "r880" ] }, "us-gaap_LossContingencyLossInPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyLossInPeriod", "crdr": "debit", "presentation": [ "http://www.haemonetics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss in period", "label": "Loss Contingency, Loss in Period", "documentation": "The amount of loss pertaining to the specified contingency that was charged against earnings in the period, including the effects of revisions in previously reported estimates." } } }, "auth_ref": [ "r1106" ] }, "us-gaap_MachineryAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MachineryAndEquipmentMember", "presentation": [ "http://www.haemonetics.com/role/PROPERTYPLANTANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plant equipment and machinery", "label": "Machinery and Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment." } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails", "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]", "documentation": "Upper limit of the provided range." } } }, "auth_ref": [ "r175", "r177", "r179", "r180", "r182", "r211", "r212", "r397", "r398", "r399", "r400", "r482", "r510", "r573", "r611", "r689", "r691", "r703", "r717", "r718", "r771", "r790", "r795", "r796", "r829", "r852", "r853", "r877", "r886", "r894", "r900", "r901", "r902", "r903", "r915", "r1111", "r1149", "r1150", "r1151", "r1152", "r1153", "r1154" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r984" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r984" ] }, "us-gaap_MediumTermNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MediumTermNotesMember", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTNarrativeDetails", "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term loan, net of financing fees", "label": "Medium-Term Note [Member]", "documentation": "Debt instruments with maturities ranging from five to ten years." } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails", "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]", "documentation": "Lower limit of the provided range." } } }, "auth_ref": [ "r175", "r177", "r179", "r180", "r182", "r211", "r212", "r397", "r398", "r399", "r400", "r482", "r510", "r573", "r611", "r689", "r691", "r703", "r717", "r718", "r771", "r790", "r795", "r796", "r829", "r852", "r853", "r877", "r886", "r894", "r900", "r901", "r902", "r915", "r1111", "r1149", "r1150", "r1151", "r1152", "r1153", "r1154" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r1003" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r1011" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r985" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r252" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Flows from Financing Activities:", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r252" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Flows from Investing Activities:", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r121", "r122", "r123" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Flows from Operating Activities:", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 }, "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME", "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.haemonetics.com/role/EARNINGSPERSHAREScheduleofEarningsPerShareReconciliationDetails", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net income", "verboseLabel": "Net income", "terseLabel": "Net income", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r110", "r123", "r158", "r219", "r239", "r242", "r246", "r256", "r264", "r268", "r269", "r271", "r272", "r273", "r277", "r278", "r285", "r335", "r405", "r406", "r408", "r409", "r410", "r411", "r412", "r414", "r415", "r535", "r542", "r567", "r582", "r665", "r745", "r761", "r762", "r933", "r1109" ] }, "hae_NetRevenuesByBusinessUnitBeforeForeignExchangeImpact": { "xbrltype": "monetaryItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "NetRevenuesByBusinessUnitBeforeForeignExchangeImpact", "crdr": "credit", "presentation": [ "http://www.haemonetics.com/role/SEGMENTANDENTERPRISEWIDEINFORMATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net revenues in constant currency", "label": "Net Revenues, By Business Unit Before Foreign Exchange Impact", "documentation": "Net Revenues, By Business Unit Before Foreign Exchange Impact" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract", "lang": { "en-us": { "role": { "terseLabel": "New Accounting Pronouncements and Changes in Accounting Principles [Abstract]", "label": "Accounting Standards Update and Change in Accounting Principle [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "presentation": [ "http://www.haemonetics.com/role/RECENTACCOUNTINGPRONOUNCEMENTS" ], "lang": { "en-us": { "role": { "terseLabel": "RECENT ACCOUNTING PRONOUNCEMENTS", "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]", "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle." } } }, "auth_ref": [ "r172", "r215", "r262", "r263", "r266", "r267", "r279", "r280", "r329", "r337", "r338", "r533", "r534", "r536", "r542", "r559", "r564", "r600", "r603", "r604", "r614", "r615", "r616", "r697", "r698", "r699", "r700", "r702" ] }, "hae_NonCashItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "NonCashItemsAbstract", "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash items:", "label": "Non-Cash Items [Abstract]", "documentation": "Non-Cash Items [Abstract]" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r984" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r948", "r958", "r968", "r992", "r1000" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r975" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r974" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r992" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r1011" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r1011" ] }, "us-gaap_NondesignatedMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NondesignatedMember", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofEffectofDerivativeInstrumentsDesignatedasCashFlowHedgesandThoseNotDesignatedasHedgingInstrumentsDetails", "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofInterestRateSwapsDetails", "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSSchedulesofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Not Designated as Hedging Instrument", "label": "Not Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": [ "r17" ] }, "hae_NumberOfInterestRateSwapsEntered": { "xbrltype": "integerItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "NumberOfInterestRateSwapsEntered", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of interest rate swaps entered", "label": "Number Of Interest Rate Swaps Entered", "documentation": "Number Of Interest Rate Swaps Entered" } } }, "auth_ref": [] }, "hae_NumberOfInterestRateSwapsRemaining": { "xbrltype": "integerItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "NumberOfInterestRateSwapsRemaining", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Interest Rate Swaps Remaining", "label": "Number of Interest Rate Swaps Remaining", "documentation": "Number of Interest Rate Swaps Remaining" } } }, "auth_ref": [] }, "hae_NumberOfInterestRateSwapsTerminated": { "xbrltype": "integerItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "NumberOfInterestRateSwapsTerminated", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number Of Interest Rate Swaps Terminated", "label": "Number Of Interest Rate Swaps Terminated", "documentation": "Number Of Interest Rate Swaps Terminated" } } }, "auth_ref": [] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfReportableSegments", "presentation": [ "http://www.haemonetics.com/role/SEGMENTANDENTERPRISEWIDEINFORMATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of reportable segments", "label": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": [ "r868", "r876", "r1063" ] }, "hae_OfficeEquipmentAndInformationTechnologyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "OfficeEquipmentAndInformationTechnologyMember", "presentation": [ "http://www.haemonetics.com/role/PROPERTYPLANTANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Office equipment and information technology", "label": "Office Equipment and Information Technology [Member]", "documentation": "Office Equipment and Information Technology" } } }, "auth_ref": [] }, "hae_OpSensIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "OpSensIncMember", "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSNarrativeDetails", "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "OpSens, Inc.", "label": "OpSens, Inc. [Member]", "documentation": "OpSens, Inc." } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses:", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "hae_OperatingExpensesTransactionCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "OperatingExpensesTransactionCosts", "crdr": "debit", "presentation": [ "http://www.haemonetics.com/role/SEGMENTANDENTERPRISEWIDEINFORMATIONDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Integration and transaction costs", "label": "Operating Expenses, Transaction Costs", "documentation": "Operating Expenses, Transaction Costs" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME", "http://www.haemonetics.com/role/SEGMENTANDENTERPRISEWIDEINFORMATIONDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Operating income", "terseLabel": "Operating income", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r162", "r867", "r1061", "r1064", "r1066", "r1067", "r1068" ] }, "hae_OperatingLeaseRevenueAsAPercentageOfTotalNetSales": { "xbrltype": "percentItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "OperatingLeaseRevenueAsAPercentageOfTotalNetSales", "presentation": [ "http://www.haemonetics.com/role/LEASESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease, revenue, as a percentage of total net sales", "label": "Operating Lease, Revenue, As A Percentage Of Total Net Sales", "documentation": "Operating Lease, Revenue, As A Percentage Of Total Net Sales" } } }, "auth_ref": [] }, "us-gaap_OperatingSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingSegmentsMember", "presentation": [ "http://www.haemonetics.com/role/SEGMENTANDENTERPRISEWIDEINFORMATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Segments", "label": "Operating Segments [Member]", "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r315", "r316", "r317", "r318", "r319", "r322", "r872", "r873" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://www.haemonetics.com/role/BASISOFPRESENTATION" ], "lang": { "en-us": { "role": { "terseLabel": "BASIS OF PRESENTATION", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r81", "r143", "r704", "r705" ] }, "us-gaap_OtherAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsMember", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSSchedulesofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Assets", "label": "Other Assets [Member]", "documentation": "Primary financial statement caption encompassing other assets." } } }, "auth_ref": [ "r69", "r77" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r227" ] }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "crdr": "credit", "calculation": { "http://www.haemonetics.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.haemonetics.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss) before reclassifications", "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax", "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r24", "r28", "r245", "r584", "r587", "r590", "r666", "r1045" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "crdr": "credit", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofEffectofDerivativeInstrumentsDesignatedasCashFlowHedgesandThoseNotDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amount of Gain (Loss) Recognized in Accumulated Other Comprehensive Loss", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r236", "r237", "r548", "r549", "r553" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.haemonetics.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.haemonetics.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSDetails", "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss)", "totalLabel": "Net current period other comprehensive income (loss)", "label": "Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r16", "r24", "r240", "r243", "r247", "r273", "r584", "r585", "r590", "r649", "r666", "r1045", "r1046" ] }, "hae_OtherCountryorRegionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "OtherCountryorRegionMember", "presentation": [ "http://www.haemonetics.com/role/SEGMENTANDENTERPRISEWIDEINFORMATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Country or Region [Member]", "documentation": "Other Country or Region [Member]" } } }, "auth_ref": [] }, "us-gaap_OtherCurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCurrentAssetsMember", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofInterestRateSwapsDetails", "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSSchedulesofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Current Assets", "label": "Other Current Assets [Member]", "documentation": "Primary financial statement caption encompassing other current assets." } } }, "auth_ref": [ "r69", "r77" ] }, "us-gaap_OtherCurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCurrentLiabilitiesMember", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSSchedulesofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Current Liabilities", "label": "Other Current Liabilities [Member]", "documentation": "Primary financial statement caption encompassing other current liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSNarrativeDetails", "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Other current liabilities", "label": "Other Liabilities, Current", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r85", "r905" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r89" ] }, "us-gaap_OtherNoncurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncurrentAssetsMember", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofInterestRateSwapsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Noncurrent Assets", "label": "Other Noncurrent Assets [Member]", "documentation": "Primary financial statement caption encompassing other noncurrent assets." } } }, "auth_ref": [] }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncurrentLiabilitiesMember", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSSchedulesofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Noncurrent Liabilities", "label": "Other Noncurrent Liabilities [Member]", "documentation": "Primary financial statement caption encompassing other noncurrent liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Interest and other expense, net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r115" ] }, "us-gaap_OtherOperatingActivitiesCashFlowStatement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherOperatingActivitiesCashFlowStatement", "crdr": "debit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Other non-cash operating activities", "label": "Other Operating Activities, Cash Flow Statement", "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities)." } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r984" ] }, "hae_OtherTechnologyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "OtherTechnologyMember", "presentation": [ "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Developed technology", "label": "Other Technology [Member]", "documentation": "Other Technology [Member]" } } }, "auth_ref": [] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r946", "r956", "r966", "r998" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r949", "r959", "r969", "r1001" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r949", "r959", "r969", "r1001" ] }, "us-gaap_PatentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PatentsMember", "presentation": [ "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Patents and other", "label": "Patents [Member]", "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law." } } }, "auth_ref": [ "r141", "r1086", "r1087", "r1088", "r1089", "r1091", "r1093", "r1096", "r1097" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r973" ] }, "us-gaap_PaymentsForLegalSettlements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForLegalSettlements", "crdr": "credit", "presentation": [ "http://www.haemonetics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments for legal settlements", "label": "Payments for Legal Settlements", "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period." } } }, "auth_ref": [ "r8" ] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Share repurchases", "label": "Payments for Repurchase of Common Stock", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": [ "r119" ] }, "us-gaap_PaymentsForRestructuring": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRestructuring", "crdr": "credit", "presentation": [ "http://www.haemonetics.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Payments", "label": "Payments for Restructuring", "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r386", "r1050" ] }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDebtIssuanceCosts", "crdr": "credit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 14.0 } }, "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Debt issuance costs", "label": "Payments of Debt Issuance Costs", "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt." } } }, "auth_ref": [ "r33" ] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cash used to net share settle employee equity awards", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [ "r251" ] }, "us-gaap_PaymentsToAcquireBusinessesGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireBusinessesGross", "crdr": "credit", "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Upfront payment", "label": "Payments to Acquire Businesses, Gross", "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price." } } }, "auth_ref": [ "r31", "r539" ] }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "crdr": "credit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSNarrativeDetails", "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Acquisition, net of cash acquired", "terseLabel": "Payments to acquire businesses, net of cash acquired", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase." } } }, "auth_ref": [ "r31" ] }, "us-gaap_PaymentsToAcquireInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireInvestments", "crdr": "credit", "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSStrategicInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payment to acquire investment", "label": "Payments to Acquire Investments", "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period." } } }, "auth_ref": [ "r117" ] }, "us-gaap_PaymentsToAcquireOtherInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireOtherInvestments", "crdr": "credit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other investing activities", "label": "Payments to Acquire Other Investments", "documentation": "Amount of cash outflow to acquire investments classified as other." } } }, "auth_ref": [ "r117" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Capital expenditures", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r118" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r983" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r983" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r975" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r992" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r985" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r974" ] }, "hae_PercentageOfNetSalesGeneratedOutsideOfUs": { "xbrltype": "percentItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "PercentageOfNetSalesGeneratedOutsideOfUs", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of sales generated outside the US", "label": "Percentage Of Net Sales Generated Outside Of The US", "documentation": "Percentage Of Net Sales Generated Outside Of The US" } } }, "auth_ref": [] }, "hae_PlasmaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "PlasmaMember", "presentation": [ "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofGoodwillDetails", "http://www.haemonetics.com/role/RESTRUCTURINGScheduleofRestructuringandRelatedCostsDetails", "http://www.haemonetics.com/role/SEGMENTANDENTERPRISEWIDEINFORMATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plasma", "label": "Plasma [Member]", "documentation": "Plasma [Member]" } } }, "auth_ref": [] }, "hae_PlasmaProductsandServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "PlasmaProductsandServicesMember", "presentation": [ "http://www.haemonetics.com/role/SEGMENTANDENTERPRISEWIDEINFORMATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plasma", "label": "Plasma Products and Services [Member]", "documentation": "Plasma Products and Services [Member]" } } }, "auth_ref": [] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Prior Service Cost", "label": "Pension Adjustments Prior Service Cost [Member]" } } }, "auth_ref": [ "r976" ] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Service Cost", "label": "Pension Adjustments Service Cost [Member]" } } }, "auth_ref": [ "r1020" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Benefits Adjustments, Footnote", "label": "Pension Benefits Adjustments, Footnote [Text Block]" } } }, "auth_ref": [ "r975" ] }, "hae_PortfolioRationalizationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "PortfolioRationalizationMember", "presentation": [ "http://www.haemonetics.com/role/RESTRUCTURINGNarrativeDetails", "http://www.haemonetics.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Portfolio Rationalization", "label": "Portfolio Rationalization [Member]", "documentation": "Portfolio Rationalization" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSNarrativeDetails", "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1044" ] }, "us-gaap_ProceedsFromConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromConvertibleDebt", "crdr": "debit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of convertible notes", "label": "Proceeds from Convertible Debt", "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": [ "r32" ] }, "us-gaap_ProceedsFromDivestitureOfBusinesses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromDivestitureOfBusinesses", "crdr": "debit", "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from divestiture", "label": "Proceeds from Divestiture of Businesses", "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period." } } }, "auth_ref": [ "r30" ] }, "us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromDivestitureOfBusinessesNetOfCashDivested", "crdr": "debit", "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds, net of cash transferred", "label": "Proceeds from Divestiture of Businesses, Net of Cash Divested", "documentation": "This element represents the cash inflow during the period from the sale of a component of the entity." } } }, "auth_ref": [ "r30" ] }, "hae_ProceedsFromIssuanceOfLongTermDebtExcludingLineOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "ProceedsFromIssuanceOfLongTermDebtExcludingLineOfCredit", "crdr": "debit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Term loan borrowings", "label": "Proceeds From Issuance Of Long-Term Debt, Excluding Line Of Credit", "documentation": "Proceeds From Issuance Of Long-Term Debt, Excluding Line Of Credit" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromLongTermLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromLongTermLinesOfCredit", "crdr": "debit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from revolving facility", "label": "Proceeds from Long-Term Lines of Credit", "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer." } } }, "auth_ref": [ "r32" ] }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "crdr": "debit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Other financing activities", "label": "Proceeds from (Payments for) Other Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities classified as other." } } }, "auth_ref": [ "r1027", "r1049" ] }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.haemonetics.com/role/PROPERTYPLANTANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of property, plant and equipment", "label": "Proceeds from Sale of Property, Plant, and Equipment", "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r116" ] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from exercise of stock options", "label": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r7", "r18" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.haemonetics.com/role/SEGMENTANDENTERPRISEWIDEINFORMATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]", "documentation": "Information by product and service, or group of similar products and similar services." } } }, "auth_ref": [ "r184", "r185", "r186", "r187", "r188", "r189", "r209", "r324", "r612", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r856", "r887", "r914", "r915", "r916", "r919", "r921", "r1043", "r1107", "r1108", "r1114", "r1158", "r1162", "r1163", "r1164", "r1165", "r1166", "r1167", "r1168", "r1169", "r1170", "r1171", "r1172", "r1173", "r1174", "r1175", "r1176", "r1177", "r1178", "r1179", "r1180", "r1181", "r1182", "r1183", "r1184", "r1185", "r1186", "r1187", "r1188", "r1189" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.haemonetics.com/role/SEGMENTANDENTERPRISEWIDEINFORMATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]", "documentation": "Product or service, or a group of similar products or similar services." } } }, "auth_ref": [ "r184", "r185", "r186", "r187", "r188", "r189", "r209", "r324", "r612", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r856", "r887", "r914", "r915", "r916", "r919", "r921", "r1043", "r1107", "r1108", "r1114", "r1158", "r1162", "r1163", "r1164", "r1165", "r1166", "r1167", "r1168", "r1169", "r1170", "r1171", "r1172", "r1173", "r1174", "r1175", "r1176", "r1177", "r1178", "r1179", "r1180", "r1181", "r1182", "r1183", "r1184", "r1185", "r1186", "r1187", "r1188", "r1189" ] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Abstract]", "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.haemonetics.com/role/PROPERTYPLANTANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r12", "r599" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://www.haemonetics.com/role/PROPERTYPLANTANDEQUIPMENT" ], "lang": { "en-us": { "role": { "terseLabel": "PROPERTY, PLANT AND EQUIPMENT", "label": "Property, Plant and Equipment Disclosure [Text Block]", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r126", "r165", "r168", "r169" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "presentation": [ "http://www.haemonetics.com/role/PROPERTYPLANTANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r127", "r223", "r663" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://www.haemonetics.com/role/PROPERTYPLANTANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Line Items]", "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r599" ] }, "us-gaap_PropertyPlantAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentMember", "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment", "label": "Property, Plant and Equipment [Member]", "documentation": "Physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSNarrativeDetails", "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.haemonetics.com/role/PROPERTYPLANTANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment, net", "negatedTerseLabel": "Property, plant and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r12", "r599", "r653", "r663", "r905" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://www.haemonetics.com/role/PROPERTYPLANTANDEQUIPMENTTables" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r12" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.haemonetics.com/role/PROPERTYPLANTANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r127", "r599" ] }, "us-gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSAllowanceforCreditLossesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Credit loss", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } } }, "auth_ref": [ "r250", "r344" ] }, "hae_PurchaseOfCappedCallRelatedToConvertibleNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "PurchaseOfCappedCallRelatedToConvertibleNotes", "crdr": "credit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 12.0 } }, "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchase of capped call related to convertible notes", "terseLabel": "Purchase of capped call related to convertible notes", "label": "Purchase Of Capped Call Related To Convertible Notes", "documentation": "Purchase Of Capped Call Related To Convertible Notes" } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r973" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r973" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails", "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]", "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r175", "r177", "r179", "r180", "r182", "r211", "r212", "r397", "r398", "r399", "r400", "r475", "r482", "r506", "r507", "r508", "r510", "r573", "r609", "r610", "r611", "r689", "r691", "r703", "r717", "r718", "r771", "r790", "r795", "r796", "r829", "r852", "r853", "r877", "r886", "r894", "r900", "r901", "r902", "r903", "r915", "r925", "r1103", "r1111", "r1129", "r1150", "r1151", "r1152", "r1153", "r1154" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails", "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]", "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r175", "r177", "r179", "r180", "r182", "r211", "r212", "r397", "r398", "r399", "r400", "r475", "r482", "r506", "r507", "r508", "r510", "r573", "r609", "r610", "r611", "r689", "r691", "r703", "r717", "r718", "r771", "r790", "r795", "r796", "r829", "r852", "r853", "r877", "r886", "r894", "r900", "r901", "r902", "r903", "r915", "r925", "r1103", "r1111", "r1129", "r1150", "r1151", "r1152", "r1153", "r1154" ] }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "crdr": "debit", "calculation": { "http://www.haemonetics.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.haemonetics.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Amounts reclassified from Accumulated Other Comprehensive Income (Loss)", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r24", "r28", "r245", "r584", "r589", "r590", "r666", "r1045" ] }, "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock", "presentation": [ "http://www.haemonetics.com/role/SEGMENTANDENTERPRISEWIDEINFORMATIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Revenues by Business Unit and Geographic Regions", "label": "Reconciliation of Revenue from Segments to Consolidated [Table Text Block]", "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues." } } }, "auth_ref": [ "r38", "r39" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r941", "r951", "r961", "r993" ] }, "hae_RegulatoryBasedPaymentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "RegulatoryBasedPaymentMember", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSSchedulesofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Regulatory-based payment", "label": "Regulatory-based payment [Member]", "documentation": "Regulatory-based payment" } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfLongTermDebt", "crdr": "credit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Repayment of term loan borrowings", "terseLabel": "Repayments of long-term debt", "label": "Repayments of Long-Term Debt", "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r120", "r708" ] }, "us-gaap_RepaymentsOfLongTermLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfLongTermLinesOfCredit", "crdr": "credit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Payments on revolving facility", "label": "Repayments of Long-Term Lines of Credit", "documentation": "The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer." } } }, "auth_ref": [ "r120" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r511", "r854", "r872", "r1155" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.haemonetics.com/role/RESTRUCTURINGScheduleofRestructuringandRelatedCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "srt_RestatementAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RestatementAdjustmentMember", "presentation": [ "http://www.haemonetics.com/role/PROPERTYPLANTANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revision of Prior Period, Adjustment", "label": "Revision of Prior Period, Adjustment [Member]", "documentation": "Cumulative increase (decrease) for adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision." } } }, "auth_ref": [ "r259", "r260", "r261", "r275", "r276", "r292", "r565", "r566", "r596", "r1028", "r1029", "r1030", "r1031", "r1033", "r1034", "r1035", "r1069" ] }, "srt_RestatementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RestatementAxis", "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSNarrativeDetails", "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails", "http://www.haemonetics.com/role/PROPERTYPLANTANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revision of Prior Period [Axis]", "label": "Revision of Prior Period [Axis]", "documentation": "Information by adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision." } } }, "auth_ref": [ "r210", "r214", "r259", "r260", "r261", "r264", "r265", "r268", "r269", "r270", "r271", "r274", "r275", "r276", "r277", "r278", "r279", "r292", "r339", "r340", "r531", "r532", "r535", "r536", "r541", "r542", "r563", "r565", "r566", "r567", "r594", "r596", "r601", "r602", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r706", "r1069" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r942", "r952", "r962", "r994" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r943", "r953", "r963", "r995" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r950", "r960", "r970", "r1002" ] }, "srt_RestatementDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RestatementDomain", "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSNarrativeDetails", "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails", "http://www.haemonetics.com/role/PROPERTYPLANTANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revision of Prior Period [Domain]", "label": "Revision of Prior Period [Domain]", "documentation": "Adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision." } } }, "auth_ref": [ "r210", "r214", "r259", "r260", "r261", "r264", "r265", "r268", "r269", "r270", "r271", "r274", "r275", "r276", "r277", "r278", "r279", "r292", "r339", "r340", "r531", "r532", "r535", "r536", "r541", "r542", "r563", "r565", "r566", "r567", "r594", "r596", "r601", "r602", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r706", "r1069" ] }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedActivitiesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Restructuring and Related Activities [Abstract]", "label": "Restructuring and Related Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "presentation": [ "http://www.haemonetics.com/role/RESTRUCTURING" ], "lang": { "en-us": { "role": { "terseLabel": "RESTRUCTURING", "label": "Restructuring and Related Activities Disclosure [Text Block]", "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled." } } }, "auth_ref": [ "r383", "r384", "r386", "r389", "r394" ] }, "us-gaap_RestructuringAndRelatedCostCostIncurredToDate1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedCostCostIncurredToDate1", "crdr": "debit", "presentation": [ "http://www.haemonetics.com/role/RESTRUCTURINGNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cumulative costs to date", "label": "Restructuring and Related Cost, Cost Incurred to Date", "documentation": "Amount of costs incurred to date for the specified restructuring cost." } } }, "auth_ref": [ "r385", "r388", "r391", "r393" ] }, "us-gaap_RestructuringAndRelatedCostExpectedCost1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedCostExpectedCost1", "crdr": "debit", "presentation": [ "http://www.haemonetics.com/role/RESTRUCTURINGNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected cost", "label": "Restructuring and Related Cost, Expected Cost", "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost." } } }, "auth_ref": [ "r385", "r388", "r391", "r393" ] }, "us-gaap_RestructuringAndRelatedCostIncurredCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedCostIncurredCost", "crdr": "debit", "presentation": [ "http://www.haemonetics.com/role/RESTRUCTURINGNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring and related cost, incurred cost", "label": "Restructuring and Related Cost, Incurred Cost", "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost." } } }, "auth_ref": [ "r385", "r388", "r391", "r393" ] }, "us-gaap_RestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCharges", "crdr": "debit", "presentation": [ "http://www.haemonetics.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails", "http://www.haemonetics.com/role/RESTRUCTURINGScheduleofRestructuringandRelatedCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Costs incurred, net of reversals", "verboseLabel": "Restructuring costs", "label": "Restructuring Charges", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r10", "r390", "r391", "r1104" ] }, "us-gaap_RestructuringCostAndReserveLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCostAndReserveLineItems", "presentation": [ "http://www.haemonetics.com/role/RESTRUCTURINGNarrativeDetails", "http://www.haemonetics.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails", "http://www.haemonetics.com/role/RESTRUCTURINGScheduleofRestructuringandRelatedCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Cost and Reserve [Line Items]", "label": "Restructuring Cost and Reserve [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r385", "r386", "r387", "r388", "r391", "r392", "r393" ] }, "us-gaap_RestructuringCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCosts", "crdr": "debit", "presentation": [ "http://www.haemonetics.com/role/SEGMENTANDENTERPRISEWIDEINFORMATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring costs", "label": "Restructuring Costs", "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r10" ] }, "us-gaap_RestructuringPlanAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringPlanAxis", "presentation": [ "http://www.haemonetics.com/role/RESTRUCTURINGNarrativeDetails", "http://www.haemonetics.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Plan [Axis]", "label": "Restructuring Plan [Axis]", "documentation": "Information by individual restructuring plan." } } }, "auth_ref": [] }, "us-gaap_RestructuringPlanDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringPlanDomain", "presentation": [ "http://www.haemonetics.com/role/RESTRUCTURINGNarrativeDetails", "http://www.haemonetics.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Plan [Domain]", "label": "Restructuring Plan [Domain]", "documentation": "Identification of the individual restructuring plans." } } }, "auth_ref": [] }, "hae_RestructuringRelatedCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "RestructuringRelatedCosts", "crdr": "debit", "presentation": [ "http://www.haemonetics.com/role/RESTRUCTURINGScheduleofRestructuringandRelatedCostsDetails", "http://www.haemonetics.com/role/SEGMENTANDENTERPRISEWIDEINFORMATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring related costs", "label": "Restructuring Related Costs", "documentation": "Restructuring Related Costs" } } }, "auth_ref": [] }, "us-gaap_RestructuringReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserve", "crdr": "credit", "presentation": [ "http://www.haemonetics.com/role/RESTRUCTURINGNarrativeDetails", "http://www.haemonetics.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring liability", "periodStartLabel": "Balance at March\u00a030, 2024", "periodEndLabel": "Balance at December\u00a028, 2024", "label": "Restructuring Reserve", "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan." } } }, "auth_ref": [ "r386", "r392" ] }, "us-gaap_RestructuringReserveAccrualAdjustment1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserveAccrualAdjustment1", "crdr": "debit", "presentation": [ "http://www.haemonetics.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Reserve, Accrual Adjustment", "label": "Restructuring Reserve, Accrual Adjustment", "documentation": "Amount of expense (reversal of expense) which increases (decreases) the restructuring reserve from an adjustment to a previously accrued restructuring liability." } } }, "auth_ref": [ "r386", "r392" ] }, "us-gaap_RestructuringReserveRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserveRollForward", "presentation": [ "http://www.haemonetics.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Reserve [Roll Forward]", "label": "Restructuring Reserve [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "hae_RestructuringandRestructuringRelatedCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "RestructuringandRestructuringRelatedCosts", "crdr": "debit", "presentation": [ "http://www.haemonetics.com/role/RESTRUCTURINGNarrativeDetails", "http://www.haemonetics.com/role/RESTRUCTURINGScheduleofRestructuringandRelatedCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring and Restructuring Related Costs", "label": "Restructuring and Restructuring Related Costs", "documentation": "Restructuring and Restructuring Related Costs" } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Retained earnings", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r93", "r138", "r660", "r697", "r702", "r709", "r726", "r905" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Retained Earnings", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r213", "r259", "r260", "r261", "r265", "r273", "r276", "r278", "r336", "r341", "r374", "r522", "r523", "r530", "r531", "r532", "r536", "r541", "r542", "r554", "r556", "r557", "r560", "r565", "r595", "r598", "r693", "r695", "r711", "r1191" ] }, "hae_RevenueBasedPaymentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "RevenueBasedPaymentMember", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSSchedulesofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue-based payment", "label": "Revenue-based payment [Member]", "documentation": "Revenue-based payment" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "terseLabel": "Revenue from Contract with Customer [Abstract]", "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME", "http://www.haemonetics.com/role/SEGMENTANDENTERPRISEWIDEINFORMATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net revenues", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r160", "r161", "r293", "r300", "r301", "r315", "r321", "r324", "r326", "r328", "r470", "r471", "r612" ] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://www.haemonetics.com/role/REVENUE" ], "lang": { "en-us": { "role": { "terseLabel": "REVENUE", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r173", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r474" ] }, "us-gaap_RevenueRemainingPerformanceObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligation", "crdr": "credit", "presentation": [ "http://www.haemonetics.com/role/REVENUEDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Performance obligation amount", "label": "Revenue, Remaining Performance Obligation, Amount", "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue." } } }, "auth_ref": [ "r166" ] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems", "presentation": [ "http://www.haemonetics.com/role/REVENUEDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "presentation": [ "http://www.haemonetics.com/role/REVENUEDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected timing of satisfaction", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period", "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r167" ] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis", "presentation": [ "http://www.haemonetics.com/role/REVENUEDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]", "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format." } } }, "auth_ref": [ "r167" ] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable", "presentation": [ "http://www.haemonetics.com/role/REVENUEDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]", "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation." } } }, "auth_ref": [] }, "us-gaap_RevenueRemainingPerformanceObligationPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligationPercentage", "presentation": [ "http://www.haemonetics.com/role/REVENUEDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Performance obligation percent", "label": "Revenue, Remaining Performance Obligation, Percentage", "documentation": "Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue." } } }, "auth_ref": [ "r1032" ] }, "hae_RevisedCreditAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "RevisedCreditAgreementMember", "presentation": [ "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revised Credit Agreement", "label": "Revised Credit Agreement [Member]", "documentation": "Revised Credit Agreement" } } }, "auth_ref": [] }, "srt_RevisionOfPriorPeriodReclassificationAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RevisionOfPriorPeriodReclassificationAdjustmentMember", "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSNarrativeDetails", "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revision of Prior Period, Reclassification, Adjustment", "label": "Revision of Prior Period, Reclassification, Adjustment [Member]", "documentation": "Cumulative increase (decrease) to previously issued financial statements for reclassification. Excludes adjustment for reclassification from amendment to accounting standards." } } }, "auth_ref": [ "r216", "r1069" ] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevolvingCreditFacilityMember", "presentation": [ "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTNarrativeDetails", "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolving credit facility", "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r1011" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r1011" ] }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": [ "http://www.haemonetics.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss)", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r28", "r1142", "r1143" ] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSNarrativeDetails", "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability." } } }, "auth_ref": [ "r56", "r57", "r537" ] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Business Acquisitions, by Acquisition", "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]", "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts." } } }, "auth_ref": [ "r56", "r57" ] }, "us-gaap_ScheduleOfDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDebtTableTextBlock", "presentation": [ "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Debt", "label": "Schedule of Debt [Table Text Block]", "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Effect of Derivative Instruments Designated as Cash Flow Hedges and Those Not Designated as Hedging Instruments", "label": "Derivative Instruments, Gain (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments." } } }, "auth_ref": [ "r70", "r73", "r552" ] }, "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value of Derivative Instruments as They Appear in Consolidated Balance Sheets", "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]", "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position." } } }, "auth_ref": [ "r71" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://www.haemonetics.com/role/EARNINGSPERSHARETables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Earnings Per Share Reconciliation", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r1060" ] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSStrategicInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Axis]", "label": "Investment, Name [Axis]", "documentation": "Information by name of investment including named security. Excludes entity that is consolidated." } } }, "auth_ref": [ "r332", "r333", "r334", "r529", "r1023", "r1024", "r1025", "r1119", "r1120", "r1121", "r1122" ] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r1126", "r1127" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock", "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination", "label": "Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]", "documentation": "Tabular disclosure of finite-lived intangible assets acquired as part of a business combination or through an asset purchase, by major class and in total, including the value of the asset acquired, any significant residual value (the expected value of the asset at the end of its useful life) and the weighted-average amortization period." } } }, "auth_ref": [ "r41" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": [ "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails", "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]", "label": "Intangible Asset, Finite-Lived [Table]", "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset." } } }, "auth_ref": [ "r360", "r367", "r371", "r372", "r373", "r613", "r854", "r879" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-Lived Intangible Assets", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": [ "r879", "r1092" ] }, "us-gaap_ScheduleOfGoodwillTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGoodwillTable", "presentation": [ "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Goodwill [Table]", "label": "Goodwill [Table]", "documentation": "Disclosure of information about goodwill, including, but not limited to, change from acquisition, sale, impairment, and other reason." } } }, "auth_ref": [ "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r878" ] }, "us-gaap_ScheduleOfGoodwillTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGoodwillTextBlock", "presentation": [ "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Goodwill", "label": "Schedule of Goodwill [Table Text Block]", "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule." } } }, "auth_ref": [ "r878", "r1074", "r1075", "r1076", "r1077", "r1078", "r1079", "r1080", "r1081", "r1082", "r1083", "r1084" ] }, "us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInterestRateDerivativesTableTextBlock", "presentation": [ "http://www.haemonetics.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Interest Rate Swaps", "label": "Schedule of Interest Rate Derivatives [Table Text Block]", "documentation": "Tabular disclosure of interest rate derivatives, including, but not limited to, the fair value of the derivatives, statement of financial position location, and statement of financial performance location of these instruments." } } }, "auth_ref": [ "r73" ] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://www.haemonetics.com/role/INVENTORIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Inventories", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r26", "r97", "r98", "r99" ] }, "us-gaap_ScheduleOfInvestmentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInvestmentsLineItems", "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSStrategicInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Investments [Line Items]", "label": "Schedule of Investments [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838" ] }, "us-gaap_ScheduleOfInvestmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInvestmentsTable", "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSStrategicInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Investments [Table]", "label": "Schedule of Investments [Table]", "documentation": "Disclosure of information about investments owned by investment company." } } }, "auth_ref": [ "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r820", "r821", "r822", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838" ] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": [ "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Maturities of Long-Term Debt", "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": [ "r13" ] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://www.haemonetics.com/role/PROPERTYPLANTANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Table]", "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r12", "r599" ] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "presentation": [ "http://www.haemonetics.com/role/RESTRUCTURINGNarrativeDetails", "http://www.haemonetics.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails", "http://www.haemonetics.com/role/RESTRUCTURINGScheduleofRestructuringandRelatedCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restructuring and Related Costs [Table]", "label": "Restructuring Cost [Table]", "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve." } } }, "auth_ref": [ "r385", "r386", "r387", "r388", "r391", "r392", "r393" ] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "presentation": [ "http://www.haemonetics.com/role/RESTRUCTURINGTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restructuring and Related Costs", "label": "Restructuring and Related Costs [Table Text Block]", "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets." } } }, "auth_ref": [ "r45", "r128", "r129" ] }, "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "presentation": [ "http://www.haemonetics.com/role/RESTRUCTURINGTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restructuring Reserve by Type of Cost", "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]", "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period." } } }, "auth_ref": [ "r46", "r130" ] }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "presentation": [ "http://www.haemonetics.com/role/SEGMENTANDENTERPRISEWIDEINFORMATIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Selected Information by Business Segment", "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]", "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries." } } }, "auth_ref": [ "r40", "r105" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": [ "http://www.haemonetics.com/role/SEGMENTANDENTERPRISEWIDEINFORMATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment." } } }, "auth_ref": [ "r35", "r36", "r37" ] }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": [ "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }, "auth_ref": [ "r879", "r1094" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://www.haemonetics.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r936" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://www.haemonetics.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r938" ] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDomain", "presentation": [ "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails", "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails", "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofGoodwillDetails", "http://www.haemonetics.com/role/RESTRUCTURINGScheduleofRestructuringandRelatedCostsDetails", "http://www.haemonetics.com/role/SEGMENTANDENTERPRISEWIDEINFORMATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Domain]", "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r160", "r161", "r162", "r163", "r293", "r296", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r321", "r322", "r323", "r328", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r373", "r388", "r393", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r869", "r872", "r873", "r878", "r918", "r1158", "r1162", "r1163", "r1164", "r1165", "r1166", "r1167", "r1168", "r1169", "r1170", "r1171", "r1172", "r1173", "r1174", "r1175", "r1176", "r1177", "r1178", "r1179", "r1180", "r1181", "r1182", "r1183", "r1184", "r1185", "r1186", "r1187", "r1188", "r1189" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.haemonetics.com/role/SEGMENTANDENTERPRISEWIDEINFORMATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]", "documentation": "Geographical area." } } }, "auth_ref": [ "r176", "r178", "r181", "r183", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r326", "r327", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r713", "r714", "r715", "r777", "r791", "r812", "r835", "r841", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r857", "r888", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r917", "r925", "r1114", "r1158", "r1162", "r1163", "r1165", "r1166", "r1167", "r1168", "r1169", "r1170", "r1171", "r1172", "r1173", "r1174", "r1175", "r1176", "r1177", "r1178", "r1179", "r1180", "r1181", "r1182", "r1183", "r1184", "r1185", "r1186", "r1187", "r1188", "r1189" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting [Abstract]", "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://www.haemonetics.com/role/SEGMENTANDENTERPRISEWIDEINFORMATION" ], "lang": { "en-us": { "role": { "terseLabel": "SEGMENT AND ENTERPRISE-WIDE INFORMATION", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r163", "r293", "r295", "r296", "r297", "r298", "r299", "r311", "r313", "r314", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r328", "r868", "r870", "r871", "r872", "r874", "r875", "r876" ] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingInformationLineItems", "presentation": [ "http://www.haemonetics.com/role/SEGMENTANDENTERPRISEWIDEINFORMATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting Information [Line Items]", "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r111" ] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSNarrativeDetails", "http://www.haemonetics.com/role/RESTRUCTURINGScheduleofRestructuringandRelatedCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative expenses", "label": "Selling, General and Administrative Expenses [Member]", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation expense", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r9" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Award Types", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509" ] }, "srt_ShareRepurchaseProgramAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ShareRepurchaseProgramAxis", "presentation": [ "http://www.haemonetics.com/role/EARNINGSPERSHAREShareRepurchaseProgramDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share Repurchase Program [Axis]", "label": "Share Repurchase Program [Axis]", "documentation": "Information by share repurchase program." } } }, "auth_ref": [ "r1113" ] }, "srt_ShareRepurchaseProgramDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ShareRepurchaseProgramDomain", "presentation": [ "http://www.haemonetics.com/role/EARNINGSPERSHAREShareRepurchaseProgramDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share Repurchase Program [Domain]", "label": "Share Repurchase Program [Domain]", "documentation": "Name of share repurchase program." } } }, "auth_ref": [ "r1113" ] }, "srt_ShareRepurchaseProgramLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ShareRepurchaseProgramLineItems", "presentation": [ "http://www.haemonetics.com/role/EARNINGSPERSHAREShareRepurchaseProgramDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share Repurchase Program [Line Items]", "label": "Share Repurchase Program [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r1113" ] }, "srt_ShareRepurchaseProgramTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ShareRepurchaseProgramTable", "presentation": [ "http://www.haemonetics.com/role/EARNINGSPERSHAREShareRepurchaseProgramDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share Repurchase Program [Table]", "label": "Share Repurchase Program [Table]", "documentation": "Disclosure of information about share repurchase program." } } }, "auth_ref": [ "r1113" ] }, "us-gaap_SharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssued", "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance (in shares)", "periodEndLabel": "Balance (in shares)", "label": "Shares, Issued", "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury." } } }, "auth_ref": [ "r16" ] }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Tax withholding on employee equity awards (in shares)", "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails", "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails", "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofGoodwillDetails", "http://www.haemonetics.com/role/RESTRUCTURINGScheduleofRestructuringandRelatedCostsDetails", "http://www.haemonetics.com/role/SEGMENTANDENTERPRISEWIDEINFORMATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Axis]", "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r160", "r161", "r162", "r163", "r217", "r293", "r296", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r321", "r322", "r323", "r328", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r373", "r376", "r388", "r393", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r869", "r872", "r873", "r878", "r918", "r1158", "r1162", "r1163", "r1164", "r1165", "r1166", "r1167", "r1168", "r1169", "r1170", "r1171", "r1172", "r1173", "r1174", "r1175", "r1176", "r1177", "r1178", "r1179", "r1180", "r1181", "r1182", "r1183", "r1184", "r1185", "r1186", "r1187", "r1188", "r1189" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.haemonetics.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSDetails", "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r16", "r91", "r94", "r95", "r213", "r244", "r245", "r246", "r259", "r260", "r261", "r265", "r273", "r276", "r278", "r294", "r336", "r341", "r374", "r459", "r522", "r523", "r530", "r531", "r532", "r536", "r541", "r542", "r554", "r555", "r556", "r557", "r558", "r560", "r565", "r584", "r586", "r587", "r588", "r589", "r590", "r595", "r598", "r602", "r666", "r693", "r694", "r695", "r711", "r763" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.haemonetics.com/role/SEGMENTANDENTERPRISEWIDEINFORMATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]", "documentation": "Information by geographical components." } } }, "auth_ref": [ "r176", "r178", "r181", "r183", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r326", "r327", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r713", "r714", "r715", "r777", "r791", "r812", "r835", "r841", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r857", "r888", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r917", "r925", "r1114", "r1158", "r1162", "r1163", "r1165", "r1166", "r1167", "r1168", "r1169", "r1170", "r1171", "r1172", "r1173", "r1174", "r1175", "r1176", "r1177", "r1178", "r1179", "r1180", "r1181", "r1182", "r1183", "r1184", "r1185", "r1186", "r1187", "r1188", "r1189" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r259", "r260", "r261", "r294", "r598", "r612", "r707", "r712", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r738", "r739", "r740", "r741", "r742", "r744", "r746", "r747", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r763", "r926" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r259", "r260", "r261", "r294", "r330", "r598", "r612", "r707", "r712", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r738", "r739", "r740", "r741", "r742", "r744", "r746", "r747", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r763", "r926" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r945", "r955", "r965", "r997" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "hae_StockCompensationWindfallsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "StockCompensationWindfallsMember", "presentation": [ "http://www.haemonetics.com/role/INCOMETAXESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Compensation Windfalls", "label": "Stock Compensation Windfalls [Member]", "documentation": "Stock Compensation Windfalls" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Employee stock purchase plan (in shares)", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": [ "r16", "r90", "r91", "r138" ] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of restricted stock, net of cancellations (in shares)", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited." } } }, "auth_ref": [ "r16", "r90", "r91", "r138" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of stock options (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r16", "r90", "r91", "r138", "r492" ] }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "crdr": "credit", "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Employee stock purchase plan", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan." } } }, "auth_ref": [ "r16", "r90", "r91", "r138" ] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "crdr": "credit", "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of restricted stock, net of cancellations", "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited." } } }, "auth_ref": [ "r16", "r138" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of stock options", "label": "Stock Issued During Period, Value, Stock Options Exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r16", "r91", "r94", "r95", "r138" ] }, "srt_StockRepurchaseProgramAuthorizedAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StockRepurchaseProgramAuthorizedAmount1", "crdr": "credit", "presentation": [ "http://www.haemonetics.com/role/EARNINGSPERSHAREShareRepurchaseProgramDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share repurchase plan, authorized amount", "label": "Share Repurchase Program, Authorized, Amount", "documentation": "Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership." } } }, "auth_ref": [ "r1113" ] }, "us-gaap_StockRepurchaseProgramPeriodInForce1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchaseProgramPeriodInForce1", "presentation": [ "http://www.haemonetics.com/role/EARNINGSPERSHAREShareRepurchaseProgramDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share repurchase program, period in force", "label": "Share Repurchase Program, Period in Force", "documentation": "Period share may be purchased under authorized share repurchase plan, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, repurchase of stock and unit of ownership." } } }, "auth_ref": [] }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "crdr": "credit", "presentation": [ "http://www.haemonetics.com/role/EARNINGSPERSHAREShareRepurchaseProgramDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining authorized amount", "label": "Share Repurchase Program, Remaining Authorized, Amount", "documentation": "Amount remaining authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership." } } }, "auth_ref": [] }, "us-gaap_StockRepurchasedDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchasedDuringPeriodShares", "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.haemonetics.com/role/EARNINGSPERSHAREShareRepurchaseProgramDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Shares repurchased (in shares)", "terseLabel": "Shares repurchased (in shares)", "label": "Stock Repurchased During Period, Shares", "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": [ "r16", "r90", "r91", "r138", "r708", "r763", "r839" ] }, "us-gaap_StockRepurchasedDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchasedDuringPeriodValue", "crdr": "debit", "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Shares repurchased", "label": "Stock Repurchased During Period, Value", "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": [ "r16", "r90", "r91", "r138", "r711", "r763", "r839", "r934" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r91", "r94", "r95", "r124", "r727", "r743", "r764", "r765", "r905", "r935", "r1053", "r1071", "r1141", "r1191" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders\u2019 equity:", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteAbstract", "lang": { "en-us": { "role": { "terseLabel": "Stockholders' Equity Note [Abstract]", "label": "Stockholders' Equity Note [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.haemonetics.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "ACCUMULATED OTHER COMPREHENSIVE LOSS", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r135", "r255", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r562", "r766", "r767", "r840" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r591", "r605" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Axis]", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r591", "r605" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Domain]", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r591", "r605" ] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r991" ] }, "us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxAdjustmentsSettlementsAndUnusualProvisions", "crdr": "debit", "presentation": [ "http://www.haemonetics.com/role/INCOMETAXESDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Discrete tax benefit (expense)", "label": "Tax Adjustments, Settlements, and Unusual Provisions", "documentation": "Amount of increase (decrease) to previously recorded tax expense. Includes, but is not limited to, significant settlements of income tax disputes, and unusual tax positions or infrequent actions taken by the entity, including tax assessment reversal, and IRS tax settlement." } } }, "auth_ref": [ "r1118" ] }, "us-gaap_TechnologyBasedIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TechnologyBasedIntangibleAssetsMember", "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSPurchasePriceAllocationDetails", "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Developed technology", "label": "Technology-Based Intangible Assets [Member]", "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights." } } }, "auth_ref": [ "r23", "r1086", "r1087", "r1088", "r1089", "r1091", "r1093", "r1096", "r1097" ] }, "us-gaap_TextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TextBlockAbstract", "lang": { "en-us": { "role": { "label": "Text Block [Abstract]" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r983" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r990" ] }, "us-gaap_TradeNamesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TradeNamesMember", "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSPurchasePriceAllocationDetails", "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails", "http://www.haemonetics.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade names", "verboseLabel": "Trade names", "label": "Trade Names [Member]", "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof." } } }, "auth_ref": [ "r60", "r1086", "r1087", "r1088", "r1089", "r1090", "r1091", "r1093", "r1095", "r1096", "r1097" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r1010" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r1012" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://www.haemonetics.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "hae_TransfersFromInventoryToFixedAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "TransfersFromInventoryToFixedAssets", "crdr": "debit", "calculation": { "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash transfers from inventory to property, plant and equipment for Haemonetics equipment", "label": "Transfers from Inventory to Fixed Assets", "documentation": "Transfers from inventory to fixed assets." } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r1013" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r1014" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Expiration Date", "label": "Trading Arrangement Expiration Date" } } }, "auth_ref": [ "r1014" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r1012" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r1012" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r1015" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r1013" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "US", "presentation": [ "http://www.haemonetics.com/role/SEGMENTANDENTERPRISEWIDEINFORMATIONDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "United States", "label": "UNITED STATES" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r1009" ] }, "us-gaap_UnsecuredDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnsecuredDebtMember", "presentation": [ "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unsecured Debt", "label": "Unsecured Debt [Member]", "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets." } } }, "auth_ref": [] }, "hae_VivasureMedicalLTDMember": { "xbrltype": "domainItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "VivasureMedicalLTDMember", "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSStrategicInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vivasure Medical LTD", "label": "Vivasure Medical LTD [Member]", "documentation": "Vivasure Medical LTD" } } }, "auth_ref": [] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year", "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]" } } }, "auth_ref": [ "r979" ] }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "calculation": { "http://www.haemonetics.com/role/EARNINGSPERSHAREScheduleofEarningsPerShareReconciliationDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.haemonetics.com/role/EARNINGSPERSHAREScheduleofEarningsPerShareReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net effect of common stock equivalents (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment", "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation." } } }, "auth_ref": [ "r1060" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://www.haemonetics.com/role/EARNINGSPERSHAREScheduleofEarningsPerShareReconciliationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME", "http://www.haemonetics.com/role/EARNINGSPERSHAREScheduleofEarningsPerShareReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in shares)", "totalLabel": "Diluted weighted average shares (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r283", "r288" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average shares outstanding", "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://www.haemonetics.com/role/EARNINGSPERSHAREScheduleofEarningsPerShareReconciliationDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.haemonetics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME", "http://www.haemonetics.com/role/EARNINGSPERSHAREScheduleofEarningsPerShareReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (in shares)", "verboseLabel": "Weighted average shares (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r282", "r288" ] }, "hae_WholeBloodBloodCenterMember": { "xbrltype": "domainItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "WholeBloodBloodCenterMember", "presentation": [ "http://www.haemonetics.com/role/SEGMENTANDENTERPRISEWIDEINFORMATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Whole Blood", "label": "Whole Blood, Blood Center [Member]", "documentation": "Whole Blood, Blood Center" } } }, "auth_ref": [] }, "hae_WholeBloodBusinessMember": { "xbrltype": "domainItemType", "nsuri": "http://www.haemonetics.com/20241228", "localname": "WholeBloodBusinessMember", "presentation": [ "http://www.haemonetics.com/role/ACQUISITIONSDIVESTITURESANDSTRATEGICINVESTMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Whole Blood Business", "label": "Whole Blood Business [Member]", "documentation": "Whole Blood Business" } } }, "auth_ref": [] }, "us-gaap_WriteOffOfDeferredDebtIssuanceCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WriteOffOfDeferredDebtIssuanceCost", "crdr": "debit", "presentation": [ "http://www.haemonetics.com/role/NOTESPAYABLEANDLONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred debt issuance cost, writeoff", "label": "Deferred Debt Issuance Cost, Writeoff", "documentation": "Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt." } } }, "auth_ref": [ "r113" ] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested", "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]" } } }, "auth_ref": [ "r977" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "16", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-16" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(j)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(k)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-14" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480463/815-10-45-5" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "SubTopic": "10", "Topic": "280", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-4" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(c)(2)", "SubTopic": "20", "Topic": "860", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4D" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13", "SubTopic": "20", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-13" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "40", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480489/718-40-50-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "25", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-23" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "55", "Paragraph": "37", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-37" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-6" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-7" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-5" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "55", "Paragraph": "182", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "25", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480238/815-25-50-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-7" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/360/tableOfContent" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-10" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-5" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481138/505-30-25-5" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/805/tableOfContent" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479613/805-30-35-1" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/815/tableOfContent" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "25", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480238/815-25-50-1" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/820/tableOfContent" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "470", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r161": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r163": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(1)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/250/tableOfContent" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "04", "Paragraph": "a", "Publisher": "SEC" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column C", "Footnote": "5", "Publisher": "SEC" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column C", "Footnote": "4", "Publisher": "SEC" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(a)", "Footnote": "4", "Publisher": "SEC" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(b)", "Footnote": "4", "Publisher": "SEC" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column C", "Footnote": "2", "Publisher": "SEC" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column F", "Footnote": "7", "Publisher": "SEC" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column A", "Publisher": "SEC" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column B", "Publisher": "SEC" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column C", "Publisher": "SEC" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column D", "Publisher": "SEC" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column E", "Publisher": "SEC" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column F", "Publisher": "SEC" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column B", "Publisher": "SEC" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column C", "Publisher": "SEC" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column D", "Publisher": "SEC" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column E", "Publisher": "SEC" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column F", "Publisher": "SEC" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column G", "Publisher": "SEC" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column H", "Publisher": "SEC" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column I", "Publisher": "SEC" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "29", "Paragraph": "Column A", "Footnote": "4", "Publisher": "SEC" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(i)", "Publisher": "SEC" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(iii)(A)", "Publisher": "SEC" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(iii)(B)", "Publisher": "SEC" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(iv)", "Publisher": "SEC" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(i)", "Publisher": "SEC" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(iii)(A)", "Publisher": "SEC" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(iii)(B)", "Publisher": "SEC" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(iii)(C)", "Publisher": "SEC" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(iv)", "Publisher": "SEC" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 11", "Section": "L", "Publisher": "SEC" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 11", "Section": "M", "Paragraph": "Question 2", "Publisher": "SEC" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 2", "Publisher": "SEC" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 4", "Publisher": "SEC" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483504/205-10-50-1" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-12" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-6" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/280/tableOfContent" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/330/tableOfContent" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/420/tableOfContent" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-2" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4E" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480627/815-20-45-3" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/842-20/tableOfContent" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(h))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-3" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column B)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r782": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r783": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r784": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r785": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r786": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r787": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r788": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "19", "Subparagraph": "(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19" }, "r789": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "19", "Subparagraph": "(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19" }, "r790": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r791": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r792": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r793": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r794": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r795": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r796": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r797": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r798": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r799": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r800": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r801": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r802": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r803": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r804": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r805": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r806": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r807": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r808": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r809": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r810": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r811": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r812": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r813": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r814": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r815": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r816": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r817": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r818": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r819": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r820": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r821": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r822": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r823": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r824": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r825": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r826": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r827": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r828": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r829": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r830": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r831": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r832": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r833": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r834": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 5)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r835": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r836": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r837": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r838": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r839": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r840": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r841": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r842": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r843": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r844": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r845": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r846": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r847": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r848": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r849": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r850": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r851": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r852": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r853": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r854": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r855": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(1)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r856": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r857": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r858": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Subparagraph": "(b)", "SubTopic": "20", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r859": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r860": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r861": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r862": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r863": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r864": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r865": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15" }, "r866": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r867": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r868": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r869": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r870": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r871": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r872": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r873": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r874": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r875": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r876": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r877": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r878": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r879": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r880": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27" }, "r881": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r882": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r883": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r884": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r885": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r886": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r887": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r888": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r889": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r890": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r891": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r892": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r893": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r894": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r895": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r896": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r897": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r898": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r899": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r900": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r901": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r902": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r903": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r904": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r905": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r906": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r907": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r908": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r909": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r910": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r911": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r912": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r913": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r914": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r915": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r916": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r917": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r918": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r919": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r920": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-14" }, "r921": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r922": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-9" }, "r923": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r924": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r925": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r926": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r927": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r928": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r929": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r930": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r931": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column B)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r932": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r933": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r934": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r935": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r936": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r937": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r938": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r939": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r940": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r941": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r942": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r943": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r944": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r945": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r946": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r947": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r948": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r949": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r950": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r951": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r952": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r953": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r954": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r955": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r956": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r957": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r958": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r959": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r960": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r961": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r962": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r963": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r964": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r965": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r966": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r967": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r968": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r969": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r970": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r971": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r972": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r973": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r974": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r975": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r976": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r977": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r978": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r979": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r980": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r981": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r982": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r983": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r984": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r985": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r986": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r987": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r988": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r989": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r990": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r991": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r992": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r993": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r994": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r995": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r996": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r997": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r998": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r999": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r1000": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r1001": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r1002": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r1003": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r1004": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r1005": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r1006": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r1007": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r1008": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r1009": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r1010": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r1011": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r1012": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r1013": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r1014": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r1015": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r1016": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r1017": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r1018": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r1019": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r1020": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r1021": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r1022": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r1023": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r1024": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r1025": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r1026": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "3", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479455/805-10-15-3" }, "r1027": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r1028": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r1029": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r1030": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r1031": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r1032": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(1)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r1033": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r1034": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r1035": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r1036": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(6))", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1037": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column A", "Subparagraph": "(ii)", "Footnote": "2", "Publisher": "SEC" }, "r1038": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r1039": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(b)", "Footnote": "1", "Publisher": "SEC" }, "r1040": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r1041": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(ii)", "Publisher": "SEC" }, "r1042": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(iii)", "Publisher": "SEC" }, "r1043": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 2", "Publisher": "SEC" }, "r1044": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1045": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r1046": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r1047": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r1048": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1049": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r1050": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r1051": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r1052": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1053": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1054": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1055": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r1056": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r1057": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r1058": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r1059": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r1060": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r1061": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r1062": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r1063": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r1064": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r1065": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r1066": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r1067": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1068": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1069": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r1070": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r1071": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r1072": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r1073": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-20/tableOfContent" }, "r1074": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1075": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1076": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1077": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1078": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1079": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1080": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1081": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1082": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1083": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A" }, "r1084": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r1085": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r1086": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r1087": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1088": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1089": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1090": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1091": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1092": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1093": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1094": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1095": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1096": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1097": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1098": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r1099": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r1100": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1101": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1102": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1103": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r1104": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3" }, "r1105": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r1106": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r1107": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r1108": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r1109": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1110": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1111": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r1112": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r1113": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r1114": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r1115": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1116": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r1117": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6" }, "r1118": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r1119": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1120": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1121": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1122": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1123": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r1124": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B" }, "r1125": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r1126": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1127": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1128": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1129": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1130": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1131": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1132": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1133": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1134": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1135": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1136": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1137": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r1138": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r1139": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r1140": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r1141": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r1142": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r1143": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r1144": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A" }, "r1145": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r1146": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r1147": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1148": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1149": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1150": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1151": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1152": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1153": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1154": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1155": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r1156": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1157": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1158": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r1159": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1160": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1161": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1162": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1163": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1164": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r1165": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r1166": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r1167": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1168": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1169": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1170": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1171": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1172": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1173": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1174": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1175": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1176": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1177": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1178": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1179": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1180": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1181": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1182": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1183": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1184": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1185": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1186": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1187": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1188": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1189": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1190": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1191": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1192": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1193": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1194": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r1195": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1196": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1197": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" } } } ZIP 82 0000313143-25-000012-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000313143-25-000012-xbrl.zip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�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¡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end XML 83 hae-20241228_htm.xml IDEA: XBRL DOCUMENT 0000313143 2024-03-31 2024-12-28 0000313143 2025-02-03 0000313143 2024-09-29 2024-12-28 0000313143 2023-10-01 2023-12-30 0000313143 2023-04-02 2023-12-30 0000313143 2024-12-28 0000313143 2024-03-30 0000313143 us-gaap:CommonStockMember 2024-03-30 0000313143 us-gaap:AdditionalPaidInCapitalMember 2024-03-30 0000313143 us-gaap:RetainedEarningsMember 2024-03-30 0000313143 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-30 0000313143 us-gaap:CommonStockMember 2024-03-31 2024-06-29 0000313143 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 2024-06-29 0000313143 2024-03-31 2024-06-29 0000313143 us-gaap:RetainedEarningsMember 2024-03-31 2024-06-29 0000313143 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 2024-06-29 0000313143 us-gaap:CommonStockMember 2024-06-29 0000313143 us-gaap:AdditionalPaidInCapitalMember 2024-06-29 0000313143 us-gaap:RetainedEarningsMember 2024-06-29 0000313143 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-29 0000313143 2024-06-29 0000313143 us-gaap:CommonStockMember 2024-06-30 2024-09-28 0000313143 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 2024-09-28 0000313143 us-gaap:RetainedEarningsMember 2024-06-30 2024-09-28 0000313143 2024-06-30 2024-09-28 0000313143 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 2024-09-28 0000313143 us-gaap:CommonStockMember 2024-09-28 0000313143 us-gaap:AdditionalPaidInCapitalMember 2024-09-28 0000313143 us-gaap:RetainedEarningsMember 2024-09-28 0000313143 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-28 0000313143 2024-09-28 0000313143 us-gaap:CommonStockMember 2024-09-29 2024-12-28 0000313143 us-gaap:AdditionalPaidInCapitalMember 2024-09-29 2024-12-28 0000313143 us-gaap:RetainedEarningsMember 2024-09-29 2024-12-28 0000313143 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-29 2024-12-28 0000313143 us-gaap:CommonStockMember 2024-12-28 0000313143 us-gaap:AdditionalPaidInCapitalMember 2024-12-28 0000313143 us-gaap:RetainedEarningsMember 2024-12-28 0000313143 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-28 0000313143 us-gaap:CommonStockMember 2023-04-01 0000313143 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 0000313143 us-gaap:RetainedEarningsMember 2023-04-01 0000313143 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 0000313143 2023-04-01 0000313143 us-gaap:CommonStockMember 2023-04-02 2023-07-01 0000313143 us-gaap:AdditionalPaidInCapitalMember 2023-04-02 2023-07-01 0000313143 2023-04-02 2023-07-01 0000313143 us-gaap:RetainedEarningsMember 2023-04-02 2023-07-01 0000313143 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-02 2023-07-01 0000313143 us-gaap:CommonStockMember 2023-07-01 0000313143 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 0000313143 us-gaap:RetainedEarningsMember 2023-07-01 0000313143 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 0000313143 2023-07-01 0000313143 us-gaap:CommonStockMember 2023-07-02 2023-09-30 0000313143 us-gaap:AdditionalPaidInCapitalMember 2023-07-02 2023-09-30 0000313143 us-gaap:RetainedEarningsMember 2023-07-02 2023-09-30 0000313143 2023-07-02 2023-09-30 0000313143 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-02 2023-09-30 0000313143 us-gaap:CommonStockMember 2023-09-30 0000313143 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0000313143 us-gaap:RetainedEarningsMember 2023-09-30 0000313143 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0000313143 2023-09-30 0000313143 us-gaap:CommonStockMember 2023-10-01 2023-12-30 0000313143 us-gaap:AdditionalPaidInCapitalMember 2023-10-01 2023-12-30 0000313143 us-gaap:RetainedEarningsMember 2023-10-01 2023-12-30 0000313143 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-10-01 2023-12-30 0000313143 us-gaap:CommonStockMember 2023-12-30 0000313143 us-gaap:AdditionalPaidInCapitalMember 2023-12-30 0000313143 us-gaap:RetainedEarningsMember 2023-12-30 0000313143 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-30 0000313143 2023-12-30 0000313143 hae:AttuneMedicalMember 2024-04-01 2024-04-01 0000313143 hae:AttuneMedicalMember 2024-04-01 0000313143 hae:AttuneMedicalMember us-gaap:TechnologyBasedIntangibleAssetsMember 2024-04-01 0000313143 hae:AttuneMedicalMember us-gaap:TechnologyBasedIntangibleAssetsMember 2024-04-01 2024-04-01 0000313143 hae:AttuneMedicalMember us-gaap:CustomerRelationshipsMember 2024-04-01 0000313143 hae:AttuneMedicalMember us-gaap:CustomerRelationshipsMember 2024-04-01 2024-04-01 0000313143 hae:AttuneMedicalMember us-gaap:TradeNamesMember 2024-04-01 0000313143 hae:AttuneMedicalMember us-gaap:TradeNamesMember 2024-04-01 2024-04-01 0000313143 hae:AttuneMedicalMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-03-31 2024-06-29 0000313143 hae:OpSensIncMember 2023-12-12 2023-12-12 0000313143 hae:OpSensIncMember 2023-12-12 0000313143 hae:OpSensIncMember us-gaap:TechnologyBasedIntangibleAssetsMember 2023-12-12 0000313143 hae:OpSensIncMember us-gaap:TechnologyBasedIntangibleAssetsMember 2023-12-12 2023-12-12 0000313143 hae:OpSensIncMember us-gaap:CustomerRelationshipsMember 2023-12-12 0000313143 hae:OpSensIncMember us-gaap:CustomerRelationshipsMember 2023-12-12 2023-12-12 0000313143 hae:OpSensIncMember us-gaap:TradeNamesMember 2023-12-12 0000313143 hae:OpSensIncMember us-gaap:TradeNamesMember 2023-12-12 2023-12-12 0000313143 hae:OpSensIncMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-12-12 2023-12-12 0000313143 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember hae:WholeBloodBusinessMember us-gaap:SubsequentEventMember 2025-01-13 2025-01-13 0000313143 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember hae:WholeBloodBusinessMember us-gaap:SubsequentEventMember 2025-01-13 0000313143 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember 2024-12-28 0000313143 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember 2024-03-31 2024-12-28 0000313143 hae:VivasureMedicalLTDMember 2024-12-28 0000313143 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember us-gaap:InventoriesMember 2024-12-28 0000313143 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember us-gaap:PropertyPlantAndEquipmentMember 2024-12-28 0000313143 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember us-gaap:GoodwillMember 2024-12-28 0000313143 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember us-gaap:AccruedLiabilitiesMember 2024-12-28 0000313143 2024-12-29 2024-12-28 0000313143 2025-12-27 2024-12-28 0000313143 hae:A2020ProgramMember 2024-12-28 0000313143 hae:A2020ProgramMember 2024-09-29 2024-12-28 0000313143 hae:A2020ProgramMember 2024-03-31 2024-12-28 0000313143 hae:A2020ProgramMember 2023-10-01 2023-12-30 0000313143 hae:A2020ProgramMember 2023-04-02 2023-12-30 0000313143 hae:PortfolioRationalizationMember 2024-09-29 2024-12-28 0000313143 hae:PortfolioRationalizationMember 2024-03-31 2024-12-28 0000313143 hae:PortfolioRationalizationMember 2023-04-02 2023-12-30 0000313143 hae:PortfolioRationalizationMember 2023-10-01 2023-12-30 0000313143 hae:PortfolioRationalizationMember 2024-03-30 0000313143 hae:A2020ProgramMember 2024-03-30 0000313143 hae:PortfolioRationalizationMember 2024-12-28 0000313143 us-gaap:CostOfSalesMember 2024-09-29 2024-12-28 0000313143 us-gaap:CostOfSalesMember 2023-10-01 2023-12-30 0000313143 us-gaap:CostOfSalesMember 2024-03-31 2024-12-28 0000313143 us-gaap:CostOfSalesMember 2023-04-02 2023-12-30 0000313143 us-gaap:ResearchAndDevelopmentExpenseMember 2024-09-29 2024-12-28 0000313143 us-gaap:ResearchAndDevelopmentExpenseMember 2023-10-01 2023-12-30 0000313143 us-gaap:ResearchAndDevelopmentExpenseMember 2024-03-31 2024-12-28 0000313143 us-gaap:ResearchAndDevelopmentExpenseMember 2023-04-02 2023-12-30 0000313143 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-09-29 2024-12-28 0000313143 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-10-01 2023-12-30 0000313143 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-03-31 2024-12-28 0000313143 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-04-02 2023-12-30 0000313143 hae:PlasmaMember 2024-09-29 2024-12-28 0000313143 hae:PlasmaMember 2023-10-01 2023-12-30 0000313143 hae:PlasmaMember 2024-03-31 2024-12-28 0000313143 hae:PlasmaMember 2023-04-02 2023-12-30 0000313143 hae:BloodCenterMember 2024-09-29 2024-12-28 0000313143 hae:BloodCenterMember 2023-10-01 2023-12-30 0000313143 hae:BloodCenterMember 2024-03-31 2024-12-28 0000313143 hae:BloodCenterMember 2023-04-02 2023-12-30 0000313143 hae:HospitalMember 2024-09-29 2024-12-28 0000313143 hae:HospitalMember 2023-10-01 2023-12-30 0000313143 hae:HospitalMember 2024-03-31 2024-12-28 0000313143 hae:HospitalMember 2023-04-02 2023-12-30 0000313143 us-gaap:CorporateMember 2024-09-29 2024-12-28 0000313143 us-gaap:CorporateMember 2023-10-01 2023-12-30 0000313143 us-gaap:CorporateMember 2024-03-31 2024-12-28 0000313143 us-gaap:CorporateMember 2023-04-02 2023-12-30 0000313143 hae:StockCompensationWindfallsMember 2024-09-29 2024-12-28 0000313143 hae:StockCompensationWindfallsMember 2023-04-02 2023-12-30 0000313143 hae:A2022AcceleratedShareRepurchaseProgramMember 2024-03-31 2024-12-28 0000313143 hae:A2022AcceleratedShareRepurchaseProgramMember 2022-08-31 0000313143 hae:A2024AcceleratedShareRepurchaseProgramMember 2024-08-28 0000313143 hae:A2024AcceleratedShareRepurchaseProgramMember 2024-08-28 2024-08-28 0000313143 us-gaap:LandMember 2024-12-28 0000313143 us-gaap:LandMember 2024-03-30 0000313143 us-gaap:BuildingAndBuildingImprovementsMember 2024-12-28 0000313143 us-gaap:BuildingAndBuildingImprovementsMember 2024-03-30 0000313143 us-gaap:MachineryAndEquipmentMember 2024-12-28 0000313143 us-gaap:MachineryAndEquipmentMember 2024-03-30 0000313143 hae:OfficeEquipmentAndInformationTechnologyMember 2024-12-28 0000313143 hae:OfficeEquipmentAndInformationTechnologyMember 2024-03-30 0000313143 hae:HaemoneticsEquipmentMember 2024-12-28 0000313143 hae:HaemoneticsEquipmentMember 2024-03-30 0000313143 us-gaap:ConstructionInProgressMember 2024-12-28 0000313143 us-gaap:ConstructionInProgressMember 2024-03-30 0000313143 srt:RestatementAdjustmentMember 2024-12-28 0000313143 2024-04-25 2024-04-25 0000313143 hae:PlasmaMember 2024-03-30 0000313143 hae:BloodCenterMember 2024-03-30 0000313143 hae:HospitalMember 2024-03-30 0000313143 hae:PlasmaMember 2024-12-28 0000313143 hae:BloodCenterMember 2024-12-28 0000313143 hae:HospitalMember 2024-12-28 0000313143 hae:OtherTechnologyMember 2024-12-28 0000313143 us-gaap:CustomerContractsMember 2024-12-28 0000313143 us-gaap:ComputerSoftwareIntangibleAssetMember 2024-12-28 0000313143 us-gaap:PatentsMember 2024-12-28 0000313143 us-gaap:TradeNamesMember 2024-12-28 0000313143 hae:InProcessSoftwareDevelopmentMember 2024-12-28 0000313143 hae:OtherTechnologyMember 2024-03-30 0000313143 us-gaap:CustomerContractsMember 2024-03-30 0000313143 us-gaap:ComputerSoftwareIntangibleAssetMember 2024-03-30 0000313143 us-gaap:PatentsMember 2024-03-30 0000313143 us-gaap:TradeNamesMember 2024-03-30 0000313143 us-gaap:InProcessResearchAndDevelopmentMember 2024-03-30 0000313143 hae:InProcessSoftwareDevelopmentMember 2024-03-30 0000313143 hae:AttuneMedicalMember us-gaap:CustomerRelatedIntangibleAssetsMember 2024-04-01 0000313143 srt:MinimumMember 2024-12-28 0000313143 srt:MaximumMember 2024-12-28 0000313143 us-gaap:ConvertibleDebtMember 2024-12-28 0000313143 us-gaap:ConvertibleDebtMember 2024-03-30 0000313143 us-gaap:MediumTermNotesMember 2024-12-28 0000313143 us-gaap:MediumTermNotesMember 2024-03-30 0000313143 us-gaap:RevolvingCreditFacilityMember 2024-12-28 0000313143 us-gaap:RevolvingCreditFacilityMember 2024-03-30 0000313143 hae:BankLoansAndOtherBorrowingsMember 2024-12-28 0000313143 hae:BankLoansAndOtherBorrowingsMember 2024-03-30 0000313143 hae:ConvertibleSeniorNotesDue2026Member us-gaap:ConvertibleDebtMember 2021-03-31 0000313143 hae:ConvertibleSeniorNotesDue2026Member us-gaap:ConvertibleDebtMember 2024-05-28 0000313143 hae:ConvertibleSeniorNotesDue2026Member us-gaap:ConvertibleDebtMember 2024-05-28 2024-05-28 0000313143 hae:ConvertibleSeniorNotesDue2026Member us-gaap:ConvertibleDebtMember 2024-12-28 0000313143 hae:ConvertibleSeniorNotesDue2026Member us-gaap:ConvertibleDebtMember 2024-09-29 2024-12-28 0000313143 hae:ConvertibleSeniorNotesDue2026Member us-gaap:ConvertibleDebtMember 2024-03-31 2024-12-28 0000313143 hae:ConvertibleSeniorNotesDue2029Member us-gaap:ConvertibleDebtMember 2024-05-28 0000313143 hae:ConvertibleSeniorNotesDue2029Member us-gaap:ConvertibleDebtMember 2024-05-28 2024-05-28 0000313143 hae:ConvertibleSeniorNotesDue2029Member us-gaap:DebtInstrumentRedemptionPeriodOneMember us-gaap:ConvertibleDebtMember 2024-05-28 2024-05-28 0000313143 hae:ConvertibleSeniorNotesDue2029Member us-gaap:DebtInstrumentRedemptionPeriodTwoMember us-gaap:ConvertibleDebtMember 2024-05-28 2024-05-28 0000313143 hae:ConvertibleSeniorNotesDue2029Member us-gaap:ConvertibleDebtMember 2024-12-28 0000313143 hae:ConvertibleSeniorNotesDue2029Member us-gaap:ConvertibleDebtMember 2024-09-29 2024-12-28 0000313143 hae:ConvertibleSeniorNotesDue2029Member us-gaap:ConvertibleDebtMember 2024-03-31 2024-12-28 0000313143 2024-05-28 0000313143 2024-05-28 2024-05-28 0000313143 hae:A2022RevisedCreditAgreementMember us-gaap:MediumTermNotesMember 2022-07-26 0000313143 hae:A2022RevisedCreditAgreementMember us-gaap:RevolvingCreditFacilityMember 2022-07-26 0000313143 srt:MinimumMember hae:A2022RevisedCreditAgreementMember us-gaap:RevolvingCreditFacilityMember 2022-07-26 0000313143 srt:MaximumMember hae:A2022RevisedCreditAgreementMember us-gaap:RevolvingCreditFacilityMember 2022-07-26 0000313143 hae:A2024RevisedCreditAgreementMember us-gaap:MediumTermNotesMember 2024-04-30 0000313143 hae:A2024RevisedCreditAgreementMember us-gaap:MediumTermNotesMember 2024-04-30 2024-04-30 0000313143 hae:A2024RevisedCreditAgreementMember us-gaap:RevolvingCreditFacilityMember 2024-04-30 0000313143 srt:MinimumMember hae:A2024RevisedCreditAgreementMember us-gaap:MediumTermNotesMember 2024-04-30 0000313143 srt:MaximumMember hae:A2024RevisedCreditAgreementMember us-gaap:MediumTermNotesMember 2024-04-30 0000313143 srt:MinimumMember hae:A2024RevisedCreditAgreementMember us-gaap:RevolvingCreditFacilityMember 2024-04-30 2024-04-30 0000313143 srt:MaximumMember hae:A2024RevisedCreditAgreementMember us-gaap:RevolvingCreditFacilityMember 2024-04-30 2024-04-30 0000313143 2024-04-30 0000313143 hae:RevisedCreditAgreementMember us-gaap:UnsecuredDebtMember 2024-09-29 2024-12-28 0000313143 hae:RevisedCreditAgreementMember us-gaap:UnsecuredDebtMember 2024-03-31 2024-12-28 0000313143 hae:A2024RevisedCreditAgreementMember us-gaap:MediumTermNotesMember 2024-12-28 0000313143 us-gaap:LineOfCreditMember 2024-12-28 0000313143 us-gaap:ForeignExchangeContractMember 2024-09-29 2024-12-28 0000313143 us-gaap:ForeignExchangeContractMember 2024-03-31 2024-12-28 0000313143 us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-12-28 0000313143 us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-30 0000313143 us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 2024-12-28 0000313143 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2024-12-28 0000313143 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2024-03-30 0000313143 us-gaap:InterestRateSwapMember 2022-09-01 2022-09-30 0000313143 us-gaap:InterestRateSwapMember 2023-06-15 2023-06-15 0000313143 us-gaap:InterestRateSwapMember 2024-09-26 2024-09-26 0000313143 2024-09-27 0000313143 us-gaap:InterestRateSwapMember 2024-09-27 0000313143 us-gaap:InterestRateSwapMember 2024-09-27 2024-09-27 0000313143 hae:InterestRateSwap408FixedInterestRateMember 2022-09-23 0000313143 hae:InterestRateSwap408FixedInterestRateMember 2024-12-28 0000313143 hae:InterestRateSwap415FixedInterestRateMember 2022-09-23 0000313143 hae:InterestRateSwap415FixedInterestRateMember 2024-12-28 0000313143 us-gaap:InterestRateSwapMember 2022-09-23 0000313143 us-gaap:InterestRateSwapMember 2024-12-28 0000313143 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 2024-12-28 0000313143 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2024-03-31 2024-12-28 0000313143 us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-12-28 0000313143 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-12-28 0000313143 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-30 0000313143 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:NondesignatedMember 2024-12-28 0000313143 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:NondesignatedMember 2024-03-30 0000313143 us-gaap:OtherCurrentAssetsMember us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:NondesignatedMember 2024-12-28 0000313143 us-gaap:OtherCurrentAssetsMember us-gaap:InterestRateSwapMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:NondesignatedMember 2024-03-30 0000313143 us-gaap:OtherNoncurrentAssetsMember us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-12-28 0000313143 us-gaap:OtherNoncurrentAssetsMember us-gaap:InterestRateSwapMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-30 0000313143 us-gaap:FairValueMeasurementsRecurringMember 2024-12-28 0000313143 us-gaap:FairValueMeasurementsRecurringMember 2024-03-30 0000313143 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-12-28 0000313143 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-30 0000313143 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:NondesignatedMember 2024-12-28 0000313143 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:NondesignatedMember 2024-03-30 0000313143 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-28 0000313143 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-28 0000313143 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-12-28 0000313143 us-gaap:ForeignExchangeContractMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-12-28 0000313143 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:NondesignatedMember 2024-12-28 0000313143 us-gaap:ForeignExchangeContractMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:NondesignatedMember 2024-12-28 0000313143 us-gaap:OtherAssetsMember us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:NondesignatedMember 2024-12-28 0000313143 us-gaap:OtherAssetsMember us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:NondesignatedMember 2024-12-28 0000313143 us-gaap:OtherAssetsMember us-gaap:InterestRateSwapMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:NondesignatedMember 2024-12-28 0000313143 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-12-28 0000313143 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-12-28 0000313143 us-gaap:InterestRateSwapMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-12-28 0000313143 hae:ContingentConsiderationMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-28 0000313143 hae:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-28 0000313143 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-28 0000313143 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-30 0000313143 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-30 0000313143 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-30 0000313143 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-30 0000313143 us-gaap:ForeignExchangeContractMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-30 0000313143 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:NondesignatedMember 2024-03-30 0000313143 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:NondesignatedMember 2024-03-30 0000313143 us-gaap:ForeignExchangeContractMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:NondesignatedMember 2024-03-30 0000313143 us-gaap:OtherAssetsMember us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:NondesignatedMember 2024-03-30 0000313143 us-gaap:OtherAssetsMember us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:NondesignatedMember 2024-03-30 0000313143 us-gaap:OtherAssetsMember us-gaap:InterestRateSwapMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:NondesignatedMember 2024-03-30 0000313143 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:NondesignatedMember 2024-03-30 0000313143 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-30 0000313143 hae:RevenueBasedPaymentMember hae:ContingentConsiderationMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-28 0000313143 hae:RegulatoryBasedPaymentMember hae:ContingentConsiderationMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-28 0000313143 hae:EventBasedPaymentMember hae:ContingentConsiderationMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-28 0000313143 us-gaap:OtherCurrentLiabilitiesMember hae:AttuneMedicalMember 2024-12-28 0000313143 us-gaap:OtherNoncurrentLiabilitiesMember hae:AttuneMedicalMember 2024-12-28 0000313143 hae:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember 2024-03-30 0000313143 hae:ConvertibleSeniorNotesDue2026Member us-gaap:FairValueInputsLevel2Member 2024-12-28 0000313143 hae:ConvertibleSeniorNotesDue2029Member us-gaap:FairValueInputsLevel2Member 2024-12-28 0000313143 2023-04-02 2024-03-30 0000313143 us-gaap:AccumulatedTranslationAdjustmentMember 2024-03-30 0000313143 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-03-30 0000313143 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-03-30 0000313143 us-gaap:AccumulatedTranslationAdjustmentMember 2024-03-31 2024-12-28 0000313143 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-03-31 2024-12-28 0000313143 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-03-31 2024-12-28 0000313143 us-gaap:AccumulatedTranslationAdjustmentMember 2024-12-28 0000313143 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-12-28 0000313143 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-12-28 0000313143 us-gaap:OperatingSegmentsMember hae:PlasmaMember 2024-09-29 2024-12-28 0000313143 us-gaap:OperatingSegmentsMember hae:PlasmaMember 2023-10-01 2023-12-30 0000313143 us-gaap:OperatingSegmentsMember hae:PlasmaMember 2024-03-31 2024-12-28 0000313143 us-gaap:OperatingSegmentsMember hae:PlasmaMember 2023-04-02 2023-12-30 0000313143 us-gaap:OperatingSegmentsMember hae:BloodCenterMember 2024-09-29 2024-12-28 0000313143 us-gaap:OperatingSegmentsMember hae:BloodCenterMember 2023-10-01 2023-12-30 0000313143 us-gaap:OperatingSegmentsMember hae:BloodCenterMember 2024-03-31 2024-12-28 0000313143 us-gaap:OperatingSegmentsMember hae:BloodCenterMember 2023-04-02 2023-12-30 0000313143 us-gaap:OperatingSegmentsMember hae:HospitalMember 2024-09-29 2024-12-28 0000313143 us-gaap:OperatingSegmentsMember hae:HospitalMember 2023-10-01 2023-12-30 0000313143 us-gaap:OperatingSegmentsMember hae:HospitalMember 2024-03-31 2024-12-28 0000313143 us-gaap:OperatingSegmentsMember hae:HospitalMember 2023-04-02 2023-12-30 0000313143 us-gaap:OperatingSegmentsMember 2024-09-29 2024-12-28 0000313143 us-gaap:OperatingSegmentsMember 2023-10-01 2023-12-30 0000313143 us-gaap:OperatingSegmentsMember 2024-03-31 2024-12-28 0000313143 us-gaap:OperatingSegmentsMember 2023-04-02 2023-12-30 0000313143 us-gaap:CorporateNonSegmentMember 2024-09-29 2024-12-28 0000313143 us-gaap:CorporateNonSegmentMember 2023-10-01 2023-12-30 0000313143 us-gaap:CorporateNonSegmentMember 2024-03-31 2024-12-28 0000313143 us-gaap:CorporateNonSegmentMember 2023-04-02 2023-12-30 0000313143 hae:PlasmaProductsandServicesMember hae:PlasmaMember 2024-09-29 2024-12-28 0000313143 hae:PlasmaProductsandServicesMember hae:PlasmaMember 2023-10-01 2023-12-30 0000313143 hae:PlasmaProductsandServicesMember hae:PlasmaMember 2024-03-31 2024-12-28 0000313143 hae:PlasmaProductsandServicesMember hae:PlasmaMember 2023-04-02 2023-12-30 0000313143 hae:BloodCenterProductsandServicesMember hae:ApheresisBloodCenterMember 2024-09-29 2024-12-28 0000313143 hae:BloodCenterProductsandServicesMember hae:ApheresisBloodCenterMember 2023-10-01 2023-12-30 0000313143 hae:BloodCenterProductsandServicesMember hae:ApheresisBloodCenterMember 2024-03-31 2024-12-28 0000313143 hae:BloodCenterProductsandServicesMember hae:ApheresisBloodCenterMember 2023-04-02 2023-12-30 0000313143 hae:BloodCenterProductsandServicesMember hae:WholeBloodBloodCenterMember 2024-09-29 2024-12-28 0000313143 hae:BloodCenterProductsandServicesMember hae:WholeBloodBloodCenterMember 2023-10-01 2023-12-30 0000313143 hae:BloodCenterProductsandServicesMember hae:WholeBloodBloodCenterMember 2024-03-31 2024-12-28 0000313143 hae:BloodCenterProductsandServicesMember hae:WholeBloodBloodCenterMember 2023-04-02 2023-12-30 0000313143 hae:BloodCenterProductsandServicesMember hae:BloodCenterMember 2024-09-29 2024-12-28 0000313143 hae:BloodCenterProductsandServicesMember hae:BloodCenterMember 2023-10-01 2023-12-30 0000313143 hae:BloodCenterProductsandServicesMember hae:BloodCenterMember 2024-03-31 2024-12-28 0000313143 hae:BloodCenterProductsandServicesMember hae:BloodCenterMember 2023-04-02 2023-12-30 0000313143 hae:HospitalProductsandServicesMember hae:InterventionalTechnologiesHospitalMember 2024-09-29 2024-12-28 0000313143 hae:HospitalProductsandServicesMember hae:InterventionalTechnologiesHospitalMember 2023-10-01 2023-12-30 0000313143 hae:HospitalProductsandServicesMember hae:InterventionalTechnologiesHospitalMember 2024-03-31 2024-12-28 0000313143 hae:HospitalProductsandServicesMember hae:InterventionalTechnologiesHospitalMember 2023-04-02 2023-12-30 0000313143 hae:HospitalProductsandServicesMember hae:HemostasisManagementHospitalMember 2024-09-29 2024-12-28 0000313143 hae:HospitalProductsandServicesMember hae:HemostasisManagementHospitalMember 2023-10-01 2023-12-30 0000313143 hae:HospitalProductsandServicesMember hae:HemostasisManagementHospitalMember 2024-03-31 2024-12-28 0000313143 hae:HospitalProductsandServicesMember hae:HemostasisManagementHospitalMember 2023-04-02 2023-12-30 0000313143 hae:HospitalProductsandServicesMember hae:HospitalMember 2024-09-29 2024-12-28 0000313143 hae:HospitalProductsandServicesMember hae:HospitalMember 2023-10-01 2023-12-30 0000313143 hae:HospitalProductsandServicesMember hae:HospitalMember 2024-03-31 2024-12-28 0000313143 hae:HospitalProductsandServicesMember hae:HospitalMember 2023-04-02 2023-12-30 0000313143 country:US 2024-09-29 2024-12-28 0000313143 country:US 2023-10-01 2023-12-30 0000313143 country:US 2024-03-31 2024-12-28 0000313143 country:US 2023-04-02 2023-12-30 0000313143 country:JP 2024-09-29 2024-12-28 0000313143 country:JP 2023-10-01 2023-12-30 0000313143 country:JP 2024-03-31 2024-12-28 0000313143 country:JP 2023-04-02 2023-12-30 0000313143 srt:EuropeMember 2024-09-29 2024-12-28 0000313143 srt:EuropeMember 2023-10-01 2023-12-30 0000313143 srt:EuropeMember 2024-03-31 2024-12-28 0000313143 srt:EuropeMember 2023-04-02 2023-12-30 0000313143 srt:AsiaMember 2024-09-29 2024-12-28 0000313143 srt:AsiaMember 2023-10-01 2023-12-30 0000313143 srt:AsiaMember 2024-03-31 2024-12-28 0000313143 srt:AsiaMember 2023-04-02 2023-12-30 0000313143 hae:OtherCountryorRegionMember 2024-09-29 2024-12-28 0000313143 hae:OtherCountryorRegionMember 2023-10-01 2023-12-30 0000313143 hae:OtherCountryorRegionMember 2024-03-31 2024-12-28 0000313143 hae:OtherCountryorRegionMember 2023-04-02 2023-12-30 shares iso4217:USD iso4217:USD shares pure iso4217:EUR iso4217:CAD shares hae:swap utr:Rate hae:segment 0000313143 --03-29 false 2025 Q3 34700000 7300000 4500000 500000 0.25 http://fasb.org/us-gaap/2024#OtherNonoperatingIncomeExpense http://fasb.org/us-gaap/2024#OtherNonoperatingIncomeExpense http://fasb.org/us-gaap/2024#OtherNonoperatingIncomeExpense 10-Q true 2024-12-28 false 001-14041 HAEMONETICS CORPORATION MA 04-2882273 125 Summer Street Boston, MA 02110 781 848-7100 Common stock, $.01 par value per share HAE NYSE Yes Yes Large Accelerated Filer false false false 50237466 348542000 336250000 1030225000 965765000 154995000 158383000 474317000 450123000 193547000 177867000 555908000 515642000 15829000 13265000 46808000 38578000 106459000 111713000 321653000 320518000 12230000 6911000 36965000 21606000 134518000 131889000 405426000 380702000 59029000 45978000 150482000 134940000 -9112000 -1949000 -9148000 -6489000 49917000 44029000 141334000 128451000 12423000 12788000 31636000 31260000 37494000 31241000 109698000 97191000 0.75 0.62 2.16 1.92 0.74 0.61 2.14 1.89 50286000 50768000 50709000 50679000 50639000 51445000 51148000 51394000 16557000 39564000 89829000 103190000 320846000 178800000 5986000 5695000 211949000 206562000 359614000 317202000 113459000 66339000 1005868000 768903000 286107000 311362000 311596000 455213000 465615000 406117000 605266000 565082000 8000000 7739000 160414000 136388000 2531270000 2195591000 5075000 10229000 62990000 73358000 45933000 80708000 139235000 136088000 253233000 300383000 1219762000 797564000 61451000 62644000 89964000 75041000 0.01 0.01 150000000 150000000 50235051 50235051 50787859 50787859 502000 508000 569629000 634627000 392230000 360456000 -55501000 -35632000 906860000 959959000 2531270000 2195591000 50788000 508000 634627000 360456000 -35632000 959959000 47000 3441000 3441000 73000 1000 4703000 -3743000 961000 280000 3000 -3000 0 -35000 0 1315000 8444000 9759000 88200000 88200000 7628000 7628000 38373000 38373000 -7035000 -7035000 51153000 512000 560881000 386642000 -42667000 905368000 5000 0 515000 -264000 251000 799000 8000 23839000 51394000 75241000 23000 0 -1000 0 39000 279000 318000 6857000 6857000 33831000 33831000 8103000 8103000 50381000 504000 544375000 368536000 -34564000 878851000 49000 3035000 3035000 12000 0 1266000 -761000 505000 209000 2000 -12761000 12867000 108000 3000 0 -1000 0 22000 172000 194000 8214000 8214000 37494000 37494000 -20937000 -20937000 50235000 502000 569629000 392230000 -55501000 906860000 50449000 504000 594706000 253168000 -30381000 817997000 40000 2871000 2871000 145000 2000 5858000 -5233000 627000 140000 2000 -2000 0 -68000 1000 812000 4960000 5773000 6989000 6989000 41042000 41042000 863000 863000 50706000 507000 609610000 284017000 -29518000 864616000 12000 0 655000 37000 692000 22000 0 0 0 11000 64000 75000 6706000 6706000 24908000 24908000 -3187000 -3187000 50740000 507000 616960000 308898000 -32705000 893660000 39000 2732000 2732000 4000 1000 189000 -4000 186000 3000 0 0 0 -1000 4000 36000 40000 7217000 7217000 31241000 31241000 8323000 8323000 50785000 508000 627094000 340099000 -24382000 943319000 109698000 97191000 87378000 69576000 12319000 0 22699000 20912000 2391000 10419000 12600000 0 -1289000 -6904000 14572000 647000 -8593000 -5138000 8114000 5748000 3379000 27743000 65629000 40721000 2638000 -1730000 34493000 15619000 -36816000 -4942000 65168000 117670000 23635000 31440000 -12649000 -25171000 150906000 243852000 20802000 1259000 13547000 10129000 -179935000 -309333000 700000000 0 185500000 0 88200000 0 250000000 0 262500000 0 0 110000000 50000000 0 3125000 8750000 23135000 0 75000000 0 6476000 5603000 1717000 1505000 10243000 5885000 -222000 -814000 260268000 101659000 -3455000 -484000 142046000 -90488000 178800000 284466000 320846000 193978000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. BASIS OF PRESENTATION </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements of Haemonetics Corporation (“Haemonetics” or the “Company”) presented herein have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of the Company’s management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. All intercompany transactions have been eliminated. Operating results for the nine months ended December 28, 2024 are not necessarily indicative of the results that may be expected for the full fiscal year ending March 29, 2025 or any other interim period. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and footnotes included in the Annual Report on Form 10-K for the fiscal year ended March 30, 2024.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the financial statements to provide additional </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">evidence relative to certain estimates or to identify matters that require additional disclosure. Subse</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">quent events have been evaluated as required. There were no material recognized or unrecognized subsequent events as of or for the nine months ended December 28, 2024, except for those discussed in Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions, Divestitures and Strategic Investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. RECENT ACCOUNTING PRONOUNCEMENTS </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:106%">Standards to be Implemented</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Codification (“ASC”) Update No. 2023-07, Segment Reporting (Topic 280). The new guidance requires public entities to provide expanded disclosures over significant segment expenses and additional disclosures related to the chief operating decision maker. ASC Update No. 2023-07 is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The new guidance is applicable to Haemonetics beginning with the fiscal 2025 Annual Report on Form 10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-K. The Company is currently evaluating the impact to its interim and annual report disclosures.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASC Update No. 2023-09, Income Taxes (Topic 740). ASC Update No. 2023-09 requires public entities to provide detailed income tax disclosures, including rate reconciliations and disaggregated income tax payment information, on an annual basis. The updated guidance is effective for fiscal years beginning after December 15, 2024 and early adoption is permitted. ASC Upda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">te No. 2023-09 is applicable to Haemonetics beginning with the fiscal 2026 Annual Report on Form 10-K and the Company is currently evaluating the impact to its annual report disclosures.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASC Update No. 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40). ASC Update No. 2024-03 requires detailed cost and expense information disaggregated in the financial statement notes. The updated guidance is effective for fiscal years beginning after December 15, 2026 and interim reporting periods within annual reporting periods beginning after December 15, 2027, with early adoption permitted. ASC Update No. 2024-03 is applicable to Haemonetics beginning with the fiscal 2028 Annual Report on Form 10-K and the Company is currently evaluating the impact to its interim and annual report disclosures.</span></div> <div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. ACQUISITIONS, DIVESTITURES AND STRATEGIC INVESTMENTS </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">cquisitions</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attune Medical</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 5, 2024, the Company entered into a definitive agreement to acquire Advanced Cooling Therapy, Inc., d/b/a Attune Medical (“Attune Medical”), the manufacturer of the ensoETM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> proactive esophageal cooling device, pursuant to which, among other things, the Company agreed to acquire all of the issued and outstanding common shares of Attune Medical. On April 1, 2024, the Company completed its acquisition of Attune Medical for total consideration of $187.7 million, which included an upfront cash payment of $162.0 million, or $150.5 million net of cash acquired, the fair value of contingent consideration of $25.3 million, and $0.4 million of working capital adjustments. The contingent consideration is based on sales growth over the next three years, which is uncapped, and the achievement of certain other milestones. The Company financed the acquisition through a combination of cash on hand and borrowings under its senior unsecured revolving credit facility.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attune Medical's ensoETM technology is designed for use across a range of medical conditions involving patient cooling or warming, including treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery, among others. The Company’s addition of the Esophageal Protection product line through its acquisition of Attune Medical expands the Hospital business unit’s presence in electrophysiology and complements its Vascular Closure product line within Interventional Technologies, which is included in the Hospital reportable segment.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Purchase Price Allocation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounted for the acquisition as a business combination, and in accordance with FASB ASC Topic 805, Business Combinations (Topic 805), recorded the assets acquired and liabilities assumed at their fair values as of the acquisition date. The fair value of assets acquired and liabilities assumed have been recognized based on management’s estimates and assumptions using the information regarding facts and circumstances that existed at the closing date.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price of $176.2 million, net of $11.5 million of cash acquired, consists of the amounts presented below, which represent the final determination of the fair value of the identifiable assets acquired and liabilities assumed:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.789%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands) </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">April 1, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,784 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">906 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,800 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,256 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets acquired</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">207,246</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,260 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll and related costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,129 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,155 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities assumed</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">31,040</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net assets acquired</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">176,206</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the identifiable intangible assets were developed technology, customer contracts and related relationships and trade names. The fair values of intangible assets were based on valuation techniques with estimates and assumptions developed by the Company. Developed technology was valued using the excess earnings method. Customer contracts and related relationships were valued using the distributor method. The trademark was valued using the relief from royalty method. The cash flows used in the valuation of the intangible assets were based on estimates used to price the transaction. In developing the discount rates applied to the cash flow projections, the discount rates were benchmarked with reference to the implied rate of return from the transaction model and the weighted average cost of capital and then adjusted to reflect the relative risk of the asset.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of the purchase price over the tangible assets, identifiable intangible assets and assumed liabilities was recorded as goodwill. As a result of the acquisition of Attune Medical, the Company recognized goodwill of $70.3 million based on expected synergies from integration into our Hospital business. The goodwill is not deductible for tax purposes and relates entirely to the Hospital reportable segment.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets acquired consist of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Amortization Period</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Risk-Adjusted Discount<br/>Rates used in Purchase Price Allocation</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer contracts and related relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,900 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">105,800</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded a long-term net deferred tax liability of $26.2 million primarily related to fair value adjustments recorded associated with definite-lived intangible assets and inventory in which there is no tax basis, partially offset by deferred tax assets primarily related to net operating losses acquired.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition-Related Costs</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred $9.8 million of acquisition-related costs during the first quarter of fiscal 2025 in connection with the Attune Medical acquisition. These costs related to legal and other professional fees, which were recognized in selling, general and administrative on the Condensed Consolidated Statements of Income.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s condensed consolidated financial statements include the results of Attune Medical from the date the acquisition was completed. Pro forma financial information has not been presented as the acquisition is not material to the Company’s overall financial results.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OpSens Inc.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 10, 2023, the Company entered into an Arrangement Agreement with OpSens Inc. (“OpSens”), a medical device cardiology-focused company delivering solutions based on its proprietary optical technology, pursuant to which, among other things, the Company agreed to acquire all of the issued and outstanding common shares of OpSens. On December 12, 2023, the Company completed its acquisition of OpSens for total consideration of approximately $254.5 million, or $243.9 million, net of cash acquired. The Company financed the acquisition through a combination of cash on hand and borrowings under its senior unsecured revolving credit facility.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OpSens offers commercially and clinically validated optical technology for use primarily in interventional cardiology. OpSens’ core products include the SavvyWire</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a sensor-guided 3-in-1 guidewire for TAVR procedures, advancing the workflow of the procedure and enabling potentially shorter hospital stays for patients; and the OptoWire</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a pressure guidewire that aims to improve clinical outcomes by accurately and consistently measuring Fractional Flow Reserve (FFR) and diastolic pressure ratio (dPR) to aid clinicians in the diagnosis and treatment of patients with coronary artery disease. OpSens also manufactures a range of fiber optic sensor solutions used in medical devices and other critical industrial applications. The addition of OpSens expands the Hospital business unit portfolio in the interventional cardiology market and is included in the Hospital reportable segment.</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Purchase Price Allocation</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounted for the acquisition as a business combination, and in accordance with FASB ASC Topic 805, Business Combinations (Topic 805), recorded the assets acquired and liabilities assumed at their fair values as of the acquisition date. The fair value of assets acquired and liabilities assumed have been recognized based on management’s estimates and assumptions using the information regarding facts and circumstances that existed at the closing date.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price of $243.9 million, net of $10.6 million of cash acquired, consists of the amounts presented below, which represe</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nt the final d</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">etermination of the fair value of the identifiable assets acquired and liabilities assumed:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.789%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands) </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 12, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,960 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,075 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,062 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,028 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,705 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets acquired</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">279,230</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,251 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll and related costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,723 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,746 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,805 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,853 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities assumed</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35,378</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net assets acquired</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">243,852</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the identifiable intangible assets were developed technology, customer contracts and related relationships and trade names. The fair values of intangible assets were based on valuation techniques with estimates and assumptions developed by the Company. Developed technology and customer contracts and related relationships were valued using the excess earnings method. Trademarks were valued using the relief from royalty method. The cash flows used in the valuation of the intangible assets were based on estimates used to price the transaction. In developing the discount rates applied to the cash flow projections, the discount rates were benchmarked with reference to the implied rate of return from the transaction model and the weighted average cost of capital and then adjusted to reflect the relative risk of the asset.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of the purchase price over the tangible assets, identifiable intangible assets and assumed liabilities was recorded as goodwill. As a result of the acquisition of OpSens, the Company recognized goodwill of $79.4 million based on expected synergies from integration into our Hospital business. The goodwill is not deductible for tax purposes and relates entirely to the Hospital reportable segment.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets acquired consist of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Amortization Period</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Risk-Adjusted Discount<br/>Rates used in Purchase Price Allocation</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,900 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer contracts and related relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,800 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">172,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company recorded a net long-term deferred tax liability of $14.8 million,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> primarily as a result of fair value adjustments recorded associated with definite-lived intangible assets and inventory in which there is no tax basis.</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition-Related Costs</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred $6.6 million of acquisition-related costs for fiscal 2024 in connection with the OpSens acquisition. These costs related to legal and other professional fees, which were recognized in selling, general and administrative on the Condensed Consolidated Statements of Income.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s condensed consolidated financial statements include the results of OpSens from the date the acquisition was completed. Pro forma financial information has not been presented as the acquisition is not material to the Company’s overall financial results.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Divestiture of the Whole Blood Product Line</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 3, 2024, the Company announced that it had entered into a definitive agreement to sell its Whole Blood product line and related assets within its Blood Center business unit to GVS, S.p.A (“GVS”), a manufacturer of filter solutions for applications in the healthcare and life sciences sectors. The divested assets include the Company’s complete portfolio of proprietary whole blood collection, processing and filtration solutions, along with the Company’s manufacturing facility in Covina, California where certain of these products are produced, and related equipment and assets located at the Company’s manufacturing facility in Tijuana, Mexico. On January 13, 2024, subsequent to the third quarter ended December 28, 2024, the Company completed the transaction with GVS for total cash consideration of up to $67.8 million, which includes $45.3 million upfront and up to $22.5 million in contingent consideration, based on sales growth over the next three years and the achievement of certain other milestones. As the related assets are considered held for sale as of December 28, 2024, the Company has reclassified $34.7 million of inventory, $7.3 million of property, plant and equipment, $4.5 million of goodwill and $0.5 million of accrued liabilities to Prepaid expenses and other current assets and other current liabilities in the Condensed Consolidated Balance Sheets, which were previously included in the Blood Center reportable segment.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Strategic Investments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Company’s business development activities, it holds strategic investments in certain entities. As of December 28, 2024, the Compan</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">y has made total investments in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vivasure Medical LTD (“Vivasure”) of €35 million. The investments include both preferred stock and a special share that allows the Company to acquire Vivasure in accordance with an agreement between the parties. In addition, the Compan</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">y made certain other strategic investments totaling </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$14.0 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $7.6 million during fiscal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025 and 2024, r</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">espectively. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s strategic investments are classified as other long-term assets on the Company’s Condensed </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Balance Sheets and the Company has not recorded any material adjustments to the carrying value of the Company’s strategic investments during </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three and nine months ended December 28, 2024 and December 30, 2023.</span></div> 187700000 162000000 150500000 25300000 400000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price of $176.2 million, net of $11.5 million of cash acquired, consists of the amounts presented below, which represent the final determination of the fair value of the identifiable assets acquired and liabilities assumed:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.789%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands) </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">April 1, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,784 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">906 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,800 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,256 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets acquired</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">207,246</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,260 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll and related costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,129 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,155 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities assumed</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">31,040</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net assets acquired</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">176,206</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price of $243.9 million, net of $10.6 million of cash acquired, consists of the amounts presented below, which represe</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nt the final d</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">etermination of the fair value of the identifiable assets acquired and liabilities assumed:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.789%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands) </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 12, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,960 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,075 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,062 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,028 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,705 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets acquired</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">279,230</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,251 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll and related costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,723 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,746 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,805 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,853 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities assumed</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35,378</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net assets acquired</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">243,852</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 176200000 11500000 3784000 26300000 906000 200000 105800000 70256000 207246000 2260000 2129000 496000 26155000 31040000 176206000 70300000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets acquired consist of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Amortization Period</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Risk-Adjusted Discount<br/>Rates used in Purchase Price Allocation</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer contracts and related relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,900 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">105,800</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets acquired consist of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Amortization Period</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Risk-Adjusted Discount<br/>Rates used in Purchase Price Allocation</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,900 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer contracts and related relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,800 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">172,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div> 96100000 P10Y 0.220 7800000 P10Y 0.215 1900000 P10Y 0.215 105800000 26200000 9800000 254500000 243900000 243900000 10600000 5960000 12075000 2062000 3028000 172000000 79400000 4705000 279230000 3251000 1723000 9746000 14805000 5853000 35378000 243852000 79400000 114900000 P15Y 0.205 52300000 P15Y 0.189 4800000 P15Y 0.205 172000000 14800000 6600000 67800000 45300000 22500000 -34700000 -7300000 -4500000 -500000 35000000 14000000 7600000 0 0 0 0 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. REVENUE </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 28, 2024, the Company had $33.3 million of transaction price allocated to remaining performance obligations related to executed contracts with an original duration of one year or more. The Company expects to recognize approximately 75% of this amount as revenue within the next twelve months and the remaining balance thereafter.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Balances</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables and contract assets, as well as customer advances, customer deposits and deferred revenue (contract liabilities) on the Condensed Consolidated Balance Sheets. The difference in timing between billing and revenue recognition primarily occurs in software licensing arrangements, resulting in contract assets and contract liabilities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 28, 2024 and March 30, 2024, the Company had contract liabilities of $35.6 million and $31.2 million, respectively. During the three and nine months ended December 28, 2024, the Company recognized $4.9 million and $26.7 million of revenue, respectively, that was included in the above March 30, 2024 contract liability balance. Contract liabilities are classified as other current liabilities on the Condensed Consolidated Balance Sheet. As of December 28, 2024 and March 30, 2024, the Company’s contract assets were immaterial.</span></div> 33300000 0.75 P12M 35600000 31200000 4900000 26700000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. RESTRUCTURING </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, the Company reviews the global economy, the healthcare industry, and the markets in which it competes to identify opportunities for efficiencies, enhance commercial capabilities, align its resources and offer its customers better solutions. In order to realize these opportunities, the Company undertakes restructuring-type activities to transform its business.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operational Excellence Program</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, the Board of Directors of the Company approved the Operational Excellence Program (the “2020 Program”) and delegated authority to the Company’s management to determine the detail of the initiatives that will comprise the program. During fiscal 2022, the Company revised the program to improve product and service quality, reduce cost principally in its manufacturing and supply chain operations and ensure sustainability while helping to offset impacts from a previously announced customer loss, rising inflationary pressures and effects of the COVID-19 pandemic. The Company expects to incur aggregate charges of approximately $85.0 million by the end of fiscal 2025 under the program. The majority of charges will result in cash outlays, including severance and other employee costs, and will be incurred as the specific actions required to execute these initiatives are identified and approved. During the three and nine months ended December 28, 2024, the Company incurred $1.9 million and</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$6.0 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively, of restructuring and restructuring related costs under this program. During the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three and nine months ended December 30, 2023, the Company incurred $2.6 million and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$6.8 million, respectively, of restructuring and restructuring related costs under this program.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cumulative charges under this progra</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">m are $83.0 million through December 28, 2024.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Portfolio Rationalization Initiatives</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Company announced its plans to end of life the ClotPro analyzer system within the Hospital business unit and certain products within the Blood Center business unit, primarily in Whole Blood, including the associated manufacturing operations and closure of certain other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">facilities. In the three and nine months ended December 28, 2024, the Company incurred $3.1 million and $12.5 million of expenses, respectively, of restructuring and restructuring related costs in connection with these portfolio rationalization initiatives. In both the three and nine months ended December 30, 2023, the Company incurred $7.8 million of restructuring and related costs related to these portfolio rationalization initiatives.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ity for restructuring reserves related to the portfolio rationalization initiatives and the 2020 Pr</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ogram for the nine months ended December 28, 2024, which relates to employee severance, other employee costs, inventory reserves and lease termination fees:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:54.097%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.102%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.102%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.103%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Portfolio Rationalization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020 Program</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 30, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,309 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,794 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs incurred, net of reversals</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,296 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,929 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,837)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(652)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,489)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,616)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,616)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 28, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,152 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,618 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents the restructuring costs by line item within our accompanying unaudited Condensed Consolidated Statements of Income and Comprehensive Income:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:53.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.589%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands) </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 28,<br/>2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 30,<br/>2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 28,<br/>2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 30,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,027 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,065 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,158 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,329 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,787 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,515 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,968 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,929 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,043 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 28, 2024, the Company had a restructuring liability of $4.6 million, all of which is payable within the next twelve months. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the restructuring expenses included in the table above, the Company also incurred costs that do not constitute restructuring costs under ASC 420, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exit and Disposal Cost Obligations,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and which the Company instead refers to as restructuring related costs. These costs consist primarily of expenditures directly related to the restructuring actions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below present restructuring and restructuring related costs by reportable segment:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:53.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.589%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restructuring costs</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands) </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 28, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 28, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plasma</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(164)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Blood Center</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">685 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,546 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,241 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,546 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">774 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,503 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,404 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,745 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,979 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">886 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">916 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,515 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,968 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,929 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,043 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restructuring related costs</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands) </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 28, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 28, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plasma</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Blood Center</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,468 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,987 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,134 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,675 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,468 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,403 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,557 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,554 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total restructuring and restructuring related costs</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,983</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,371</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18,486</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,597</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 85000000.0 1900000 6000000.0 2600000 6800000 83000000.0 3100000 12500000 7800000 7800000 <div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ity for restructuring reserves related to the portfolio rationalization initiatives and the 2020 Pr</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ogram for the nine months ended December 28, 2024, which relates to employee severance, other employee costs, inventory reserves and lease termination fees:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:54.097%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.102%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.102%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.103%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Portfolio Rationalization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020 Program</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 30, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,309 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,794 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs incurred, net of reversals</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,296 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,929 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,837)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(652)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,489)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,616)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,616)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 28, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,152 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,618 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 11309000 485000 11794000 12296000 633000 12929000 10837000 652000 11489000 8616000 0 8616000 4152000 466000 4618000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents the restructuring costs by line item within our accompanying unaudited Condensed Consolidated Statements of Income and Comprehensive Income:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:53.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.589%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands) </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 28,<br/>2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 30,<br/>2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 28,<br/>2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 30,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,027 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,065 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,158 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,329 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,787 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,515 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,968 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,929 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,043 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below present restructuring and restructuring related costs by reportable segment:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:53.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.589%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restructuring costs</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands) </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 28, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 28, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plasma</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(164)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Blood Center</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">685 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,546 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,241 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,546 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">774 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,503 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,404 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,745 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,979 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">886 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">916 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,515 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,968 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,929 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,043 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restructuring related costs</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands) </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 28, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 28, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plasma</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Blood Center</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,468 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,987 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,134 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,675 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,468 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,403 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,557 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,554 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total restructuring and restructuring related costs</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,983</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,371</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18,486</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,597</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 3027000 7065000 11158000 7329000 -4000 343000 -16000 343000 492000 560000 1787000 371000 3515000 7968000 12929000 8043000 4600000 77000 33000 284000 -164000 685000 4546000 4241000 4546000 774000 2503000 1404000 2745000 1979000 886000 7000000 916000 3515000 7968000 12929000 8043000 37000 72000 263000 315000 31000 93000 120000 166000 -68000 251000 40000 398000 1468000 1987000 5134000 5675000 1468000 2403000 5557000 6554000 4983000 10371000 18486000 14597000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. INCOME TAXES </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company conducts business globally and reports its results of operations in a number of foreign jurisdictions in addition to the United States. The Company’s reported tax rate differs from the statutory tax rate due to the jurisdictional mix of earnings in any given period as the foreign jurisdictions in which it operates have tax rates that differ from the U.S. statutory tax rate. The Company’s effective tax rate is adversely impacted by non-deductible expenses including executive compensation and transaction costs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended December 28, 2024, the Company reported income tax expense of $12.4 million and $31.6 million, respectively, representing effective tax rates of 24.9% and 22.4%. The effective tax rate for the nine months ended December 28, 2024 includes $3.3 million of discrete tax benefit, primarily related to stock compensation windfalls. The discrete benefit also includes other items such as provision to return differences.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended December 30, 2023, the Company reported income tax expense of $12.8 million and $31.3 million, respectively, representing effective tax rates of 29.0% and 24.3%, respectively. The effective tax rate for the nine months ended December 30, 2023 includes $1.1 million of discrete tax benefit, of which $2.6 million relates to stock compensation windfalls, partially offset by other discrete items.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in the reported tax rate for the three months ended December 28, 2024, compared to the same period in fiscal 2024, relates primarily to the decrease in non-deductible acquisition-related expenses. The decrease in the reported tax rate for the nine months ended December 28, 2024, compared to the same period in fiscal 2024, relates primarily to increased discrete tax benefits year-over-year and decreased non-deductible acquisition-related expenses.</span></div> 12400000 31600000 0.249 0.224 3300000 12800000 31300000 0.290 0.243 1100000 2600000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. EARNINGS PER SHARE </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of the numerators and denominators of the basic and diluted earnings per share computations. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.578%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"> (In thousands, except per share amounts)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 28,<br/>2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 30,<br/>2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 28,<br/>2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 30,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic EPS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,494 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,241 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,698 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,191 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,286 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,768 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,709 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,679 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic income per share</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.75</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.62</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.16</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.92</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted EPS</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,494 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,241 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,698 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,191 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted average shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,286 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,768 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,709 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,679 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net effect of common stock equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">677 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">715 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted average shares</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,639 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,445 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,148 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,394 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted income per share</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.74</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.61</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.14</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.89</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Basic earnings per share is calculated using the Company’s weighted-average outstanding common shares. Diluted earnings per share is calculated using its weighted-average outstanding common shares including the dilutive effect of stock awards as determined under the treasury stock method and the outstanding convertible senior notes as determined under the net share settlement method. From the time of the issuance of the convertible senior notes, the average market price of the Company's common shares has been less than the applicable initial conversion prices, and consequently no shares have been included in diluted earnings per share for the co</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">nversion values of both convertible senior notes. For the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">three and nine months ended December 28, 2024, weighted average shares outstanding, assuming dilution, excludes the impact of $0.8 million anti-dilutive shares for both periods. For the three and nine months ended December 30, 2023, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">weighted average shares outstanding, assuming dilution, excludes the impact of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$0.6 million </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">anti-dilutive shares for both periods.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Share Repurchase Program</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, the Company announced that its Board of Directors had approved a three-year share repurchase program authorizing the repurchase of up to $300.0 million of Haemonetics common stock, based on market conditions, through August 2025. Under the share repurchase program, the Company is authorized to repurchase, from time to time, outstanding shares of common stock in accordance with applicable laws on the open market, including under trading plans established pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and in privately negotiated transactions. The actual tim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ing, number and value of shares repurchased will be determined by the Company at its discretion and will depend on a number of factors, including market conditions, applicable legal requirements and compliance with the terms of loan covenants. The share repurchase program may be suspended, modified or discontinued at any time, and the Company has no obligation to repurchase any amount of its common stock under the program. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2024, the Company completed a $75.0 million repurchase of its common stock pursuant to an accelerated share repurchase agreement (“ASR”) entered into with Citibank N.A. (“Citibank”) in August 2024. The total number of shares repurchased under the ASR was 1.0 million at an average price per share upon final settlement of $74.36. As of December 28, 2024, the total remaining authorization for repurchases of the Company's common stock under the share repurchase program was $150.0 million.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of the numerators and denominators of the basic and diluted earnings per share computations. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.578%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"> (In thousands, except per share amounts)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 28,<br/>2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 30,<br/>2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 28,<br/>2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 30,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic EPS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,494 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,241 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,698 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,191 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,286 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,768 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,709 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,679 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic income per share</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.75</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.62</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.16</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.92</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted EPS</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,494 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,241 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,698 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,191 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted average shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,286 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,768 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,709 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,679 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net effect of common stock equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">677 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">715 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted average shares</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,639 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,445 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,148 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,394 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted income per share</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.74</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.61</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.14</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.89</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 37494000 31241000 109698000 97191000 50286000 50768000 50709000 50679000 0.75 0.62 2.16 1.92 37494000 31241000 109698000 97191000 50286000 50768000 50709000 50679000 353000 677000 439000 715000 50639000 51445000 51148000 51394000 0.74 0.61 2.14 1.89 800000 800000 600000 600000 P3Y 300000000 75000000 1000000 74.36 150000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. INVENTORIES</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value and include the cost of material, labor and manufacturing overhead. Cost is determined with the first-in, first-out method.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 28,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 30,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,989 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,150 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,120 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,488 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,505 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167,564 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">359,614</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">317,202</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the third quarter of fiscal 2025, the Company announced the divestiture of its Whole Blood product line within its Blood Center business unit and all related assets and liabilities were recognized as held for sale. The related inventory has a value of $34.7 million, which has been reclassified to Prepaid expenses and other current assets in the Condensed Consolidated Balance Sheets.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value and include the cost of material, labor and manufacturing overhead. Cost is determined with the first-in, first-out method.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 28,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 30,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,989 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,150 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,120 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,488 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,505 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167,564 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">359,614</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">317,202</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the third quarter of fiscal 2025, the Company announced the divestiture of its Whole Blood product line within its Blood Center business unit and all related assets and liabilities were recognized as held for sale. The related inventory has a value of $34.7 million, which has been reclassified to Prepaid expenses and other current assets in the Condensed Consolidated Balance Sheets.</span></div> 101989000 134150000 32120000 15488000 225505000 167564000 359614000 317202000 -34700000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. PROPERTY, PLANT AND EQUIPMENT</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 28,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 30,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,999 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,130 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and building improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,665 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,338 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plant equipment and machinery</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,063 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204,622 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment and information technology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,123 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,979 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Haemonetics equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412,561 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456,414 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,046 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,694 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">867,457 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">959,177 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(581,350)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(647,815)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Property, plant and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">286,107</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">311,362</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended December 28, 2024, depreciation expense was $15.2 million and $44.8 million, respectively. During the three and nine months ended December 30, 2023, depreciation expense was $14.2 million and $41.1 million, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the third quarter of fiscal 2025, the Company announced the divestiture of its Whole Blood product line within its Blood Center business unit and all related assets and liabilities were recognized as held for sale. The related property, plant and equipment has a gross value of $39.8 million and a net carrying value of $7.3 million, which has been reclassified to Prepaid expenses and other current assets in the Condensed Consolidated Balance Sheets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of fiscal 2025, the Company received $19.9 million of cash upon the sale of a manufacturing facility and related assets that previously met held for sale criteria, which resulted in a gain of $14.1 million that was recorded in selling, general and administrative expenses on the Condensed Consolidated Statements of Income.</span></div> <div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 28,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 30,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,999 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,130 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and building improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,665 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,338 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plant equipment and machinery</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,063 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204,622 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment and information technology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,123 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,979 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Haemonetics equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412,561 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456,414 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,046 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,694 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">867,457 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">959,177 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(581,350)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(647,815)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Property, plant and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">286,107</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">311,362</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1999000 4130000 107665000 124338000 191063000 204622000 129123000 129979000 412561000 456414000 25046000 39694000 867457000 959177000 581350000 647815000 286107000 311362000 15200000 44800000 14200000 41100000 39800000 -7300000 19900000 14100000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. LEASES </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lessor Activity</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets on the Company’s balance sheet classified as Haemonetics equipment primarily consist of medical devices installed at customer sites but owned by Haemonetics. These devices are leased to customers under contractual arrangements that typically include an operating or sales-type lease as well as the purchase and consumption of a certain level of disposable products. Sales-type leases are not significant. Contract terms vary by customer and may include options to terminate the contract or options to extend the contract. Where devices are provided under operating lease arrangements, a substantial majority of the entire lease revenue is variable and subject to subsequent non-lease component (disposable products) sales. The allocation of revenue between the lease and non-lease components is based on estimated stand-alone selling prices. Operating lease revenue represents less than 3 percent of the Company’s total net sales.</span></div> 0.03 <div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. GOODWILL AND INTANGIBLE ASSETS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the carrying amount of goodwill by operating segment for fiscal 2025 are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.094%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Plasma</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Blood Center</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying amount as of March 30, 2024</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,043 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,484 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502,555 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565,082 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets held for sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,475)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,475)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase accounting adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,248)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,248)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,542 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,542 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(268)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,367)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,635)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying amount as of December 28, 2024</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29,043</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28,741</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">547,482</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">605,266</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in goodwill of $19.2 million for purchase accounting adjustments was primarily related to the Company obtaining additional facts and information to finalize the pre-acquisition tax returns and associated analyses for OpSens. This resulted in the Company revising its estimate of the net deferred tax liability recorded as of the acquisition date.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions, Divestitures and Strategic Investments,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information regarding the acquisitions of OpSens and Attune Medical.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the third quarter of fiscal 2025, the Company announced the divestiture of its Whole Blood product line within its Blood Center business unit and all related assets and liabilities were recognized as held for sale. The related goodwill of $4.5 million has been reclassified to Prepaid expenses and other current assets in the Condensed Consolidated Balance Sheets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gross carrying amount of intangible assets and the related accumulated amortization as of December 28, 2024 and March 30, 2024 is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.784%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of December 28, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortizable:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505,323 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,898 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358,425 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer contracts and related relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,181 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,261 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,920 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,528 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,722 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,806 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,504 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,579 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,925 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,927 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,136 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,791 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">770,463</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">311,596</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">458,867</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-amortizable:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process software development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,748 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,748</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.784%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of March 30, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortizable:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464,291 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,413 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285,878 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer contracts and related relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,144 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,033 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,111 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,837 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,491 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,346 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,504 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,820 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,684 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,320 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,456 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,864 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">843,096</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">455,213</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">387,883</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-amortizable:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,667 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process software development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,567 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18,234</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal 2025, the Company acquired Attune Medical and recorded $96.1 million of developed technology, $7.8 million of customer contracts and related relationships and $1.9 million of trade name intangibles based on the purchase accounting valuation. Refer to Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions, Divestitures and Strategic Investments,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information regarding the acquisition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of fiscal 2025, the Company announced the commercialization of MVP XL and moved the related in-process research and development intangible asset to developed technologies and commenced amortization. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of fiscal 2024, the Company recorded an intangible asset impairment charge of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$10.4 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related to the intangibles acquired as part of the e</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nicor GmbH acquisition completed in fiscal 2021 within the Hospital business unit.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the third quarter of fiscal 2025, the Company announced the divestiture of its Whole Blood product line within its Blood Center business unit and all related assets and liabilities were recognized as held for sale. The related intangible assets are fully amortized and have a net book value of zero. The gross intangible assets value is $185.6 million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets include the value assigned to license rights and other developed technology, patents, customer contracts and relationship</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s and trade names. The estimated useful lives for all of these intangible assets are approximately 5 to 15 years.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended December 28, 2024, amortization expense was $13.9 million and $42.6 million, respectively. During the three and nine months ended December 30, 2023, amortization expense was $9.3 million and $28.5 million, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future annual amortization expense on intangible assets for the next five years is estimated to be as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:83.504%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.563%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of Fiscal 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,995 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,879 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,931 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,160 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,965 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the carrying amount of goodwill by operating segment for fiscal 2025 are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.094%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Plasma</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Blood Center</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying amount as of March 30, 2024</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,043 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,484 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502,555 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565,082 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets held for sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,475)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,475)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase accounting adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,248)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,248)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,542 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,542 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(268)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,367)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,635)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying amount as of December 28, 2024</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29,043</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28,741</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">547,482</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">605,266</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 29043000 33484000 502555000 565082000 0 4475000 0 4475000 0 0 -19248000 -19248000 0 0 69542000 69542000 0 -268000 -5367000 -5635000 29043000 28741000 547482000 605266000 -19200000 -4500000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gross carrying amount of intangible assets and the related accumulated amortization as of December 28, 2024 and March 30, 2024 is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.784%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of December 28, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortizable:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505,323 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,898 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358,425 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer contracts and related relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,181 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,261 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,920 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,528 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,722 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,806 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,504 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,579 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,925 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,927 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,136 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,791 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">770,463</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">311,596</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">458,867</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-amortizable:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process software development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,748 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,748</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.784%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of March 30, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortizable:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464,291 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,413 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285,878 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer contracts and related relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,144 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,033 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,111 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,837 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,491 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,346 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,504 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,820 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,684 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,320 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,456 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,864 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">843,096</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">455,213</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">387,883</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-amortizable:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,667 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process software development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,567 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18,234</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td></tr></table></div> 505323000 146898000 358425000 136181000 70261000 65920000 85528000 74722000 10806000 27504000 13579000 13925000 15927000 6136000 9791000 770463000 311596000 458867000 6748000 6748000 464291000 178413000 285878000 255144000 190033000 65111000 84837000 69491000 15346000 24504000 11820000 12684000 14320000 5456000 8864000 843096000 455213000 387883000 13667000 4567000 18234000 96100000 7800000 1900000 10400000 0 185600000 P5Y P15Y 13900000 42600000 9300000 28500000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future annual amortization expense on intangible assets for the next five years is estimated to be as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:83.504%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.563%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of Fiscal 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,995 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,879 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,931 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,160 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,965 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 12995000 49879000 47931000 46160000 44965000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. NOTES PAYABLE AND LONG-TERM DEBT </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes payable and long-term debt consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:65.029%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.468%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.470%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 28, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">982,731 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494,813 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan, net of financing fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241,266 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261,971 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolving credit facility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other borrowings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,009 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,075)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,229)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-term debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,219,762</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">797,564</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Senior Notes</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026 Notes</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, the Company issued $500.0 million aggregate principal amount of 0% convertible senior notes due 2026 (the “2026 Notes”). The 2026 Notes are governed by the terms of the Indenture between the Company and U.S. Bank National Association, as trustee. The 2026 Notes will mature on March 1, 2026, unless earlier converted, redeemed or repurchased. In the first quarter of fiscal 2025, the Company repurchased $200.0 million of the aggregate principal amount for $185.5 million, resulting in a gain of $14.5 million related to the discount on repurchase. As the repurchase of the 2026 Notes met the criteria for extinguishment accounting, $1.9 million of unamortized debt issuance costs were allocated to the repurchase, resulting in a net gain of $12.6 million, which was recorded in Interest and other income (expense), net on the Condensed Consolidated Statements of Income.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of fiscal 2025, the conditions allowing holders of the 2026 Notes to convert have not been met. The 2026 Notes were therefore not convertible as of December 28, 2024 and were classified as long-term debt on the Company’s Condensed Consolidated Balance Sheets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 28, 2024, the $300.0 million principal balance was netted down by $1.9 million of remaining debt issuance costs, resulting in a net convertible note payable of $298.1 million. Interest expense related to the 2026 Notes was $0.4 million and $1.4 million for the three and nine months ended December 28, 2024, respectively, which is entirely attributable to the amortization of the debt issuance costs. The remaining debt issuance costs are amortized at an effective interest rate of 0.5%.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2029 Notes</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 28, 2024, the Company issued $700.0 million aggregate principal amount of 2.5% convertible senior notes due 2029 (the “2029 Notes”). The 2029 Notes are governed by the terms of the Indenture between the Company and U.S. Bank National Association, as trustee. The total net proceeds from the sale of the 2029 Notes, after deducting the initial purchasers’ discounts and debt issuance costs, were $682.8 million, with a portion of funds used to repay the entirety of the balance on the revolving credit facility under the Company’s second amended and restated credit agreement, to repurchase a portion of the Company’s 2026 Notes, to complete capped call transactions in connection with the issuance of the 2029 Notes, as described further below, with the remaining proceeds available for other working capital requirements. The 2029 Notes will mature on June 1, 2029, unless earlier converted, redeemed or repurchased.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders may convert their notes at their option at any time prior to the close of business on the business day immediately preceding December 1, 2028 only under the following circumstances:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">During any calendar quarter (and only during such calendar quarter) beginning after September 30, 2024, if, the last reported sale price per share of the Company’s common stock exceeds 130% of the applicable conversion price on each applicable trading day for at least 20 trading days (whether or not consecutive) in the period of the 30 consecutive trading day period ending on, and including, the last trading day of the immediately preceding calendar quarter;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">During the five business day period after any five consecutive trading day period in which, for each day of that period, the trading price per $1,000 principal amount of the 2029 Notes for such trading day was less than 98% of the product of the last reported sale price of the Company’s common stock and the applicable conversion rate on such trading day;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company issues to common stockholders any rights, options, or warrants, entitling them, for a period of not more than 60 days, to purchase shares of common stock at a price per share less than the average closing sale price of 10 consecutive trading days, or the Company’s election to make a distribution to common stockholders exceeding 10% of the previous day’s closing sale price;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Upon the occurrence of specified corporate events, as set forth in the indenture governing the 2029 Notes; or</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Prior to the related redemption date if the Company calls the 2029 Notes for redemption.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or after December 1, 2028, until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert all or a portion of their 2029 Notes, in multiples of $1,000 principal amount, at any time, regardless of the foregoing circumstances. The conversion rate for the 2029 Notes is 8.5385 shares of common stock per $1,000 principal amount of notes (which is equal to an initial conversion price of approximately $117.12 per share of the Company’s common stock), subject to adjustment as set forth in the Indenture. Upon conversion, the Company will pay cash up to the aggregate principal amount of the notes to be converted and pay or deliver, as the case may be, cash, common stock or a combination of cash and common stock, at the Company’s election, in respect of the remainder, if any, of the Company’s conversion obligation in excess of the aggregate principal amount of the notes being converted. If a make-whole adjustment event, as described in the Indenture, occurs and a holder elects to convert its 2029 Notes in connection with such make-whole adjustment event, such holder may be entitled to an increase in the conversion rate as described in the Indenture.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of fiscal 2025, the conditions allowing holders of the 2029 Notes to convert have not been met. The 2029 Notes were therefore not convertible as of December 28, 2024 and were classified as long-term debt on the Company’s consolidated balance sheets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2029 Notes will be redeemable, in whole or in part, at the Company’s option at any time, and from time to time, on or after June 5, 2027 and on or before the 50th scheduled trading day immediately before the maturity date, if the last reported sale price per share of the Company’s common stock exceeds 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive), including the trading day immediately preceding the date on which the Company provides notice of redemption, during any 30 consecutive trading day period ending on, and including, the trading day immediately before the date the Company sends the related redemption notice at a redemption price equal to 100% of the principal amount of the 2029 Notes to be redeemed, plus accrued and unpaid interest to, but excluding the redemption date. Upon the occurrence of certain fundamental changes involving the Company, holders of the 2029 Notes may require the Company to repurchase for cash all or part of their 2029 Notes at a repurchase price equal to 100% of the principal amount of the 2029 Notes to be repurchased, plus</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accrued and unpaid interest.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the issuance of the 2029 Notes, the Company recorded debt issuance costs of $17.2 million, which will be amortized to interest expense over the contractual term of the 2029 Notes at an effective interest rate of 3.0%.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 28, 2024, the $700.0 million principal balance was netted down by $15.4 million of remaining debt issuance costs, resulting in a net convertible note payable of $684.6 million. Interest expense related to the 2029 Notes was $5.2 million and $12.1 million for the three and nine months ended December 28, 2024, respectively, which includes nominal interest expense and the amortization of the debt issuance costs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Capped Calls</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the issuance of the 2029 Notes, the Company entered into capped call transactions with certain counterparties (“Capped Calls”). The Capped Calls each have an initial strike price of approximately $117.12 per share, subject to certain adjustments, which corresponds to the initial conversion price of the 2029 Notes. The Capped Calls have initial cap prices of $180.18 per share, subject to certain adjustments. The Capped Calls are expected to partially offset the potential dilution to the Company’s common stock upon any conversion of the 2029 Notes, with such offset subject to a cap based on the cap price. The Capped Calls cover, subject to anti-dilution adjustments, approximately 5.98 million shares of the Company’s common stock. For accounting purposes, the Capped Calls are separate transactions, and not part of the 2029 Notes. As these transactions meet certain accounting criteria, the Capped Calls are recorded in stockholders’ equity and are not accounted for as derivatives. The cost of $88.2 million incurred to purchase the Capped Calls was recorded as a reduction to additional paid-in capital and will not be remeasured.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Facilities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On July 26, 2022, the Company entered into an amended and restated credit agreement to refinance its credit facilities initially entered into in 2018 and extend their maturity date through June 2025. The amended and restated credit agreement provided for a $280.0 million senior unsecured term loan and a $420.0 million senior unsecured revolving credit facility (together, the “2022 Revised Credit Facilities”) with applicable interest rates during the period established using an annual rate equal to the Adjusted Term SOFR Rate plus an applicable rate ranging from 1.125% to 1.750% based on the Company’s consolidated net leverage ratio, as specified in the agreement.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On April 30, 2024, the Company entered into a second amended and restated credit agreement with certain lenders to refinance the 2022 Revised Credit Facilities and extend their maturity date through April 2029. The second amended and restated credit agreement provides for a $250.0 million senior unsecured term loan, the proceeds of which, along with $12.5 million of cash on hand, were used to retire the balance of the term loan under the 2022 Revised Credit Facilities, and a $750.0 million senior unsecured revolving credit facility (together, the “2024 Revised Credit Facilities”). Loans under the 2024 Revised Credit Facilities bear interest at an annual rate equal to the Adjusted Term SOFR Rate (as specified in the second amended and restated credit agreement), which is subject to a floor of 0.0%, plus an applicable rate ranging from 1.125% to 1.750% based on the Company’s consolidated net leverage ratio (as specified in the second amended and restated credit agreement) at the applicable measurement date. The revolving credit facility carries an unused fee that ranges from 0.125% to 0.250% annually based on the Company’s consolidated net leverage ratio at the applicable measurement date. The 2024 Revised Credit Facilities mature on April 30, 2029. The principal amount of the term loan under the 2024 Revised Credit Facilities amortizes quarterly through the maturity date at a rate of 2.5% for the first three years following the closing date, 5.0% for the fourth year following the closing date and 7.5% for the fifth year following the closing date, with the unpaid balance due at maturity. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the 2024 Revised Credit Facilities, the Company is required to maintain a consolidated leverage ratio not to exceed 4.0:1.0 or, on up to two occasions during the term of the facility, 4.5:1.0 for the four consecutive fiscal quarters ended immediately following acquisitions meeting certain criteria specified in the agreement.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company applied modification accounting for the credit facility refinancing, which resulted in the capitalization of an additional $5.9 million in lender fees and third-party costs. During the three and nine months ended December 28, 2024, the Company recognized $4.6 million and $16.6 million, respectively, of interest expense and amortization of debt issuance costs related to its credit facilities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 28, 2024, $246.9 million was outstanding under the term loan with an effective interest rate of 6.1%, which was netted down by the $5.6 million of remaining debt discount, resulting in a net note payable of $241.3 million. The Company has scheduled principal payments of $6.3 million required during the 12 months following December 28, 2024. There were no outstanding borrowings under the revolving credit facilities at December 28, 2024. The Company also had $18.0 million of uncommitted operating lines of credit to fund its global operations under which there were no outstanding borrowings as of December 28, 2024.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was in compliance with the consolidated net leverage and interest coverage ratios specified in the 2024 Revised Credit Facilities as well as all other bank covenants as of December 28, 2024.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The future aggregate amount of debt maturities are as follows: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:88.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.442%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of Fiscal 2025</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,597 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2026</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306,349 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2027</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,308 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2028</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,999 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2029</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,252 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">905,210 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes payable and long-term debt consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:65.029%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.468%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.470%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 28, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">982,731 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494,813 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan, net of financing fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241,266 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261,971 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolving credit facility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other borrowings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,009 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,075)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,229)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-term debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,219,762</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">797,564</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 982731000 494813000 241266000 261971000 0 50000000 840000 1009000 5075000 10229000 1219762000 797564000 500000000 0 200000000 185500000 14500000 1900000 -12600000 300000000 1900000 298100000 400000 1400000 0.005 700000000 0.025 682800000 1.30 0.98 0.10 8.5385 117.12 1.30 1 1 17200000 0.030 700000000 15400000 684600000 5200000 12100000 117.12 180.18 5980000 88200000 280000000 420000000 0.01125 0.01750 250000000 12500000 750000000 0.000 0.01125 0.01750 0.00125 0.00250 0.025 0.050 0.075 4.0 4.5 5900000 4600000 16600000 246900000 0.061 5600000 241300000 6300000 0 18000000.0 0 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The future aggregate amount of debt maturities are as follows: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:88.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.442%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of Fiscal 2025</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,597 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2026</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306,349 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2027</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,308 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2028</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,999 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2029</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,252 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">905,210 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1597000 306349000 6308000 10999000 17252000 905210000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manufactures, markets and sells its products globally. During the three and nine months ended December 28, 2024, 26.1% and 26.0%, respectively, of the Company’s sales were generated outside the U.S. in local currencies. The Company also incurs certain manufacturing, marketing and selling costs in international markets in local currency.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, earnings and cash flows are exposed to market risk from changes in foreign currency exchange rates relative to the U.S. Dollar, the Company’s reporting currency. The Company has a program in place that is designed to mitigate the exposure to changes in foreign currency exchange rates. That program includes the use of derivative financial instruments to minimize, for a period of time, the impact on its financial results from changes in foreign exchange rates. The Company utilizes foreign currency forward contracts to hedge the anticipated cash flows from transactions denominated in foreign currencies, primarily Japanese Yen and Euro, and to a lesser extent, Swiss Franc and Mexican Peso. This does not eliminate the impact of the volatility of foreign exchange rates. However, because the Company generally enters into forward contracts one year out, rates are fixed for a one-year period, thereby facilitating financial planning and resource allocation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Designated Foreign Currency Hedge Contracts</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company’s designated foreign currency hedge contracts as of December 28, 2024 and March 30, 2024 were cash flow hedges under ASC 815, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“ASC 815”). The Company records the effective portion of any change in the fair value of designated foreign currency hedge contracts in other comprehensive income until the related third-party transaction occurs. Once the related third-party transaction occurs, the Company reclassifies the effective portion of any related gain or loss on the designated foreign currency hedge contracts to earnings. In the event the hedged forecasted transaction does not occur, or it becomes probable that it will not occur, the Company will reclassify the amount of any gain or loss on the related cash flow hedge to earnings at that time. The Company had designated foreign currency hedge contracts outstanding in the contract amount of $45.5 million as of December 28, 2024 and $74.0 million as of March 30, 2024. At December 28, 2024, a loss of $1.1 million, net of tax, will be reclassified to earnings within the next twelve months. Substantially all currency cash flow hedges outstanding as of December 28, 2024 mature within twelve months.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Designated Foreign Currency Contracts</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages its exposure to changes in foreign currency on a consolidated basis to take advantage of offsetting transactions and balances. It uses foreign currency forward contracts as a part of its strategy to manage exposure related to foreign currency denominated monetary assets and liabilities. These foreign currency forward contracts are entered into for periods consistent with currency transaction exposures, generally one month. They are not designated as cash flow or fair value hedges under ASC 815. These forward contracts are marked-to-market with changes in fair value recorded to earnings. The Company had non-designated foreign currency hedge contracts under ASC 815 outstanding in the contract amount of $82.7 million as of December 28, 2024 and $39.9 million as of March 30, 2024.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Rate Swaps</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Part of the Company’s interest rate risk management strategy includes the use of interest rate swaps to mitigate its exposure to changes in variable interest rates. The Company’s objective in using interest rate swaps is to add stability to interest expense and to manage and reduce the risk inherent in interest rate fluctuations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To mitigate the interest rate risk on the Company’s senior unsecured term loan, in September 2022, the Company entered into four interest rate swaps, two of which expired in June 2023 and the remaining two were amended and extended in September 2024.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The amendment and extension of the two interest rate swaps did not have a material impact on the Condensed Consolidated Financial Statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Loans under the 2024 Revised Credit Facilities bear interest at an annual rate equal to the 1-month USD Term SOFR, plus an applicable rate ranging from 1.125% to 1.750% based on the Company’s consolidated net leverage ratio. As a result of the amendment and extension in September 2024, the two modified interest rate swaps have an average blended fixed interest rate of 3.31% plus the applicable rate on approximately 80% of the notional value of the unsecured term loan, until their maturity in April 2029. The Company has determined both of these interest rate swaps are effective and qualify for hedge accounting treatment. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company held the following interest rate swaps as of December 28, 2024:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.268%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.458%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hedged Item</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Original Notional Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount as of December 28, 2024</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Designation Date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Termination Date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fixed Interest Rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value Assets (Liabilities)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1-month USD Term SOFR</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/27/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/30/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/30/2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.32%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,806 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1-month USD Term SOFR</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/27/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/30/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/30/2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.30%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205,800 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205,800 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,806 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended December 28, 2024, the Company recorded a gain of $3.4 million, net of tax, in accumulated other comprehensive loss to recognize the effective portion of the fair value of the swaps that qualify as cash flow hedges.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trade Receivables</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, the Company grants trade credit to its customers on normal credit terms. In an effort to reduce its credit risk, the Company (i) establishes credit limits for all customers, (ii) performs ongoing credit evaluations of customers’ financial condition, (iii) monitors the payment history and aging of customers’ receivables, and (iv) monitors open orders against an individual customer’s outstanding receivable balance.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s allowance for credit losses is maintained for trade accounts receivable based on the expected collectability, the historical collection experience, the length of time an account is outstanding, the financial position of the customer and information provided by credit rating se</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rvices. The Company has not experienced significant customer payment defaults, or identified other significant collectability concerns.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a roll forward of the allowance for credit losses:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.274%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 28, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 28, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,912</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,044</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,695</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,932</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">653 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">833 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs (recoveries)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,986</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,725</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,986</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,725</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Fair Value Measurements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exit price that would be received from the sale of an asset or paid to transfer a liability, using assumptions that market participants would use in pricing an asset or liability. The fair value guidance establishes the following three-level hierarchy used for measuring fair value:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 — Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 — Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 — Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s money market funds carried at fair value are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Derivative Instruments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the effect of the Company’s derivative instruments designated as cash flow hedges and those not designated as hedging instruments under ASC 815 in its unaudited Condensed Consolidated Statements of Income and Comprehensive Income for the nine months ended December 28, 2024:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:23.422%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.493%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.203%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount of Gain (Loss) Recognized<br/>in Accumulated Other Comprehensive Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount of Gain (Loss) Reclassified<br/>from Accumulated Other Comprehensive Loss into<br/>Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location in<br/>Condensed Consolidated Statements of Income and Comprehensive Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount of Gain Excluded from<br/>Effectiveness<br/>Testing</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location in<br/>Condensed Consolidated Statements of Income and Comprehensive Income</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designated foreign currency hedge contracts, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,095)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(220)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues, COGS and SG&amp;A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">959 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-935">Interest and other expense, net</span></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-designated foreign currency hedge contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,092 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-939">Interest and other expense, net</span></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designated interest rate swaps, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,353 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-942">Interest and other expense, net</span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company did not have fair value hedges or net investment hedges outstanding as of December 28, 2024 or March 30, 2024. As of December 28, 2024, no material deferred taxes were recognized for designated foreign currency hedges. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 815 requires all derivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. The Company determines the fair value of its derivative instruments using the framework prescribed by ASC 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, by considering the estimated amount it would receive or pay to sell or transfer these instruments at the reporting date and by taking into account current interest rates, currency exchange rates, current interest rate curves, interest rate volatilities, the creditworthiness of the counterparty for assets, and its creditworthiness for liabilities. In certain instances, the Company may utilize financial models to measure fair value. Generally, the Company uses inputs that include quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; other observable inputs for the asset or liability; and inputs derived principally from, or corroborated by, observable market data by correlation or other means. As of December 28, 2024, the Company has classified its derivative assets and liabilities within Level 2 of the fair value hierarchy prescribed by ASC 815, as discussed below, because these observable inputs are available for substantially the full term of its derivative instruments.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the fair value of the Company’s derivative instruments as they appear in its Condensed Consolidated Balance Sheets as of December 28, 2024 and March 30, 2024:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.863%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location in Condensed Consolidated<br/>Balance Sheets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 28, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivative Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designated foreign currency hedge contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,186 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,353 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-designated foreign currency hedge contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designated interest rate swaps</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,734 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,673 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designated interest rate swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,072 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,063</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,242</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivative Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designated foreign currency hedge contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,219 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-designated foreign currency hedge contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,566</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">931</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measured on a Recurring Basis</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets and financial liabilities measured at fair value on a recurring basis consist of the following as of December 28, 2024 and March 30, 2024.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 28, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,773 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,773 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designated foreign currency hedge contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,186 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,186 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-designated foreign currency hedge contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designated interest rate swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,806 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,806 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">170,773</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,063</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">177,836</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designated foreign currency hedge contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,219 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,219 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-designated foreign currency hedge contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designated interest rate swaps</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,133 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,133 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,566</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23,133</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24,699</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,073 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,073 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designated foreign currency hedge contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,353 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,353 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-designated foreign currency hedge contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designated interest rate swaps</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">43,073</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,242</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">46,315</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designated foreign currency hedge contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-designated foreign currency hedge contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">931</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">931</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign currency hedge contracts - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of foreign currency hedge contracts was measured using significant other observable inputs and valued by reference to over-the-counter quoted market prices for similar instruments. The Company does not believe that the fair value of these derivative instruments differs significantly from the amount that could be realized upon settlement or maturity, or that the changes in fair value will have a significant effect on its results of operations, financial condition or cash flows.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest rate swaps - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of interest rate swaps are measured using the present value of expected future cash flows using market-based observable inputs, including credit risk and interest rate yield curves. The Company does not believe that the fair values of these derivative instruments differ significantly from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a significant effect on its results of operations, financial condition or cash flows.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The fair value of contingent consideration liabilities is based on significant unobservable inputs, including management estimates and assumptions, and is measured based on the probability-weighted present value of the payments expected to be made. Accordingly, the fair value of contingent consideration has been classified as level 3 within the fair value hierarchy. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The level 3 fair value measurements of contingent consideration liabilities include the following significant unobservable inputs:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.560%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.450%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value at</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 28, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Technique</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Input</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue-based payments</span></td><td colspan="3" style="padding:0 1pt"></td><td rowspan="2" style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td rowspan="2" style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,179 </span></td><td rowspan="2" style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monte Carlo Simulation Model</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3%</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected year of payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 - 2027</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regulatory-based payment</span></td><td colspan="3" style="padding:0 1pt"></td><td rowspan="3" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td rowspan="3" style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,804 </span></td><td rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monte Carlo Simulation Model</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1%</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of payment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50%</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected year of payment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026 - 2028</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Event-based payment</span></td><td colspan="3" style="padding:0 1pt"></td><td rowspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td rowspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,150 </span></td><td rowspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monte Carlo Simulation Model</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected year of payment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of contingent consideration associated with the Attune Medical acquisition was $23.1 million at December 28, 2024. As of December 28, 2024, $1.7 million was included in other current liabilities and $21.4 million was included in other long-term liabilities on the Condensed Consolidated Balance Sheets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the change in the fair value of contingent consideration is included in the following table:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.393%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 30, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition date fair value of contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase accounting adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,167)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 28, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23,133</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Fair Value Disclosures</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the 2026 Notes and 2029 No</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tes were $282.0 million and $688.9 million as o</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f December 28, 2024, respectively, which were determined by using the market price on the last trading day of the reporting period and are considered as level 2 in the fair value hierarchy.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The senior unsecured term loan (which is carried at amortized cost), accounts receivable and accounts payable approximate fa</span>ir value. 0.261 0.260 P1Y 45500000 74000000.0 1100000 82700000 39900000 4 2 2 2 0.01125 0.01750 2 0.0331 0.80 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company held the following interest rate swaps as of December 28, 2024:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.268%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.458%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hedged Item</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Original Notional Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount as of December 28, 2024</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Designation Date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Termination Date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fixed Interest Rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value Assets (Liabilities)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1-month USD Term SOFR</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/27/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/30/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/30/2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.32%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,806 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1-month USD Term SOFR</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/27/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/30/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/30/2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.30%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205,800 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205,800 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,806 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 103600000 103600000 0.0332 2806000 102200000 102200000 0.0330 3000000 205800000 205800000 5806000 3400000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a roll forward of the allowance for credit losses:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.274%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 28, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 28, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,912</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,044</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,695</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,932</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">653 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">833 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs (recoveries)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,986</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,725</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,986</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,725</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 5912000 5044000 5695000 4932000 -123000 -653000 -339000 -833000 49000 -28000 48000 40000 5986000 5725000 5986000 5725000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the effect of the Company’s derivative instruments designated as cash flow hedges and those not designated as hedging instruments under ASC 815 in its unaudited Condensed Consolidated Statements of Income and Comprehensive Income for the nine months ended December 28, 2024:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:23.422%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.493%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.203%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount of Gain (Loss) Recognized<br/>in Accumulated Other Comprehensive Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount of Gain (Loss) Reclassified<br/>from Accumulated Other Comprehensive Loss into<br/>Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location in<br/>Condensed Consolidated Statements of Income and Comprehensive Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount of Gain Excluded from<br/>Effectiveness<br/>Testing</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location in<br/>Condensed Consolidated Statements of Income and Comprehensive Income</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designated foreign currency hedge contracts, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,095)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(220)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues, COGS and SG&amp;A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">959 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-935">Interest and other expense, net</span></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-designated foreign currency hedge contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,092 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-939">Interest and other expense, net</span></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designated interest rate swaps, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,353 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-942">Interest and other expense, net</span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> -1095000 -220000 959000 0 0 2092000 3353000 37000 0 0 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the fair value of the Company’s derivative instruments as they appear in its Condensed Consolidated Balance Sheets as of December 28, 2024 and March 30, 2024:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.863%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location in Condensed Consolidated<br/>Balance Sheets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 28, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivative Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designated foreign currency hedge contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,186 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,353 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-designated foreign currency hedge contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designated interest rate swaps</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,734 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,673 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designated interest rate swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,072 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,063</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,242</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivative Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designated foreign currency hedge contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,219 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-designated foreign currency hedge contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,566</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">931</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1186000 1353000 71000 154000 1734000 1673000 4072000 62000 7063000 3242000 1219000 395000 347000 536000 1566000 931000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets and financial liabilities measured at fair value on a recurring basis consist of the following as of December 28, 2024 and March 30, 2024.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 28, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,773 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,773 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designated foreign currency hedge contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,186 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,186 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-designated foreign currency hedge contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designated interest rate swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,806 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,806 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">170,773</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,063</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">177,836</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designated foreign currency hedge contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,219 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,219 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-designated foreign currency hedge contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designated interest rate swaps</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,133 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,133 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,566</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23,133</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24,699</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,073 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,073 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designated foreign currency hedge contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,353 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,353 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-designated foreign currency hedge contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designated interest rate swaps</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">43,073</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,242</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">46,315</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designated foreign currency hedge contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-designated foreign currency hedge contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">931</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">931</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The level 3 fair value measurements of contingent consideration liabilities include the following significant unobservable inputs:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.560%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.450%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value at</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 28, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Technique</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Input</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue-based payments</span></td><td colspan="3" style="padding:0 1pt"></td><td rowspan="2" style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td rowspan="2" style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,179 </span></td><td rowspan="2" style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monte Carlo Simulation Model</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3%</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected year of payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 - 2027</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regulatory-based payment</span></td><td colspan="3" style="padding:0 1pt"></td><td rowspan="3" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td rowspan="3" style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,804 </span></td><td rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monte Carlo Simulation Model</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1%</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of payment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50%</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected year of payment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026 - 2028</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Event-based payment</span></td><td colspan="3" style="padding:0 1pt"></td><td rowspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td rowspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,150 </span></td><td rowspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monte Carlo Simulation Model</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected year of payment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td></tr></table></div> 170773000 0 170773000 0 1186000 1186000 0 71000 71000 0 5806000 5806000 170773000 7063000 177836000 0 1219000 1219000 0 347000 347000 0 0 0 23133000 23133000 0 1566000 23133000 24699000 43073000 0 43073000 0 1353000 1353000 0 154000 154000 0 1735000 1735000 43073000 3242000 46315000 0 395000 395000 0 536000 536000 0 931000 0 931000 17179000 0.063 4804000 0.061 1150000 0.058 23100000 1700000 21400000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the change in the fair value of contingent consideration is included in the following table:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.393%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 30, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition date fair value of contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase accounting adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,167)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 28, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23,133</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 0 25000000 300000 -2167000 23133000 282000000 688900000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. COMMITMENTS AND CONTINGENCIES</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a party to various legal proceedings and claims arising out of the ordinary course of its business. The Company believes that, except for those matters described below, there are no other proceedings or claims pending against it the ultimate resolution of which could have a material adverse effect on its financial condition or results of operations. At each reporting period, management evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for all matters. Legal costs are expensed as incurred.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of fiscal 2021, a putative class action complaint was filed against the Company in the Circuit Court of Cook County, Illinois by Mary Crumpton, on behalf of herself and similarly situated individuals. The Company removed the case to the United States District Court for the Northern District Illinois. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mary Crumpton v. Haemonetics Corporation, Case No. 1:21-cv-1402</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In her complaint, the plaintiff asserts that between June 2017 and August 2018 she donated plasma at a center operated by one of the Company’s customers, that the center required her to scan her fingerprint on a finger scanner that stored her fingerprint to identify her prior to plasma donation, and that the Company’s eQue donor management software sent her biometric information to a Company-owned server to be collected and stored in a manner that violated her rights under the Illinois Biometric Information Privacy Act (“BIPA”). The plaintiff seeks statutory damages, attorneys’ fees and injunctive and equitable relief. In March 2021, the Company moved to dismiss the complaint for lack of personal jurisdiction and concurrently filed a motion to dismiss for failure to state a claim and a motion to stay. In March 2022, the court denied the Company’s motion to dismiss for lack of personal jurisdiction but did not address the merits of the Company’s other positions. In March 2023, the Company filed a second motion to dismiss the complaint, which is pending before the court. During the second quarter of fiscal 2024, the Company entered into a Memorandum of Understanding providing terms that would resolve the litigation and recorded an additional loss contingency related to this matter. In the third quarter of fiscal 2024, the parties requested preliminary court approval of a final settlement agreement, which was granted in February 2024, and the Company recorded an immaterial additional loss contingency related to settlement administration, resulting in an accrual of $8.7 million within other current liabilities in its consolidated balance sheets. In March 2024, notice of the settlement was mailed to class members and the parties are now awaiting the complete administration of the settlement through the third-party administrator. In the first quarter of fiscal 2025, the Company issued payment of the $8.7 million settlement amount following the court’s final approval of the settlement agreement and dismissal of the matter with prejudice.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the fourth quarter of fiscal 2024, a complaint was filed in the U.S. District Court for the District of Delaware by Knoninklijke Philips N.V. and IP2IPO Innovations, Ltd. (together, the “Plaintiffs”) against OpSens, OpSens Medical, Inc., a wholly-owned subsidiary of OpSens, and Haemonetics (1:24-cv-00206-CFC). The complaint alleges, inter alia, that OpSens’ interventional cardiology systems, including its OptoWire and OptoMonitor technology, infringe a single patent held by the Plaintiffs and seeks both injunctive relief and damages. The Company believes it has valid and meritorious defenses to the complaint and plans to vigorously defend against the complaint. During the first quarter of fiscal 2025, the Company recorded a loss contingency related to this matter, which did not have a material impact on its Condensed Consolidated Financial Statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Recall</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, the Company issued a voluntary recall of certain products within the Whole Blood portion of our Blood Center business unit sold to customers in the U.S. and certain foreign jurisdictions. In fiscal 2024, the Company recorded cumulative charges of $6.8 million related to inventory, returns and customer claims associated with this recall. Substantially all outstanding claims have been paid as of December 28, 2024.</span></div> 8700000 8700000 6800000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. ACCUMULATED OTHER COMPREHENSIVE LOSS </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of Accumulated Other Comprehensive Loss, net of tax, are as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.164%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.164%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.164%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.168%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Unrealized Gain (Loss) on Derivatives</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of March 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(38,274)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,748</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">894</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(35,632)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,943)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,257 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,686)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(183)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(183)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,943)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,074 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,869)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 28, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(60,217)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,748</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,968</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(55,501)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Presented net of income taxes, the amounts of which are insignificant.</span></div></td></tr></table></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of Accumulated Other Comprehensive Loss, net of tax, are as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.164%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.164%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.164%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.168%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Unrealized Gain (Loss) on Derivatives</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of March 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(38,274)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,748</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">894</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(35,632)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,943)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,257 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,686)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(183)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(183)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,943)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,074 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,869)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 28, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(60,217)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,748</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,968</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(55,501)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Presented net of income taxes, the amounts of which are insignificant.</span></div></td></tr></table></div> -38274000 1748000 894000 -35632000 -21943000 0 2257000 -19686000 0 0 183000 183000 -21943000 0 2074000 -19869000 -60217000 1748000 2968000 -55501000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16. SEGMENT AND ENTERPRISE-WIDE INFORMATION </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines its reportable segments by first identifying its operating segments, and then by assessing whether any components of these segments constitute a business for which discrete financial information is available and where segment management regularly reviews the operating results of that component. The Company’s reporting structure aligns with its operating structure of three global business units and the information that is regularly reviewed by the Company’s chief operating decision maker.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s reportable and operating segments are as follows: </span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Plasma</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Blood Center</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Hospital</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management measures and evaluates the operating segments based on operating income. Management excludes certain corporate expenses from segment operating income. In addition, certain amounts that management considers to be non-recurring or non-operational are excluded from segment operating income because management evaluates the operating results of the segments excluding such items. Although these amounts are excluded from segment operating income, as applicable, they are included in the reconciliations that follow. Management measures and evaluates the Company’s net revenues and operating income using internally derived standard currency exchange rates that remain constant from year to year; therefore, segment information is presented on this basis.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selected information by reportable segment is presented below:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:53.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.589%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 28,<br/>2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 28,<br/>2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 30,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plasma</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,389 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,560 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408,996 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">429,694 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Blood Center</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,730 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,528 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,373 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,167 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,248 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,625 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417,038 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325,003 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net revenues in constant currency</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349,367 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337,713 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,032,407 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">967,864 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(825)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,463)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,182)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,099)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">348,542</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">336,250</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,030,225</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">965,765</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Beginning in fiscal 2025, the Company integrated service revenue within its three business units. Prior periods were conformed to current presentation.</span></div></td></tr></table></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:53.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.589%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 28,<br/>2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 28,<br/>2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 30,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment operating income</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plasma</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,337 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,450 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205,902 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234,190 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Blood Center</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,955 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,654 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,744 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,244 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,114 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,355 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,710 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,132 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment operating income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,406 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,459 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458,356 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447,566 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70,273)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83,694)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(214,660)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(234,753)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(401)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(879)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,230)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,911)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,965)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,606)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of fair value inventory step-up</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,341)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,319)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integration and transaction costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(244)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,869)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,449)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,768)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,515)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,968)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,929)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,043)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring related costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,468)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,403)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,557)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,554)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Digital transformation costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,620)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,415)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,823)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,712)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write downs of certain assets and PCS2 related charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(210)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(621)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MDR and IVDR costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,008)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,433)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,125)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,587)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation-related charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(177)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,057)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,684)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,391)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,419)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,134 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">59,029</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">45,978</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">150,482</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">134,940</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Reflects shared service expenses including quality and regulatory, customer and field service, research and development, manufacturing and supply chain, as well as other corporate support functions.</span></div></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenues by business unit are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.578%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 28,<br/>2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 28,<br/>2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 30,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Plasma</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">134,224</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">147,641</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">408,695</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">430,056</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apheresis</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,388 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,565 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158,814 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,704 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Whole Blood</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,957 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,814 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,304 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,537 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Blood Center</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">70,345</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">72,379</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">205,118</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">211,241</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interventional Technologies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,253 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,007 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,220 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,168 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Blood Management Technologies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,720 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,223 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228,192 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205,300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Hospital</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">143,973</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">116,230</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">416,412</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">324,468</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">348,542</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">336,250</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,030,225</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">965,765</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Interventional Technologies includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection product lines of the Hospital business unit.</span></div></td></tr><tr><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Blood Management Technologies includes Hemostasis Management, Cell Salvage and Transfusion Management product lines of the Hospital business unit. </span></div></td></tr><tr><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Beginning in fiscal 2025, the Company integrated service revenue within its three business units. Prior periods were conformed to current presentation.</span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenues generated in the Company’s principle operating regions on a reported basis are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.578%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 28,<br/>2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 28,<br/>2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 30,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,665 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,804 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">762,628 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">724,222 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,174 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,825 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,303 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,609 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,163 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,035 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,379 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,088 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of Asia</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,597 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,935 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,148 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,710 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,943 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,651 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,767 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,136 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">348,542</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">336,250</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,030,225</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">965,765</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 3 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selected information by reportable segment is presented below:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:53.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.589%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 28,<br/>2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 28,<br/>2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 30,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plasma</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,389 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,560 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408,996 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">429,694 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Blood Center</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,730 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,528 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,373 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,167 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,248 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,625 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417,038 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325,003 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net revenues in constant currency</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349,367 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337,713 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,032,407 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">967,864 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(825)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,463)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,182)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,099)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">348,542</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">336,250</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,030,225</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">965,765</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Beginning in fiscal 2025, the Company integrated service revenue within its three business units. Prior periods were conformed to current presentation.</span></div></td></tr></table></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:53.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.589%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 28,<br/>2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 28,<br/>2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 30,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment operating income</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plasma</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,337 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,450 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205,902 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234,190 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Blood Center</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,955 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,654 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,744 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,244 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,114 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,355 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,710 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,132 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment operating income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,406 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,459 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458,356 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447,566 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70,273)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83,694)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(214,660)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(234,753)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(401)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(879)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,230)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,911)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,965)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,606)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of fair value inventory step-up</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,341)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,319)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integration and transaction costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(244)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,869)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,449)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,768)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,515)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,968)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,929)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,043)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring related costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,468)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,403)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,557)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,554)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Digital transformation costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,620)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,415)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,823)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,712)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write downs of certain assets and PCS2 related charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(210)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(621)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MDR and IVDR costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,008)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,433)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,125)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,587)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation-related charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(177)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,057)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,684)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,391)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,419)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,134 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">59,029</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">45,978</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">150,482</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">134,940</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Reflects shared service expenses including quality and regulatory, customer and field service, research and development, manufacturing and supply chain, as well as other corporate support functions.</span></div></td></tr></table></div> 134389000 147560000 408996000 429694000 70730000 73528000 206373000 213167000 144248000 116625000 417038000 325003000 349367000 337713000 1032407000 967864000 -825000 -1463000 -2182000 -2099000 348542000 336250000 1030225000 965765000 70337000 80450000 205902000 234190000 26955000 27654000 76744000 81244000 62114000 49355000 175710000 132132000 159406000 157459000 458356000 447566000 70273000 83694000 214660000 234753000 304000 -401000 267000 -879000 12230000 6911000 36965000 21606000 3341000 0 12319000 0 244000 4869000 13449000 7768000 -3515000 -7968000 12929000 8043000 1468000 2403000 5557000 6554000 4620000 3415000 15823000 10712000 -4000000 -210000 4000000 -621000 1008000 1433000 3125000 4587000 -18000 177000 1057000 6684000 0 0 2391000 10419000 0 0 14134000 0 59029000 45978000 150482000 134940000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenues by business unit are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.578%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 28,<br/>2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 28,<br/>2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 30,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Plasma</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">134,224</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">147,641</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">408,695</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">430,056</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apheresis</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,388 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,565 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158,814 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,704 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Whole Blood</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,957 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,814 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,304 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,537 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Blood Center</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">70,345</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">72,379</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">205,118</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">211,241</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interventional Technologies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,253 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,007 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,220 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,168 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Blood Management Technologies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,720 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,223 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228,192 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205,300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Hospital</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">143,973</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">116,230</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">416,412</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">324,468</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">348,542</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">336,250</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,030,225</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">965,765</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Interventional Technologies includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection product lines of the Hospital business unit.</span></div></td></tr><tr><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Blood Management Technologies includes Hemostasis Management, Cell Salvage and Transfusion Management product lines of the Hospital business unit. </span></div></td></tr><tr><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Beginning in fiscal 2025, the Company integrated service revenue within its three business units. Prior periods were conformed to current presentation.</span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenues generated in the Company’s principle operating regions on a reported basis are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.578%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 28,<br/>2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 28,<br/>2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 30,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,665 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,804 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">762,628 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">724,222 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,174 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,825 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,303 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,609 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,163 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,035 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,379 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,088 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of Asia</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,597 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,935 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,148 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,710 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,943 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,651 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,767 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,136 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">348,542</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">336,250</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,030,225</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">965,765</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 134224000 147641000 408695000 430056000 55388000 52565000 158814000 156704000 14957000 19814000 46304000 54537000 70345000 72379000 205118000 211241000 63253000 43007000 188220000 119168000 80720000 73223000 228192000 205300000 143973000 116230000 416412000 324468000 348542000 336250000 1030225000 965765000 257665000 250804000 762628000 724222000 16174000 14825000 46303000 41609000 44163000 37035000 133379000 115088000 25597000 30935000 71148000 80710000 4943000 2651000 16767000 4136000 348542000 336250000 1030225000 965765000 false false false false

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